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The innate immunity provides the first line of defence against infection and 
inflammation. Zebrafish are a proven model for understanding the in vivo biology 
of infection and immunity. Here I describe how I have developed and used 
zebrafish models to understand three different aspects of infection and immunity: 
1) The development and use of a zebrafish model of the human fungal infection 
Cryptococcus neoformans 2) Understanding the virulence of the hypervirulent 
Cryptococcus gattii and 3) The mechanisms of action of the immunosuppressive 
drug mycophenolate mofetil (MMF).  
I have established an innate in vivo model for macrophage response to 
Cryptococcus by injecting cryptococci into zebrafish embryos. I have developed 
a high-content imaging method in a zebrafish model of cryptococcosis. This 
approach enabled me the discovery that while macrophages are critical for 
control of C. neoformans, a failure of macrophage response is not the limiting 
defect in fatal infections. I found that phagocytosis is inhibited early in infection 
and that increases in cryptococcal number are driven by intracellular proliferation. 
Moreover, macrophages favourably phagocytose cryptococci with smaller 
polysaccharide capsules and that capsule size is greatly increased over twenty-
four hours of infection, a change that is sufficient to severely limit further 
phagocytosis.  
I then used the zebrafish model of cryptococcosis to determine the virulence of 
C. gattii. I have identified a mutant in the hyper virulent strain R265 that is 
attenuated in vivo. The attenuation of the mutant, R265 GFP14 was further 
confirmed in a mouse model of infection. I analysed the interaction of 
macrophages and R265 GFP cryptococci in zebrafish and found that the 
transgenic R265 GFP was rapidly cleared. Whole genome sequences revealed 
that R265 GFP14 has 32 kb deletion in chromosome 1, resulting in the loss of six 
genes. R265 wild-type and R265 GFP14 were characterised for carbon sources 
utilisation.  
Finally, following up on colleagues’ use of my zebrafish model of cryptococcosis, 
I investigated the action of MMF on neutrophilic inflammation. I showed that MMF 
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treatment resulted in neutrophil cell death by apoptosis in vivo, thereby reducing 
neutrophilic inflammation.  
Thus in this thesis, I demonstrate how I combined the study of infection and 
immunity to better understand diseases that cause the biggest disease burden in 
humans. I pioneered novel approaches to studying cryptococcosis using an 
experimental zebrafish model, which demonstrated for the first time how the early 
interactions with macrophages determined the outcome of infection.  
I subsequently used my model to study the virulence of an emerging pathogen, 
Vancouver strain R265 of C. gattii, identifying a genome region that may be 
important for virulence. Finally, from my cryptococcosis model a new mechanism 
for the immunosuppressant mycophenolate mofetil was identified in 
macrophages. Using my expertise in neutrophilic inflammation I was able to show 
that there was a second mechanism in neutrophils and this may explain the 
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Chapter 1: Introduction  
1.1 Significance of the research proposed 
 
Infectious and inflammatory diseases are the biggest burdens onto human health, 
with little prospect this will change in the coming decades. Infection and immunity 
are drivers of a huge number of diseases from cancer to heart disease to 
neurodegeneration. We still do not know much details of how the immunity works 
or how diseases develop. By studying infection and immunity we intend to 
develop new strategies to prevent, fight and defeat infection, and to prevent and 
target immune and inflammatory disorders. Here, in this chapter I will introduce 
the background underlying my thesis aims and results.  
 
Firstly, I aim to understand fundamental mechanisms through which  
C. neoformans and C. gattii infections develop. Currently, novel infectious 
diseases are emerging and old infectious diseases are spreading. Infectious 
diseases may be unpredictable with the potential for global outbreaks (McArthur, 
2019). Lately, the increasing incidence of C. neoformans infection as a 
concomitant disease of AIDS patients, the outbreak of a hyper virulent C. gattii 
strain in Vancouver Island and cryptococcosis associated high mortality urged 
the medical mycology community to study these organisms (reviewed by (Idnurm 
and Lin, 2015)). The study of Cryptococcus has been made possible due to its 
well-defined virulence factors, along with advanced technical improvements. In 
the Introduction chapter I review the recent advances in our understanding of  
C. neoformans and C. gattii, including Cryptococcus biology, virulence factors 
and key signalling pathways regulating virulence, along with the interaction 
between these pathogens and the host immune system. I think for anyone else 
who wants to read my thesis a general understanding of the immunity as well as 
immune response to Cryptococcus is important. 
In order to determine how infections cause disease in humans, a complex 
biological system is often required. Such a model enables studying the myriad of 
host-pathogen interactions associated with infections. While conventional 
mammalian models have the advantage of relatively close similarity to humans, 
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they have limits. Thus, I review advantages and disadvantages of animal models. 
This is an important research area as at the time I started my work in the Johnston 
lab, there was no model, which would enable tracking macrophages (that are the 
dominant phagocytic cells interacting with Cryptococcus) and cryptococci in the 
entire body of a host and so host-pathogen interactions in real-time. I therefore 
pay attention to zebrafish as a model host for invasive fungal infections, with a 
great emphasis that this animal has a potential to be used as an experimental 
model of cryptococcal infection. Thus, one way to overcome the problem of the 
lack of zebrafish model of Cryptococcus infection is just to establish such a 
system. Therefore, the first part of the project asks whether zebrafish can serve 
as a model. This system could also be used to answer a question regarding the 
difference between C. neoformans and C. gattii infections. The literature is not 
evident in terms of how C. gattii causes a disease and what the difference 
between them two species in this aspect is. The second part of the project asks 
whether C. gattii assessment in the zebrafish model of cryptococcosis will reveal 
the cause of its virulence 
Various pathogenic factors, such as infection or tissue damage, can induce 
inflammation. In this sense, infection is linked with inflammation and vice versa. 
These cells specified and maintained to resolve inflammation, destroy pathogens 
and return to homeostasis, communicate together and regulate each other. A 
growing number of inflammatory conditions have been described, wherein the 
initiating trigger does not involve infection. In addition, more clinicians are now 
turning to immunosupressants to treat inflammatory diseases. I aim to understand 
immune responses to inflammation under immunosuppressive regime.  
As my research is focussed on understanding the mechanisms of normal, 
physiological and pathological immune responses and due to the fact that 
infection and inflammation signalling pathways very often overlap, it is  
sensible to review inflammation and disease as well as the course of 
inflammation/infection. Not only macrophages are reviewed in this thesis, but also 
neutrophils since they have aroused a lot of interest in the inflammatory process. 
Neutrophilic inflammation is crucial for the maintenance of health and life. Failure 
to resolve the response in a timely manner might cause detrimental damage to 
21 
healthy tissue because of the release of toxic granule contents of persisting 
neutrophils (Haslett, 1992). Such neutrophils cause chronic inflammation. This in 
turn is linked with infections and autoimmune conditions. These cases require 
immunosuppression (reviewed by (Kanterman et al., 2012)). Despite the clinical 
problem of unresolved neutrophilic inflammation, few effective therapies are 
available, none of which directly target the neutrophil. One of the widely used 
treatments in immune-mediated diseases is mycophenolate mofetil (MMF). 
Despite its long clinical success in inflammatory diseases, no previous study has 
investigated MMF mechanism of action in terms of inflammation. The third part of 
the project aims to reveal such a mechanism. 
The thesis is written in an alternative format with the following chapters: 
Introduction section (Chapter 1), Materials and Methods section (Chapter 2) and 
three Result chapters (Chapter 3-5), of which Chapter 3 is a published article 
whereas Chapter 4 is written in a conventional way and Chapter 5 is based on a 
preprint version of the manuscript in revision. A general discussion (Chapter 6) is 
given at the end to summarise all the work. 
1.2 Cryptococcus spp. 
Cryptococcus is an environmental, saprophytic yeast that causes opportunistic 
infection and has become medically important over the last half century due to 
the AIDS pandemic, becoming one of the leading causes of death in AIDS, and 
causing rare severe infections within immunocompetent individuals. The 
pathogenic Cryptococcus species complex consists of two sibling 
basidiomycetous yeast taxa, Cryptococcus neoformans and Cryptococcus gattii 
(reviewed by (Kwon-Chung and Varma, 2006; Ngamskulrungroj, Gilgado, et al., 
2009; Hagen et al., 2015; Kwon-Chung et al., 2017)). However, the debate 
regarding the lineages and nomenclature of C. neoformans/C. gattii species 
complex is still ongoing. 
The sister pathogenic species are closely related but distinguishable. Major 
differences exist in basidiospore morphology (reviewed by (Kwon-Chung et al., 
2014; You and Xu, 2018)) and their environmental niche (reviewed by (Lin and 
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Heitman, 2006)), and morphologic characteristics in vivo, e.g. C. neoformans var. 
gattii undergoes reversible phenotype switching during murine infections, 
whereas this process is irreversible in C. neoformans var. neoformans and C. 
neoformans var. grubii (Jain et al., 2006).  
Two varieties: C. neoformans var. grubii (serotype A) (Franzot et al., 1999) and 
C. neoformans var. neoformans (serotype D) (Kwon-Chung, 1975), as well as AD 
hybrid strains (Lucas et al., 2010) were assigned to C. neoformans with serotype 
A causing most of cryptococcal disease (reviewed by (Mitchell and Perfect, 1995, 
Steenbergen and Casadevall, 2000)). C. gattii consisted of 2 serotypes: B and C 
((Wilson et al., 1968), reviewed by (Mitchell and Perfect, 1995)). There have also 
been several molecular types: C. neoformans var. grubii represented by VNI and 
VNII corresponding to AFLP1 and AFLP1A, respectively; C. neoformans var. 
neoformans was represented by VNIV and AFLP2; serotype AD was assigned to 
VNIII and AFLP3. C. gattii serotypes have been classified as: VGI- VGIV 
corresponding to AFLP4, AFLP6, AFLP5, and AFLP7, respectively (Meyer et al., 
2009). Recently, it has been accepted to separate C. neoformans var. grubii from 
C. neoformans var. neoformans, and to introduce five species within C. gattii 
upon biological and genetic differences between species (Table1) (Hagen et al., 
2015; Kwon-Chung et al., 2017). 
In this thesis, when I mention C. neoformans and C. gattii, I am denoting the  
C. neoformans species complex (C. neoformans, C. deneoformans) and C. gattii 


























Clade F, AFLP1 VNI A Cryptococcus  





















Cryptococcus gattii Clade D, AFLP4 VGI B Cryptococcus 
gattii 
Clade C, AFLP5 VGIII C Cryptococcus 
bacillisporus 
Clade A, AFLP6 VGII B Cryptococcus 
deuterogattii 
Clade E, AFLP7 VGIV C Cryptococcus 
tetragattii 





Table 1.1 (continued) 
 
 


































1.2.1 Cryptococcus biology 
 
The route of infection and infectious propagules 
Cryptococcus is predominantly found in the environment as a budding yeast, the 
form most commonly associated with clinical infection (reviewed by (Hull and 
Heitman, 2002; Kwon-Chung et al., 2014)). Infections are developed from the 
environment, supposedly by inhalation of airborne desiccated yeast or spores, 
which are believed to be infectious propagules ((Velagapudi et al., 2009; Walsh 
et al., 2019); reviewed by (Levitz, 1991; Kwon-Chung et al., 2014)). The 
environmental sources include bird guano and certain trees (Mitchell et al., 2011). 
Infectious propagules are inhaled into the lungs, which become the primary site 
of infection (Figure 1.1). Spores are produced by mating (Kwon-Chung, 1975, 
1976b) or monokaryotic fruiting (Erke, 1976; Wickes et al., 1996). The yeast form 
is also infectious as shown in the wide range of mice or zebrafish studies. It is 
widely accepted that the small size of the cell is perfect to enter the lungs 
(reviewed by (Hull and Heitman, 2002)). For instance, the typical median size of 
intracellular cryptococcal cells (H99 GFP) cultured in vitro in YPD is from 3 to  
8 µm at 25°C (Johnston et al., 2016). The literature emphasises that the size of 
the infectious propagule can restrict the pulmonary entry and that particles larger 
than 5 µm are subjected to the mucociliary action of the human lung epithelium 
(Hatch, 1961; Knowles and Boucher, 2002). However, mice inhalation model is a 
forced inhalation system, which is probably quite different to how a human might 
breathe in a yeast cell. In a laboratory setting Cryptococcus can grow as a yeast 
and reproduce by budding. The yeast is the form that is isolated from human 
infection (Bovers et al., 2008, Senghor et al., 2018). Budding mode provides the 
fastest reproduction method and gives rise to two independent cells in mitosis 
(reviewed by (Lin, 2009)). Cryptococcus is also able to produce pseudohyphae 
and this distinguished type has sporadically been observed in patients infected 
by both C. neoformans serotypes A and D, and C. gattii (Lee et al, 2012). 
Interestingly, Neilson and colleagues showed that after co-incubation of yeast 
from C. neoformans with Acanthamoeba polyphaga, the fungus cells are 




perhaps pseudohyphal forms of the fungus always exist and the amoeba aids 
their survival by absorbing the yeast cells without absorbing the pseudohyphae, 
or, alternatively the amoeba stimulates the morphological switch. It could also be 
that pseudohyphae formation provides an anti-phagocytic strategy, if the 
pseudhyphae are too large to be engulfed, or an escaping strategy to exit the host 
cell after phagocytosis (Neilson et al., 1978). Pseudohyphae grow in an elongated 
chain with mother and daughter cell attachments (reviewed by (Hull and Heitman, 
2002, Trevijano-Contador et al., 2016). 
Nonetheless, sexual reproduction is a route by which infectious basidiospores 










Figure 1.1 Infection route. Birds, certain trees, many animals as well as insects, worms 
and amoebae have been found to harbour Cryptococcus. Infectious propagules are 
inhaled into the lungs, which become the primary site of infection. Cryptococcal 




















Cryptococcus sexual reproduction and life cycle 
Sexual reproduction of C. neoformans var. neoformans, serotype D, and  
C. neoformans var. gattii, serotypes B and C, was discovered in mid-1970 (Kwon-
Chung, 1975, 1976a, 1976b). A haploid Cryptococcus cell possesses one mating 
type locus, this being compared to a sex chromosome in more advanced 
organisms. The fungal MAT locus encodes either a or α allele that is responsible 
for the cell gender. Sexual reproduction is maintained by mating (Sun et al., 
2019). Bisexual mating involves partners of opposite mating types a and α 
whereas unisexual involves the same mating types, namely α and α (reviewed by 
(Wang and Lin, 2011)). To be exact, there are 3 pathways of sexual reproduction: 
mating between a and α, diploid filamentation upon the opposite mating type fuse 
and haploid fruiting in the α cell type (Figure 1.2). In mating, two opposite mating 
haploids fuse and maintained at 25°C, grow as dikaryon filaments, with clamp 
cells tied to the filaments. In response to an unknown signal, the dikaryon makes 
a specialised basidium, in which nuclear fusion and meiosis occur. This is 
followed by mitosis and production of haploid a and α basidiospores by budding 
on four characteristic chains on the basidium. In diploid filamentation, two 
haploids fuse when are maintained at 37°C. In the moment of fusion, haploid cells 
and their nuclei fuse to make a yeast form diploid cell that grows as a diploid 
yeast. As a result of the decreased temperature, brought to 25°C, this diploid 
changes into monokaryotic filaments with unfused clamp cells. A basidium is 
made, meiosis followed by mitosis produces a and α basidiospores by budding 
on the basidium. 
In both cases, as for mating and diploid filamentation, 50% a and 50% α is 
obtained. The next mechanism of sexual breeding is haploid fruiting. Haploid cells 
under nutrient deprived conditions make monokaryotic filaments with unfused 
clamp cells, basidia and fruit haploid α spores. In this strategy, diploid 
monocaryotic results from haplo α cells endoduplication or cell and nuclear 
fusion. Clamp cells remain unfused, basidium and haplo basidiospores are 
formed. Basiodspores are proficient to germinate and grow as haploid cells. 
Alternatively, they inaugurate one of the three fates all over again (reviewed by  







Figure 1.2 Phases of the C. neoformans life cycle. (A) mating, (B) diploid 




















Cryptococcus distribution  
C. neoformans has a global distribution and has been isolated from a variety of 
sources with particularly high concentrations in avian excreta and soil (Ellis and 
Pfeiffer, 1990; Levitz, 1991; Cafarchia et al., 2006; Mitchell et al., 2011). In 
contrast, C. gattii is not as widespread and it is mainly localised to the tropical 
and subtropical zones and associated trees, in particular with Eucalyptus (Kwon-
Chung and Bennett, 1984; Sorrell, 2001; Ellis and Pfeiffer, 1990). However, C. 
gattii has also been isolated in temperate regions of Europe, e.g. C. bacillisporus 
and C. tetragattii (Hagen et al., 2015). Moreover, it was the tropical fungus C. 
deuterogattii that caused the fatal fungal outbreak on Vancouver Island spreading 
to the Canadian mainland and into the USA (Stephen et al., 2002; Hoang et al., 
2004; MacDougall et al., 2007). This highlights continual evolution of this 
pathogen into a new environment. 
While Cryptococcus is not an obligate human pathogen, it possesses 
sophisticated mechanisms enabling it to adapt to human hosts (reviewed by 
(Kronstad et al., 2011)); understanding these mechanisms will enable more 
specific targeting of this opportunistic and increasingly significant pathogen. 
1.2.2 Cryptococcal disease 
Cryptococcosis, also known as cryptococcal disease, refers to infection caused 
by fungi from the genus Cryptococcus, mostly by the species C. neoformans and 
C. gattii. The interaction between Cryptococcus and the host leads to a broad 
range of outcomes, from asymptomatic to systemic infections (reviewed by (Lin 
and Heitman, 2006; Taylor-Smith and May, 2016). 
C. neoformans (serotype A) is thought to be responsible for approximately 95% 
of cryptococcal infections and the remaining 4% to 5% of infections are assigned 
to C. neoformans (serotype D) or C. gattii (serotypes B/C) (reviewed by (Maziarz 
and Perfect, 2016)).  
Most people exposed to the fungus never get sick from it. Disseminated 
cryptococcosis is rare in hosts with intact immunity. This means that host defence 




et al., 2018). In fact, individuals who never reported crytococcal infection have 
antibodies to C. neoformans (Chen et al., 1999). However, when the immune 
system is affected, cryptococci will proliferate and disseminate. This is the case 
of the immunocompromised such as HIV/AIDS patients. Dissemination might 
reach the brain by crossing the blood barrier to cause meningoencephalitis and 
central nervous system (CNS) infection without treatment is lethal. In contrast to 
C. neoformans, which predominantly affects the immunocompromised, C. gattii 
predominantly attacks the immunocompetent in North America (MacDougall et 
al., 2007). However, a subsequent report indicated that some of the patients were 
immunosuppressed (Galanis and MacDougall, 2010).  
1.1.2.1 C. neoformans and C. gattii infections in HIV/AIDS, otherwise 
compromised and immunocompetent individuals 
C. neoformans infection principally affects AIDS patients worldwide, especially in 
sub-Saharan Africa (Park et al., 2009). It was estimated that globally, the annual 
number of cryptococcal meningitis was 223 100 cases among HIV/AIDS patients 
with fatalities estimated at 181 100 (Rajasingham et al., 2017). There is also 
clinical evidence of infections in other immunocompromised cases related to, e.g. 
lymphoma or being under immunosuppressive regimen due to lupus 
erythematosus (Korfel et al., 1998; Kiertiburanakul et al., 2006). The majority of 
infections in the immunocompromised are caused by serotypes A and D of  
C. neoformans, whereas C. gattii serotypes B and C account for a smaller 
proportion of cryptococcosis that often affects the immunocompetent (Jarvis and 
Harrison, 2008). 
If C. neoformans infection is not controlled, it can result in life threatening 
meningitis and/or meningoencephalitis, again in both compromised (Luma et al., 
2013) and competent individuals (Malhotra et al., 2017). The literature often 
reports that HIV-associated cryptococcosis frequently presents with meningitis 
rather than a respiratory disease. This does not mean that there is no pulmonary 
involvement. Pulmonary features of cryptococcosis are involved in patients with 
AIDS (Meyohas et al., 1995; Woodring et al., 1996). It is just that the CNS 




2017). As mentioned, globally, in 2014, 223 100 cases of cryptococcal meningitis 
were estimated resulting in 181 100 deaths. Globally, cryptococcal meningitis 
was estimated to be responsible for 15% of AIDS-related deaths. Thus, 
cryptococcosis is associated with AIDS-related mortality (Rajasingham et al., 
2017). Cumulative data enrolled in the two largest prospective trials on AIDS 
patients described the most common symptoms of HIV-associated  
C. neoformans meningitis: fever, meningismus, visual disturbance and cough 
(Saag et al., 1992; van der Horst et al., 1997). What is worrying is the fact that 
while annually 278 000 people are estimated to have cryptococcal antigenaemia, 
73% of cryptococcal meningitis cases occur in sub-Saharan Africa (Rajasingham 
et al., 2017). This means that Africa suffers the greatest burden of this disease 
(Rajasingham et al., 2017) and remains a huge challenge particularly in resource 
limited settings. 
In contrast to C. neoformans, C. gattii infections mainly present with pulmonary 
disease and mostly the immunocompetent are affected (reviewed by (Chen et al., 
2014); (Speed and Dunt, 1995; Dewar and Kelly, 2008) but may also cause 
respiratory disease among HIV-infected persons (Bruner et al., 2018). In addition, 
cases of C. gattii meningoencephalitis in HIV-infected patients have been 
reported rarely in areas with high HIV prevalence, such as Botswana and sub-
Saharan Africa (Steele et al., 2010) and in the USA (Bruner et al., 2018). 
To note, the general trend is that C. neoformans causes CNS infection, whereas 
C. gattii causes pulmonary diseases. Similarly, mice infected with C. neoformans 
succumb due to CNS involvement, while BALB/c and C57BL/6 mice (two strains 
used to exclude difference in pathogenesis between the two species) infected 
with C. gattii- due to pulmonary infection (Ngamskulrungroj, Chang, Sionov, et 
al., 2012).  
The trend is also that C. neoformans affects the immunocompromised and C. 
gattii- the immunocompetent. However, there are counter examples, e.g.  
C. neoformans genotypes infecting HIV negative patients (Chau et al., 2010) or 
C. gattii infection of HIV-infected individuals (Steele et al., 2010; Springer et al., 
2014). Apart from the CNS or pulmonary involvement, Cryptococcus can affect 
other less frequent body sites such as skin (Jarašūnienė et al., 2020), prostate 




(Maziarz and Perfect, 2016)). C. neoformans primary cutaneous infection is rare 
and it is usually associated with skin injury and direct inoculation of the yeast. 
However, this type of infection can occur in normal host immune state and 
immunocompromised (Christianson et al., 2003). The skin usually presents with 
papules, nodules, ulcers or draining sinuses (Neuville et al., 2003). Bone 
involvement is usually associated with osseous lesions (Vender et al., 1988), 
swollen soft tissue and pain in the affected area (Wood and Miedzinski, 1996). 
Prostatic cryptococcosis presents with severe urinary retention (M. R. Chang et 
al., 2007) and eye disease-with cystic growth (Chapman-Smith, 1977).  
1.1.2.2 HIV naïve patients  
The most common manifestation of the disease in HIV-negative patients is 
pulmonary cryptococcosis (Kiertiburanakul et al., 2006). It is hard to estimate the 
proportion of cryptococcosis in HIV naïve patients given there will be a number 
of people living with AIDS not in care and undiagnosed or misdiagnosed, 
especially in low-income countries (Oladele et al., 2017; Rajasingham et al., 
2017). 
Solid organ transplant patients  
Cryptococcosis is one of the most commonly reported invasive fungal infections 
in solid organ transplants (SOTs) (Rubin et al., 1981; Pappas et al., 2010; Taimur, 
2018). Cryptococcosis usually occurs after 16 to 21 months post-transplantation. 
Most cases of cryptococcosis in SOTs develop after acquiring a new primary 
fungal infection or upon a quiescent infection reactivation that has been dormant 
due to the course of immunosuppressants during the post-transplant period 
(Pappas et al., 2010). The overall incidence of cryptococcosis globally in 1988 
was estimated as 2.8% with an overall death rate of 42% (Husain et al., 2001). 
Approximately 33% of the SOT patients have cryptococcosis confined to the 
lungs (Singh et al., 2007). However, the disease might spread to the CNS. It is 
estimated that 39-55% of SOT recipients have CNS involvement (Husain et al., 
2001; Singh et al., 2007). The patients suffer from headaches, meningismus, and 




Interestingly, cryptococcal meningitis is less common in SOT recipients when 
compared to HIV patients (Davis et al., 2009). SOT requires immunosuppression. 
The immunosuppression following organ transplant is a major risk for developing 
cryptococcal disease (Baddley and Forrest, 2013). The immune suppression is 
to minimise the chance of the organ being rejected. The primary 
immunosuppressants in SOTs are calcineurin inhibitors such as cyclosporine or 
tacrolimus. SOT recipients treated with calcineurin inhibitors develop 
cryptococcosis. Interestingly, calcineurin inhibitors treatment is likely to result in 
cryptococcosis limited to the lungs but not to a disseminated disease (Singh et 
al., 2007). Antibodies against T cells are also used in immunosuppression in SOT 
(Mahmud et al., 2010; Jasiak and Park, 2016). However, increasing use of these 
antibodies may lead to more frequent occurrence of cryptococcosis in SOT 
(Silveira et al., 2007). This is because these antibodies are used as 
immunosuppressants (Wofsy, 1990; Focosi et al., 2011). There are also cases of 
donor-derived cryptococcosis (Baddley et al., 2011; Camargo et al., 2017). The 
literature is not evident which serotype of C. neoformans causes most infections 
in SOT patients. With regard to C. gattii, although the infections are prevalent in 
the immunocompetent, the species can also affect SOT patients. For example, 
the Oregon subtype VGIIc is responsible for 70% mortality in SOTs in that region 
between 2004 and 2011 (Forrest et al., 2015). Mortality rates in SOT recipients 
with cryptococcosis have typically ranged from 33% to 42% and may go up to 
49% when CNS is involved (Husain et al., 2001). 
HIV-negative and non-transplant patients  
Cryptococcus can also affect individuals with other predisposing factors, such us 
liver cirrhosis (Lin et al., 2015), cancers (Kontoyiannis et al., 2001), steroids 
(Wilson et al., 1970; Nidhi et al., 2017), diabetes mellitus (Li et al., 2017), systemic 
lupus erythematosus (Matsumura et al., 2011; Fang et al., 2016) or combinations 
of other immunocompromised groups. It is important to note that medical 
conditions underlying diseases are indeed predisposing factors likely due to 
identifiable immunodeficiency. However, there are reports of cryptococcal 
infections in apparently healthy individuals. It is plausible to think that expanded 




cryptococcosis patients (Kwon-Chung et al., 2014). For instance, recently anti- 
granulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies 
were detected in the plasma of otherwise immunocompetent patients and the 
strains from these patients were reported as C. gattii and C. neoformans (Saijo 
et al., 2014). Anti-GM-CSF autoantibodies were also detected in HIV-uninfected 
otherwise healthy patients with cryptococcal meningitis and it was suggested that 
this antibody might predispose patients to cryptococcosis (Rosen et al., 2013). 
Since GM-CSF is important in alveolar macrophages differentiation and function 
(Shibata et al., 2001), autoantibodies will inhibit GM-CSF signalling and thus 
predispose patients to cryptococcosis, wherein GM-CSF is critical for control of 
cryptococcal lung infection in mice (Chen et al., 2007, 2016). Thus, immunological 
tests seem useful to perform to diagnose risks associated with the development 
of cryptococcosis. 
Cryptococcosis can be also environment-acquired, e.g. an immunocompetent 
patient with newly diagnosed metastatic cancer develops the disease after 
occupational exposure to avian excreta (Malhotra et al., 2017). There is also a 
report that C. neoformans was isolated from bagpipes. Whether or not the patient 
was infected from the bagpipes or bagpipes were secondarily infected-will always 
remain a mystery (Cobcroft et al., 1978). The plausible answer would be that it 
was the patient who infected the bagpipes with his sputum. 
Diagnostics  
There are several diagnostic methods available to detect Cryptococcus. The 
standard is cerebrospinal fluid (CSF) culture. CSF analysis is invaluable because 
diseases either develop within its bounding membranes (such as meningitis) or 
parameningeal structures of the brain (e.g. brain abscess) (Jurado and Walker, 
1990). Unfortunately the procedure is long (up to two weeks) (Rajasingham et al., 
2019) and can produce false negatives (reviewed by (Rhein and Boulware, 
2012)). The India ink microscopy enables easy visualisation of the capsule and is 
the primary diagnostic tool because it is relatively cheap. Although the India ink 
was recommended as a routine workup on cryptococcosis where its efficacy was 




showed that the sensitivity of the India ink is highly dependent on the fungal 
burden, i.e. the sensitivity decreases with lower burden. The sensitivity of the 
India ink was calculated at 86% when the fungal burden was high. This means 
that 1 in 7 diagnoses can be missed. In the case of lower burden (CSF value 
<1000/ml of CSF), the sensitivity was only 42% (Boulware et al., 2014). The 
standard is also the detection of cryptococcal antigen (CrAg) in serum or in CSF 
(Rajasingham et al., 2019). This can be achieved by CrAg including latex 
agglutination or lateral flow immunochromatographic assay (LFA). CrAg testing 
by either latex agglutination or LFA was more sensitive than CSF culture, 
although there were false negative results for LFA (Boulware et al., 2014). Latex 
agglutination has a sensitivity and specificity of >99% in serum and CSF (Jaye et 
al., 1998; Kambugu et al., 2008). However it is expensive, laborious and the work 
of (Boulware et al., 2014) demonstrated that LFA is more sensitive to lower 
antigen levels compared to the latex method. LFA seems a faster and easier 
technique as it is a dipstick. Anticryptococcal antibodies on the test strip bind 
CrAg present in the drop of serum/ plasma/CSF sample, which results in a visible 
line (Rajasingham et al., 2012). LFA shows the best performance (99.3% 
sensitivity and 99.1% specificity in CSF). LFA is recognised as “point-of-care” 
testing for cryptococcosis prior pre-emptive administration of antifungals in 
resource-limited settings with a high incidence of HIV and cryptococcal diseases 
(Perfect and Bicanic, 2015; Mamuye et al., 2016). 
Treatment 
The choice of treatment for cryptococcal disease depends on both the affected 
organs and the host's immune status. There are guidelines for cryptococcosis in 
patients: 1) without HIV infection (pulmonary and non-CNS disease; CNS 
disease), and 2) AIDS-related cryptococcosis (cryptococcal meningitis, 
cryptococcal pneumonia) (Saag et al., 2000). In HIV-negative, it is crucial to 
perform lumbar puncture (LP) to rule out the possibility of CNS infection. LP 
procedure is performed with a hollow needle inserted into the fluid around the 
lower part of the spinal cord to collect CSF (Saag et al., 2000). In the first case, 
the goal is prevention of dissemination into the CNS. This is achieved by 




In case of significant bone/skin infection, surgery is recommended. The 
immunocompromised with non-CNS pulmonary and extrapulmonary disease 
should be treated as patients with CNS disease (Dromer, Mathoulin, Dupont, 
Brugiere, et al., 1996).  
In case of CNS involvement in non-HIV patients, the ultimate objective is the CSF 
sterilisation and achieved by amphotericin B and flucytosine treatment in the 
immunocompetent for two weeks (Bennett et al., 1979; Dismukes et al., 1987; 
Yao et al., 2005). This is the induction phase aimed for the rapid sterilisation of 
CFS. The immunosuppressed should follow the induction, consolidation and 
maintenance described for treating cryptococcal meningitis in HIV disease. As for 
non-HIV patients the consolidation phase introduced designed to kill any 
remaining cryptococcal cells relies on fluconazole for eight-ten weeks (van der 
Horst et al., 1997; Beardsley et al., 2019). The maintenance therapy to minimise 
the risk of the relapse includes fluconazole for a year (Perfect et al., 2010).  
In AIDS-related cryptococcal pneumonia, the treatment commonly involves 
fluconazole (Saag et al., 2000; Krysan, 2015).  
In case of AIDS- associated meningeal cryptococcosis, the recommendations are 
amphotericin B combined with flucytosine (Larsen et al., 1990; van der Horst et 
al., 1997; Warkentien and Crum-Cianflone, 2010) or amphotericin B when 
flucytosine cannot be given (Saag et al., 1992, Tenforde et al., 2018). This is the 
induction phase. After the two week period of successful induction therapy, 
consolidation therapy. This is achieved with fluconazole administered for 8 weeks 
(van der Horst et al., 1997). If fluconazole cannot be given, itraconazole is 
acceptable (Denning et al., 1989). Next, the maintenance therapy is introduced. 
This is achieved with fluconazole for 6-12 months (Perfect et al., 2010). 
In HIV patients with cryptococcal meningitis and CD4-positive T cell counts below 
100 cells/µl, antiretroviral therapy (ART) is recommended following the 
completion of the antifungal induction treatment, preferably when CSF has been 
sterilised (Perfect and Bicanic, 2015). ART decreased the incidence of 
cryptococcosis among AIDS patients during the 1990s in the USA but the fact 
that these patients continue to develop cryptococcosis might result from limited 




most common HIV-associated disease in sub-Saharan Africa and this region 
continues to have the greatest burden of the disease globally (Rajasingham et 
al., 2017) it raises a concern whether those patients have access to ART. 
Complications of cryptococcosis 
Raised intracranial pressure is a common complication of cryptococcal 
meningitis. It is dangerous and linked to visual abnormalities and hearing loss 
(Graybill et al., 2000; Temfack et al., 2019). In both HIV-negative and HIV-positive 
patients with cryptococcal meningitis, elevated intracranial pressure is one of the 
cryptococcal indices. Elevated intracranial pressure is defined as opening 
pressure 200 mm H2O, measured as an opening pressure at lumbar puncture 
with the patient in a lateral decubitus position (Doherty and Forbes, 2014). The 
ultimate objective of the induction treatment is CSF drainage and a radiographic 
imaging of the brain (Denning et al., 1991). The next complication is cryptococcal 
immune reconstitution inflammatory syndrome (C-IRIS). The treatment of 
cryptococcal meningitis and ART commencement might trigger a paradoxical 
immune response, wherein deterioration of cryptococcal disease that is thought 
to be caused by recovery of Cryptococcus-specific immune responses (reviewed 
by (Haddow et al., 2011)). This was reported in 30% of HIV patients with  
C. neoformans (Shelburne et al., 2005). The problem is C-IRIS might be caused 
by too early or too late introduced ART (Perfect and Bicanic, 2015). The 
management of C-IRIS includes prednisone or dexamethasone tapered over a 
2-6 week period as well as LP (Abassi et al., 2015). 
1.2.3 Virulence of Cryptococcus 
A common term in the description of pathogens is a virulence factor. In its 
simplest definition, it describes the relative infectiousness or a microorganism’s 
ability to overcome the natural host defences. Nevertheless, virulence is an 
expression of the interaction of the pathogen with its host (reviewed by 
(Swearengen, 2018)). Thus, in studying fungal virulence, the use of experimental 
models, such as in vitro or in vivo systems, is amenable. A successful model of 




factors of the model. Such model aids understanding of how a disease develops 
and enables testing potential treatment approaches. The reported experimental 
models of cryptococcosis are described in section 1.2.4 Experimental models of 
cryptococcosis. The study of virulence traits among Cryptococcus represents a 
growing focus in the field with the aim of revealing new biological principles or to 
better understand and treat cryptococcosis. Apart from the use of in vitro or 
animal systems, several tools are available to study cryptococcal virulence. 
Whole genome sequencing of representatives of both sibling species resulted in 
hundreds of reference assemblies (reviewed by (Cuomo et al., 2018)), enabling 
comparative genome studies and microarray studies. This allows to explore 
virulence genes and understand the molecular basis of virulence mechanisms 
during cryptococcosis (Kraus et al., 2004; Fan et al., 2005). Fungal genomics 
opens up a range of experimental opportunities. For instance dynamic genome 
changes were revealed between C. gattii and C. neoformans with a hypothesis 
that those contributed to speciation and virulence (D’Souza et al., 2011).  
Serial analysis of gene expression (SAGE) to compare the C. neoformans 
transcriptomes at different time-points of mice lung infection with expression 
patterns from in vitro culture or from CSF in a rabbit model of experimental 
meningitis, revealed that pulmonary infections led to elevated expression of 
genes related the production and utilisation of acetyl-CoA (Hu et al., 2008). Gene 
expression microarray analysis comparing highly virulent C. gattii R265 and less 
virulent R272 strains from Vancouver Island revealed virulence candidate genes, 
e.g. capsule-associated gene, cas3 or linked to cell wall assembly: glucan 1,3 β-
glucosidase and chitin synthase 7 (chs7) (Ngamskulrungroj et al., 2011). Another 
way to investigate virulence is to study gene loss and characterisation of e.g. 
phenotypes related to virulence. This can be achieved in vitro or in vivo. Gene 
loss also enables virulence candidate genes discovery. A recent work from 
Nielsen lab found novel genes associated with virulence in mice, e.g. sugar 
transporter itr4, antiphagocytic app1, one hypothetical protein-encoding gene 
(CNAG_02176), as well as genes encoding two additional hypothetical proteins 
that have orthologues only in C. neoformans var. grubii (CNAG_04922 and 
CNAG_06332) and one hypothetical protein with broad taxonomic distribution 




Collectively, these studies outline a critical role for cryptococcal virulence. As part 
of their defence mechanism many pathogenic species express a wide array of 
virulence factors adding to their effectiveness, or pathogenesis, enabling them to 
replicate and disseminate within a host. This brings up an opportunity to discuss 
the origin of cryptococcal virulence as at first glance Cryptococcus seems to be 
an evolved human pathogen. The vast majority of publications completely ignore 
the origin of cryptococcal virulence. Moreover, most publications make an 
impression that Cryptococcus is an evolved human pathogen. This is not true. 
Cryptococcus is not a primary pathogen of humans. It is an environmentally 
occurring pathogen. It does not live with people, humans do not get infected with 
it unless they are immunocompromised or inhale it with contaminated air. 
Moreover, Cryptococcus is mainly found in soil and trees, so humans probably 
represent inadvertent hosts rather than a primary niche (Ma, 2009). 
Simultaneously, the literature demonstrates that Cryptococcus is more than just 
an opportunistic pathogen because it is equipped to evade, subvert and 
manipulate the host immunity system, while maintaining intracellular growth 
(Springer et al., 2012). However, from the point of view of virulence origin, it is 
thought that Cryptococcus virulence originated due to accidental pathogenesis 
(Casadevall and Pirofski, 2007). This concept posits that Cryptococcus virulence 
has arisen independently of a host, by chance alone, to generate microbes that 
possess attributes necessary for virulence in some hosts (Casadevall and 
Pirofski, 2007).  
Studies of the determinants for pathogenicity have implications for our 
understanding of host-pathogen interactions. Cryptococcus displays several 
virulence factors, equipping the pathogen for successful invasion of the host, 
causing fungal pneumonia and meningitis. The following subsections will expand 
on these virulence factors. 
Thermotolerance 
Fungi grow between 20°C and 40°C. C. neoformans grows at 37°C and its growth 
rate is highly suppressed between 39°C and 40°C. In contrast, C. gattii is not as 




24 hours ((Hagen et al., 2015), reviewed by (Mitchell and Perfect, 1995)).  
However, despite growing slowly or failing to grow at 37°C in vitro (Mitchell and 
Perfect, 1995; Bemis et al., 2000), cryptococci are thermotolerant and growing at 
mammalian temperature is essential for their virulence (Martinez et al., 2001; 
Perfect, 2006). The ability to survive at elevated temperature is therefore crucial 
and this is regulated by calcineurin (Odom et al., 1997; Chen et al., 2013), a 
Ca2+/calmodulin-activated serine/threonine-specific phosphatase (Liu et al., 
1991). A good indication of this is the fact, that C. neoformans can survive in the 
avian gastrointestinal tract (about 40°C) (Swinne-Desgain, 1976; Soltani et al., 
2013) and proficiently escape avian macrophages via vomocytosis or cell 
enlargement (Johnston et al., 2016).  
Virulence-associated enzymes 
It appears that although opportunistic, the fungus seems to be highly adapted to 
the host environment. Some of the earliest work looking at host-pathogen 
interactions employed macrophages cultures (Diamond and Bennett, 1973). 
Cryptococci do not necessarily leave the phagosome as they can survive acidic 
status of phagolysosome as well as alkaline induced phagocyte killing (Levitz et 
al., 1997, 1999; Ost et al., 2015)). Killing by reactive oxygen or nitrogen species 
production has yielded conflicting findings. For instance, hydrogen peroxide 
(Diamond et al., 1972; Chaturvedi et al., 1996, Upadhya et al., 2013), 
hypochlorous acid or hydroxide kill the fungus efficiently (Chaturvedi et al., 1996, 
Brown et al., 2009). Contrarily, resistance to reactive oxidative and nitrosative 
species is maintained through the production of a variety of enzymes that break 
down the oxygen and nitrogen compounds. Superoxide dismutase (SOD) (Figure 
1.3) converts superoxide radicals into hydrogen peroxide and molecular oxygen 
(Fridovich, 1995). C. neoformans sod1 mutant strains were more prone to be 
influenced by reactive oxygen species in vitro and less virulent in the mouse 
inhalational model (Cox et al., 2003). Flavohemoglobin denitrosylase (Figure 1.3) 
has been reported to detoxify nitric oxide and flavohemoglobin FHB1 gene knock-
out showed reduced virulence in murine macrophages (De Jesús-Berríos et al., 
2003). Another virulence enzyme is thiol peroxidase (Figure 1.3) encoded by 3 




sensitive to hydrogen peroxide and nitrogen oxide in inhalation and tail vein mice 
models, which resulted in attenuated virulence (Missall et al., 2004). Mice 
receiving urease restored strains were characterised by high cryptococcal loads 
in the brains (Olszewski et al., 2004) and alternative oxidase (Figure 1.3) aox1 
mutant strain was strikingly less virulent than both the wild-type and the 
reconstitute strain in the murine inhalational model and its growth was attenuated 
in alveolar macrophages (Akhter et al., 2003). 
There is some evidence Cryptococcus boosts essential nutrients via membrane 
disruption by phospholipase secretion (reviewed by (Djordjevic, 2010; DeLeon-
Rodriguez and Casadevall, 2016)) (Figure 1.3) and therefore hydrolyses 
phospholipids. Phospholipases contribute to encountering the host, injury and 
lysis (Ghannoum, 2000). Evans and colleagues (2015) showed PLB1 knock-out 
strain of C. neoformans had a thorough defect in intracellular growth within host 
macrophages ascribable to a 50% decrease in proliferation and a 2-fold 
escalation in cryptococcal killing within the phagosome (Evans et al., 2015). 
Interestingly, the Plb1 protein of C. gattii is larger in mass with a preference for 
saturated lipid substrates, e.g. dipalmitoyl phosphatidylcholine (Latouche et al., 
2002). Since C. gattii often causes large lung lesions and dipalmitoyl 
phosphatidylcholine is abundant in the surfactant lining with the small air spaces 
of the mammal lung (Gupta et al., 1994; Holm et al., 1996; Bernhard et al., 2001), 
this may explain why C. gattii usually targets the lungs. 
Although not previously concerned as proteolytic, Cryptococcus can hydrolyse 
peptide bonds via secretion of proteases (Figure 1.3). Proteolysis of human 
plasma proteins in vitro by C. neoformans (Muller and Sethi, 1972) and the 
synthesis of proteases in vitro by a clinical isolate of the C. neoformans have 
been reported (Brueske, 1986). 
Cryptococcus also synthesises trehalose (Ngamskulrungroj, Himmelreich, et al., 
2009; Botts et al., 2014) (Figure 1.3) that has been reported to protect proteins 
and stabilise a biological membrane under heat and cold, starvation, desiccation, 
osmotic or oxidative stress, exposure to toxicants, and hypoxia in yeasts 




genes mediating the trehalose pathways are required for growth in vitro at 37°C 
(Petzold et al., 2006), which might appear to be the reason for causing diseases 
in humans. The trehalose mutant is avirulent in rabbits and mice (Petzold et al., 
2006). The trehalose pathway is also evident in virulence of the highly virulent 
Vancouver Island C. gattii strain, R265 (Ngamskulrungroj, Himmelreich, et al., 
2009). The authors showed that deletion of three genes putatively involved in 
trehalose biosynthesis resulted in the yeast cell death in vitro.  
A harsh host environment is not only represented by low levels of CO2, but O2 is 
deprived, too. Cryptococcus grows very well under atmospheric oxygen 
conditions and has to overcome hypoxic conditions. Two independent studies 
conducted by Chang (Y. C. Chang et al., 2007) and Chun (Chun et al., 2007), 
revealed similar conclusions about the role of SRE1 (a homologue of the 
mammalian sterol regulatory element-binding protein (SREBP) and SCP1 (the 
SREBP cleavage-activating protein (SCAP)) in response to low levels of oxygen. 
Chang identified the homologs of Sre1 and Scp1, mutated the genes and 
analysed phenotypes whereas Chun screened a number of deletion mutants with 
disrupted growth under low oxygen revealing four genes involved: SCP1, SRE1, 
STP1 and TOC2. In both investigations, although using different serotypes of  
C. neoformans, deletions of either SRE1 or SCP1 resulted in impaired growth of  
C. neoformans under low oxygen conditions (<3%).  
Melanin 
One of the defining characteristics of C. neoformans is its ability to synthesise 
melanin (Figure 1.3), a brown to black, hydrophobic, high mass, cell wall 
associated pigment produced by laccase (Figure 1.3) (Wang et al., 1995, Lee et 
al., 2019) contributing to the virulence (reviewed by (Butler and Day, 1998; 
Jacobson, 2000; Zaragoza, 2019)). Rhodes and colleagues showed melanin 
mutants of C. neoformans were less virulent in mice (Rhodes et al., 1982). 
Amongst many mechanisms by which the pigment adds to pathogenesis, the 
most important one is scavenging activities against ROS and nitrogen-derived 
radicals (Jacobson and Tinnell, 1993; Wang and Casadevall, 1994). The fungus 




al., 1998), of which only the first enzyme, Lac1 primarily contributes to melanin 
synthesis. The corresponding gene however is disunited amongst C. neoformans 
and C. gattii (Sugita et al., 2001; Tanaka et al., 2005). Melanisation within C. gattii 
is promoted by SOD1 as shown in Narasipura’s work (Narasipura et al., 2003). It 
appears that some antibodies can access melanin during infection in a mouse 
model (Nosanchuk et al., 1998), which is encouraging from a medical point of 
view, given the pigment is hidden in the cell wall, not in the capsule constituting 
the first barrier marking off the host. Nevertheless, the first line of defence against 
ROS weapons provides the yeast capsule and its protective role corresponds to 
its size (Zaragoza et al., 2008).  
Mannitol 
C. neoformans synthesises D-mannitol in vitro (Onishi and Suzuki, 1968; Wong 
et al., 1990) and CSF D-mannitol concentrations correspond with severity of 
infection during experimental meningitis in vivo in rabbits (Wong et al., 1990). 
Under certain assumptions, this was construed as the reason for the raised 
intracranial pressure in cryptococcal meningitis seen in patients and it is thought 
to be responsible for the high mortality of this group (Loyse, Wainwright, et al., 
2013).  
Nevertheless, the best studied virulence factor is the yeast capsule, absent in 
other fungal pathogens (reviewed by (Zaragoza et al., 2008)). 
The polysaccharide capsule 
The unique morphological component of C. neoformans and C. gattii when 
stained with India ink is a polysaccharide capsule. This technique serves as the 
main approach to visualise the pathogen both clinically in patients’ samples in 
order to diagnose cryptococcosis, and in experimental settings to detect changes 
in the size of the capsule. The capsule has been studied for many decades 
highlighting its importance in driving virulence (Goren and Warren, 1968; Wang 
et al., 2018; Casadevall et al., 2019). The most studied work on the fungal 
capsule has been performed using C. neoformans as this is its main virulence 




significant variable in a regression analysis to estimate the relative contributions 
of virulence factors (McClelland, et al., 2006). Given its importance in promoting 
cryptococcal infection potentially leading to a fatal disease, a great effort has 
been put into capsule research to understand its impact on human health. 
The composition of the capsule started to be extensively researched in the 
eighties and is now well described. Classically the capsule is described as 
composed of two polysaccharides: glucuronoxylomannan (GXM) (Figure 1.3), 
comprising 90-95% of its mass and galactoxylomannan (GalXM) (Figure 1.3) 
accounting for 5-8%, together with mannoproteins (MPs) (Figure 1.3) contributing 
in less than 1%. The GXM is made of a chain of mannose residues with 
substitutions of glucuronic acid and xylose. The GalXM consists of a chain of 
galactose residues with substitutions of xylose and mannose (Frases et al., 2009; 
McFadden, et al., 2006; Bhattacharjee et al., 1979a; Bose et al., 2003; 
Walenkamp et al., 1999; Cherniak and Jones, 1988; Cherniak and Sundstrom, 
1994). The distinctive difference between C. neoformans and C. gattii are 
differences in the structure of GXMs (Cherniak et al., 1992; Young and Kozel, 
1993; Otteson et al., 1994). 
The capsule composition is worldwide accepted with MPs being a subject of 
conflict. MPs are considered as the minor components, however, their role in 
capsule architecture remains unknown (reviewed by (Zaragoza et al., 2009)). 
Nonetheless, the knowledge regarding MPs has to be improved. A recent 
publication has shown MPs are efficiently uptaken and presented by dendritic 
cells to T cells (Mansour et al., 2006). 
Some articles explored the localisation of MPs in the capsule and did not find they 
were integrated with GXM or GalXM, but rather constituted in the inner cell wall 
(Vartivarian et al., 1989). Reiss and colleagues (Reiss et al., 1984) found MPs 
and GalXM in sera of cryptococcosis patients. Walenkamp et al. investigated the 
role of whole cryptococci, GXM, GalXM, and MPs on leukocytes in vitro and found 
increased levels of tumour necrosis factor alpha (TNFα) after 3 hours incubation 
with all of the tested treatments on monocytes sourcing this protein of healthy 
patients (Walenkamp et al., 1999). The findings were also reproduced by Delfino 




Cryptococcus. Pitzzura and colleagues demonstrated MPs induced interleukin-
12 (IL-12), a cytokine that is involved in protective signalling against the pathogen 
(Pitzurra et al., 2000). The interaction of GalXM and MPs with polymorphonuclear 
leukocytes was also investigated by Dong and Murphy showing in vitro that  
C. neoformans GXM, but not GalXM or MPs appear in culture filtrates in 
significant quantities, induces leukocyte chemotaxis (Dong and Murphy, 1993). 
Leukocytes locomotion was also tested in a murine model using a cryptococcal 
antigen and sponge implantation where it was observed that culture filtrates 
antigens of C. neoformans var. gattii (serotype B and C) isolates inhibited 
chemotactic responses of polymorphonuclear leukocytes as compared to  
C. neoformans var. neoformans (Dong and Murphy, 1995). The finding could 
suggest C. gattii manipulates phagocytic cells to escape killing. 
Specht et al. suggested MPs were potent immunogenic compounds triggering 
mammalian T-cell responses. It is not clear though which of the Th lineages they 
evoke (Levitz and Specht, 2006). Despite MPs promoting protective responses 
(Vecchiarelli, 2000), research to develop a vaccine using a recombinant 
mannoprotein showed very little protection (Specht et al., 2017).  
GXM and MPs have contrasting roles in the regulation of the immune system. 
Not only GXM provides a negative signal for T cell proliferation, but it is proposed 
that actively shed GXM, having a large molecular mass and being viscous in a 
solution (McFadden et al. 2006), contributes to elevated intracranial pressure, a 
crucial contributor to patient morbidity, due to its weight (Bicanic et al., 2009). 
Raised pressure is established by mechanical obstruction of cerebrospinal fluid. 
Clinical studies have supported this hypothesis but there are currently no 
experimental models that allow the mechanistic study. The disruption of the blood 
brain barrier (BBB) and choroid plexus (CP) has been proposed as a mechanism 
for the raised intracranial pressure ((Loyse, Thangaraj, et al., 2013), reviewed by 
(Profaci et al., 2020)). The BBB and CP (where CSF is produced) are potential 
entry points of cryptococci into the CNS. 
The first study examining ex vivo capsular phenotype in cryptococcal meningitis 
and its correlation with host clinical and immune parameters revealed that strains 




measured by lumbar puncture to look for evidence of conditions affecting the 
brain (E. J. Robertson et al., 2014). When disseminated into the brain, the fungus 
can cause meningoencephalitis with symptoms that include headache, fever, 
vision issues and personality changes (reviewed by (Brizendine and Pappas, 
2010)).  
Elevated GXM concentrations can be found in serum and cerebrospinal fluid of 
patients with cryptococcal disease (McFadden et al., 2006) and GXM serves as 
a cryptococcal antigen in cryptococcosis detection (Monari et al., 2006). GXM 
inhibits T lymphocytes proliferation by reducing phagocytosis (Syme et al., 1999) 
and induces apoptosis of lymphocytes from rats in vitro (Chiapello et al., 2003). 
This phenomenon was further confirmed by the same authors in vivo (Chiapello 
et al., 2004). Lately, it was found that T cell apoptosis is induced in vitro by binding 
Fas ligand expressed by GXM loaded macrophages (Monari et al., 2005). GXM 
modulates inflammatory cytokine response, which varies among neutrophils and 
macrophages and the phagocytes responses will be discussed further in section 
1.5 The innate immune response to Cryptococcus. 
The capsule pertains in and of itself to a physical barrier between the fungal cell 
and the host immune system. McGaw and Kozel demonstrated that IgG binds 
encapsulated cryptococci but this is found on the surface of a cell wall thereby 
masking the IgG in a manner such that Fc-mediated phagocytosis is disrupted 
(McGaw and Kozel, 1979). Kozel and Pfrommer showed that encapsulated 
cryptoccocci activate complement through the alternative pathway, which results 
in deposition of iC3b on the capsular surface, implying this is the ligand that 
interacts with phagocytic cells C3 receptors during phagocytosis (Kozel and 
Pfrommer, 1986). Interestingly, the C. neoformans capsule is highly dynamic as 
it is able to change its structure and size in response to various stimuli. The 
composition varies tremendously in multiple biological contexts, even between 
strains. Cherniak and colleagues analysed 106 isolates, identifying 6 structure 
motifs in GXM and 8 chemotypes, suggesting each strain has a distinctive 
capsule (Cherniak, Valafar, et al., 1998). Capsule structures in both lab strains 
and clinical isolates of the same strain can change over time (Garcia-Hermoso 
and Janbon, 2004; Franzot et al., 1998). Capsules grown in vitro usually have an 




et al., 1998) and sizes vary between strains (Neilson et al., 1977, Fernandes et 
al., 2016). 
Cryptococcus utilises complex signalling networks systems to sense its 
environments and control development of virulence (reviewed by (Kozubowski et 
al., 2008)). In the case of the capsule, these involve, e.g. cAMP (Alspaugh et al., 
2002), cAMP-MAPK (Bahn et al., 2005), calcium–calmodulin–calcineurin 
pathway, cap60 expression (Lian et al., 2005) or Ras1 pathway (Zaragoza et al., 
2003). Therefore, modulation of capsule size is possible by testing a range of 
factors influencing these pathways, i.e. HCO3, iron or serum. As for HCO3, the 
biosynthesis of cryptococcal capsule is dependent on adenylyl cyclase activity 
(Alspaugh et al., 2002). The dissolved bicarbonate directly stimulates adenylyl 
cyclase to induce cAMP synthesis (Klengel et al., 2005). C. neoformans senses 
CO2, which diffuses across the plasma membrane and in the form of HCO3 
directly stimulates adenylyl cyclase encoded by CAC1 gene (Alspaugh et al., 
2002) to induce cAMP synthesis (Klengel et al., 2005). Next, iron distress results 
in an elevated transcript level for CAP60 gene that is required for capsule 
synthesis while iron-replete conditions elevate components of the calcium– 
calmodulin–calcineurin pathway (Lian et al., 2005). Then, cAMP and Ras1 
pathway are both necessary for serum-induced capsule enlargement pointing to 
the role of CAC1, PKA1 and RAS1 (Zaragoza et al., 2003). Most experiments in 
the field have been carried out with 10% heat-inactivated fetal calf serum as a 
potent inducing factor for capsule growth. This is the percentage and serum type 
that was used in the publication of (Zaragoza et al., 2003). Given early evidence 
for complement opsonisation of C. neoformans in phagocytosis assays with heat‐
inactivated serum (Diamond et al., 1972), the inactivation is to inactivate 
complement proteins and to avoid confounding effects, e.g. in immune response 
studies using immune cell cultures.  
Capsule size also changes in response to temperature. One major issue in earlier 
(Zaragoza et al., 2003) research concerned serum induced capsule growth at 24, 
30, and 37°C. Importantly, the volume of the capsule was significantly larger at 
37°C and showed a discrepancy between the absolute volumes and the relative 
amount of capsule compared to the cell size. This discrepancy attributed to the 




does not impact the proportion of capsule produced by the cell, but it affects the 
cell body size (Zaragoza et al., 2003). 
In contrast, addition of sodium chloride produces a reduction in capsule size 
(Dykstra et al., 1977). The salt induces physico‐chemical contraction of capsular 
gel (Jacobson et al., 1989). The signalling downstream of sodium for capsule 
restriction is not understood. However, the most likely, a high osmotic pressure 
causes a loss of a significant part of the water content of the capsule, which in 
turn, results in an increased packed cell volume and thereby a decreased capsule 
size (Zaragoza et al., 2009). Nonetheless, the high-osmolarity glycerol (HOG) 
pathway is also involved in the response to osmotic shock (reviewed by 
(Kozubowski et al., 2008)). 
In a laboratory set up, the size of the capsule appears to be rather small (Littman, 
1958). The author studied the effects of various nutrients on C. neoformans 
encapsulation and successfully demonstrated the dependence of the capsule 
size on constitutes such as amino acids, vitamins, and carbon sources. However, 
he was not able to verify which component of the capsule was responsible for this 
phenomenon. Granger et al. discovered that encapsulation highly increases in 
vitro within C. neoformans H99 strains isolated from cerebrospinal fluid when 
exposed to high concentration of CO2/HCO3 and became resistant to phagocytic 
engulfment after serum addition used as opsonin (Granger et al. , 1985). 
However, the study did not indicate the phenomenon was due to the serum only. 
In contrast, some studies showed inhibitory effects of serum on cryptococci 
growth (Reiss and Szilagyi, 1967). CO2 availability and its role in capsular 
enlargement was also tested by Vartivarian and colleagues, reflecting upon 
physiological conditions confronting the host environment (Vartivarian et al., 
1993). The study was linked to iron level where the group found in vitro iron 
deprivation increased the effect of CO2 on capsule thickness. Finally, Zaragoza 
and colleagues proved the capsule enlargement in physiological media was due 
to the presence of serum, however this was not due to the iron limitation 
(Zaragoza et al, 2003). This was the first study to indicate that the serum alone 
is a potent inducing factor, i.e. in the absence of CO2 and after incubation in 




of both serum and CO2. Capsule size was dependent on the type of a media used 
and the media determined whether the strain was efficiently responsive to serum 
or CO2. Sera from a number of animals showed the ability to promote capsule 
growth. The increase in capsule size observed in vitro suggests a mechanism for 
the capsular enlargement observed during animal infection (Zaragoza et al, 
2003).  
A number of authors have recognised that the capsule size increases dramatically 
during mammalian infection (Cruickshank et al., 1973; Love et al, 1985, 
Mukaremera et al., 2019). The increase in the capsule volume for C. neoformans 
has also been confirmed in vivo in the zebrafish embryo (Bojarczuk et al., 2016). 
Cruickshank et al. reported an unusual isolate reaching up to 40 µm in the lungs 
of an African patient, despite the same isolate having a normal appearance on 
Sabouraud dextrose agar plates (Cruickshank et al., 1973). Another 
compartment that stimulates capsule enlargement is the brain (Love et al. 1985). 
Conversely, a dramatic reduction in capsule size is increased by high osmotic 
pressure, high salt (NaCl) concentration or the binding of a large quantity of 
antibody to the capsule (Dykstra et al., 1977; Zaragoza and Casadevall, 2006). 
Modulation of the capsule in vitro with NaCl prior to infection of zebrafish was not 
sufficient to inflate macrophages uptake or survival of fish as compared to 
acapsular mutant cap59 (Bojarczuk et al., 2016). Interestingly, strains with 
severely compromised capsule formation are not virulent in murine models. 
Fromtling (1982) obtained acapsular strains by mutagen treatment of  
C. neoformans in order to construe the genes involved in capsule synthesis. Both 
antibody labelling and India ink stain along with immunochemical analysis 
showed the dearth of exterior negative charge in acapsular mutants, which is 
apparent in wild type strains. Genetic analysis revealed chromosomal genes 
important for capsule synthesis (Fromtling et al., 1982). The analysis was further 
explored by Chang and colleagues (Chang and Kwon-Chung, 1994, 1998, 1999; 
Chang et al., 1996). The first gene discovered to play a role in capsule production 
was CAP59, the removal of which resulted in the absence of the capsule. Their 
aim was to establish the function of the gene, using the deletion mutant and 




of GXM. Secretion of hydrolysing enzymes was normal in cap59 mutant leading 
to the hypothesis that the gene was involved in the export of GXM from the 
cytoplasm (García-Rivera et al., 2004). Moreover, virulence can be restored by 
complementation of the acapsular phenotype (Chang and Kwon-Chung, 1994). 
Authors also identified three other genes linked with the capsule synthesis: 
CAP64, CAP60 and CAP10 along with their locations in the genome (Chang et 
al., 1996; Chang and Kwon-Chung, 1998, 1999). Deletion of these genes 
confirmed the lack of virulence in a murine model (Chang and Kwon-Chung, 
1994, 1998, 1999; Chang et al., 1996).  
Acapsular strains cannot replicate in phagocytic cells in vitro (Feldmesser et al., 
2000), which is also conserved in the zebrafish model of cryptococcosis using 
cap59 mutant (Bojarczuk et al., 2016). Thus, the capsule and its components are 
recognised to be an important virulence factor. 
Glycosphingolipid glucosylceramide 
Glycosphingolipid glucosylceramide (GlcCer) is a wall component of  
C. neoformans (Rodrigues et al., 2000). GlcCer is another adaptation to the host 
environment, thus considered as a virulence regulator. Knock-out of the  
C. neoformans glucosylceramide synthase (Figure 1.3) in a immunocompetent 
mouse model delivered two phenotypes: a) avirulent in nasal infection, unable to 
disseminate into the brain and contained in the lungs and b) virulent resulting in 
a fatal infection, when mice were injected intravenously (Rittershaus et al., 2006). 
GlcCer was required for fungal growth in alveolar spaces and in the bloodstream 
(neutral/alkaline pH), but not in the host intracellular (acidic) environment, such 
as in the phagolysosome of lung macrophages. Indeed, a GlcCer mutant did not 
grow in vitro at a neutral/alkaline pH, yet it had no growth defect at an acidic pH 
(Rittershaus et al., 2006). Even if the mutant was introduced intranasally, 
cryptococcal growth in the alveoli was arrested. When the mutant grew 
intracellularly, mice produced a lung granuloma, which efficiently contained the 
mutant. This resulted in longer host survival as compared with mice challenged 
with the mutant intravenously. A possible explanation of this is behind the pH and 




approximately 5%. Therefore, the mutant growth in the blood was arrested until 
cryptococci were either internalised by phagocytic cells or left the bloodstream to 
infect the organs, in which they formed abscesses. In both the intracellular 
environment and in abscesses, the pH is acidic, and the mutant can grow. For 
instance, in the brain of mice challenged intravenously, the mutant was contained 
within abscesses. The author hypothesised that once the acidic abscess is 
formed, the mutant resumes its growth, and this will lead to meningoencephalitis 
(Rittershaus et al., 2006). 
Reflecting upon the study, other authors explored further and used T- and NK-
cell-immunodeficient mice that do not produce granulomas (Kechichian et al., 
2007). In those, the gcs1 (GlcCer synthase) mutant introduced intranasally 
efficiently proliferated in the acidic alveolar macrophages of the lungs and was 
able to disseminate into the brain (Kechichian et al., 2007). The possible 
explanation of the proliferation in the lungs is that the cryptococci 
glycosphingolipid might be adapted to CO2 concentrations in the host tissues. 
Usually it reaches 5%. Since GlcCer is required for experimental murine 
infections that are initiated by inhalation, but not by injection (Rittershaus et al., 
2006), it is speculated that gcs1 mutant prefers the acidic lysosome of alveolar 
macrophages over extracellular niche (Mitchell, 2006). This also highlights 
targeting GlcCer could be beneficial in the immunocompromised.  
Interestingly, glucosylceramide and sterols accumulate in extracellular vesicles 
produced by cryptococci. It has been shown in vitro in J774 cells and in vivo in 
mice that these vesicles are secreted across the cell wall. They also contain 
GXM. These findings provide a novel mechanism for the release of the major 
virulence factor of C. neoformans (Rodrigues et al., 2007). The research group 
also identified seventy-six protein components of C. neoformans extracellular 
vesicle, of which was oxidative stress related. Vesicles were also characterised 
by laccase and urease activity (Rodrigues, Nakayasu, et al., 2008). The vesicles 
are successfully established as “virulence bags” (Figure 1.3) (Rodrigues, 
Nakayasu, et al., 2008; Rodrigues, Nimrichter, et al., 2008) and transported 





Metal homeostasis  
Upon the host entrance, beside oxygen and nutrient paucity, cryptocci experience 
low metal ion concentrations that are required for virulence enzymes such as 
urease (Figure 1.3), laccase or superoxide dismutase. A question could be 
raised: do low metal ion levels influence Cryptococcus virulence? Results 
demonstrate that this is true and that again, Cryptococcus possesses its exit 
strategies, e.g. C. neoformans expresses ferroxidases, which enable the 
reductive iron uptake system to promote the utilisation of transferrin, an important 
iron source (Jung et al., 2009). 
Copper is involved in iron acquisition, oxygen transport, and cellular metabolism. 
It is also required in melanin synthesis through iron homeostasis or membrane 
trafficking likely to be leading to laccase loading in the cell wall (Silva et al., 2011). 
With limited copper, cryptococci activate the transcription of the copper transport 
genes. As for zinc, C. neoformans var. grubii and C. gattii express ZAP1 gene 
encoding the transcription factor Zap1p regulating Zrt1p and Zrt2p zinc 
transporters homologs (Silva et al., 2011). It has been demonstrated in C. gattii 
that disruption of the ZAP1 gene diminishes the virulence of the pathogen (de 
Oliveira Schneider et al., 2012).  
Mating types 
Clinical and environmental strains represent one of two mating type alleles: MATa 
or MATα (Kwon-Chung, 1976b). It has been put forward that a mating type plays 
a role in the pathogenesis. This is supported by the fact the vast majority of clinical 
cases are of MATα (Kwon-Chung and Bennett, 1978). MATα strains elicit more 
virulence than congenic MATa strains in mice infected with Cryptococcus 
neoformans var. neoformans (Kwon-Chung et al. , 1992), and isolates from the 
Vancouver Island cryptococcosis outbreak in 1999 also representing the MATα 
mating type (Fraser et al., 2005).  
C. neoformans has never been reported to undergo sexual reproduction in nature 
(reviewed by (Fu et al., 2015)). However, C. neoformans can readily mate 




guano (Nielsen et al., 2007) and live plants (Xue et al., 2007). Interestingly,  
C. gattii opposite mating does not occur on pigeon guano medium (Nielsen et al., 
2007) but it does on plant medium (Xue et al., 2007). This suggests that guano 
is not a realised ecological niche for C. gattii and might correlate with the fact that 
C. neoformans is often isolated from pigeon guano whereas C. gattii is not. 
Instead, C. gattii is readily isolated from plants (Nielsen et al., 2007). On the other 
hand, the fact that under laboratory conditions C. neoformans mates on plant 
medium, might suggest that this species can complete its sexual cycle in nature. 
It is suggested that plant derived materials can overcome the inhibition of mating 
by light (Xue et al., 2007), which was recognised as an inhibiting factor in mating 
(Idnurm and Heitman, 2005). 
However, most clinical and environmental isolates of C. neoformans and C. gattii 
are of the α mating type, which indicates uncommon opportunity for opposite-sex 
mating (reviewed by (Phadke et al., 2014)). It is not clear why the populations are 
largely unisexual if sexual reproduction is a significant component of species 
survival (Nielsen et al., 2007). On the other hand, it is likely that unisexual 
reproduction might happen on purpose. Most clinical cases are of A serotype 
having MATα mating-type allele (Litvintseva and Mitchell, 2009). Unisexual 
mating between two closely related α isolates of C. gattii is thought to give rise to 
a hipervirulent alpha type, the causative agent of an outbreak in the Pacific 
Northwest of the United States and Canada (Fraser et al., 2005; Byrnes, 2011). 
Within A serotype congenic a and α are comparable in terms of virulence in 
cryptococcal murine meningitis using a rabbit virulence model (Nielsen et al., 
2003). As for serotype D, in mice MATα is more virulent that MATa (Kwon-Chung 
et al., 1992; Chang et al., 2000). Within serotype B, C. gattii MATα strains are 
suggested to be more virulent than MATa strains based on the prevalence of 
MATα in human infection in a global collection of 163 C. gattii strains 
(Ngamskulrungroj et al., 2008). Within serotype C, it is hard to access which of 
the mating type is more virulent as the literature is not evident in such 
comparisons. However, the 176 strains of serotype C isolated from HIV patients 
in South Africa were MATα (Litvintseva et al., 2005). Indeed, serotype C seems 





One of the stress resistance mechanisms evolved by the fungus is biofilm 
formation. These are masses of microorganisms formed on surfaces and held 
together by an extracellular matrix (Blankenship and Mitchell, 2006). 
Cryptococcus forms biofilms by the release of capsular polysaccharide to the 
solid surface to create an exopolysaccharide matrix. It has been demonstrated in 
vitro some antibodies can inhibit production of biofilms by encapsulated 
cryptococci (Martinez and Casadevall, 2005). 
Titan and microcells 
C. neoformans can greatly modulate its own cell size during infection by forming 
titan cells that can be up to 100 microns in diameter, in contrast to typical size 
cells of 5-7 microns (Zaragoza and Nielsen, 2013). The earlier study of (Zaragoza 
et al., 2010) indicated the capsule was tough, highly cross-linked and resilient to 
the cryptococcal cell in a murine model of cryptococcosis. Giant cells are defiant 
to oxidative and nitrosative stress (Okagaki et al., 2011), still too big to be 
phagocytosed and killed in the lungs (Okagaki and Nielsen, 2012). This 
emphasises gigantism becoming a new facet in cryptococcal pathogenesis. 
 In addition to the large cells, Cryptococcus can also produce very small cells, 
called microcells. Alanio and colleagues identified a subpopulation both in vitro in 
J774 macrophage and in vivo in OF1 or BALB/c mice, less prone to grow under 
standard conditions. Perhaps this reflects upon dormancy (Alanio, et al., 2015). 
Phenotypic switching  
Another attribute of the fungus that has been extensively explored is phenotype 
switching (Jain and Fries, 2008; Guerrero, et al. Fries, 2006). Phenotypic 
switching occurs in both C. neformans and C. gattii. C. neoformans var. gattii 
undergoes reversible phenotype switching during murine infections, whereas this 
process is irreversible in C. neoformans var. neoformans and C. neoformans var. 
grubii (Jain et al., 2006). With C. neoformans, the switching occurs in vivo 




calling changes to the capsule and/or the cell wall (Fries, et al., 2001). Colonies 
might appear as smooth, mucoid, wrinkled, serrated or as pseudohyphal 
(reviewed by (Gupta and Fries, 2010)). 
Vomocytosis 
Vomocytosis was first reported in 2006 by two independent groups showing the 
ability of C. neoformans to exit phagocytes non-lytically, with the survival of both 
cells (Alvarez and Casadevall, 2006; Ma et al., 2006). It occurs through fusion of 
the phagosome and plasma membrane, which could possibly be due to the 
pathogen modulating the intracellular signals (Johnston and May, 2010), with the 
plasma membrane, releasing the cryptococcal cell (Ma et al., 2006). The process 
of C. neoformans and C. gattii expulsion has been seen in macrophages cell lines 
(Alvarez and Casadevall, 2006; Ma et al., 2006; Alvarez et al., 2008), primary 
murine macrophages (Alvarez and Casadevall, 2006), primary birds 
macrophages (Johnston et al., 2016) and primary human macrophages (Alvarez 
and Casadevall, 2006; Alvarez, et al., 2009). It is also conserved in zebrafish 
(Bojarczuk et al., 2016; Gilbert et al., 2017). The non-lytic escape of the pathogen 
from immune cells is thought to aid in the dissemination and therefore to have a 
great impact on the progression of disease. However, this implication does not 
apply to birds that despite being vectors of the disease, do not succumb to 
cryptococcosis (Littman and Borok, 1968; Johnston et al., 2016). The questions 
that then naturally arise are: does vomocytosis protect host macrophages from 
parasitism or is it fundamental to the dissemination of C. neoformans in 
cryptococcal meningitis (Bojarczuk et al., 2016) or C. gattii infections? 
It is evident now cryptococci are adept intracellular pathogens, with complex 
pathways, that enable them to proliferate within and eventually exit from host 
phagocytes. However, while virulence of C. neoformans has been discussed by 
a great number of authors in literature, additional studies to understand more 
completely the key tenets of C. gattii are required. Why C. gattii, which is found 
mostly in association with trees and how it causes diseases in healthy humans- 
are still unsolved questions. Could more have been known about C. neoformans 




was developed, that would allow for detailed cellular analysis and concentrate on 
the innate immunity, which is the first line of defence against any invasion of the 
human body? Having the animal model, research on cryptococcosis can 
massively expand and my work can definitively add novel data that represents an 













Figure 1.3 Principle virulence factors of Cryptococcus species. Dashed dotted line represents enlarged area of the cell membrane (CM), 
the cell wall (CW) and the capsule (CAP). CM area in beige, CW area in light green, CAP in blue-grey. Dashed arrow represents the content 
of a virulence bag. Solid arrow represents soluble excreted enzymes. Adapted from (Gilbert et al., 2011; Almeida and Wolf, 2015). Figure 





Table 1.2 Legend to figure 1.3 
      symbol description 
 nucleus 
 endoplasmic reticulum 
 mitochondrion 
 Golgi apparatus 
 vacuole 
 phospholipase B1 
 virulence bag 
 chitin deacetylase 2 (Cda2); mannoprotein type 














 flavinhemoglobin denitrosylase (FHB1) 
 alternative oxidase (Aox1)  










 glutathione peroxidase (Glr1) 
 protease 





1.2.4 Experimental models of cryptococcosis 
 
There have been many different experimental models of cryptococcosis. In case 
of Cryptococcus, primary cells such as macrophages (Bolaños and Mitchell, 
1989; Levitz and DiBenedetto, 1989), neutrophils (Kozel et al., 1984; Dong and 
Murphy, 1997), endothelial (Ibrahim et al., 1995; Coenjaerts et al., 2006), 
epithelial (Guillot, Carroll, Badawy, et al., 2008), dendritic (Bauman et al., 2000; 
Vecchiarelli et al., 2003), NK cells (Ma et al., 2004) or lymphocytes (Zheng et al., 
2007; Cheng et al., 2009) have been widely studied. So have been their lines, e. 
g. macrophages (Ma et al., 2006; Qin et al., 2011), neutrophils (Qureshi et al., 
2011), endothelial (Chang et al., 2004; Vu et al., 2009), epithelial (Merkel and 
Cunningham, 1992), dendritic (Lupo et al., 2008), NK cells (Ma et al., 2004) or 
lymphocytes (Pericolini et al., 2009). However, in vivo models seem more 
convincing than in vitro because they are a complex living system, encompassing 
the process, pathway, or function under study while being part of a larger “living 
test tube.” The complexity of the host-pathogen interaction cannot be mimicked 
by in vitro studies. Data obtained from an animal aid us in demonstrating events 
or interactions that are not possible to collect by other reliable alternative way 
(reviewed by (Capilla et al., 2007)). In vivo models complement in vitro studies 
and can stand alone. Moreover, laboratory animal research models may be 
modified using genetic technologies that enable testing of specific pathways. 
There is a significant number of in vivo experimental models of cryptococcosis, 
which can be grouped into invertebrate and vertebrate. Advantages of 
invertebrates are fewer ethical restrictions, low costs, a well-developed innate 
immunity, widely available molecular tools and the possibility of enabling high-
throughput infection and drug screening assays (Mylonakis et al., 2007). 
However, no single model can answer all questions and in this aspect it should 
be noted that invertebrates do not possess the adaptive immune system. The 
basic underlying mechanisms of immune response can therefore be studied 
relying on the innate system, which is the most ancient form of pathogen 
(reviewed by (Sabiiti et al., 2012)). Many invertebrates have been studied in the 
cryptococcal field, e.g. Galleria mellonella (a larvae of the greater wax moth) 




nematode) (Mylonakis et al., 2002), Dictyostelium discoideum (a soil-living social 
amoeba) (Steenbergen et al., 2001), Acantamoeba castellanii (Fuchs and 
Mylonakis, 2006) and Drosophila melanogaster (a fruit fly) (Thompson et al., 
2014). However, these models suffer some disadvantages. For instance, some 
invertebrates are less susceptible to infection as compared to mice (G. mellonella 
(Bouklas et al., 2015), represent restriction to a specific organ (infection in C. 
elegans restricted to intestine; reviewed by (Sabiiti et al., 2012)), there is no 
consistency with a natural route of infection (neither the fruit fly nor the moth do 
not do not represent the natural route of infection unless an opening in cuticle is 
made) or inability to study phagocytosis (C. elegans lack professional 
phagocytes). 
For this reason, any, including cryptococcal research very often uses vertebrates, 
namely mammals that are biologically very similar to humans in evolutionary 
terms. These include mice (Wozniak et al., 2011; Ngamskulrungroj, Chang, 
Sionov, et al., 2012), rats (Goldman et al., 2000; Wright et al., 2002) and rabbits 
(Steen et al., 2003; Lee et al., 2010). Rats are used as a model of latency and 
rabbits of meningitis (reviewed by (Gerstein and Nielsen, 2017)). However, mice 
are most commonly used. They are a popular choice because they are well 
established and characterised. The mouse and human genome share 
approximately 30,000 homologous genes and the proportion of genes without 
homology between them is less than 1% (reviewed by (Capilla et al., 2007)). This 
means that parallels and gaps can be identified readily, allowing for the design of 
robust experimental approaches. However, a controversial publication on the 
recapitulation of human conditions also exists. A recent study that compared 
human and mouse immune responses, reported poor correlation between the two 
organisms (Seok et al., 2013). Yet, whether mice accurately recapitulate the 
differences in human disease and whether the mouse model identifies subtle 
variations in virulence factors that impact the outcome of human disease remains 
unexplored (Mukaremera et al., 2019). 
Mice are sensitive to minor changes in food, bedding and light exposure. This 
might impact experimental results (Reardon, 2016). However, a few mice 




intraperitoneal (Lim et al., 1980), intravenous (Ngamskulrungroj, Chang, Sionov, 
et al., 2012; Neal et al., 2017) or intracranial (Thompson et al., 2012), which 
opens up a range of experimental opportunities. The downside of the mouse 
model is that pulmonary infection will disseminate to the CNS and yet human 
infection is rarely synchronous. There are also differences in cryptococcal 
disease presentations. For instance, R265, VGIIa type strain of C. gattii from the 
Vancouver Island outbreak typically presents with pulmonary disease in humans 
(Galanis et al., 2009; Harris et al., 2011) whereas C. neoformans manifests in 
meningitis in both compromised (Luma et al., 2013) and competent individuals 
(Malhotra et al., 2017). Currently, it is difficult to establish an organ specific 
infection model. Most recently this shortfall has been partly addressed by (Neal 
et al., 2017) that established a model of meningoencephalitis. Another limitation 
is susceptibility. For instance, CBA/J mice are more susceptible to intratracheal 
C. neoformans infection than BALB/c mice (Zaragoza et al., 2007). The next issue 
is reduced imaging potential. Mice do not allow real-time visualisation of the 
dynamic interaction between innate immune cells and the pathogen. Therefore, 
they are used for specific experimental time-points. In addition, similarly to rats 
and rabbits, a variety of genetic backgrounds and genetic tools are available. Of 
note, a guinea pig model also exists (Kirkpatrick et al., 2007), where oral doses 
of antifungals sufficient to control fungal infections are similar to the doses in 
humans (Odds et al., 2000). However, the zebrafish emerges as an attractive 
model system for a number of human diseases. Zebrafish are ideally suited to be 
a model for infection and immunity to Cryptococcus due to embryos being 
transparent and hence the potential for in vivo subcellular resolution imaging in 
the entire body of a living vertebrate, which allows interpretation of the whole 
organismal immune response. In addition, zebrafish are easily bred and when 
infected-make large-scale studies possible. They give power to complex 
correlations between host and pathogen at a scale that is not possible in other 
vertebrates. Zebrafish are proven models of human disease (Lieschke and 
Currie, 2007), infection biology (Tobin et al., 2010; Volkman et al., 2010; Adams 
et al., 2011) and of immune cell (Renshaw et al., 2006). They are also proven in 
high throughput drug discovery (Bowman and Zon, 2010; MacRae and Peterson, 




G. mellonella), the zebrafish immune system is highly similar to humans 
(Lieschke and Trede, 2009) and more than 80% of human genes related to 
diseases are present in zebrafish (Howe et al., 2013). The study of the innate 
immune response to C. neoformans is not confounded by adaptive immunity 
because innate and adaptive immune systems develop at different rates. Thus, 
few ethical restraints apply to zebrafish research at the stage <5.2 days post 
fertilisation, after which they become protected animals. Zebrafish are also 
genetically tractable (Lieschke and Currie, 2007). Genome analysis shows that 
zebrafish share many orthologous genes, and even conserved synteny, with 
mammals. Zebrafish are vertebrates and thus evolutionarily closer to humans 
than are, e.g. the fruit fly and the nematode, and they are easier to work with and 
to study than mice (Van Der Sar et al., 2004). Paralogues divergence is mostly 
limited to differences in the timing and tissue specificity of expression. This 
highlights that extra care should be taken in constructing knockout mutations and 
designing antisense oligonucleotides (Van Der Sar et al., 2004). Another 
drawback is that although pathogen sensing occurs through PRRs as in 
vertebrates and zebrafish have a set of 20 putative orthologs of mammalian 
TLRs, only half of these are orthologs of human TLR family members (Jault et 
al., 2004). This means the immune response might be slightly different than in 
humans. In addition, zebrafish lack lungs, which means that this infection route 
cannot be achieved. The next pitfall applies to inbreeding. Zebrafish do not 
tolerate it well and rapidly lose fertility (Monson and Sadler, 2010). Nevertheless, 
zebrafish have become an important animal model to study host-pathogen 
interactions in vivo. Mammalian models do not allow real-time visualisation of the 
dynamic interaction between innate immune cells and yeasts at distinct sites 
within the host. They do not permit good visual access to events of pathogenesis 
at the cellular lever, either (Feldmesser et al., 2000; Tenor et al., 2015; Rosowski 
et al., 2018). This is important when the aim is to investigate early events 
following dissemination of Cryptococcus in a transparent host (Bojarczuk et al., 
2016). Therefore, the zebrafish model is ideal. Of note, it is not intentional to 
replace other vertebrate models such as mice with zebrafish. Instead, zebrafish 




and therefore can help to develop innovative therapies to combat human infection 
(reviewed by (Gomes and Mostowy, 2020)). 
1.3 The innate immunity 
The innate immune system constitutes the first line of defence against invading 
microbial pathogens and is a key for the resolution of inflammation. The innate 
immune response is non-specific as anything identified as non-self becomes a 
target. The system comprises: 1) a physical barrier to infection, e.g. epithelial 
surfaces and tight-junctions between them (reviewed by (Guttman and Finlay, 
2009)), mucus and cilia in the lung (reviewed by (Bustamante-Marin and 
Ostrowski, 2018)) 2) anti-microbial molecules, such as lysozyme (reviewed by 
(Callewaert and Michiels, 2010)) or defensins (reviewed by (Lisowski et al., 
2013)) and 3) innate immune cells.  
The innate immunity can be recognised as two branches, the afferent arm for 
sensing, and the efferent side for combating, with each having cellular and 
humoral components. The afferent humoral elements include, e.g. 
lipopolysaccharide binding protein (LBP), that binds to bacterial 
lipopolysaccharide (LPS), collectins, soluble pattern‐recognition molecules, 
whereas efferent humoral involve, e.g. cytokines, small secreted proteins 
released by various cells, acting in an autocrine, paracrine or endocrine manner, 
modulating immune cell behaviour. Other examples of the humoral effector arm 
include antimicrobial lysozyme, lactoferrin and the complement system. The 
complement is a series of serum proteins critical for defence from microbial 
invasion and clearance of immune complexes and injured cells, activated by 3 
pathways: classical (antigen/antibody-mediated), lectin or alternative (microbial 
surface-mediated) (reviewed by (Noris and Remuzzi, 2013)). The afferent cellular 
can be represented by pattern recognition receptors (PRRs) and the efferent 
cellular by cell adhesion proteins expressed on the cell surface involved in binding 
with other cells or with the extracellular matrix (ECM) in the process of cell 
migration. Other examples of the effector cellular arm include reactive oxygen 




neutrophils, such as hydrogen peroxide or nitric oxide ((Garaude et al., 2016) and 
(reviewed by (Beutler, 2004; Nguyen et al., 2017)).  
The cellular innate system in vertebrates largely relies on cells of myeloid origins, 
including polymorphonuclear phagocytes (basophils, eosinophils and 
neutrophils), and mononuclear (macrophages and dendritic cells (DCs) (reviewed 
by (Romo et al., 2016)). The reliance on those cells is important in cases where 
physical barriers are crossed and pathogens gain entry into the host tissues. The 
innate immune cells recognise the presence of foreign pathogens via pattern 
recognition. PPRs expressed on the plasma membrane of these cells detect 
conserved microbial components known as pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular patterns (DAMPs). The 
PRRs family includes Toll-like receptors (TLRs), nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs), RIG-I-like receptors 
(RLRs), C-type lectin receptors (CLRs) and AIM2 (absent in melanoma 2)-like 
receptors ((reviewed by (Chen and Nuñez, 2010; Takeuchi and Akira, 2010)). 
DAMPs are endogenous (intracellular and extracellular) molecules released 
following tissue injury, stress or cell death. The PRRs, PAMPs and DAMPs are 
reviewed in Recognition of infection. DAMPS are described in more detail in 
section 1.6.1.2 Sterile inflammation. 
Activated innate immune cells at the site of infection or injury initiate immune 
pathways that degrade pathogens via signalling cascades, which results in 
cytokine release, immune cell chemotaxis, inflammation and phagocytosis 
(reviewed by (Newton and Dixit, 2012)). Phagocytosis can be initiated via two 
routes: via contact with particles that have been decorated (opsonised) with 
complement/antibody allowing the phagocyte to recognise the particle indirectly 
via Fc receptors (FcRs) and complement receptors (CRs) (reviewed by 
((Henneke and Golenbock, 2004)) or direct binding via pattern recognition 
receptors (reviewed by (Ofek et al., 1995)). 
Innate immune system links to the adaptive immune system, which is the targeted 
response and refers to the long lasting antigen-specific immunity against 
previously encountered non-self particles. There is a cross talk between the 




antigen/antibody complexes initiate the classical pathway of complement 
activation. DCs of the innate system present an antigen to T and B cells of the 
adaptive and T cells can also regulate DCs (Ruedl et al., 1999; Manickasingham 
and e Sousa, 2000; Mailliard et al., 2002; Muraille et al., 2002). Epithelium, initially 
considered as a physical barrier acting as the first line of defence against invading 
organisms, also express PRRs (Kauffman, 2006; Kato et al., 2007), chemokines 
(Manzer et al., 2006), cytokines (Jung et al., 1995) and defensins (McCray and 
Bentley, 1977). Moreover, epithelial cells can trigger and modify the activation 
and differentiation of DCs, B cells, and T cells (reviewed by (Schleimer et al., 
2007)). However, e.g. DCs secrete pro-inflammatory cytokines, which upregulate 
the expression of class I major histocompatibility complex (MHC-I) on airway 
epithelial cells to enhance the antiviral responses (Ank and Paludan, 2009). In 
regards to B cells, it is recognised, they produce cytokines (pro- and anti-
inflammatory). The production of pro-inflammatory cytokines by B lymphocytes 
(Harris et al., 2000), specifically interferon gamma (IFNγ) and TNFα have direct 
injurious effects on both endothelial and epithelial cells, thereby contributing to 
both allograft rejection and inflammatory renal disease (Haas et al., 1997; Ishii et 
al., 2011). 
The adaptive immune system requires professional antigen presenting cells 
(APCs). They phagocytose and degrade pathogens, and present pathogen 
antigens on MHC-II molecules for recognition by CD4+ T cells. This promotes a 
further immune response, including the further release of cytokines resulting in 
recruitment of more immune cells (reviewed by (Iwasaki and Medzhitov, 2010)). 
Non-professional APCs, such as eosinophils, basophils, neutrophils and mast 
cells, express MHC class I molecules. Only in certain settings they can upregulate 
MHC class II molecules (reviewed by (Kambayashi and Laufer, 2014)). Antigens 
displayed by MHC I are recognised by cytotoxic CD8+ T cells that kill cells that 
contain pathogens (reviewed by (Chaplin, 2010)). What links the two systems are 
also natural killer cells (NK cells). They are cytotoxic lymphocytes of T and B 
lymphoid progenitor, important in cytokine production (reviewed by (Geiger and 
Sun, 2016)). NK cells respond rapidly against pathogens and do not possess 
antigen-specific receptors (only T and B cells do), which classifies them to be the 




effector and memory CD8+ T by mediating cytotoxicity upon encounter of its 
cognate ligand on a target cell. Moreover, NK cells possess a specific receptor 
for the murine cytomegalovirus (MCMV). Those characteristics categorise NK 
cells also to the adaptive immune cells (reviewed (Sun and Lanier, 2010)). 
1.3.1 Neutrophils 
 
1.3.1.1 Neutrophils in infection and inflammation  
 
Neutrophils are the most abundant (40% to 70%) granulocytes in most mammals. 
They are of myeloid origin and possess one nucleus typically divided into 2–5 
lobes.  
Neutrophils provide a first line of defence against numerous infectious pathogens, 
such as bacteria, fungi, and protozoa. Neutrophils are involved in infection and 
inflammation. Infection means the invasion of an organism by disease-causing 
agents, e.g. pathogens. Inflammation is a general term for the local accumulation 
of fluid, plasma proteins and white blood cells that is initiated by physical injury, 
local immune response or infection. Neutrophils are the first cells that come out 
of the blood to deal with infection, i.e. they migrate to infected or injured sites to 
kill pathogens and remove cellular debris. At the site of infection or inflammation, 
they will recognise and phagocytose pathogens with the goal of killing microbes 
via different cytotoxic mechanisms (reviewed (Rosales et al., 2016)). From this 
point of view, neutrophils are beneficial during infection as neutropenic patients 
are susceptible to infections (reviewed by (Wang, 2018)). The vast majority of the 
literature describes neutrophils as being involved mostly in inflammation. 
However, this results from the fact that researchers interested in inflammation 
very often concentrate on neutrophils. What cannot go unnoticed is that 
neutrophils evolved to leave the blood to prevent infection. Thus, their primordial 
role is to prevent infection. Their role in inflammation evolved from the role of 
infection because every infection is associated with inflammation and the fact that 
neutrophils have to be controlled. Otherwise, neutrophils can be damaging and 
implicated in tissue damage, e.g. upon the spillage of their cytotoxic content when 




caused by neutrophils is seen in chronic inflammation (reviewed by (Medzhitov, 
2010). Other example represents a situation, when neutrophils detect TNFα but 
do not encounter a microorganism after migrating to tissues, they release their 
granules into the extracellular space to create a harsh environment for nearby 
pathogens (Nathan, 2006). In this sense, the tissue damage aids microbes 
containment but is also harmful to the host.  
1.3.1.2 Neutrophil recruitment 
 
Neutrophils are produced in the bone marrow from haematopoietic stem cells. 
This process is regulated by the cytokine granulocyte-colony stimulating factor 
(G-CSF) driving the maturation and functional activation of neutrophils (reviewed 
by (Berliner, 2008)). The bone marrow pool serves as a reserve, available for 
release. In addition, intravascular (marginated) neutrophil pools within the 
capillary beds of the spleen, liver and lung exist (reviewed by (Summers et al., 
2010)). Mature neutrophils are continually released into the circulation. The 
neutrophils exit the bone marrow at a rate of 1011 cells per day (reviewed by 
(Furze and Rankin, 2008). In response to inflammation or infection, neutrophils 
are mobilised to exit the bone marrow. The stimuli to leave the bone marrow are 
pro-inflammatory chemoattractant factors such as leukotriene B4 (LTB4), 
complement factor C5a, IL-8 (reviewed by (Furze and Rankin, 2008). Resting 
neutrophils from the circulation can be primed by bacterial products and cytokines 
or chemokines, e.g. TNFα, GM-CSF, IL-8 and IFNγ (reviewed by (Hallett and 
Lloyds, 1995)). Thus, the neutrophils become primed to be recruited to the sites 
of injury, inflammation or infection. The priming is a two-step process. In the first 
one, the key players are TNFα, IL-1β, and pathogen associated molecular 
patterns (PAMPs) such as endotoxins. In the second, IL-8, LTB4 and GM-CSF, 
are important (reviewed by (Summers et al., 2010)). A proper priming ensures 
augmented respiratory burst activity, degranulation and longevity (reviewed by 
(Vogt et al., 2018)). Activated and primed neutrophils will roll, adhere and 
transmigrate to the site of inflammation/infection (reviewed by (Muller, 2013; Liew 
and Kubes, 2019)). The pathways involved in neutrophils recruitment are well 




Activated Protein Kinase (MAPK) signalling (Curnock et al., 2002; Heit et al., 
2002).  
1.3.1.3 Neutrophil diapedesis and chemotaxis 
 
TNFα, IL-1β, and IL-17 that are produced during inflammation/infection, initiate 
the process of neutrophil recruitment to the site of infection/inflammation. These 
cytokines generate expression of P-selectin, E-selectin and members of the 
integrin superfamily on the luminal surface (reviewed by (Borregaard, 2010)). E- 
and P-selectins are expressed by inflamed endothelial cells whereas L-selectin 
is expressed by most leukocytes. P-selectin is also expressed by activated 
platelets (reviewed by (Ley et al., 2007; Filippi, 2016)). E- and P-selectins bind P-
selectin ligand 1 (PSGL-1) and L-selectin, which are expressed constitutively on 
neutrophil microvilli (reviewed by (Borregaard, 2010)). E-selectin also binds to 
glycosylated CD44 and E-selectin ligand 1 (reviewed by (Ley et al., 2007)). 
Selectins bind ligands on the surface of neutrophils to facilitate the rolling 
process. After rolling, firm adhesion occurs. This is via integrins. Neutrophils 
express high levels of the lymphocyte function-associated antigen (LFA-1) or 
macrophage antigen‐1 (Mac‐1) (reviewed by (Ley et al., 2007)). Chemokines and 
cytokines activate leukocyte integrins binding to immunoglobulin superfamily 
members, such as ICAM-1 (Campbell et al., 1996; Wooten et al., 2008). This is 
termed ‘inside‐out’ signalling (anchoring leukocytes to the extracellular matrix 
(ECM)), which alters the conformation of β2 integrins such as LFA-1 or Mac-1. 
The next step is ‘outside-in’ signalling. This is described as extracellular stimuli 
induce intracellular changes, i.e. ligation of a cell-surface receptor activates 
signalling pathways inside the cell. The signalling initiates transmigration 
(reviewed by (Zarbock and Ley, 2008)). Inside-out and outside-in signalling can 
occur concurrently (reviewed by (Legate et al., 2009)) or a switch from a 
paracellular to a transcellular route can take place (reviewed by (Petri et al., 
2008)). 
Once firm adhesion is established, neutrophils will travel transcellularly, across 
one epithelial cell, at non-junctional locations, through the endothelial cell, or 




et al., 2008)). The main players in either type of migration are LFA-1 and Mac-1 
adhesion molecules on neutrophils and their ligands ICAM-1 and ICAM-2 
(reviewed by (Borregaard, 2010)). Mac-1 points to paracellular migration 
(Phillipson et al., 2009; Woodfin et al., 2009) whereas ICAM-1 to transcellular 
migration (Yang et al., 2005), although other signalling molecules are also 
acknowledged. For example, in paracellular migration, endothelial cell-selective 
adhesion molecule (ESAM), ICAM-2 and CD99, platelet/endothelial-cell adhesion 
molecule 1 (PECAM1) and possibly endothelial-cell junctional molecules, such 
as junctional adhesion molecule A (JAM-A), are involved. In transcellular, ICAM-
1 ligation translocates ICAM-1 to actin- and caveolae-rich regions. ICAM-1 
containing caveolae link together forming vesiculo-vacuolar organelles (VVOs) 
that form an intracellular channel through which a leukocyte can migrate 
(reviewed by (Ley et al., 2007)). 
Next, in response to chemical signals, such as C5a, LTB4, IL-8 and chemokines 
(e.g. CXCL4) neutrophils perform a directional migration along a chemical 
gradient (chemotaxis) (reviewed by (Cichetti et al., 2002; Petri and Sanz, 2018)). 
The chemoattractant hierarchy is as follows: lipid mediators, such as LTB4 
appear to initiate neutrophil recruitment cascades. Then, the attracted leukocytes 
produce cytokines, which in turn, induce the local release of chemokines, thus 
amplifying neutrophil recruitment. This is termed lipid–cytokine–chemokine 
cascade (Sadik and Luster, 2012). 
1.3.1.4 Neutrophils phagocytosis, degranulation, respiratory burst, swarms 
and extracellular traps 
Neutrophils internalise both opsonised and non-opsonised particles. The 
principal opsonic receptors of neutrophils are Fc receptors and a sub- group of 
β2 integrins, bind to immunoglobulin or complement-coated particles, 
respectively. The main Fc receptors of human resting neutrophils are FcγRIIA 
(CD32) and FcγRIIIb (CD16) (reviewed by (Lee et al., 2003; Rosales, 2017; Wang 
and Jönsson, 2019)) (Table 1.5 in section 1.6.1.1.3 Control of infection and 
elimination of pathogens). Non-opsonic receptors include pattern recognition 




phagocytic target is crucial to the initiation of phagocytosis (Herant et al., 2006). 
During phagocytosis an increase of intracellular free calcium is detected 
immediately after initiation of phagocytosis in neutrophils (Sawyer et al., 1985). 
More specifically, in Fcγ-receptor (FcγR) induced phagocytosis an increase of 
intracellular calcium occurs (Young et al., 1984). The role of calcium in FcγR-
mediated phagocytosis remains controversial. FcγR mediated phagocytosis in 
neutrophils was reported calcium dependent (Kobayashi et al., 1995) or 
independent (Della et al., 1990). However, for complement CR3-mediated 
phagocytosis in neutrophils, calcium plays no role (Lew et al., 1985; Della et al., 
1990). Internalisation of a pathogen requires actin polymerisation (Aderem and 
Underhill, 1999; Engqvist-Goldstein and Drubin, 2003) and later on actin 
depolarisation to complete phagosome closure. This is regulated by calcium, 
which also is required for fusion of antimicrobial neutrophilic granules with 
phagosomes (Bengtsson et al., 1991) and at least in part, for respiratory burst 
(Kim-Park et al., 1997). A few types of cytotoxic granules exist: primary 
(azurophilic), secondary (specific) and tertiary (gelatinase). Azurophils are 
secreted first in myelopoiesis at the promyelocyte stage and are myeloperoxidase 
(MPO) positive. They also contain various proteolytic enzymes, such as 
defensins, lysosomal hydrolases, and neutral serine proteinases, such as 
elastase, proteinase 3 (Pr3), and cathepsin G, which are antimicrobial (reviewed 
by (Falloon and Gallin, 1986; Van Der Veen et al., 2009; Yin and Heit, 2018)). 
The secondary and tertiary granules formed later during neutrophil maturation, 
contain overlapping sets of proteins, but are peroxidase negative (Faurschou and 
Borregaard, 2003; Van Der Veen et al., 2009). Neutrophils release granules 
content by degranulation, or exocytosis, of membrane-bound secretory granules 
(reviewed by (Lacy, 2006)). The primed granules exocytosis is hierarchical. First 
secondary and tertiary granules are discharged and then primary (Van Der Veen 
et al., 2009; Vogt et al., 2018). This is because of the order of the synthesis, 
wherein the secondary and tertiary are produced last. It is critical that neutrophil 
granules do not spill their cytotoxic content into surrounding tissue. Therefore a 
control mechanism exists, wherein the granules do not spill out until receptors in 
the plasma membrane or phagosome membrane signal to the cytoplasm to 




degranulation (reviewed by (Lacy, 2006; Mollinedo, 2019; Lodge et al., 2020)). 
Particular importance attaches to the azurophils’ myeloperoxidase. This enzyme 
reacts with hydrogen peroxide (H2O2), formed by the NADPH oxidase and with 
chloride anion to produce hypochlorous acid (Harrison and Schultz, 1976). This 
forms a strong antimicrobial system (reviewed by (Klebanoff, 2005; Lazarevic-
Pasti et al., 2015; Ndrepepa, 2019)). This is linked to a respiratory burst, which is 
the rapid release of reactive oxygen species (ROS). During phagocytosis, the 
oxygen species are of paramount importance because they contribute to the 
destruction and killing of engulfed pathogens. Not only is hypochlorous acid 
produced. For instance, the superoxide anion O2- and H2O2, the products of 
NADPH oxidase (reviewed by (Roos et al., 1988; Babior, 2004)) give rise to 
several additional ROS. Both H2O2 and O2- are potent oxidising and antimicrobial 
agents. The cytotoxic effects of O2- and H2O2 are achieved due to reactions with 
other antimicrobial systems to generate more ROS, e.g. hydroxyl radical (OH·), 
singlet oxygen (1O2). For instance, superoxide reacts with either hypochlorous 
acid (HOCl) or nitric oxide (NO·) to form the hydroxyl radical (OH·). As mentioned, 
hypochlorous acid (HOCl) is formed by the action of myeloperoxidase (MPO). 
The nitric oxide (NO·) is produced by the action of nitric oxide synthase (NOS). 
Singlet oxygen can be formed by the non-enzymatic dismutation of O2− and in a 
reaction between hydrogen peroxide and hypochlorite (OCl−). Singlet oxygen has 
recently been shown to react with H2O in an antibody-catalysed reaction to form 
hydrogen peroxide and ozone (O3) (reviewed by (Robinson et al., 2004; 
Onyango, 2016)). Apart from oxygen species, the process of phagocytosis is 
facilitated by reactive nitrogen species (RNS). The above-mentioned nitric oxide 
(NO·) is in fact considered as RNS by means of nitric oxide synthase (NOS). 
Apart from the reaction with superoxide (O2−) to form hydroxyl radical (OH·) 
(Ramos et al., 1992), it can also produce peroxynitrite (ONOO−) from superoxide 
(O2−) (Carreras et al., 1994). Peroxynitrite is another type of RNS that oxidises 
tissue non-protein and protein sulfhydryl groups making it a cytotoxic agent (Radil 
et al., 1991). Recently, it has been shown that peroxynitrite mediates the failure 
of neutrophil migration (Torres-Duẽas et al., 2007). This means that the 
respiratory burst and RNS products are not only able to destroy pathogens but 




generated as by-products of cellular metabolism. Fortunately, the housekeeping 
production of reactive species is generally neutralised by constitutive antioxidant 
defences (reviewed by (Paiva and Bozza, 2014)) e.g. superoxide dismutase 
(SOD) converts O2− to H2O2.  
Neutrophils can also produce swarms in response to an inflammatory stimulus or 
infection. This has recently been explored in vivo in the zebrafish embryo by 
inducing sterile inflammation via tail injury or infecting the zebrafish with S. aureus 
by otic vesicle injection (Isles et al., 2019). The ‘pioneer neutrophil’ is thought to 
release additional chemoattractants to recruit more neutrophils (Ng et al., 2011; 
Lämmermann et al., 2013). The swarming has also been observed in vitro in 
response to C. neoformans (Sun and Shi, 2016).  
Neutrophils perform also another distinct antimicrobial activity termed neutrophil 
extracellular traps (NETs). This is described as extruding a meshwork of 
chromatin fibres furnished with granule-derived antimicrobial peptides and 
enzymes such as neutrophil elastase, cathepsin G, and MPO. The stimuli for 
NETs production are IL-8 and lipopolysaccharides (LPS) (Brinkmann et al., 
2004). At the same time, defects in the signalling cascades that cause NET 
formation (such as deficiencies in generating ROS in chronic granulomatous 
disease or neutrophil serine proteases in Papillon–Lefèvre syndrome) are linked 
to pathologies characterised by chronic autoimmunity and inflammation, both of 
sterile and infectious origin (reviewed by (Boeltz et al., 2019)).  
1.3.1.5 Neutrophil response to infection/inflammation 
Various pathogenic factors, such as infection or tissue injury, can induce 
inflammation by causing tissue damage. A response to inflammation in the 
absence of microbial organisms is termed the sterile inflammatory response. It is 
well known that the immune system recognises foreign particles via pattern 
recognition. In case of microbial infection, Toll-like receptors (TLRs) expressed 
on the plasma membrane of phagocytic cells such as neutrophils, detect 
conserved microbial components known as pathogen-associated molecular 




damage-associated molecular patterns (DAMPs) are detected by TLRs 
(reviewed by (Chen and Nuñez, 2010)). Pathways that have evolved to respond 
to infection are also used to respond to non-microbial triggers (sterile 
inflammation), although some distinct pathways exist, e.g. receptor for advanced 
glycation end products (RAGE) is distinct to the sterile inflammation (reviewed by 
(Shen et al., 2013)). Generally, both infectious and non-infectious stimuli and cell 
damage activate inflammatory signalling pathways, most commonly the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), mitogen-activated 
protein kinase (MAPK) and Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathways (reviewed by (Chen et al., 2018)). 
1.3.1.6 Neutrophil longevity and death 
Circulating neutrophils have a short half-life of approximately 8 hours (Dancey et 
al., 1976) while activated neutrophils that have migrated into tissue have a half-
life of up to four days (Edwards et al., 2004). That means that under inflammatory 
conditions, their longevity significantly increases, which ensures the presence of 
primed neutrophils at the site of inflammation (reviewed by (Summers et al., 
2010)). The longevity results from exposure to pro‐inflammatory mediators such 
as GM-CSF, IL-1β, TNFα and IFNγ, which interfere with apoptotic pathways 
(Colotta et al., 1992). The extended lifespan of inflammatory neutrophils at the 
site of inflammation is also supported by their continuous recruitment and 
inhibition of the normal spontaneous neutrophil apoptosis. This is to allow 
neutrophils to perform their function effectively. 
Of note, more recently, literature has emerged that offers a contradictory finding 
about circulating life span. In vivo 2H2O labelling of human neutrophils suggested 
a mean lifespan of 5.4 days (Pillay et al., 2010). 
However, it should be emphasised there is a reason why neutrophils are 
considered as suicidal killers and concomitantly key effectors of immunity 
(Selders et al., 2017). The half-life in the circulation is short because they 
constitutively undergo apoptosis. As mentioned, under steady-state conditions 
about 1011 neutrophils turn over per day in a healthy human adult (reviewed by 




(constitutive) neutrophil apoptosis is crucial for the maintenance of immune 
system homeostasis. This occurs in the absence of cytokines or other pro-
inflammatory mediators prior to their removal by macrophages through the 
process of efferocytosis (Savill et al., 1989). If neutrophils are not removed, they 
accumulate. This disadvantage would be further exacerbated by neutrophilia. 
The accumulation of neutrophils and their toxic cargo in the tissues is linked to 
e.g. shortness of breath and hypoxia as well as neurologic deficits. This might be 
due to increased blood viscosity and obstructed blood flow (reviewed by 
(Summers et al., 2010)).  
Activated neutrophils do not undergo apoptosis. This means they do not undergo 
apoptosis just yet because if they are activated they are performing their function 
e.g. at a site of injury or infection. 
Once that is done, inflammation is resolved. Inflammatory neutrophils undergo 
apoptosis and then are cleared by tissue macrophages (Savill and Haslett, 1995).  
This is how affected or damaged cells during disease conditions are eliminated 
and promotion of the resolution of inflammatory responses occurs (Bratton and 
Henson, 2011). If neutrophils are not removed, i.e. the inflammatory response 
fails to resolve, host tissue injury occurs resulting in chronic inflammatory 
diseases. 
Apoptosis (type 1-programmed cell death) is the most common type of death. 
However, others exist: necrosis or suicidal NETosis (reviewed by (Iba et al., 
2013)). All of these death types have a significant implication in health and 
disease. For instance, necrosis is disadvantageous because it is crucial to keep 
the neutrophil cell membrane integrity, which is assured by apoptosis (Savill and 
Haslett, 1995). If apoptotic neutrophils are not effectively removed from inflamed 
sites, they may undergo secondary necrosis, losing their membrane integrity and 
spilling out their destructive contents (Majno and Joris, 1995) again initiating 
inflammatory signalling (Ward et al., 1999). If apoptosis is delayed, neutrophils 
persist and this may cause host tissue injury. Uncontrolled degranulation and 
release of ROS into the ECM medium contribute to tissue damage. Normally the 
uncontrolled activity of elastase, Pr3, and cathepsin G is counterbalanced by 
endogenous serine protease inhibitors (reviewed by (Korkaz et al., 2010)). The 




damage the ECM (reviewed by (Weiss, 1989)). Thus, it is understandable that 
delayed apoptosis delays the resolution of inflammation (Loynes et al., 2010). 
Apoptosis includes DNA fragmentation (Matute-Bello et al., 1997). Apoptotic 
neutrophils expose phosphatidylserine (PS) (Frasch et al., 2004), which functions 
as an eat-me signal to macrophages (Fadok, De Cathelineau, et al., 2001). In 
NETosis, PS is not exposed (Fuchs et al., 2007). The exposure of PS in necrotic 
cells is debatable (see section 1.6.1.1.4 Termination of inflammation). In contrast 
to apoptosis and necrosis, the cell membrane breaks (Fuchs et al., 2007). 
Apoptotic and necrotic cells are removed by macrophages. However, necrotic to 
a lesser extent (Brouckaert et al., 2004). NETosis suicidal neutrophils are also 
removed by macrophages, representing an anti-inflammatory mechanism 
(Farrera and Fadeel, 2013). 
Of note, accelerated neutrophil death leads to neutropenia and delayed 
neutrophil death results in neutrophilia. The balance between neutrophil life-and-
death is an important determinant of the degree of tissue injury, infection and 
inflammation. 
An intriguing phenomenon of resolving the inflammatory response is represented 
by reverse migration. This is described as a migration phenotype away from 
inflamed sites back to the circulation, promoting neutrophils clearance at the 
wound (Tharp, 2005; Buckley et al., 2006; Mathias et al., 2006). Perhaps in this 
manner neutrophils are preserved when they are no longer needed to fight 
infection. However, a question might be raised whether re-entering circulation 
could disseminate inflammation into other organs, eventually leading to damage 
(reviewed by (Kolaczkowska and Kubes, 2013)). The contribution of reverse 
migration to resolution of inflammation remains to be elucidated (reviewed by (De 
Oliveira et al., 2016)). 
Inflammation (including the sterile one) and infection encompassing the time-
course, control and termination of these processes are described in section 1.6 




1.3.1.7 Inflammatory disease 
As described above neutrophils are a major cause of inflammation driving a 
number of significant diseases. The diseases result from a failed inflammatory 
response and persistent neutrophilic inflammation. Associated risks are a 
significant host tissue damage and chronic inflammation. The latter is usually 
accompanied by tissue destruction. In this aspect, neutrophils contribute to the 
pathogenesis of many inflammatory diseases. The examples of pathological and 
chronic diseases are: asthma, chronic obstructive pulmonary disease (COPD), 
cystic fibrosis (CF), bronchiectasis (reviewed by (Gernez et al., 2010)) or 
idiopathic pulmonary fibrosis (IPF) (Kinder et al., 2008).  
1.3.2 Macrophages  
 
Macrophages functions are phagocytosis, antigen presentation and 
immunomodulation through cytokine production (reviewed by (Dale et al., 2008)).  
1.2.2.1 Origin of macrophages 
In the past few years, the understanding of macrophage origin has been 
drastically changed.  
Macrophages, similar to neutrophils, are myeloid immune cells. This means that 
they also originate in the bone marrow. The common myeloid progenitor is the 
precursor of macrophages and neutrophils. However, in the blood the 
haematopoietic stem cells give rise to e.g. neutrophils and monocytes. Only when 
there is tissue damage or infection, the monocytes will leave the circulation and 
differentiate into macrophages (J. Yang et al., 2014). Blood monocytes can also 
give rise to monocyte-derived dendritic cells under inflammatory conditions 
(reviewed by (Ginhoux and Jung, 2014; Qu et al., 2014)). It was long thought all 
macrophages originated from a continuum of monocytic differentiation. However, 
tissue-resident macrophage populations exist within specific organs/tissue. Adult 
tissue resident macrophages derive from embryonic progenitors that seed 
developing tissues before birth (reviewed by (Ginhoux and Jung, 2014)). This 




tissues and persist into adulthood independently of blood monocyte input in the 
steady state (Ginhoux et al., 2010; Jakubzick et al., 2013). Tissue macrophages 
can undergo self-renewal, e.g. arterial ones (Ensan et al., 2016) from embryonic 
precursors seeded at birth rather than constant recruitment from blood (reviewed 
by (Ginhoux and Jung, 2014)). Tissue macrophages are derived from three 
different developmental programs in humans. The first wave (primitive) begins in 
the yolk sac. Here, amongst others, macrophage progenitors arise and 
afterwards give rise to pre-macrophages and then yolk sac or primitive 
macrophages at the origin of microglia. Primitive macrophages infiltrate all tissues 
and generate microglia in the brain. The primitive wave is without monocytic 
intermediates. The second wave (transient) also occurs in the yolk sac and gives 
rise to erythro-myeloid progenitors. These give rise to the first fetal monocytes. 
Erythro-myeloid progenitors derived fetal monocytes seed most embryonic 
tissues apart from the brain. These fetal monocytes differentiate into most adult 
resident macrophage populations. The last wave (definitive) starts in the aorta-
gonads-mesonephros in the yolk sac and generates first haematopoietic stem 
cells. During this wave, haematopoietic stem cells-derived monocytes also 
emerge from the fetal liver. These monocytes contribute to the long-lived 
macrophage pool established at birth whereas the adult haematopoiesis starts in 
the bone marrow. To summarise, most tissue-resident macrophages are long- 
lived cells derived from a transient haematopoietic wave of erythromyeloid 
progenitors emerging in the yolk sac (reviewed by (Yoder, 2014; Hoeffel and 
Ginhoux, 2018)). This means that a definition of macrophages should reflect on 
two types: 1) resident macrophages- fetally derived resident white blood cells that 
live and proliferate within tissues and 2) monocyte derived macrophage- definitive 
derived monocyte that differentiates into a macrophage following extravasation.  
1.2.2.2 Macrophage recruitment in infection/inflammation 
After maturation monocytes are discharged by the bone marrow into the 
bloodstream (reviewed by (Teh et al., 2019)). The recent mice data suggest that 
chemokines, namely MCP-3 and MCP-1 activate C-C chemokine receptor type 2 
(CCR2) and this mobilises monocytes to exit the bone marrow (Tsou et al., 2007). 




tissue. Thus, they egress the circulation and in tissues, depending on the received 
signal from the environment, differentiate into either tissue macrophages or 
dendritic cells. Granulocyte-macrophage colony stimulating factor (GM-CSF) 
together with IL-4 differentiates monocytes into dendritic cells. Macrophage 
colony-stimulating factor (M-CSF) induces them to become a macrophage 
(Chapuis et al., 1997). Interestingly, GM-CSF results in M1-like inflammatory 
phenotype of macrophages whereas M-CSF (also known as CSF-1) stimulation 
results in a homeostatic or anti-inflammatory M2-like macrophage phenotype 
(Verreck et al., 2004). 
The literature classifies blood monocytes as: classical, intermediate and non-
classical. Human and mice monocytes types are listed in Table 1.3. The literature 
is not consistent in terms of nomenclature and classification of human and mice 
monocytes. Some publications describe three subsets (classical, intermediate 
and non-classical) in both species (Ziegler-Heitbrock et al., 2010) and some three 
in humans but two in mice (classical and non-classical) (Shi and Pamer, 2011). 
Some classify mice monocytes upon the level of expression of an inflammatory 
monocyte marker Ly6C rising three subsets with high, middle and low 
(Sunderkötter et al., 2004; J. Yang et al., 2014) and others differentiate between 
high and low (Serbina et al., 2008; Ziegler-Heitbrock et al., 2010; Shi and Pamer, 
2011). The exit from the bone marrow requires expression of the chemokine 
receptor CCR2 (Shi and Pamer, 2011). Classical monocytes are Ly6C++ in mice, 
which correspond to CD14+CD16− monocytes in humans. Non-classical are 
Ly6C+ monocytes in mice, which correspond to CD14l-CD16+ in humans. 
Intermediate are represented by CD14++CD16 in humans (Wolf et al., 2019). 
Human classical monocytes constitute about 80–95% of circulating monocytes, 
intermediate about 2–8% and non-classical about 2–11% (reviewed by (Sampath 
et al., 2018)). The classical Ly6C++ in mice are described as pro-inflammatory 
(Geissmann et al., 2003). However, recently a subset of mice monocytes lacking 
expression of Ly6C was found to patrol blood vessels as these monocytes 
crawled on the luminal side of the endothelium, in steady-state condition, within 
most blood vessels in the dermis and within branches of the mesenteric vein and 




There is some discrepancy between human non-classical and intermediate 
monocytes characteristics. A publication of (Cros et al., 2010) described the 
intermediate as primarily responsible for pro-inflammatory cytokine production 
and non-classical as patrolling. In the work of (Mukherjee et al., 2015) the non-
classical were the dominant producers of pro-inflammatory cytokines. Moreover, 
the intermediate were also phagocytic and inflammatory.  
Human in vivo deuterium labelling depicted that classical monocytes circulate in 
the blood for a day, intermediate for 4 days and non-classical for 7 days (Patel et 
al., 2017). Most classical monocytes leave the circulation or die, whereas the 
remaining cells transition into intermediate monocytes. Intermediate monocytes 
all transition to non-classical monocytes. Non-classical monocytes either leave 
the circulation or die. The half-lives possibly correlate to functional attributes of 
the monocytes subgroups (Patel et al., 2017).  
Classical murine monocytes exit the bone marrow and extravasate into peripheral 
inflamed tissues, in response to Listeria monocytogenes infection, thus are 
described as antimicrobial (Serbina and Pamer, 2006). The extravasation for 
non-classical is rare in the absence of an inflammatory stimulus. However, they 
show extravasation upon Listeria infection and thus they could be described as 

















Table 1.3 Mouse and human blood monocyte subsets  
 
Human monocytes divided into three subsets based on the cell surface expression of 
the cell surface expression of CD14 and CD16. Mice monocytes divided into two subsets 
based on the cell surface expression of Ly6C.The + denotes an expression level that is 
low, whereas ++ denotes high, - is undetectable. CCR2, CC-chemokine receptor 2; 
CX3CR1, CX3C-chemokine receptor 1. Adapted from (Shi and Pamer, 2011; J. Yang et 














classical CD14++CD16- CCR2++CX3CR1+ phagocytosis 
(Mukherjee et al., 
2015) 
intermediate CD14++CD16+ CX3CR1++CCR2+ phagocytosis an 
and pro-
inflammatory 
(Mukherjee et al., 
2015) 
non-classical CD14+CD16++ CX3CR1++CCR2+ 
 
pro-inflammatory 
(Wong et al., 
2011; Mukherjee 
et al., 2015) 
patrolling (Cros et 
al., 2010) 






non-classical Ly6C-/Ly6C+ CX3CR1++CCR2+ patrolling (Auffray 




1.2.2.3 Macrophage activation and polarisation 
Macrophages can undergo polarisation, which results in a specific macrophage 
phenotype. Polarisation enables macrophages to gain specific functional 
programs in response to the signals from their environment. This is linked to the 
roles they play in immunity (reviewed by (Wynn et al., 2013)). The stimuli for 
polarisation can be cytokines, microbial ligands or cell damage ligands. 
Depending on the type of the stimulus that macrophages are exposed to, they 
can be subjected to classical (Th1) or alternative (Th2) activation. For instance 
Th1 cytokine IFNγ (Nathan et al., 1983) or LPS (Pabst and Johnston, 1980) 
polarise macrophages to M1 phenotype. LPS can also lead to the switch from M2 
to M1 cell phenotype (Zheng et al., 2013). M1 phenotype displays pro-
inflammatory and antimicrobial properties whereas M2 promotes tissue repair 
and healing (reviewed by (Italiani and Boraschi, 2014; Ley, 2017)). Biomarkers 
to identify M1 macrophages include IL-12, nitric oxide synthase (iNOS), 
chemokine (C-X-C motif) ligand CXCL9, CXCL10. As for M2 there will be, e.g. IL-
27Rα, CCL17, Insulin-like growth factor (IGF-1) or CXCL11 (reviewed by (Mosser 
and Edwards, 2008)). 
As mentioned, polarisation enables the performance of different programs. For 
example, activation of murine macrophages with IFNγ in vitro and in vivo 
enhances hydrogen peroxide release (Murray et al., 1985), which is a known 
agent used for pathogen degradation. The treatment of zebrafish embryos that 
lack the adaptive system with IFNγ results in C. neoformans improved clearance 
explained by enhanced macrophage infiltration to the site of infection and linked 
to pro-inflammatory IL-1β expression (Kamuyango, 2017). LPS treated 
macrophage THP-1 cells produce cytokines such IL-6, IL-8 and TNFα (Liu et al., 
2018). Pro-inflammatory cytokine production is a hallmark of acute inflammation. 
However, macrophages stimulated by Th2 cytokines adopt an alternative 
phenotype characterised by a high capacity for endocytic clearance. For 
example, IL-4 reduces pro-inflammatory TNFα production and enhances 
mannosylated ligands clearance (Stein et al., 1992). IL-4 also enhances the 
turnover of anti-inflammatory IL-6 mRNA in LPS-stimulated monocytes (Fenton 




of inflammation. Thus, macrophage activation and polarisation is important in 
tissue homeostasis, disease pathogenesis, resolved and unresolved 
inflammation (Murray et al., 2014). There has to be a balance between M1 and 
M2 polarisation to ensure homeostasis. In terms of disease, M1 macrophages 
can be implicated in sustaining inflammation, thus to be detrimental to health. 
LPS activated macrophages release nitric oxide (Hibbs et al., 1988) and this 
molecule is highly antimicrobial but its overproduction, by the logic, can lead to 
tissue damage. This complicates inflammation resolution (Pfeilschifter et al., 
1996). This means that when the M1/M2 balance is not assured, chronic 
inflammation and diseases might ensue. For instance a disequilibrium is linked 
to correlates with development of inflammatory bowel disease (Lissner et al., 
2015). 
1.2.2.4 Macrophages diapedesis and chemotaxis 
The migration is dictated by the inflammatory environment (Serbina et al., 2011). 
The important question is how macrophages arrive at the site of 
infection/inflammation. Considering that macrophages are derived from 
monocytes and monocytes in the blood do the same as neutrophils, the monocyte 
migration will apply (see section 1.3.1.3 Neutrophil diapedesis and chemotaxis). 
Simultaneously, a population of resident macrophages might already be at the 
site of infection/infection. 
1.2.2.5 Macrophages phagocytosis and phagosome maturation 
Macrophages internalise both opsonised and non-opsonised particles. The 
opsonic receptors of macrophages are Fc receptor family, which bind antibodies 
(on macrophages IgG, IgM or IgA), or the complement family. Non-opsonic 
phagocytic receptors are pattern recognition receptors (PRRs), e.g. Dectin-1 or 
mannose receptor. The examples of these receptors are displayed in Table 1.4. 
Fc receptor- induced phagocytosis results in the production of pro-inflammatory 
molecules such as reactive oxygen intermediates and arachidonic acid 




secretion of either of these molecules (Wright and Silverstein, 1983; Aderem et 
al., 1985).  
Macrophage phagosomes follow the endocytic pathway, with processes 
transforming it into a phagolysosome (Vieira et al., 2002). As mentioned, 
neutrophils phagocytosis represents an event of the phagosome integrating with 
neutrophil granules. As described, in neutrophils, during phagocytosis, increases 
of intracellular ionised calcium are observed and these are essential for 
phagosome-granule (lysosome) fusion. In contrast, for macrophages, the 
literature suggests the calcium dependence phagosomal maturation might be 
less rigorous than in neutrophils (reviewed by (Nunes and Demaurex, 2010)).  
While in macrophages ROS are produced only during FcγR mediated 
phagocytosis (Wright and Silverstein, 1983; Aderem et al., 1985), in neutrophils, 
ROS are produced in both FcγR and CR3-mediated phagocytosis (Follin and 
Dahlgren, 1992). During phagocytosis by macrophages, calcium was not 
required for the oxidative burst, and although macrophages did require a basal 
amount of calcium to generate RNS, rises in calcium were not necessary for 
generation of nitric oxide (NO) (Myers and Swanson, 2002). Perhaps 
macrophages are successful killers because nitric oxide synthase (iNOS) does 
not require calcium rises (reviewed by (Mitchell and Feron, 1997)).  
The respiratory burst is performed, as in the case of neutrophils, the main 
products of NADPH oxidase are the superoxide anion O2- and H2O2 (reviewed by 
(Roos et al., 1988)). Therefore, the ROS formed will be the same as for 
neutrophils. The exception will pertain to MPO-deficient macrophages. 
Recognised sources for MPO are primarily neutrophils and monocytes. 
Monocytes contain about one third of MPO found in neutrophils (Bos et al., 1978). 
During monocyte differentiation to tissue macrophages, MPO expression is 
generally lost (reviewed by (Klebanoff, 2005)). However, some macrophages 
contain MPO, e.g. Kupffer cells (Brown et al., 2001), which are specialised 
resident macrophages. Therefore, for these cells the production of hypochlorous 
acid will be anticipated. As mentioned, hydrogen peroxide reacts with a 
combination of chloride and MPO from azurophils, to form hypochlorous acid 




The killing of macrophages is also facilitated by reactive nitrogen species (RNS). 
These are derived from nitric oxide produced via the enzymatic activity of 
inducible nitric oxide synthase (iNOS) (reviewed by (Fang, 2004)). iNOS 
expression is related to classically activated macrophages, i.e. after induction by 
IFNγ or LPS (Ding et al., 1988). Elevated iNOS expression is observed in 
inflamed human tissue macrophages (Moilanen et al., 1997) and infiltrating 
monocyte-derived macrophages (Kashem et al., 1996). The product of iNOS, 
nitric oxide (NO·), as reviewed is cytotoxic (Hibbs et al., 1988). It also gives rise 
to many downstream toxic metabolites that together constitute the M1 killing 
machinery (reviewed by (Ley, 2017)). For instance NO· reacts with superoxide to 
form peroxynitrite. At acidic pH, peroxynitrite is protonated and forms 
peroxynitrous acid, which decomposes to form a strong oxidant with the 
properties of hydroxyl radical (OH·) (Beckman et al., 1990). Macrophages also 
synthesise nitrite and nitrate (Iyengar et al., 1987). Nitrate is relatively harmless 
unless reduced to nitrite (reviewed by (Drew and Leewenburgh, 2002)). Nitrite is 
bactericidal in combination with MPO and hydrogen peroxide (Klebanoff, 1993).  
Of note, reactive oxygen intermediates seem to be important in some signalling 
pathways, e.g. NF-κB (reviewed by (Iles and Forman, 2002)). 
1.2.2.6 Macrophage longevity and death 
Pioneer work from van Furth demonstrated, using radiolabelled cells in vivo, that 
57% of the monocytes in the peripheral blood circulated for 48 hours and only a 
small fraction (14%) were found at 7 days (van Furth and Cohn, 1968).  
The lifespan of macrophages is not clearly defined. Some tissue macrophages 
can survive by self-renewal (Ensan et al., 2016) and long-lived tissue-resident 
macrophages of embryonic origin can develop (Ginhoux et al., 2015; Gordon and 
Plüddemann, 2017). Some macrophages are not self-renewed. Intestinal 
macrophages have a half-life of 4–6 weeks and are not self-renewed, relying on 
a constant replenishment by the bone marrow-derived monocytes (Bain et al., 
2014). Heart macrophages are not capable of self-maintenance either and have 
an estimated half-life of 8-12 weeks (Epelman et al., 2014; Molawi et al., 2014). 




data on macrophages exact longevity. The literature mostly talks about 
compulsory neutrophils clearance. In fact, macrophage perform efferocytosis. 
This was shown in zebrafish (Loynes et al., 2010), mouse (Cox et al., 1995) or 
humans (Grigg et al., 1991). Clearance of macrophages in the resolution of 
inflammation is not clear. The fate of macrophages that engulfed apoptotic 
neutrophils is unclear. It seems they should withstand the harsh environment of 
infection/inflammation to enable the clearance of apoptotic or necrotic corpses. 
They are resistant to, e.g. Fas-induced apoptosis. Macrophages express Fas and 
FasL (Kiener et al., 1997). These ligands can induce apoptotic cell death in cells 
that express them but macrophages do not undergo spontaneous apoptosis upon 
stimulation by an agonistic anti-Fas antibody (Kiener et al., 1997). It is suggested 
that the expression of Fas-associated death domain–like interleukin 1β–
converting enzyme (FLICE)–inhibitory protein (Flip) in macrophages spares 
macrophages from death by Fas-mediated apoptosis (Perlman et al., 1999). 
However, they do undergo apoptosis in vivo without the interference of the 
adaptive when challenged with immunosuppressant, mycophenolate mofetil 
(MMF). The pathway remains unknown (Gibson et al., 2018). In vitro, TNFα, an 
apoptotic stimulus (Rath and Aggarwal, 1999), induces macrophage apoptosis 
when NF-κB is suppressed (Liu et al., 2004). Thus, apoptosis could be one of the 
fates of macrophages. Other death types are described as, e.g. pyroptosis, 
necroptosis or and parthanatos (reviewed by (Liu and Sun, 2019; Robinson et al., 
2019)). Pyroptosis is a form of programmed cell death, which is highly pro-
inflammatory due to a rapid rupture of the plasma-membrane releasing its 
contents (Fink and Cookson, 2006) (Bergsbaken et al., 2009). Necroptosis is a 
programmed cell death regulated by receptor- interacting protein kinase 1 
(RIPK1) and receptor-interacting protein kinase 3 (RIPK3) (Vandenabeele et al., 
2010). As in the case of any cell when the immunity is dysregulated and 
overwhelmed, it seems also possible that macrophages can die by necrosis. The 
general concept of macrophages being cleared by emigration from the previously 
inflamed site to lymph nodes (Bellingan et al., 1996) has recently been refuted. 
The newest mice data showed a local death of macrophages (Gautier et al., 
2013). Retention of macrophages has to be reduced because macrophages can 




macrophage/monocyte count is a hallmark of several autoimmune diseases, e.g. 
rheumatoid arthritis (Janossy et al., 1981), Crohn’s disease (Demetter et al., 
2005). The issue is that in chronic wounds, pro-inflammatory macrophages do 
not change their phenotype into anti-inflammatory and they remain in the tissue. 
This is thought to be associated with the impairment in tissue repair (reviewed by 
(Zhao et al., 2016)). Nonetheless, regardless of their function, no previous 
research has investigated the life span of all types of macrophages.  
1.2.2.7 Other cells 
Other cells making up the cellular component are DCs and natural killer (NK) 
cells. Dendritic cells arise from the bone marrow and are present in the peripheral 
tissues such as the epithelial layer of the skin, gut, parenchyma and organs 
interstitial. They are bone marrow derived from the same lineage of cells as 
monocytes and act as powerful antigen presenters to CD4+ and CD8+ T cells 
(reviewed by (León et al., 2005; Merad et al., 2009)), thereby providing a link 
between innate and adaptive immunity. Natural killer cells generate rapid 
responses to viruses and tumors. They are cytotoxic lymphocytes of T and B 
lymphoid progenitor, important in cytokine production (reviewed by (Geiger and 
Sun, 2016)). Originally, they were defined as effector lymphocytes of innate 
immunity. Nowadays they are also described as mounting a form of antigen-
specific immunologic memory. This view moves them to be adaptive immune 
cells (reviewed by (Vivier et al., 2016)). 
1.4 The adaptive immune system  
The adaptive immune system provides a long lasting immune response against 
previously encountered pathogens. The adaptive immune response is induced 
upon activation of specialised antigen-presenting cells, namely dendritic and B 
cells (Lemke, 2018). DCs are activated directly by pathogen-associated 
molecular pattern recognition and indirectly via inflammatory mediators produced 
by other cells that recognise conserved pathogen molecules (reviewed by (Reis 
e Sousa, 2004; Gallo and Gallucci, 2013)). An immature DC uptakes and 




cell. Mature DC will present the antigen and activate T cells (reviewed by 
(Banchereau and Steinman, 1998)). 
Cells of the adaptive immune system include the effectors of cellular immune 
responses, the T lymphocytes and the B-lymphocytes. They are named after their 
tissues of maturation, the thymus gland and bone, respectively. Adaptive 
immunity represents a tightly regulated interplay between antigen-presenting 
cells and T and B cells (reviewed by (Bonilla and Oettgen, 2010; Gaudino and 
Kumar, 2019)). 
Lymphocytes 
T cells can be categorised into two main groups CD4+ and CD8+ for the different 
glycoproteins present on their cell surface and interact with other cells through 
the T cell receptor (TCR). The TCRs recognise antigens only if coupled with MHC 
molecules. Cytotoxic T cells have CD8+ co-receptor on their cell surface. Helper 
express CD4+. CD4+ cells have two distinct phenotypes Th1 and Th2. The 
cytokines they produce are known as Th1-type and Th2-type cytokines. Th1-type 
cytokines are considered as pro-inflammatory while Th2 anti-inflammatory 
(reviewed by (Kaiko et al., 2008)).  
B cells drive humoral immunity by producing antibodies. There are many B cell 
types, thus can be categorised by the cytokine milieu that they secrete (reviewed 
by (Mauri and Bosma, 2012)). After encountering the antigen, it can either 
become a memory cell to be activated again or a plasma cell to secrete antibodies 
(reviewed by (Liu and Banchereau, 1997; Cyster and Allen, 2019)). 
Antibodies 
Antibodies are produced by plasma cells arising from B cells under the 
supervision of T cells and other cells, such as dendritic cells (Bonilla and Oettgen, 
2010). As a class, they are known as immunoglobulins (Igs). Their different 
suffixes of the antibody isotypes indicate the different types of heavy chains the 
antibody contains, i.e. α, γ, δ, ε and μ. Accordingly, antibodies isotopes are 




antibody region, binds the antigen. Fc is the antibody tail region responsible for 
generation of an appropriate immune response for a given antigen by binding to 
a specific class of Fc receptors. These receptors are important in the engagement 
of phagocytes with opsonised microbes (reviewed by (Koenderman, 2019)). Fc 
receptors are found on various cell types. Internalisation and killing of organisms 
is more efficient if the particle is first opsonised with specific antibody or 
complement. Antibodies recognise the structure of antigen epitopes, and such 
antigens do not need to be processed (reviewed by (Parkin and Cohen, 2001)). 
The elegance and complexity of the adaptive immune system are largely due to 
lymphocytes working closely together with innate immune cells. For instance, 
CD4+ Th1 cells activate DCs (Mailliard et al., 2002) and these will present the 
antigen to T cells. Thus, antigen presentation bridges the innate and adaptive 
immune responses. 
1.5 The innate immune response to Cryptococcus 
 
A detailed introduction to the immune response to cryptococcal infection is in 
Chapter 3. 
The complement  
C. neoformans strongly activates the complement via the alternative pathway 
(Diamond et al., 1974; Laxalt and Kozel, 1979). Recently it has been shown that 
both C. gattii and C. neoformans activate complement inhibited serum. This 
suggests they can activate the alternative pathway. However, complement 
activation was seen with factor B (required for the alternative pathway activation) 
deficient serum suggesting activation can also occur in the absence of a 
functional alternative pathway. Moreover, the complement is not activated in the 
absence of mannose-binding lectin (MBL) proteins. Activation of the alternative 
pathway by C. neoformans requires both MBL-A and MBL-C types. In contrast, 
C. gattii requires either MBL-A or MBL-C. This suggests the complement might 
be activated by the pathogen via a few pathways. The most surprising finding is 
that the alternative pathway requires the presence of C4 fragment shown by C3 




The dependency on the alternative pathway for effective cryptococcal 
phagocytosis and innate protection is demonstrated by increased mortality in C3 
but not C4 complement deficient guinea pigs (Diamond et al., 1973) and mice 
(Shapiro et al., 2002). The classical pathway does not seem to play a role in 
complement activation because there is no difference in complement activation 
using C1q-deficient serum as compared to the wild-type serum (Mershon-Shier 
et al., 2011). In addition, the polysaccharide capsule inhibits the classical pathway 
activation (Kozel et al., 1991).  
Macrophages 
Alveolar macrophages are the first line of defence against pulmonary pathogens 
(Green and Kass, 1964; Goldstein et al., 1974). Primary infection with 
Cryptococcus is through the pulmonary route and thus macrophages are the 
dominant phagocytic cells that interact with the fungus. 
The function of macrophages is complex, from cryptococcal killing to contributing 
to disease development (reviewed by (Voelz and May, 2010; Taylor-Smith and 
May, 2016)). If cryptococci are not killed they can proliferate intracellularly, e.g. 
in vitro in human macrophages (Diamond and Bennett, 1973; Garelnabi et al., 
2018) and human fetal microglia (Lee et al., 1995). They also cause lysis of host 
cells. There are three types of proteins linked to the host cell lysis, i.e. proteases, 
phospholipases, and pore-forming proteins (reviewed by (Flieger et al., 2018)). 
To date, no pore-forming proteins have been identified in the fungus genome. 
Thus, proteases and phospholipases seem potential candidate molecules that 
may be involved in the permeabilisation of C. neoformans-containing 
phagosomes. Lateral transfer is reported in macrophage lines and primary 
macrophages (Alvarez and Casadevall, 2007; Ma et al., 2007). The mechanism 
of lateral transfer remains unclear, although it is actin-dependent (Ma et al., 
2007). Finally, cryptococci can be expelled. This is reported in macrophage lines 
(Alvarez and Casadevall, 2006; Ma et al., 2006; Johnston and May, 2010), 
primary murine macrophages (Alvarez and Casadevall, 2006). The non-lytic 
extrusion might impinge the host, e.g. Cryptococcus can temporarily reside in 




barrier, or can maintain the dormant state to be activated upon 
immunocompromised conditions (reviewed by (Johnston and May, 2013)). 
Vomocytosis, the non-lytic expulsion, is believed to be dependent on polymerised 
actin flashes on fungal phagosome through WASP-Arp2/3 pathway (Johnston 
and May, 2010). A schematic interaction between macrophages and 
Cryptococcus is depicted in Figure 3.1 in section 3.1.1 The importance of  
C. neoformans, interactions with macrophages and the polysaccharide capsule.  
Neutrophils 
In contrast to discrepancies between the fungicidal activities of different types of 
macrophages and the fate of internalised yeast, there is more agreement about 
neutrophils. They efficiently kill in vitro via oxidative burst (Tacker et al., 1972; 
Chaturvedi et al., 1996, Ueno et al., 2019). In vivo neutrophils are very potent 
(Wozniak et al., 2006; Tenor et al., 2015; Davis et al., 2016; Zhang et al., 2016), 
yet they manage only a partial clearance of cryptococci (Perfect et al., 1980; 
Gadebusch and Johnson, 1996). Killing is mediated by antimicrobial granules, 
reactive oxygen species and myeloperoxidase catalysing production of 
hypochlorous acid, an extremely potent microbicidal agent. However, it has to be 
highlighted that there is no clinical association between neutrophils and 
Cryptococcus. There are no neutrophils in the lungs in health. Neutrophils are 
recruited into the lungs during the early phase of cryptococcal infection 
(Feldmesser et al., 2000). This means that neutrophils recruitment occurs in 
disease. In this light, macrophages are more important in cryptococcal disease 
because a population of alveolar macrophages already occupies the lungs, the 
portal of entry for Cryptococcus. 
Natural killer and dendritic cells 
NK cells also effectively kill C. neoformans in vitro (Ma et al., 2004; Wiseman et 
al., 2007), but Cryptococcus suppresses this by inhibiting cytokine secretion 
(reviewed by (Schmidt et al., 2013)). In vitro data shows DCs are more potent 




Cryptococcus in vitro (Kelly et al., 2005) and this is also seen in vivo in a murine 
model of infection (Wozniak et al., 2006).  
Phagocytosis 
Uptake of cryptococci has been shown in murine macrophages (Kozel and 
Follette, 1981), human neutrophils (Dong and Murphy, 1997; Rocha et al., 2015), 
in vivo in zebrafish neutrophils (Tenor et al., 2015) and macrophages (Bojarczuk 
et al., 2016) as well as in human DCs in vitro (Syme et al., 2002) and in mouse 
DCs (Wozniak et al., 2006). 
Autophagy 
The host self-degradation pathway of autophagy has been implicated to support 
intracellular survival and dissemination of C. neoformans. Autophagy genes such 
as ATG2a, ATG5 and ATG9a, were shown to be required for growth through RNA 
interference (RNAi) in RAW 264.7 macrophages (Qin et al., 2011). A similar RNAi 
approach resulting in Atg5 loss, led to decreased macrophage fungistatic ability. 
This suggests that autophagy is important in host defence (Nicola et al., 2012). 
Interestingly, J774 macrophages infected with C. gattii outbreak strains were 
poorly decorated with LC3 phagosome marker, suggesting no clear role for 
autophagy in cryptococcal mitochondrial tabularisation, that is thought to be 
protective from cell death (Voelz et al., 2014) and from autophagic degradation 
(Gomes et al., 2011).  
1.6 Inflammation and disease 
Inflammation was originally described as heat, redness, swelling and pain by 
Cornelius Celsus in the 1st century AD. Inflammation is a general term describing 
a multistep process triggered by the innate immune cells in response to sterile 
tissue damage, infection or a combination of both (reviewed by (Barton, 2008; 
Newton and Dixit, 2012)). The main role of inflammation is to obviate infection or 
repair damage and thus restore homeostasis (reviewed by (Barton, 2008; Feehan 
and Gilroy, 2019)). The response is elicited by recognition of an inflammatory 




to inflammatory signalling cascade and the production of pro-inflammatory 
mediators. Termination of the inflammatory response and transition to the 
homeostatic state requires the switch to anti-inflammatory signalling and is 
termed as the resolution of inflammation (reviewed by (Medzhitov, 2010)).  
Neutrophils are the first inflammatory cells to arrive at the site of tissue 
perturbation (reviewed by (Haslett, 1992; Butterfield et al., 2006)) and are 
followed by monocytes, which differentiate into tissue macrophages or DCs, 
depending on the precise signals they receive locally. However, a rapid response 
requires guarding cells already present in the tissues, provided by residential 
mast cells and macrophages (reviewed by (Benoist and Mathis, 2002)). The latter 
are considered to be most prominent and act as sentinels in the early sensing of 
infection (reviewed by (Barton, 2008)), alongside DCs (reviewed by (Mellman and 
Steinman, 2001; Webster et al., 2016)). Mature macrophages are important in 
promoting resolution of inflammation, elimination of apoptotic cells and tissue 
repair following injury (reviewed by (Koh and DiPietro, 2011)). Neutrophils, in 
contrast, are important for the host defence but are also implicated in disease 
pathogenesis. Neutrophils therefore are believed to occupy a pivotal position in 
the initiation, amplification and resolution processes of inflammation (reviewed by 
(Haslett, 1992; Mortaz et al., 2018)). They also form extracellular traps (NETs) 
with extruded DNA strands anchoring bactericidal proteins (Brinkmann et al., 
2004). Generally, microbial killing is facilitated by antimicrobial granules of many 
types, including peroxidase-positive (reviewed by (Faurschou and Borregaard, 
2003)), degranulation, respiratory burst and cytokine production (reviewed by 
(Borregaard, 2010)). During the acute inflammation phase, which occurs over 
minutes or hours, the influx of neutrophils is rapid. This is followed promptly by 
an inflow of monocytes maturating into inflammatory macrophages. These 
sustain the inflammatory response and alter the tissue-resident macrophages 
role (reviewed by (Serhan and Savill, 2005)). 
Inflammation must resolve to allow tissue repair and a return to normal 
homeostasis; this occurs through a shift in the overarching response to anti-
inflammatory signals (reviewed by (Barton, 2008)). The change in the 




initiating stimuli, catabolism of pro-inflammatory mediators and inhibition of 
further neutrophil recruitment and their clearance. Transformation from tissue 
damage signals to tissue repair occurs as complement and phagocytes kill 
microbes (reviewed by (Nathan, 2002)). Successful inflammation resolution is 
facilitated by the constitutive apoptosis of neutrophils and their uptake by 
macrophages (Savill et al., 1989; Sun et al., 2015). Additionally, macrophages 
can also induce neutrophil death via a direct cell-cell contact mechanism 
(Meszaros et al., 2000). Removal of neutrophils can also occur via their reverse 
migration from inflamed tissue (Tharp, 2005; Buckley et al., 2006; Mathias et al., 
2006). 
Induction of neutrophil apoptosis and their removal by macrophages is of dual 
importance. Firstly, it promotes macrophage reprogramming from pro- to anti-
inflammatory phenotype (Fadok et al., 1998). Secondly, it preserves neutrophil 
cell membrane integrity (Savill and Haslett, 1995). If the membrane of apoptotic 
cells is disrupted very early in their life-span, this leads to secondary necrosis, 
leading to spillage of the contents of necrotic cells into the adjacent environment, 
again initiating inflammatory signalling (reviewed by (Ward et al., 1999; Gaipl et 
al., 2004; Grabiec and Hussell, 2016)). Macrophages engulf apoptotic cells 
before they lyse, which blocks the release of cytotoxic contents (Fadok, Bratton, 
Guthrie, et al., 2001). Without this, the elimination of dying cells is perturbed and 
might evoke autoimmunity (reviewed by (Gaipl et al., 2003)). For example, in 
systemic lupus erythematosus disorder, impaired apoptotic cell clearance leads 
to secondary necrosis and inflammation (reviewed by (Shao and Cohen, 2011)). 
It is critical that inflammation resolution is well-timed as persisting neutrophils can 
cause irreversible tissue damage via release of their cytotoxic granules (reviewed 
by (Haslett, 1992; Schett and Neurath, 2018)). If inflammation continues 
unchecked, the inflammatory process can lead to the saturation of tissue by 
lymphocytes and leukocytes which then subsequently form granulomas 
(reviewed by (K. K. Shah et al., 2017)). Dysregulation of granulocyte apoptosis 
and clearance leads to persisting inflammation and excessive tissue injury 
(Haslett, 1997). For instance, disruption of constitutive apoptotic pathways 
prevents successful resolution and delays neutrophil apoptosis in acute 




are essential for the maintenance of health and life and these processes occur 
all the time, e.g. in skin injuries (Suárez-Peñaranda et al., 2002). In contrast, 
unresolved inflammation can cause serious host tissue injury resulting in chronic 
inflammatory diseases, such as chronic obstructive pulmonary disease or 
autoimmunity, e.g. systemic lupus erythematosus (reviewed by (Nathan and 
Ding, 2010; Kaplan, 2013)). This potentially leaves the host vulnerable to chronic 
infections. Therefore, chronic inflammation is linked with infections and 
autoimmune conditions. These cases, as well as organ transplants, require 
immunosuppression (reviewed by (Kanterman et al., 2012)). Despite the clinical 
problem of unresolved neutrophilic inflammation, few effective therapies are 
available, none of which directly target the neutrophil. One of the widely used 
treatments in transplantations and immune-mediated diseases, such as immune-
related pulmonary fibrotic conditions- is mycophenolate mofetil (MMF). However, 
data on its mechanism of action in the context of inflammation during 
immunosuppression and the drug’s immunosuppressive impact on the innate 
immune system are scarce. 
Inflammation can be classified as either acute or chronic. The former starts 
rapidly and becomes severe in a short space of time. Examples include acute 
bronchitis, acute appendicitis, sinusitis, a physical injury. The latter is 
characterised by persistence of signs and symptoms, e.g. asthma, chronic 
sinusitis, rheumatoid arthritis. There are also diseases resulting from an aberrant 
immune response and termed autoimmune diseases. Neutrophil- related include, 
i.e. lupus erythematosus, small vessel vasculitis and rheumatoid arthritis 
(reviewed by (Kaplan, 2013)). Significantly elevated neutrophil numbers are the 
hallmark of neutrophilic inflammatory disease and their protracted presence and 
activation can escalate the immune response (Haslett, 1997). 
1.6.1 Inflammation and infection 
1.6.1.1 The course of inflammatory response to infection 
Infection, injury and tissue damage cannot heal without an inflammatory 
response. Every infection is associated with inflammation and these cells 




to homeostasis communicate together and regulate each other. Most injuries are 
associated with accompanying infection because wounds include the disruption 
of a physical barrier, such as cuts that microbes will use to bypass the skin. 
However, in certain cases injury and cell death are found in a sterile setting 
(reviewed by (Barton, 2008)). The inflammatory response to infection or injury 
proceeds in four phases: recognition of infection/injury, recruitment of 
inflammatory cells, control of infection and elimination of the pathogen and 
termination of inflammation. 
1.6.1.1.1 Recognition of infection  
The inflammatory response can be initiated by either endogenous or exogenous 
stimuli. The most well described inflammatory response is that induced by 
microbial infection (reviewed by (Medzhitov, 2008)). In vertebrates, the innate 
system recognition occurs via pattern recognition receptors (PRRs), expressed 
on the plasma membrane of cells, e.g. neutrophils, macrophages and DCs 
(reviewed by (Medzhitov, 2001; Troutman et al., 2012)). The best characterised 
PRRs are the Toll-like receptors (TLRs), which detect structurally conserved 
microbial molecules known as pathogen-associated molecular patterns (PAMPs), 
e. g. lipopolysaccharides (LPS), flagellin or double- or single-stranded RNA 
(reviewed by (Medzhitov, 2007)). Upon binding of a pathogen ligand, TLRs trigger 
a cascade of signalling pathways. This includes the elicitation of pro-inflammatory 
and anti-inflammatory cytokines (reviewed by (Ozato et al., 2002)). PAMPs are 
derived from microorganisms. In contrast, damage-associated molecular patterns 
(DAMPs) are cell-derived. PAMPs initiate and maintain the infectious pathogen-
induced inflammatory response, whereas DAMPs initiate and perpetuate a non-
infectious inflammatory response, which is discussed in section 1.6.1.2 Sterile 
inflammation. Five classes of PRRs have been characterised: transmembrane 
cell surface or endosomal Toll-like receptors (TLRs), cytoplasmic NOD-like 
receptors (NLRs) and inflammasome, intracellular RIG-I (retinoic acid-inducible 
gene-I)-like receptors (RLRs), transmembrane C-type lectin receptors (CLRs), 
and AIM2 (interferon-inducible protein also known as absent in melanoma 2)-like 
receptors (reviewed by (Chen and Nuñez, 2010)). PRRs can perform as 




receptors) (reviewed by (Johnston and May, 2013)) or proteins implicated in 
opsonisation and complement activation (e.g., mannose-binding lectin) (reviewed 
by (Medzhitov, 2001; Barton, 2008)).  
TLRs stimulate tissue-resident macrophages to secrete pro-inflammatory 
cytokines, including TNFα, IL-1β and IL-6. TNFα and IL-1β in turn mobilise the 
local endothelium to dilate blood vessels enabling the recruitment of serum 
proteins and leukocytes to the site of infection response (reviewed by 
(Rosenwasser, 1998; Sprague and Khalil, 2010; Duque and Descoteaux, 2014)). 
TLRs can also directly drive antimicrobial functions by inducing macrophages to 
upregulate inducible nitric oxide synthase (iNOS) ((Wager et al., 2014); reviewed 
by (Medzhitov, 2007)). Activation of mouse macrophages by bacterial 
lipoproteins triggers a nitric oxide mediated killing of Mycobacterium tuberculosis 
(Thoma-Uszynski, 2001). Binding of TLRs and PAMPs results in a pro-
inflammatory cascade activating signalling molecules, e.g. nuclear factor-B (NF-
B) and interferon-regulatory factors (IRFs), which in turn drive expression of pro-
inflammatory genes including TNFα and IL-1 (reviewed by (Barton, 2008; 
Mogensen, 2009)). TLRs-PAMP binding drives activation of neutrophils and 
macrophages, intensifying phagocytosis and the oxidative burst. 
The TLR-PAMP binding induces a pro-inflammatory signalling cascade. 
Transcription factors are activated, e.g. nuclear factor-B (NF-B), which induces 
the pro-inflammatory cytokines expression, such as TNFα, IL-6 and IL-12 
(reviewed by (Takeda and Akira, 2005; Ospelt and Gay, 2010)). Interferon-
regulatory factors (IRFs) also activate TNFα as well as inflammatory IL-12, IL-18. 
Cytokine secretion is a ‘go’ signal and results in recruitment of leukocytes from 
the blood (reviewed by (Muller, 2002; Nathan, 2002)). Examples of other pro-
inflammatory cytokines include: chemokine-monocyte chemoattractant 1 (MCP-
1) and IFNγ (Rossi et al., 2006). Cytokines including TNFα and IL-1 enhance the 
expression of a collection of adhesion molecules on vascular endothelial cells, in 
particular E-, P- and L-selectins. Selectins are involved in trafficking of both the 
innate cells immune system and T lymphocytes and platelets (reviewed by (Ley, 




rolling process, and induces ‘inside-out’ signalling that alters integrin 
conformation on the neutrophil surface (reviewed by (Muller, 2003; Zarbock and 
Ley, 2008)). 
In addition to membrane-targeted TLRs, inflammatory responses can initiate via 
activation of cytosolic PRRs, which include nucleotide-binding oligomerisation 
domain–like (Nod-like) receptors (NLRs) (reviewed by (Strober et al., 2006; 
Barton, 2008)). NLRs are pivotal in the innate immunity by recognising PAMPs 
and DAMPs (Y. K. Kim et al., 2016). Nod1 and Nod2 function similarly to that of 
TLRs, activating NF-B, and enhancing expression of pro-inflammatory genes 
(reviewed by (Strober et al., 2006; Barton, 2008)). Other NLRs detect non-
microbial signals triggering activation of cytosolic complexes-inflammasomes 
involved in activation of inflammatory caspases (reviewed by(Martinon et al., 
2009)). 
RLRs are also a group of cytosolic PRRs that belong to the RNA helicases family. 
They specifically recognise RNA species derived from viruses and execute anti-
viral signalling via type I interferon (IFN) induction (reviewed by (Yoneyama and 
Fujita, 2008)). 
Another group of cytosolic sensors are AIM2-like receptors. These sense 
cytoplasmic viral DNA and activate inflammasomes, resulting in IL-1β and IL-18 
maturation (reviewed by (Sparrer and Gack, 2016)). 
An example of PRRs is Dectin-1. It is a non-opsonic receptor belonging to CLRs 
and recognising β-glucans. Β-glucan is an important t cell wall component in 
fungi. However, Dectin-1 seems to have little role in the macrophage interaction 
with cryptococci and not likely to be crucial for the protective host response to  
C. neoformans (Nakamura et al., 2007). Contrary to this, it has been reviewed 
that Dectin-1 contributes to the production of IL-23, needed for Th17-cell function 
and protection against fungi (reviewed by (Medzhitov, 2007)). 
Innate immune recognition of PAMPs instruct adaptive immune responses. The 
recognition via pattern recognition receptors on antigen-presenting cells, leads to 





1.6.1.1.2 Recruitment of inflammatory cells to site of infection  
Neutrophils are the first inflammatory cells to arrive at the site of tissue 
perturbation (reviewed by (Haslett, 1992; Peiseler and Kubes, 2019)). This 
occurs via the process termed diapedesis. It involves adhesion to the endothelial 
wall using selectins, integrins and adhesion molecules. Rolling arrest introduces 
transmigration through the endothelium of the blood vessel, and chemotaxis to 
sites of inflammation (reviewed by (Wright et al., 2010)). The neutrophil adhesion 
cascade is highly complex and involves the following stages: the capture and 
rolling of neutrophils on activated endothelial cells (ECs), slow rolling, firm 
adhesion to ECs through, luminal crawling along the endothelium until they reach 
their site of transendothelial cell migration (reviewed by (Voisin and Nourshargh, 
2013)). Apart from tissue-resident macrophages already present at the inflamed 
site (reviewed by (Davies et al., 2013)), another population of macrophages will 
accumulate within the affected tissue site, governed by Th1 inflammatory 
response (reviewed by (Helming, 2011)).  
1.6.1.1.2.1 Mediators of inflammation 
There are many mediators coordinating the course of inflammation (Table 1.4) 
having various effects on the local environment, either promoting the 
inflammatory phase of inflammation or triggering pro-resolution events. 
Lipid mediators (e.g. prostaglandins, lipoxins, resolvins, protectins) reduce 
inflammation, increase resolution and tissue repair. They also enhance 
leukocytes recruitment. Cytokines: TNFα, IL-1, IL-6 activate leukocytes and 
endothelium as well as induce acute-phase systemic response. Chemokines (i.e. 
IL-8, MCP-1) affect leukocyte extravasation and chemotaxis (reviewed by 
(Medzhitov, 2007, 2008; Serhan and Levy, 2018)). 
Both neutrophils and macrophages secrete lipid mediators of inflammation: 
prostaglandins, leukotrienes and platelet-activator factor (PAF). These are rapidly 
produced to degrade pathogen membrane phospholipids (Janeway et al., 
2012b). PAF, IL-8 and CXC chemokines are attractants for neutrophils migration. 




Here they mature into macrophages and are crucial in wound healing (Maddox 



































Table 1.4 Inflammatory mediators  
 






lipid mediators PGE2 , PGI2 , 
LTB4 , LTC4 
PGJ2, PGA1/2 , 
lipoxins 
complement C3a, C5a C1q  

















Taken from (Lawrence et al., 2002). 
cAMP- cyclic adenosine monophosphate; cGMP- cyclic guanosine monophosphate; 
ICAM-1- intercellular adhesion molecule 1; IL- interleukin; LT- leukotriene; MCP1-
monocyte chemotactic protein 1; MIP1α-macrophage inflammatory protein 1α; PG- 
prostaglandin; PS-phosphatidylserine; TGFβ1- transforming growth factor β1; TNFα 
tumor necrosis factor α; TSP- thrombospondin; VCAM-1- vascular cell adhesion 
molecule 1; C1q- first subcomponent of the C1 complex of the classical pathway of 
complement activation receptor, GRO/KC- keratinocyte chemoattractant of human 
growth-regulated oncogene; CXCL- chemokine (C-X-C motif) ligand, CCL- chemokine 











1.6.1.1.3 Control of infection and elimination of pathogens 
Inflammation resolution is a highly controlled process. Transmigrating cells 
reorganise their cytoskeleton and change their structural polarisation (reviewed 
by (Springer, 1994; Garrood et al., 2006)) to permit endocytosis of foreign 
molecules into phagosomes (reviewed by (Dale et al., 2008)). Neutrophils secrete 
the antimicrobial components contained in their granules upon cell activation via 
exocytosis (reviewed by (Lacy, 2006)). These and other secretory vesicles 
enable destruction of pathogens either extracellularly or following degranulation 
into the phagolysosome after phagocytosis, with these events primed by TNFα 
(reviewed by (Lesavre and Halbwachs-Mecarelli, 2000)). Phagocytosis also 
begins, mediated by a broad array of phagocytic receptors. Examples of human 
phagocytic receptors are presented in Table 1.5. 
Phagocytosis activates a respiratory burst, where NADPH oxidase catalyses the 
production of reactive oxygen species (reviewed by (Roos et al., 1988)). 
Superoxide anion O-2 and hydrogen peroxide H2O2 are formed to produce yet 
more reactive oxygen species (ROS) that are highly toxic and able to induce 
apoptosis in other immune cells (reviewed by (Dahlgren and Karlsson, 1999)). 
Neutrophils produce myeloperoxidase (MPO) (Agner, 1958) and the MPO 
secreted into the phagosome during the degranulation (reviewed by (Klebanoff, 
2005)), forms hypochlorous acid, a potent oxidant in killing (reviewed by (Kettle 
and Winterbourn, 1997)). Interestingly, in macrophages Fc receptor-, but not 
complement receptor-mediated, phagocytosis elicits reactive oxygen 
intermediates (reviewed by (Aderem and Underhill, 1999)).  
Another mechanism of pathogens killing is via low pH. For instance, pH below 
2.5 efficiently kills Escherichia coli 690, E. coli K-12 and Helicobacter pylori (Zhu 
et al., 2006). However, cryptococci can survive acidic status of phagolysosome 
(Levitz et al., 1999). Proteases also facilitate pathogens elimination. Neutrophil 
elastase lacking mice are susceptible to Klebsiella pneumoniae and E.coli 
(Belaaouaj et al., 1998) and macrophage cathepsin L executes non-oxidative 




















Mincle (C-type lectin), 
MDL-1(C-type lectin), 









CR4(CD11c/CD18)   
Dectin-1 (C-type 
lectin)  
DEC 205 (C-type 
lectin) 




Adapted from (Aderem and Underhill, 1999; Lesavre and Halbwachs-Mecarelli, 2000; 













1.6.1.1.4 Termination of inflammation  
Termination of inflammation determines restoration of tissue integrity and return 
to homeostatic state. The inflammatory stimulus must be removed, pro-
inflammatory mediators catabolised, further recruitment of inflammatory 
leukocytes arrested, and their numbers returned to basal tissue levels (reviewed 
by (Serhan, 2007)). Previous studies have emphasised that the active, complex 
process of resolution of inflammation initiated in the first few hours after an 
inflammatory insult, constitutes an integral component of the program of 
inflammation. Under normal conditions the inflammation resolution is composed 
of two stages: pro- and anti- inflammatory, therefore a number of authors have 
recognised the beginning of inflammation programs the end of inflammation 
(reviewed by (Serhan and Savill, 2005; Headland and Norling, 2015)). It becomes 
apparent, there has to be a switch from pro- to anti-inflammatory signalling. One 
of the mechanisms facilitating the anti-inflammatory signalling is granulocyte 
production of lipoxins, resolvins and protectins that triggers the inhibition of 
neutrophil recruitment and decrease in vascular permeability, and promotes 
healing. This occurs post entering tissues, to initiate the termination of 
inflammation (reviewed by (Serhan and Savill, 2005)).  
The mechanism of inflammation resolution also involves clearance of neutrophils 
by macrophages (Savill et al., 1989). Uptake of apoptotic neutrophils by 
macrophages reprograms macrophage phenotype from a pro- to an anti-
inflammatory, thus to a resolving phenotype, which facilitates the restoration of 
tissue homeostasis (reviewed by (Ortega-Gómez et al., 2013)). In addition, 
macrophages can also induce neutrophil death via a direct cell-cell contact 
mechanism contact that requires the constitutive presentation on macrophages 
effectors of β3 integrin subunits, CD36, and membrane-bound TNFα (shown in 
vitro using PMNs and macrophages purified from a wound in rats (Meszaros et 
al., 2000)). In contrast, macrophage can exert pro-inflammatory properties. This 
includes responses to necrotic cells, e.g. necrotic cells from uncleared apoptotic 
cells (reviewed by (Gregory and Devitt, 2004)). Some authors have demonstrated 
that incubation of macrophages with physically lysed neutrophils, led to the 




(Fadok, Bratton, Guthrie, et al., 2001). The effect was due to the cleavage of 
phosphatidylserine receptor (PSR) on the surface of the macrophages by a 
protease released upon the lysis of neutrophils, which could be a physiological 
effect since normally proteases are stored in neutrophil granules and released 
after neutrophil exposure to inflammatory stimuli. Phosphatidylserine (PS) 
exposure is critical for the uptake of apoptotic cells (reviewed by (Fadok, Bratton 
and Henson, 2001)). PS expressed on the apoptotic cell is recognised by 
macrophages through PSR (Fadok et al., 2000) and believed to be expressed on 
apoptotic cells due to loss of plasma membrane asymmetry (reviewed by 
(Henson et al., 2001)) in apoptotic cells. However a recent study by (Krysko et 
al., 2004) showed PS exposure in late necrotic JB6 cells (caspase -8 deficient, 
BCL-2 overexpressing subline derived from the Jurkat E human T-cell lymphoma 
cell line). Furthermore, the Brouckaert group concluded that necrotic L929 cells 
become PS positive and were taken up by Mf4/4 macrophages, which did not 
elicit pro-inflammatory cytokine signalling. However, the extent of the uptake was 
lesser as compared to apoptotic neutrophils (Brouckaert et al., 2004). 
Nevertheless, the uptake of apoptotic/necrotic cells is crucial for the successful 
inflammation resolution. 
1.6.1.2 Sterile inflammation 
 
Sterile inflammation occurs in the absence of any microorganisms. It can be 
triggered by, e.g. endoplasmic reticulum (ER) stress, hypoxic stress, nutrient 
stress, ischemia reperfusion injury (I/R), trauma including crush injury, crystal-
induced inflammation, cellular necrosis and toxin exposure (reviewed by 
(Rubartelli et al., 2013; Shen et al., 2013)). Examples of triggers of sterile 
inflammation are presented in Table 1.6.  
Similar to that caused by microbes, sterile inflammation can be either resolved or 
lead to disease. A number of factors are suggested to be important in distinct 
types of sterile inflammation. These include redox responses, the occurrence of 
DAMPs and immune stimulatory heat shock proteins (HPs), and vascular 
remodelling (reviewed by (Rubartelli et al., 2013)). For instance, in I/R which 




blood flow and oxygen, ROS production is enhanced (e.g. in isolated perfused 
rat lung model (Fisher et al., 1991) and necrosis is also induced (e.g. in a rat 
gracilis muscle model (Wang et al., 2008)). 
The innate immune pathways sensing infection have been involved in sterile 
inflammation. Sterile inflammatory responses engage receptors that are also 
known to respond to pathogens. This means that PRRs recognise DAMPs. 
However, a distinct signalling also exists (reviewed by (Shen et al., 2013; Gong 


















Table 1.6 Examples of intracellular and extracellular triggers of sterile 
inflammation 
DAMP trigger     type of DAMP sensor+signalling 
pathway 
associated 
diseases              
nuclear proteins 
*HMGB1 
intracellular  *TLR2/4 
*RAGE 
*CD24 
*acute kidney injury 
*acute hepatic 
injury 
























*acute lung injury 
induced by 
bleomycin 
hyaluronan  extracellular *TLR2/4 
*CD44 
*NLRP3 
*acute lung injury 
induced by 
bleomycin 
cholesterol extracellular *NLRP3 *atherosclerosis 
particles: silica, 
asbestos 
extracellular *NLRP3 *lung fibrosis 
 
Broad division of intracellular and extracellular triggers of sterile inflammation. HMGB1-
high-mobility group box 1; RAGE-receptor for advanced glycation end products; NLRP3-
NOD-, LRR- and pyrin domain-containing 3; MyD88- innate immune signal transduction 
















As described earlier, the detection, containment and restoration to homeostatic 
tissue state requires foreign molecule recognition by TLRs, which activate an 
array of signalling pathways. In sterile inflammation, DAMPs (also termed 
alarmins) play important intracellular roles. In contrast to PAMPs associated with 
microbes and viruses, DAMPs are endogenous danger signals derived from self 
and released upon tissue damage or stress, resulting in the activation of an 
immune response (reviewed by (Fleshner et al., 2017)). DAMPs are regarded as 
endogenous danger signals due to the induction of potent inflammatory 
responses by activating the innate immune system during non-infectious 
inflammation (reviewed by (Chen and Nuñez, 2010; Vénéreau et al., 2015)). Two 
classes of DAMPs are described, intracellular and extracellular (reviewed by 
(Chen and Nuñez, 2010; Schaefer, 2014; Patel, 2018)). Intracellular include, e.g. 
Necrosis-associated the chromatin-associated high-mobility group box 1 
(HMGb1) proteins, heat shock proteins (HSPs,) and purine metabolites, e.g. ATP, 
uric acid. Intracellular DAMPs can also be released into extracellular matrix upon 
tissue stress and injury or cell death (reviewed by (Chen and Nuñez, 2010; 
Schaefer, 2014)). Extracellular DAMPs include heparan sulphate and biglycan, 
hyaluronan. These extracellular matrix fragments are generated through the 
degradation of the matrix through proteases in response to necrosis or to trigger 
tissue repair (reviewed by (Chen and Nuñez, 2010; Frevert et al., 2018)). 
The most well characterised DAMP is HMGb1. This nuclear protein, bound 
loosely to chromatin, is present in most cells (reviewed by (Müller et al., 2004)) 
and enhances DNA bending (reviewed (Agresti and Bianchi, 2003)). When 
programmed cell death occurs, chromatin is rearranged such that HGMB1 binds 
irreversibly; in case of unprogrammed cell death the HMGB1 is released from 
necrotic cells (Scaffidi et al., 2002). Interestingly, FLIP (Fluorescence Loss in 
Photobleaching) analysis of HeLa cells undergoing mitosis, comprising bleaching 
of cytoplasmic HMGB1–GFP leads to a rapid and parallel loss of fluorescence 
from condensed chromosomes and from the cytoplasm. This shows how motile 
the protein is between the nucleus and cytosol states (Scaffidi et al., 2002). 
Outside the cell, HMGB1 can bind to the pro-inflammatory receptor RAGE and is 
internalised via endocytosis. This triggers pyroptosis (another form of 




HMGB1 is increased in murine renal I/R models (Rabadi et al., 2012) and linked 
to hepatic I/R (Kamo et al., 2013).  
Examples of other alarmins include HSPs, uric acid, defensins, and annexins 
(reviewed by (Bianchi, 2007)). Uric acid for instance, is the main alarmin released 
by injured cells (Shi et al., 2003). Precipitation of this chemical within cells as 
monosodium urate (MSU) crystals activates nucleotide-binding oligomerisation 
domain-like (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing 3 
(NLRP3) inflammasome, a cytosolic multi-protein signalling platform known to 
activate inflammatory responses. For instance, in vitro studies have shown, that 
monocytes/macrophages express NLRP3 under inflammatory stimulus, e.g. 
murine bone marrow-derived macrophages (BMDM) stimulated with LPS 
(Sutterwala et al., 2006) or silica (Franchi et al., 2009).  
The hallmarks of inflammasome activation are the production of the pro-IL-1β, its 
processing to activate caspase-1-activating complex and IL-1β and IL-18 release 
((Martinon et al., 2006; Franchi et al., 2009), reviewed by (Jo et al., 2016)). For 
instance, a recent study by Martinon et al. confirmed the features of 
inflammasome in THP1 monocytic cell line. The addition of MSU crystals elevated 
IL-1β and IL-18, and the caspase-1 dependency of the pro-IL-1β cleavage was 
shown by the addition of the capsase-1 inhibitor, zYVAD, which abolished the IL-
1β activation. Interestingly, in an in vivo model of crystal-induced peritonitis mice 
deficient in caspase-1 or IL-1R, a natural inhibitor of IL-1 signalling, exhibited 
peritoneal reduced neutrophil recruitment, indicating a pivotal role of the 
inflammasome (Martinon et al., 2006). 
It is also clear that mutations of NLRP can activate inflammasome 
inappropriately, resulting in auto-inflammatory diseases, e.g. familial cold 
autoinflammatory syndrome (reviewed by (Chen and Nuñez, 2010; Shaw et al., 
2011)).  
DAMPs, similar to PAMPs, are detected by PRRs. For example, knock-out mice 
studies revealed that TLR2 and TLR4, together with MyD88, the adaptor protein, 
which is required for TLR signalling, are necessary for the detection of hyaluronan 
(Jiang et al., 2005). Interestingly, hyaluronan initiates an inflammatory response 




acute lung injury by the activation of NF-κB in a TLR-dependent manner (Jiang 
et al., 2005). 
Another receptor of key importance is the DAMP-specific receptor for advanced 
glycation end products (RAGE) (reviewed by (Chen and Nuñez, 2010; Gong et 
al., 2020)). As mentioned, innate immune cells respond to the triggers of sterile 
inflammation through a variety of pathways, some of which are shared with 
pathways that respond to microorganism. However, some pathways are distinct 
to sterile inflammation. An example of such signalling is RAGE because RAGE 
is DAMP-specific receptor. This means that not all sterile inflammatory responses 
engage receptors that are also known to respond to pathogens (reviewed by 
(Shen et al., 2013)). RAGE is expressed on a wide-range of cells including 
neutrophils, DCs, monocytes/macrophages, lymphocytes, cardiomyocytes, and 
neurons (Brett et al., 1993; Schmidt et al., 1993), and responds to a number of 
ligands, e.g., advanced glycated end products, DNA, RNA, HMGB1 (reviewed by 
(Shen et al., 2013; Sorci et al., 2013)). Binding to ligands induces inflammatory 
cascades including, NF-κB, Janus kinase (JAK)–signal transducer and activator 
of transcription (STAT) and MAPK signalling pathways. This results in induction 
of pro-inflammatory cytokines such as TNFα ((Hofmann et al., 1999; Huang et 
al., 2001; Shang et al., 2010), reviewed by (Dukic-Stefanovic et al., 2001)). 
As with non-sterile inflammation, the resolution of sterile inflammation requires 
both the inhibition of inflammatory cell recruitment and prompt removal of 
apoptotic and necrotic cells that remain at the site of injury. Previous studies using 
PMNs have demonstrated apoptotic neutrophils secrete an anti-inflammatory 
regulator annexin A1 (ANXA1) and that treatment of monocytes with the ANXA1-
containing supernatants of apoptotic granulocytes led to significantly decreased 
release of pro-inflammatory cytokines, such as TNFα, when the monocytes were 
endotoxin-challenged (Pupjalis et al., 2011). This treatment hampers monocyte 
interactions with activated endothelium. In zymosan (glycan derived from yeast 
cell walls) peritonitis mouse models, Anxa1 deficient animals display increased 
PMNs recruitment, as measured by flow cytometry. Intravital microscopy 
confirmed the neutrophil trafficking of the leukocyte-endothelium interaction 
process (Chatterjee et al., 2005). Interestingly, PMNs influx was observed in 




study describing early defects in phagocytosis of mice Anxa1 null macrophages 
(Yona et al., 2004). In vitro, Anxa1 deficient PMNs were more susceptible to 
activation shown by CD11b (integrin) expression when PAF was added 
(Chatterjee et al., 2005). In the light of existing reports, it is conceivable that this 
mediator triggers neutrophil apoptosis, regulates monocyte recruitment, and 
promotes apoptotic cell disposal by macrophages. It also induces macrophage 
reprogramming towards a resolving phenotype (reviewed by (Sugimoto, Vago, et 
al., 2016)).  
As for necrosis, necrotic cells are sensed by the NLRP3 inflammasome. Sterile 
inflammation triggers a robust accumulation of neutrophils to the site of tissue 
injury. However, in the absence of NLRP3 inflammasome neutrophil recruitment 
in the peritoneal cavity was reduced in mice injected with pressure-disrupted B16 
cells (a murine melanoma cell line) to induce necrosis. Furthermore, LPS-primed 
macrophages were stimulated with necrotic pressure-disrupted B16 cells, 
characterised by increased pro-inflammatory IL-1β release. This cytokine recruits 
neutrophils to sites of injury but also causes a number of auto-inflammatory 
syndromes. Thus, this could be a potential therapeutic target. Moreover, in 
NLRP3-deficient mouse macrophages exposed to B16 cells grown under hypoxic 
conditions and macrophages exposed to complement-lysed splenocytes failed to 
secrete IL-1β. This suggests that NLRP3, apart from sensing cellular injury 
induced by pressure disruption can also sense cellular hypoxia or complement-
mediated damage (Iyer et al., 2009). 
CLRs can also sense non-homeostatic death without microorganism 
involvement. One of such receptors is Mincle. Mincle is shown to induce pro-
inflammatory responses after sensing SAP130 released from dead cells. The 
nuclear protein SAP130 is a Mincle ligand (Yamasaki et al., 2008).  
To summarise, tissue injury in the absence of infection is detected via TLRs and 
other innate receptors. Although a distinct pathway exists (e.g. RAGE), it remains 
unclear whether tissue injury and microbial infection represent distinct stresses 
to the host. The issue is that these processes converge on the same receptors. 




transduction and gene expression when activated by an endogenous or a 
microbial stimulus (reviewed by (Barton, 2008)). This view is supported by the 
findings of (Li et al., 2001). It was found that necrotic cells can also induce a 
TLR2-dependent transcriptional response that is distinct from the response 
induced by microbial TLR2 ligands. In necrotic cells, TLR2 mediates NF-B 
activation and expression of inflammatory genes such KC and MIP-2 (Li et al., 
2001). 
As described, sterile inflammation notifies the host to the presence of a noxious 
stimulus and activates the innate immunity. However, there are no foreign 
antigens derived from microbes. Thus, activation of adaptive responses is not the 
point. This is open to debate whether sterile inflammation enhances the induction 
of adaptive immunity as compared to inflammation induced by a microorganism 
(reviewed by (Shen et al., 2013)). The question of inflammation but not sterile 
inflammation linking to the adaptive immunity as well as the differential signalling 
by microbial versus endogenous TLR ligands was also reviewed by (Iwasaki and 
Medzhitov, 2010). The differential signalling by exogenous (microbial) versus 
endogenous TLR ligands is suggested to be induced through the engagement of 
different co-receptors. Accordingly, microbial ligands lead to the induction of 
genes leading to inflammation, tissue repair and the initiation of adaptive 
immunity. Endogenous ligands are responsible for the induction of TLR signalling 
for activation of inflammation and tissue repair and do not trigger adaptive 
immunity (reviewed by (Iwasaki and Medzhitov, 2010)). 
Finally, sterile inflammation can be seen as a mechanism of a disease. In this 
aspect this type of inflammation can contribute to disease progression. For 
instance, the NLRP3 inflammasome has a critical role in the development of 
insulin resistance (Zhou et al., 2010; Vandanmagsar et al., 2011) and insulin 
resistance increases the risk of developing type 2 diabetes. Sterile inflammation 
is a hallmark of the pathology of many liver diseases, e.g. alcoholic and non-
alcoholic steatohepatitis wherein the trigger is hepatocyte death (reviewed by 
(Kubes and Mehal, 2012)). The importance of sterile inflammation in pathologies 




When sterile inflammation is not resolved, it has dramatic consequences. An 
example of this concerns sterile neuroinflammation. Even though it is intended to 
have a protective role, an excessive inflammatory response can result in further 
tissue damage (reviewed by (Banjara and Ghosh, 2017)). S100 protein is 
released at sites of inflammation (Foell et al., 2006) and S100B in Alzheimer’s 
disease, the S100B level is highest in the most severely affected regions of the 
brain, being associated with plaques (Eldik and Griffin, 1994). 
Sterile inflammation is linked to autoimmunity. For instance, systemic lupus 
erythematosus, is associated with increased circulating levels of double stranded 
DNA; Muckle–Wells syndrome is caused by missense mutations in the 
nucleotide-binding oligomerisation domain (NOD)-like receptor family member 
NLRP3 (reviewed by (Chen and Nuñez, 2010)), NLRP3 inflammasome is 
upregulated in rheumatoid arthritis (Mathews et al., 2014). 
To conclude, further research should be done to investigate the initiation and 
resolution of sterile inflammation as this could lead to novel therapeutics.  
1.7 Thesis aims 
 
When in 2012 I was appointed to the Johnston lab as a research assistant, my 
role was to complete a research programme with the goal of understanding how 
cryptococcal infection causes a disease in humans. At the time there was no 
model, which would enable tracking macrophages (that are the dominant 
phagocytic cells interacting with Cryptococcus) and cryptococci in the entire body 
of a host. Therefore, there was a pressing demand to extend the range of existing 
models to study immunity to cryptococcal infection. Zebrafish seemed an 
attractive tool considering these animals have been used successfully to study 
fungal pathogens (Brothers et al., 2013; Herbst et al., 2015). 
Therefore, I started with the question of developing a zebrafish model of 
cryptococcosis. I also wanted to address the question of macrophages behaviour 
during the early phases of infection. More work was added and with the help of 
colleagues, this resulted in a publication (Bojarczuk et al., 2016), which is 




Chapter 4 concerns C. gattii and was linked to the general question I asked when 
appointed to the Johnston lab- how Cryptococcus causes a disease? I focused 
on R265, which is a clinical hyper virulent C. gattii VIO isolate and the mechanism 
underlying its pathogenicity, growth requirements and mechanism of infection 
remained unknown. Thus, the question was how C. gattii R265 strain has 
acquired a hyper virulent phenotype that causes disease in immunocompetent 
individuals. 
In science, some discoveries are goal-orientated but some discoveries come 
about from curiosity and secondary experiments. My colleagues and I showed 
that MMF reduced macrophages numbers during cryptococcal infection. The 
reduced numbers in macrophages resulted from cell death (Gibson et al., 2018). 
One critical innate immune response is triggering neutrophilic inflammation, 
which subsequent resolution of is essential for the return to homeostasis. Despite 
the frequent use of MMF in autoimmune and inflammatory conditions, little was 
known about MMF’s direct effects on neutrophils. Therefore, I wanted to ask 
whether the induction of neutrophil cell death can occur under MMF treatment 
upon the observation of the macrophage cell death (Gibson et al., 2018). 
Thus, I have addressed the following three core hypotheses in this thesis: 
1) Zebrafish can be used as an experimental model of cryptococcosis to 
understand the role of macrophages in cryptococcosis. 
2) C. gattii growth assessment in the zebrafish model of cryptococcosis will reveal 
the cause of its virulence.  
3) Immunosuppression therapy with the common immunosuppressant 
mycophenolate mofetil (MMF) has an effect on neutrophils. 
In regards to 1), the lack of the in vivo model of cryptococcocis was the gap in 
knowledge at the time the aim of my work was formulated. I aimed to develop a 
new infection model of the opportunistic fungal pathogen C. neoformans in 
zebrafish. Zebrafish are ideal to be a model of cryptoccocal infection due to the 




vertebrate. Cell biology data can be interpreted in the context of the whole 
disease and organism. 
The objectives were to investigate the host-pathogen interaction on the 
(sub)cellular level through imaging of infection using fluorescently labelled 
pathogen and immune cells, enabling detailed analysis of cell biology data in the 
context of the whole disease and organism. The study of host and pathogen 
factors was to determine disease progression and outcome in vivo. The focus 
was on macrophages in particular as they have undoubted significance in anti-
cryptococcal immunity. 
In regards to 2), the aim was an assessment of R265 virulence in vivo in the 
zebrafish model developed in 1) and an identification of the reasons as to why 
the strain is virulent. The objectives were to employ R265 GFP14 to facilitate the 
pathogen visualisation in zebrafish. Both R265 wt and R265 GFP14 show normal 
growth in macrophages in vitro (Voelz et al., 2010). Again, the focus was on 
macrophages to study host-pathogen interactions in vivo in zebrafish. To answer 
the hypothesis that R265 assessment in vivo and in vitro will reveal the cause of 
its virulence, a mouse model of infection as well as metabolic screen were 
employed.  
In regards to 3), the aim of this project was to understand neutrophil responses 
influenced by MMF with the hypothesis MMF has a direct effect on neutrophil 
function. 
MMF is an immunosuppressive agent used not only in solid organ 
transplantations, but also in the treatment of autoimmune and inflammatory 
conditions. A great deal of research on MMF has been conducted on 
lymphocytes, monocytes, and macrophages. MMF significantly reduces the 
number of macrophages due to macrophage cell death in the absence of 
lymphoid cells (Gibson et al., 2018). MMF’s direct effects on neutrophils are less 
clear. No significant progress has been made in this area in spite of frequent MMF 
use in inflammatory, including neutrophilic conditions. Considering that MMF is 




the question has arisen if MMF might directly influence neutrophils independent 
of lymphoid factors. Many questions remain regarding not only the mechanism of 
MMF by which neutrophils are regulated in inflammatory diseases, where MMF 
effect is very likely to be founded on innate-adaptive relationship of 
interdependence. Moreover, what is unknown is the direct effect of MMF on 
neutrophils in the absence of adaptive immunity. The objectives were to use 
existing models of inflammation initiation and resolution in zebrafish. I address 
the question of specific effects of MMF on neutrophils using an in vivo zebrafish 
model of neutrophilic inflammation to understand the mechanism of the 


















Chapter 2: Materials and Methods 
2.1 Ethics statement 
These studies have been subjected to guidelines set out in UK law in the Animals 
(Scientific Procedures) Act 1986, under relevant project licenses (infection 
40/3574 and P1A4A7A5E; and inflammation 70/8178). Ethical approval was 
granted by the University of Sheffield Local Ethical Review Panel. 
2.2 Fish husbandry 
Zebrafish were maintained according to standard protocols (Nüsslein-Volhard 
and Dahm, 2002) and local animal welfare regulations. Adult fish were maintained 
on 14-10 hour light cycle at 28°C in UK Home Office approved facilities in the 
Bateson Centre aquaria at the University of Sheffield. Adults were bred by either 
marbling or pairing. Marbling technique is with the use of receptacle containing 
marbles placed into a fish tank overnight. Pairing technique involves placing one 
female and one male into a small mating tank with a plastic grid at the bottom to 
enable the embryos to fall into a separate space below and dividing the fish over 
night with a plastic divider. In all cases, embryos were collected the following 
morning by pouring the pairing or marble tank water through a plastic tea strainer. 
Embryos were collected into petri dishes (Scientific Laboratory Supplies Ltd 
(SLS), UK, Cat. No. PET3004) filled with aquarium water.  
After collection, embryos were sorted with a pasteur pipette (Starlab Ltd, UK, Cat. 
No E1414-0300) in petri plates filled with 1X E3 solution diluted in distilled water 
and 0.00005% methylene blue was added (E3 10X stock 5 mM NaCl, 0.17 mM 
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4 and 0.5% methylene blue (Sigma Aldrich, 
UK, Cat. No. 50484) were provided by the aquarium). Healthy and representing 
the same developmental age embryos were then moved into a new petri dish with 
1X E3 and incubated at 28°C. The fish density was 60 embryos per plate. E3 
medium consists of the salts required to maintain the pH for optimal embryo 
development. Methylene blue is an anti-fungal agent, which  disrupts classical 




(Schirmer et al., 2011). In experiments with Cryptococcus methylene blue was 
not added after zebrafish injections. 
Embryos at 2 days post fertilisation (dpf) were dechorionated using two pairs of 
Dumont No. 5 forceps (SLS, UK, Cat. No. F6521-1EA). Dechorionation occurred 
in a petri dish filled with 1X E3 containing 0.00005% methylene blue. Using one 
pair of forceps to hold the chorion, a tear was made in the chorion with the other 
pair of forceps, releasing the embryo. Dechorionated animals were transferred in 
a pasteur pipette into another petri plate with 1X E3 and methylene blue. 
Embryos were immobilised/anaesthetised by immersion in 0.0168% 3-amino 
benzoic acid ethyl ester, referred to as tricaine (Henry Schein Animal Health, UK, 
Cat. No. TJMS222) in 1X E3 for injuring, infection or imaging purposes. 
In all experiments, zebrafish were below 5.2 dpf and thus were not protected 
animals under the Animals (Scientific Procedures) Act 1986. 
2.2.1 Zebrafish lines used in the study 
The wild-type and transgenic zebrafish lines used in this work are listed in Table 
2.1. Zebrafish AB and nacre (Lister et al., 1999) were used as wild-types. The 
transgenic zebrafish lines, Tg(fms:Gal4.VP16)i186; Tg(UAS:nfsB.mCherry)i149 
(Gray et al., 2011), Tg(mpeg1:mCherryCAAX)sh378 (Bojarczuk et al., 2016), 
Tg(mpx:GFP)i114 referred to as mpx:GFP (Renshaw et al., 2006) and 
Tg(mpx:Gal4)i222(UAS:Kaede)s1999t referred to as mpx:Kaede (A. L. Robertson et 
al., 2014), were used in this project.  
Tg(fms:Gal4.VP16)i186; Tg(UAS:nfsB.mCherry)i149 (Gray et al., 2011), is a 
compound transgenic line generated by in-crossing Tg(fms:Gal4.VP16)i186 and 
Tg(UAS-E1b:nfsB.mCherry)i149. The Tg(fms:Gal4.VP16)i186 was made by using 
bacterial artificial chromosome (BAC) recombineering. In this line, the fms 
promoter drives the expression of the hybrid transcription factor Gal4-VP16. 
Tg(UAS-E1b:nfsB.mCherry)i149 line expresses a fusion protein of nitroreductase 
and mCherry under the UAS promoter. Thus, the resulting compound transgenic 




GAL4-UAS system, wherein the fms promoter drives Gal4 expression, which, in 
turn, drives expression of the nitroreductase. mCherry fusion protein under the 
control of UAS. The line labels macrophages where the fms promoter is active. 
The line is in AB background. 
Tg(mpeg1:mCherryCAAX)sh378 (Bojarczuk et al., 2016) was generated using the 
Gateway Tol2Kit system (Kwan et al., 2007) by recombining mpeg1, 
mCherryCAAX and a 3’polyA with the gateway destination vector. In this line a 
membrane targeted mCherry is under the control of the macrophage-specific 
mpeg1 promoter (Ellett et al., 2011). The line is in nacre background. 
In mpx:GFP neutrophils are labelled with GFP. Expression of the 
myeloperoxidase (mpx, also called mpo) gene is confined to neutrophils 
(Lieschke et al., 2001). The line was made using BAC recombination. A BAC 
(zC91B8) containing promoter sequence to the mpo gene was modified to contain 
green fluorescent protein (GFP) sequence. The modified BAC prep was 
microinjected into one cell stage AB wild-type zebrafish embryos to create the 
transgenic line (Renshaw et al., 2006). 
Mpx:Kaede was made by crossing Tg(mpx:Gal4.VP16)i222 and 
Tg(UAS:Kaede)s1999t (A. L. Robertson et al., 2014).  
The Tg(mpx:Gal4.VP16)i222 was made using BAC recombineering, replacing 
GFP with GAL4. The Tg(UAS:Kaede)s1999t was imported from the Institute of 
Molecular and Cell Biology fish facility (Singapore) and originally made by 
(Davison et al., 2007). The mpx:Kaede line is defined as Tg(mpx:Gal4)i1222 
(UAS:Kaede)s1999t. This line recapitulates mpx:GFP and expresses Kaede, a 
photoactivatable fluorescent protein, in neutrophils when crossed to UAS:Kaede. 















Table 2.1 Zebrafish lines used in the study  
 
 Zebrafish line Zebrafish line 
Description  
Reference 
nacre  wild-type with loss of pigment cells (Lister et al., 1999) 
AB wild-type The AB line is derived 
from two lines, A and 
B, purchased by 
Streisinger at different 
times from a pet shop 




fms promoter drives GAL4 expression, which, in turn, 
drives expression of the nitroreductase.mCherry fusion 
protein under the control of UAS; nfsB.mCherry labelled 
macrophages  
 
(Gray et al., 2011) 
Tg(mpeg1:mCherryCAAX)sh378 mCherry labelled macrophages under the control of  
mpeg1 promoter 
(Bojarczuk et al., 
2016) 
Tg(mpx:GFP)i114 referred to as mpx:GFP; neutrophils labelled with GFP 
under mpx promoter  
(Renshaw et al., 
2006) 
Tg(mpx:Gal4)i222(UAS:Kaede)s1999t referred to as mpx:Kaede; GFP labelled neutrophils that 
express Kaede after photoconversion 





2.3 Cryptococcal strains cultivation 
 
C. neoformans or C. gattii stocks were kept in -80°C freezer (Wolf Laboratories 
Ltd., UK, Cat. No. U9400-0001) in Microbank™ vials (Fisher Scientific Ltd., UK, 
Cat. No. 15937902), commonly used in laboratories (Hagen et al., 2015). The 
Microbank™ incorporate beads and a cryopreservative solution to ensure longer 
survival of the cultures and higher quantitative recoveries. One bead from a frozen 
stock was streaked in the laminar flow cabinet with a 2-200 µl filtered tip (SLS, 
UK, Cat. No. E0030077784) on a petri plate containing yeast extract peptone 
dextrose agar (YPDA) plate (50g/l YPD broth + agar 2g/l – both from Sigma-
Aldrich, Cat. No. Y1375 and 05039, respectively and made up in distilled water) 
and grown at 28°C for two days. Then the cultures were re-streaked with an 
inoculation loop (Fisher Scientific Ltd, UK, Cat. No. 11715229 ) onto fresh YPDA 
plates in the laminar flow cabinet and cultured for another two days at 28°C. 
These were the working stocks, kept in the 4°C for the maximum period of 4 
weeks (if not contaminated).  
 2.3.1 Cryptococcus strains used in this study  
Cryptococcus strains used in this study are listed in Table 2.2. 
C. neoformans H99, KN99 and C. gattii R265 were used as wild-types, hereafter 
referred to as H99 wt, KN99 wt and R265 wt, respectively. H99 wt is serotype A 
mating type α and it is C. neoformans var. grubii strain. KN99 wt is a congenic 
strain in the H99 genetic background and obtained from the Heitman lab (Nielsen 
et al., 2003). H99 wt and its GFP-expressing derivative H99 GFP were obtained 
from the May lab (Voelz et al., 2010). H99 GFP is a biolistically transformed H99 
wt (Voelz et al., 2010).  
C. neoformans cap59 has severely compromised capsule formation (Chang and 
Kwon-Chung, 1994). Cap59 mutant was generated by disrupting CAP59 gene in 
H99 by biolistic bombardment (Nelson et al., 2001). Cap59 was obtained from 
the May lab. 
KN99 GFP is a biolistically transformed KN99 wt generated in the May lab 




C. gattii R265 wt and R265 GFP14 were obtained from the May lab. R265 GFP14 















































A, VNIb  clinical isolate, 
USA, mating 
type α 














































Table 2.2 (continued) 
C. gattii  
R265 

















(Voelz et al., 2010), sequence reads used in Chapter 4 obtained from 
https://www.ncbi.nlm.nih.gov/sra/SRX213992 
C. gattii  
WM276 





the genome used in Chapter 4 was obtained from 
https://www.ncbi.nlm.nih.gov/genome/45142?genome_assembly_id=27














2.4 Preparation of C. gattii culture for phenotypic microarrays 
 
The protocol was optimised based on (Zhou et al., 2003; Nielsen et al., 2005).  
C. gattii strains (R265 wild-type (wt) and R265 GFP14) were cultivated as in 
section 2.3 Cryptococcal strains cultivation.  
A day before the infection experiment, petri plates with R265 wt and R265 GFP14 
were taken from the 4°C. In the hood, a few colonies were scooped up from 
across the plate taken with the inoculation loop. The sample was introduced to 2 
ml of yeast peptone dextrose (YDP) broth medium (50g in 1 litre of distilled water) 
added to a 14 ml culture tube (Fisher Scientific Ltd, UK, Cat. No. 11681460) and 
placed in a rotator, to prevent fungal cells clumping, at 28°C and 20 rotations per 
minute (rpm) overnight (for 16-18 hours). The minimum of seven samples of each 
strain was set up for overnight rotation. This was due to 30 ml capacity of 
turbidimeter tubes (Technopath Distribution Ltd., UK, Cat. No. 72101) used later 
in the protocol. 
The overnight 2 ml liquid culture was mixed by pipetting up and down. 1 ml of this 
culture was then pelleted at 6,000 rpm, room temperature (RT) for 1 minute in a 
1.5 ml microcentrifuge tube (University of Sheffield, UK, Cat. No. 100326Z). 
Supernatant was removed and cells were washed with 1 ml of 1X phosphate 
buffered saline ((PBS); ThermoFisher Scientific Ltd, UK, Cat. No. BR0014). To 
obtain 1X PBS a single tablet was dissolved in 100 ml of distilled water, and 
autoclaved to sterilise before use. After the wash the cells were resuspend in 12X 
YNB (Generon, UK, Cat. No. S507-100g) supplemented with histidine (HIS), 
leucine (LEU) and uracil (URA) (all Sigma-Aldrich, UK, Cat. No. H0750000, 
L8000-25G and UO750-25G, respectively). The contents of microcentrifuge 
tubes with fungal cells, 12X YNB and amino acids were transferred into relevant 
R265 wt and R265 GFP14 turbidimeter tubes. The blank was the supplemented 
12X YNB without the cells. The cells were adjusted to 18% transmittance using 
turbidimeter tubes and a turbidimeter (Biolog, USA, Cat. No. 3587). The fungal 





The 12X YNB was made according to manufacturer’s instructions. 10X YNB is 
achieved by dissolving 6.7 g in 100 ml distilled water. Thus, 12X YNB was made 
by adding 8.04 g into 100 ml distilled water. Next, 12X concentrated amino acids 
(24 mg HIS, 120 mg LEU, and 24 mg URA) were added, i.e. the final 
concentration of amino acid in the well after addition of IFY-0 was 20 µg/ml HIS 
and URA, 100 µg/ml LEU. After supplementing YNB medium with amino acids, 
which are supplements for corresponding auxotrophic markers commonly 
present in Saccharomyces laboratory (personal communication with Biolog, 
which supplies Technoplast Distribution Ltd. in the UK), the pH of the medium 
was adjusted to 5.4 and sterilised with 0.22 µm filters (Sigma-Aldrich, UK, Cat. 
No. SLMPL25SS)  in the hood, in agreement with the manufacturer’s instructions. 
Of note, the YNB preparation includes glucose of dextrose addition. Sugar was 
not added in my protocol as cryptococci will use those substrates instead of what 
is in the plate. 
Next, 10 ml of PM additive was prepared. This comprised 1.2X IFY-0 base 
(Technopath Distribution Ltd., UK, Cat. 72231) supplemented with 5 mg/ml 
(NH4)2SO4, (VWR International Ltd, UK, Cat. No. 444445Q), 0.85 mg/ml KH2PO4, 
0.15 mg/ml K2HPO4 and 0.5 mg/ml MgSO4 (Sigma-Aldrich, UK, Cat. No. P5655, 
60353, M2643 respectively), all at 12X. PM additive was then 0.22 µm filter-
sterilised in the hood. 
The fungal cells along with the PM additive were then carried to Sheffield Institute 
for Translational Neuroscience (SITraN). With the help of Dr Scott Allen, Senior 
Non-Clinical Fellow, the experiment was set up as follows: one hour before cells 
arrived to SITraN, two PM1 plates (Technopath Distribution Ltd., UK, Cat. No 
12111) along with a 1.2X IFY-0 base solution were taken out from the 4°C cold 
room to warm up. In the laminar hood, two centrifuge 15 ml universals (Sigma-
Aldrich, UK, Cat. No. CLS430055-500EA) were used: one for R265 wt and one 
for R265 GFP14. Into each tube, 9.84 ml of IFY-0 base, 1 ml of PM additive, 0.16 
ml of dye D (Technopath Distribution Ltd., UK, Cat. No. 74224) and 1 ml of fungal 




light was off in the hood. Next, 100 µl of this master mix was added to R265 wt/ 
R265 GFP14 PM1 plates. 
The plates were sealed with sterile seal-plate film (Sigma-Aldrich, UK, Cat. No. 
Z369667-100EA) to stop gas transfer and incubated in an OmniLog Phenotype 
Microarray system at 30°C. The dye colour change was measured every 15 min 
for 36 hours. 
Unfortunately, little that can be said about reagents used in the phenotypic assay 
because Biolog considers most of the information proprietary (personal 
communication with Biolog Technical Support). The exact concentrations of 
chemicals are not important, as long as the concentrations are in a typical range 
that cells prefer. For example, typical ranges for carbon sources would be 2 to 20 
mM (Biolog’s policy on disclosing PM MicroPlate Chemistry). 
2.5 Phenotypic microarrays  
PM1 are only-carbon utilisation plates, which are carbohydrate plates used for 
metabolic tests for bacteria and fungi. This is a system where fungal cells are 
metabolically profiled using a 96 well plate assay where every single well is 
coated with a different energy substrate. Essentially the cells are added to the 
plate in supplemented media without any carbohydrates as the cells will use 
those substrates instead of what is in the plate. Therefore, although dextrose is 
recommended by the supplier to be added to YNB, it was not added on top of 
amino acids. The plates were incubated at 30°C for 36 hours in an OmniLog 
machine. The dye D is a redox dye, which picks up electrons from NADH+ 
produced by the cells metabolising the energy substrate in the well. When 
reduced the dye turns purple and the colour change can be kinetically monitored 
in the OmniLog machine. The system has a charge-coupled device (CCD) 
camera taking pictures every 15 minutes and converts the differences in the 
colour change into CCD Camera Units and then into kinetic data. The metabolic 
profile of the cells at 144 different points in the cellular metabolic pathway is 





2.6 Cryptococcal culture and counting 
 
A day before any experiment including cryptococcal culture, a petri plate with the 
strain of interest was taken from the 4°C. In the laminar flow cabinet, a few 
colonies were scooped up from across the plate taken with the inoculation loop. 
This assures heterogeneity of the sample. The sample was introduced to 2 ml of 
yeast peptone dextrose (YDP) broth medium (50g/l) added to a 14 ml culture tube 
(Fisher Scientific Ltd, UK, Cat. No. 11681460) and placed in a rotator, to prevent 
the cells from clumping. This was at 28°C, 20 rotations per minute (rpm) and 
overnight (for 16-18 hours).  
The overnight 2 ml liquid culture was mixed by pipetting up and down in the 
laminar flow cabinet. 1 ml of this culture was then pelleted at 6,000 rpm, room 
temperature (RT) for 1 minute in a 1.5 ml microcentrifuge tube (University of 
Sheffield, UK, Cat. No. 100326Z) using Genfuge 24D centrifuge (Progen 
Scientific Ltd, UK, Cat. No. C-2400). While the sample was centrifuging, 95 μl of 
PBS in the laminar flow hood was added to another microcentrifuge tube. The 
collected pellet was re-suspended in 1 ml of PBS. 5 μl of re-suspended culture 
was then added to the previously dispensed 95 μl of PBS (making 1:20 dilution) 
and mixed by pipetting up and down prior to counting. This was also done in the 
hood. The sample was then centrifuged and only the pellet was kept. The number 
of C. neoformans/C. gattii cells from the 1:20 diluted sample were counted using 
the Neubauer haemocytometer (Camlab, UK, Cat. No. 1127884). 
The haemocytometer was assembled by placing the coverslip carefully on the top 
of the middle section of the chamber slide. To count each culture, 10 μl of the 
diluted culture was taken and carefully pipetted between the coverslip and the 
counting chamber. The cells were counted in the most central 25 squares using 
a 10X objective lens (Figure 2.1) Each red square of the haemocytometer 
represents the total volume of 0.1 mm3=10-4 cm3 (1 mm2 area x 0.1 mm depth). 
Since 1 cm3 corresponds to the volume of 1 ml, the subsequent cell concentration 
per ml (and the total number of cells) was calculated as: number of cells per ml= 
average cell count in the most central 25 squares x dilution (20) x 104 (to correct 






Figure 2.1 Haemocytometer grid. Red square area= 1 mm2, to convert into volume: 
1 mm2 x 0.1 mm (depth)=0.1 mm3=0.1 µl=100 nl; green square area=0.25 mm x 0.25 
mm=0.0625 mm2, to convert into volume: 0.0625 mm2 x 0.1 mm (depth)=0.00625 
mm3=0.00625 µl=6.25 nl; yellow square area=1 mm2/25=0.04 mm2, to convert into 
volume: 0.04 mm2 x 0.1 mm (depth)= 0.004 mm3=0.004 µl= 4 nl; blue square 
area=1/25/16=0.0025 mm2, to convert into volume: 0.0025 mm2 x 0.1 mm 
(depth)=0.00025 mm3=0.00025 µl=0.25 nl 
The correction of 104 results from the following proportions: if there are, e.g. 200 
cells in 0.1 mm3 (red square in Figure 2.1) being equal to 200 cells in 0.1 µl, then 
the number of cells in 1 ml is calculated as: 
200 cells-0.1mm3 (1 red square)      
X cells-1 ml                                                                         
                                                                              
this equals to        200 cells-0.1 µl (1 red square) 
                             X cells-1000 µl 
X cells= (1000 µl x 200 cells)/0.1 µl=200 x104 
2.7 In vitro growth of C. gattii strains in rich and minimal media 
 
On day 0 two cultures of R265 wt and two of R265 GFP14 were set up overnight 
as described in section 2.6 Cryptococcal culture and counting. Each sample was 
in 2 ml of YPD. On day 1, the two R265 wt samples were mixed with each other 




volume. Out of these samples, three samples of 1 ml in YPD for each strain were 
prepared. This was without knowing their concentrations. Then 50 µl of each 
sample was introduced to 1950 µl of either YPD or the minimal medium. These 
six samples were incubated overnight at 28°C, 20 rpm. On day 2, the samples 
were counted in 1ml of PBS on a haemocytometer as described in section 2.6 
Cryptococcal culture and counting. However, no difference was observed. 
Therefore, the cells were re-introduced to either YPD or minimal media and grown 
for one more day, i.e. incubated overnight at 28°C, 20 rpm. On day 3 final counts 
were taken.  
2.8 General zebrafish techniques 
2.8.1 Tail fin injury 
Zebrafish larvae were anaesthetised by immersion in 0.0168% of tricaine in a 
petri dish in 1X E3. A surgical scalpel blade (Fisher Scientific, Cat. No.11738373) 
was used to fully transect the caudal fin in order to initiate inflammatory response. 
The injury was always performed at the distal-most point of the pigment gap at 2 
dpf (Figure 2.2). After tail transection, fish were transferred into another E3 plate 
















Figure 2.2 Tail transection of 2 dpf zebrafish larva. The tail fin was transected at 
the point indicated by the dotted black line. The blue dashed line with an arrowhead 


























2.8.2 Time course counting 
 
Following tail transection, larvae were anaesthetised in 0.0168% tricaine and 
viewed under a fluorescent stereo microscope both in bright field and GFP 
channels (Nikon SMZ1000). GFP brightness was of 100% on the Nikon C-HGFI 
Intensilight Precentered Fiber Illuminator whereas bright field lighting was 
adjusted with the control knob without the illuminator. In each individual fish, the 
number of neutrophils at the site of injury was counted by eye. The count involved 
only neutrophils posterior to the circulatory loop. 
In all experiments, larvae were immersed in a solution of the test compound 
diluted in 1X E3 embryo media. In experiments including 1 time-point, larvae were 
transferred into separate petri dishes with 1X E3 and anaesthetised in 0.0168% 
tricaine (1 fish per dish). After counting the number of neutrophils persisting at 
the site of injury, fish were culled. 
In experiments including 2 time-points, the number of neutrophils was assessed 
as described above. Following the count, fish were transferred into fresh 1X E3 
medium to allow recovery. Thereafter larvae were added to new wells to achieve 
the desired concentration of test compounds. Only after the final count, fish were 
culled. 
2.8.3 Compound treatment of zebrafish larvae 
96-well plates (SLS, UK, Cat. No. 324001) were set up for experiments involving 
chemical treatment of larvae. Compounds tested were made up in dimethyl 
sulfoxide (Sigma Aldrich, UK, Cat. No. D8418). Compound administration was by 
immersion of the larvae in a solution of the test compound diluted in 1X E3 
embryo media. The total well volume was 200 µl. 
Mycophenolate mofetil (MMF) was dissolved in dimethyl sulfoxide (DMSO) to a 
concentration of 10 mM and then diluted to 1 mM in DMSO. 1 mM aliquots were 
used to make 1 μM in 1X E3 medium stored in -20°C. The final working 




SP600125 was dissolved in DMSO to 30 mM and stored in -20°C. This was then 
diluted in 1X E3 to a working concentration of 30 μM. 
Azathioprine (AZA) was dissolved in DMSO at 37°C into 83 mM aliquots, which 
were stored at -20°C. These were diluted in 1X E3 to a working concentration of 
200 μM. 
Z-VAD was dissolved in DMSO to 20 mM and stored at -20°C. The working 
concentration was 100 μM in 1X E3. 
The concentration of DMSO used in vehicle controls was always equal to the 
highest concentration of DMSO used to dilute compounds in an experiment 
(Table 2.3). For instance, if MMF and SP600125 were used, the concentration of 
DMSO used as a control would be equivalent to SP600125 (0.1%). 
Table 2.3 Compound treatments in MMF study 
 
Treatment Final DMSO 
concentration  
Supplier Product code 
0.5 µM MMF 0.05% DMSO Sigma-Aldrich, UK SML0284 
30 µM SP600125 0.1% DMSO Cambridge 
Bioscience, UK 
SM41 
200 µM AZA 0.2% DMSO Sigma-Aldrich, UK A4638 
100 µM Z-VAD  0.5% DMSO Santa Cruz 
Biotechnology, UK 
sc-311561A 
100 µM Z-VAD with 0.5µM 
MMF 





Suggested therapeutic range of MMF in liver transplant recipients falls between 
1.0–3.5 µg/ml (through serum or plasma levels, equivalent of 3.125 μM -10.9 μM, 
respectively) (Tredger et al., 2004). In the body of liver transplant patients it 




However, in zebrafish MMF produces some toxic effects. The concentration of 
0.9 µM/l significantly reduces blood vessel formation and above 1.5 µM/l prevents 
any extended development of intersegmental blood vessels (Wu et al., 2006). 
Due to inability to introduce therapeutic doses resulting in the inhibition of 
angiogenesis, a safe concentration of 0.5 μM has been established in the 
Johnston lab (Gibson et al., 2018). 
2.8.3.2 SP600125 
 
SP600125 is an inhibitor of c-Jun N-terminal kinase that has been suggested to 
promote TNFα mediated neutrophil apoptosis (Avdi et al., 2001; Hallett et al., 
2008). The compound demonstrated a great ability to drive inflammation 
resolution in zebrafish by significantly reducing the number of neutrophils at 12 
hpi as compared to DMSO and GSK650394 (personal communication; A. 
Robertson). GSK650394 is an inhibitor of serum- and glucocorticoid-regulated 
kinase-1 (SGK-1) and drives inflammation resolution (Burgon and Renshaw, 
2013) but SP600125 is even more potent. Its effect was demonstrated in a 
zebrafish compound screen for accelerators of inflammation resolution (A. L. 
Robertson et al., 2014). To minimise the chance of picking up false positives or 
inhibitors of recruitment, larvae with mounted inflammatory response at 4 hpi 
were chosen and treated with library compounds. These were tested alongside 
untreated controls, DMSO vehicle and either 10 µM GSK650394 or 30 µM 
SP600125 as a positive controls (A. L. Robertson et al., 2014).This was followed 
by manual scoring at 12 hpi, when inflammation resolution is only partially 
complete in controls (Renshaw et al., 2006). The manual scoring was between 0 
and 3, based on the number of larvae within the well that appeared to have a 
reduced number of neutrophils at the site of injury at 12 hpi (A. L. Robertson et 
al., 2014). The mean score of 1.5 was used as the threshold for positive hit 
selection. In some instances GSK650394 treatment produced a precipitate, thus 
SP600125, at the concentration of 30 µM was considered to represent a better 
and more stable control (personal communication; A. Robertson). The secondary 





Based on those results, SP600125 was used in resolution assays in my zebrafish 
experimental work. However, it should be noted, the compound has also been 
reported to affect granulocyte chemotaxis (Zhang et al., 2008) and in zebrafish to 
block neutrophil recruitment to damaged neuromasts in the lateral line (d’Alençon 
et al., 2010). Moreover, SP600125 attenuates JUN N-terminal kinase (JNK) 
mediated recruitment of neutrophils and monocytes to the lungs in a mouse 
model of LPS-induced lung injury (Arndt et al., 2005; Young and Arndt, 2009). 
SP600125 inhibits macrophage migration to the wound in the tail injury zebrafish 
model and this is partially via the inhibition of matrix metalloproteinase 1 
(MMP13), which is a down-stream target of the JNK-AP-1 transduction pathway, 
important in remodelling of the extracellular matrix to assist chemotaxis (Zhang 
et al., 2008). The line used in the study was transgenic Tg(zlyz:EGFP) labelling 
neutrophils, recruitment of which was suppressed by SP600125. Based on this 




AZA is composed of 6MP in 55% by molecular weight and 88% of AZA is 
converted to 6MP (Bradford and Shih, 2011). Metabolism of AZA, as described 
in section 5.1.6 Azathioprine (AZA), involves three competitive pathways through: 
1) hypoxanthine phosphoribosyltransferase (HPRT) activity to convert 6-
mercapturine (6MP) into 6-thioinosic acid (6TA) followed by inosine-5’-
monophosphate dehydrogenase (IMPDH) activity to convert 6TA into 6-
thioguanine monophosphate (TGMP), further forming 6-thioguanine nucleotides 
(6TGNs), of which 6-thioguanine triphosphate (TGTP)-is the main compounds 
associated with immunosuppression (Lennard et al., 1989); 2) TPMT activity in 
6MP conversion into methylmercaptopurines (MeMPNs) associated with hepatic 
toxicity (Lennard et al., 1989); 3) xanthine oxidase (XO) activity in transformation 
of 6MP into inactive 6TU (Chan et al., 1990). An assay to detect the major AZA 
and 6MP toxic metabolites, namely 6TGNs was established using red blood cells 
(RBCs) (Lavi and Holcenberg, 1985). The level of the toxic metabolites in RBCs 




check levels of TPMT as patients’ genetic polymorphism in TPMT enzyme 
influences their responsiveness to therapy (Cuffari, 2006). The recommended 
dose for AZA is 2-2.5 mg/kg per day (Bradford and Shih, 2011).  
AZA has been used in zebrafish in two separate studies. Firstly, to investigate 
drug-induced seizures with no positive result seen at the concentration of 200 
and 600 µM in water (Koseki et al., 2014). Secondly, to study the effects on 
macrophages during cryptococcal infection. The concentration used was 200 µM 
in 0.16 mM NaOH (Gibson et al., 2018). In this present work, AZA was at the 
same concentration but dissolved in DMSO.  
2.8.3.4 Z-VAD 
 
Z-VAD is a dipeptide pan-caspase inhibitor. It has been shown to have good cell-
permeation properties through the plasma membrane to reach caspases (Reed, 
2002), where it binds irreversibly to the active site catalytic cysteine of caspases 
(Mittl et al., 1997). Caspases are related to cysteine proteases mediating cell-
suicide proteolytic reactions (Thornberry and Lazebnik, 1998), therefore critical 
in the intracellular signalling that triggers apoptosis (Jaeschke et al., 2000). 
Several lines of evidence indicated genetic or pharmacological inhibition of 
caspases can avert the cell death caused by endogenous and exogenous 
apoptosis stimuli (Yaoita et al., 1998; Braun et al., 1999; Mocanu et al., 2000). Z-
VAD was tested in zebrafish inflammation assays at 100 µM (Loynes et al., 2010). 
Thus, this dose was used in my work. 
2.8.4 Inflammation assays 
 
2.8.4.1 Recruitment  
 
To test neutrophil recruitment to tissue injury larvae were injured at 2 dpf by tail 
fin transection (Figure 2.2) to initiate an inflammatory response involving 
recruitment of neutrophils to the site of injury (Renshaw et al., 2006). The number 
of fluorescent neutrophils was counted by eye at 6 hpi at the wound site under a 
stereo microscope (Nikon SMZ1000 with Nikon C-HGFI Intensilight Precentered 




recruitment inhibiting effects of MMF. Neutrophils counted were posterior to the 
circulatory loop. Zebrafish were anesthetised by immersion in 0.0168% tricaine 
in 1X E3 prior to the count.  
2.8.4.2 Resolution  
 
To assess MMF activity in accelerating resolution of inflammation, larvae were 
injured at 2 dpf (Figure 2.2). The number of fluorescent neutrophils recruited to 
the inflammation site was assessed in the region posterior to the circulatory loop. 
Neutrophil number was counted manually by eye under a fluorescent stereo 
microscope (Leica MZ10F, GFP plus filter) at 6 hpi and 24 hpi (2 and 20 hours 
after addition of MMF, respectively). After 6 hpi count larvae were recovered in 
fresh 1X E3 and returned to a new well plate. Zebrafish were anesthetised by 
immersion in 0.0168% tricaine in 1X E3 prior the counts.  
2.8.4.3 Total number of neutrophils  
To evaluate the total number of neutrophils, uninjured fish were incubated with 
compounds for 24 hours and imaged at 6 and 24 hours. Prior to each time- point, 
fish were anesthetised by immersion in 1X E3 with 0.0168% tricaine and mounted 
in agar channels for imaging. Channels were made by adding 200 µl of 1% agar 
(Sigma Aldrich, UK, Cat. No. 05039) in 1X E3 containing 0.168% tricaine into 
glass-bottomed, 96-well plates (SLS, UK, Cat. No. 324001). Channels were cut 
in cooled agar using GelX4 tips (Alpha Laboratories Ltd, UK, Cat. No. EL2650). 
Each zebrafish was imaged as two or three contiguous fields of view depending 
on the age of fish (at 2 dpf fish are shorter and do not require three fields of view; 
however sometimes 3 dpf did not need three fields either) that were assigned 
from bright-field images. 81 z sections, 5 µm apart, were captured in GFP channel 
and a reference bright-field image was taken. Zebrafish were imaged on a Nikon 
Ti-E microscope with a CFI Plan Apochromat λ 10X, N.A.0.45 objective lens and 
using Intensilight fluorescent illumination with ET/sputtered series fluorescent 
filters 49002 (Chroma, Bellow Falls, VT, USA). Images were captured with a Neo 




Richmond, UK). Nikon Ti-E was fitted with a climate controlled incubation 
chamber (28 °C; Okolabs, Pozzuoli, Italy).  
After 6 hpi imaging, larvae were recovered in fresh 1X E3 and returned to a new 
numbered 96-well plate to be then imaged at 24 hpi. Image analysis of total 
neutrophil number was performed using a manual cell counter (VWR 
International Ltd, UK, Cat. No. 720-0162).  
2.8.4.5 Apoptosis 
To assess the rate of apoptotic neutrophils in vivo, mpx:GFP larvae were injured 
and selected as described in the resolution assay. At 12 hpi larvae were fixed 
overnight in 4% paraformaldehyde ((PFA); Fisher Scientific Ltd, UK, Cat. No. 
11406582) at 4°C. The next day Tyramide Signal Amplification (TSA) staining 
was performed using TSA plus kit (Fluorescence Systems, Perkin Elmer Inc., 
Waltham, USA, Cat. No. NEL741001KT). This tags neutrophils mpx to allow their 
visualisation under GFP filter. Before staining, larvae were washed in phosphate 
buffer saline ((PBS); Oxoid, UK, BR0014G) followed by a brief wash in 
amplification diluent from TSA kit. Larvae were then incubated at 28°C for 10 min 
in the dark in a 1:50 dilution of FITC TSA in amplification diluent. This step 
enabled fluorescence detection because the tyramide amplification reagent is 
directly labelled with a fluorophore. After the incubation, larvae were washed 3x5 
minutes in PBS and checked for successful stain before continuing with fixing at 
room temperature (RT) for 20 minutes in 4% PFA. To stain for an apoptotic DNA 
fragmentation- TUNEL (Rhodamine Apoptag Red In Situ) kit was performed 
(Millipore Ltd, UK, Cat. No S7165) (Figure 2.3). The assay utilises terminal 
deoxynucleotidyl transferase enzyme (TdT) to catalyse attachment of 
deoxyuridine triphosphate (dUTP) nucleotides contained in the reaction buffer to 
the broken DNA, specifically to its free 3'-OH termini. The nucleotides in the 
reaction buffer are linked with dioxygenin and are further detected by anti-
dioxygenin-rhodamine. The new DNA ends generated upon DNA cleavage and 
detection by enzymatically labeling the free 3'-OH termini with modified 
nucleotides are typically localised in morphologically identifiable nuclei and 




characterised by insignificant numbers of DNA 3'-OH ends. ApopTag Kit detects 
single and double-stranded breaks associated with apoptosis. For ApopTag Red 
in situ apoptosis detection staining larvae were washed for 3 times 5 min each in 
PBS, then left at room temperature in 10 µg/ml proteinase K for 90 min, washed 
2x5 minutes in PBT (PBS plus 0.1% Tween 20 (Sigma Aldrich, UK, Cat. No. 
P139)) and fixed for 20 minutes in 4% PFA at RT. This was followed by another 
2x5 minutes PBT washes and adding 1:2 of -20°C cold acetone:ethanol (acetone 
Sigma Aldrich, UK, Cat. No.650501; ethanol Fisher Scientific Ltd, UK, Cat. No. 
10428671) for 7 minutes at -20°C. After further 3x5 minutes PBT washes, larvae 
were incubated in 50 µl equilibration buffer for 1 hr at RT, which was then 
replaced with 16 µl TdT enzyme and 30 µl reaction buffer for 90 minutes at 37°C. 
Next, 200 µl Stop Buffer for 3 hours at 37°C was added. This was followed by 
3x5 minutes PBT washes, adding 62 µl anti-dig-rhodamine and 68 µl ul blocking 
solution, and overnight gently shaking at 4°C. The following day larvae were 
washed 4 x 30 minutes in PBT, fixed for 30 minutes in 4% PFA at RT, again 
washed 4 x 5minutes in PBT and finally stored at -20°C in 80% glycerol (VWR 
International Ltd, UK, Cat. No. 356350) until imaging. For this purpose, the tail 
was removed using a surgical blade while fish were placed in a petri dish in 80% 
glycerol. Then the tails were mounted with 75% glycerol on 76x26 mm glass 
microscope slides (Thermo Scientific Menzel, UK, Cat. No. 12404070) with a 
22x22 mm # 0 (0.08-0.12mm) cover glass (Fisher Scientific Ltd, UK, Cat. No. 
015717582) and imaged by confocal microscopy. Confocal images were 
captured using a Ultraview Nipkow spinning disk confocal (Perkin Elmer) on an 
Olympus IX81 inverted microscope with 1000x1000 Hamamatsu 9100-50 front 
illuminated EMCCD camera, with UPLSAPO 20x NA 0.75 objective lens, using 
Volocity 6.3 (Perkin Elmer, UK). GFP was visualised by excitation at 488 nm and 
TxRed at 561 nm using GFP emission filter, 527(55), and a 455(80)/ 
615(70)TxRed filter. At least 15 sections 5.57 µm apart, were captured in each 
channel. Image processing was manual by counting the number of apoptotic 
dual-positive neutrophils for green and red fluorescence. Rates of apoptosis were 









Figure 2.3 Zebrafish model of neutrophil apoptosis at the tail fin injury site. 
The fin was transected at the point indicated by the dashed black line. The brown line 
indicates the main circulatory system. Green represents neutrophils. Red indicates 
























2.8.4.6 Reverse migration 
 
In reverse migration assay, tail transection (Figure 2.4) was performed on 
Tg(mpx:Gal4)i222(UAS:Kaede)s1999t line (referred in this thesis to as mpx:Kaede) 
(A. L. Robertson et al., 2014). The line recapitulates expression of mpx:GFP line 
and expresses Kaede specifically in neutrophils. Kaede acts as a green 
chromophore that is converted to red under UV or violet light (Ando et al., 2002). 
At 2 dpf, Kaede-positive larvae were selected and the inflammatory response was 
initiated as in the resolution assay at 2dpf and at 4 hpi larvae with comparable 
numbers of recruited neutrophils were immediately treated with MMF or DMSO. 
At 5 hpi larvae were mounted in 0.8% low melting point agarose (Sigma-Aldrich, 
UK, Cat. No. A9414) containing the required concentration of MMF or DMSO 
covered in 1X E3 also containing the required concentrations of test and control 
compounds in a Lab-TekRII four well chamber slide (Fisher Scientific Ltd, UK, 
Cat. No. 10717931). This was followed by photoconversion at the peak of 
inflammation (6 hpi) in the region posterior to the circulatory loop. For the 
conversion, 10X UPLSAPO NA 0.4 objective and an UltraVIEW PhotoKinesis 
device on an Ultraview Nipkow spinning disk confocal microscope (PerkinElmer 
Life and Analytical Sciences) was used. Kaede-marked neutrophils were photo-
converted from green to red using 120 pulses of the 405 nm laser at 40% laser 
power (Elks et al., 2011; Dixon et al., 2012). The UltraVIEW PhotoKinesis 
apparatus was calibrated using fluorescent ink (Stabilo BossTM Berks, UK) as a 
photo-bleachable substance, marked on a glass microscopic slide. To ensure 
only the neutrophils in the region posterior were photo-converted, a region of 
interest was drawn. To ensure Kaede neutrophils were photo-converted, the cells 
were checked for the loss of green at 488 nm and appearance of red fluorescence 
at 561 nm (GFP and TxRed diode lasers, respectively). However, the green 
fluorescence was not always lost completely. Due to technical issues, larvae were 
time-lapsed on three different microscopes. In the first experiment larvae were 
imaged on Ultraview Nipkow spinning disk confocal (Perkin Elmer) on an 
Olympus IX81 inverted microscope with 1000x1000 Hamamatsu 9100-50 front 
illuminated EMCCD camera, fitted with 10X UPLSAPO NA 0.4 objective lens; 




filters (527(55) and 455(80)/615(70), respectively) were used with excitation at 
488 nm and 561 nm, respectively. In the second experiment- Nikon Eclipse 
TE2000-U inverted compound fluorescence microscope fitted with a 10X, 0.30 
NA Plan Flour objective and a 1394 ORCA-ERA camera (Hamamatsu Photonics, 
Hamamatsu City, Japan) with NIS Elements 391 (Nikon, Richmond, UK). 89201 
ET GFP/mCherry filters were used. The last set of imaging was performed using 
a Nikon Ti-E with a CFI Plan Apochromat λ 10X, N.A.0.45 objective lens, a 
custom built 500 µm Piezo Z-stage (Mad City Labs, Madison, WI, USA) and using 
Intensilight fluorescent illumination with ET/sputtered series fluorescent filters: 
GFP 49002 and mcherry 49008 (Chroma, Bellow Falls, VT, USA). Images were 
captured with Neo sCMOS, 2560 × 2160 Format, 16.6 mm x 14.0 mm Sensor 
Size, 6.5 µm pixel size camera (Andor, Belfast, UK) and NIS-Elements (Nikon, 
Richmond, UK). In all cases, 8 hours time-lapses were recorded with acquisition 
at 2-minute intervals.  
For consistency, robustness and fairness of data, vehicle control and the 
compound of interest treated fish were photo-converted alternately and time-
lapsed in the same order. 
Reverse migration was assessed by counting the number of neutrophils that 
migrated away from the site of injury every 30 minutes over the period 8 hours in 
the posterior and anterior region to the circulatory loop. The region of interest was 
at the anterior of the tail and this data set was extracted to plot the number of 
photo-converted neutrophils leaving the area of transection (Figure 2.4). The 
length of the anterior region of the tail considered for measurement was on 









Figure 2.4 Zebrafish model of neutrophil reverse migration. The tail fin was 
transected at the point indicated by the dashed black line. The brown line indicates the 
main circulatory system. Green represents not photo-converted neutrophils. Red 
indicates photo-converted neutrophils. Pink box indicates the posterior region of the tail 
in which neutrophil were photo-converted. Blue box indicates the anterior region of the 
tail where reverse migration was assessed. (A) Recruited neutrophils photo-converted 
at 6 hpi (equal to 0 hours post conversion (hpc)). (B) Red photo-converted neutrophils 





















2.8.5 Infection assay 
2.8.5.1 Preparation of C. neoformans/C. gattii culture prior to injection 
A day before infection, a petri plate with the strain of interest was taken from the 
4°C. The culture preparation and counting was as described in Cryptococcal 
culture and counting. If, e.g. 200 cells were counted then in 1 ml there are 200 
cells x 20 x 104=4 x107 cfu/ml. 
After calculating the number of cryptococci cells per 1 ml PBS, the pelleted 
sample was then re-suspended in the correct amount of sterile 10% (vol/vol) 
Polyvinylpyrrolidinone (PVP), 0.5% Phenol Red (SLS, UK, Cat. No. P0290) in 
PBS. PVP is a polymer that increases the viscosity of the injection fluid and 
prevents microbes clustering in the injection needle (Carvalho et al., 2011; Spaink 
et al., 2013). Phenol Red is a dye used to visualise the infections. The following 
formula was used to calculate the volume of PVP-Phenol Red: 
C1V1=C2V2, where C1V1 is concentration/amount (start) and volume (start) and 
C2V2 is concentration/amount (final) and volume (final of 10% PVP, 0.5% Phenol 
Red in PBS). 
This example was to give a 1000 cfu (colony forming unit) injected in the volume 
of 1 nl into zebrafish based on a suspension containing 4 x107cfu/ml: 
 















=4 x10-2 ml=0.04 ml=40 µl 
This volume then (40 ul) of 10% PVP, 0.5% Phenol Red in PBS was then added 
in the hood to the pellet and pipetted up and down to achieve a well mixed 
injecting solution. Serial dilutions of 1000 cfu/nl, to make 500 cfu/nl, 100 cfu/nl 






2.8.5.2 Needles for microinjections 
 
Needles were acquired by stretching borosilicate glass capillaries (Wolf 
Laboratories Ltd., UK, Cat. No. TW100-4) using P-1000 Next Generation 
Micropipette Puller micropipette puller located in the Fly Facility (The University 
of Sheffield, Bateson Centre, Firth Court) pulled into 51-gauge needles. Before 
injections, a needle was back loaded with an appropriate Cryptococcus 
suspension (see Preparation of C. neoformans/ prior to injection section) using a 
microloading pipette and microloading tip ((Fisher Scientific Ltd, UK, Cat. No. 
5242956003), then assembled into a holder of a PicoPump (PV 820P) 
microinjector. The injector had the following settings: pressure 40 pound per 
square inch (PSI), vent, timed mode, the duration of the solenoid open time of 
100 ms. The needle tip was brought into the plane of view of the microscope with 
the focus on the thinnest region of the tip to be broken using forceps to obtain the 
correct bevel shape.  
The injection volume of 1 nl was then determined using a graticule, on which one 
drop of mineral oil (Sigma-Aldrich, UK, Cat. No. 330760-1L) was placed. When 
injected into the oil, a bead of cryptococcal suspension was adjusted through 
manipulation of the Pneumatic PicoPump. The bead with a diameter of nine bars 
equalled to 0.5 nl. Therefore, the foot pedal of the PicoPump was depressed 
twice. 
2.8.5.3 Zebrafish microinjections 
Microinjections occurred at 24 hpf. On the injection day, zebrafish embryos were 
first de-chorionated with Dumont forceps (Sigma-Aldrich, UK, Cat. No. F6521-
1EA) in a petri plate containing 1X E3 medium with 0.00005% methylene blue. 
Then de-chorionated embryos were transferred in a disposable 2 ml graduated 
pasteur pipette (SLS, UK, Cat. No. PIP4208) into another petri plate with 1X E3 
medium, 0.00005% methylene blue and 0.0168% tricaine. The embryos were 
then pipetted out with a glass pipette (SLS, UK, Cat. No. PIP4101) onto a 




with 3.5% E3 (no methylene blue) based methylcellulose (Sigma-Aldrich, UK, 
Cat. No. M0512). Preparation of 3.5 % methylcellulose included mixing, partial 
freeze and defrost several times in order to facilitate methylcellulose 
solubilisation. The solution was aliquoted into 20 ml syringes (VWR International 
Ltd, UK, Cat. No. 613-2046P) and stored at -20°C until shortly before use when 
it was stored at 28.5ºC.  
Excess liquid (1X E3 containing tricaine) from the microscopy slide with embryos 
lined up on methylcellulose was removed to prevent the embryos sliding and 
methylcellulose being diluted.  
Once dispensed the size of cryptococcal solution was calibrated, the larvae were 
ready to be injected with 1 nl of the required fungus dose, into the yolk sac 
circulation valley providing a systematic intravenous infection (Figure 2.5).  
The mounted microscopy slide was placed under the needle and larvae were 
injected in one smooth stroke by piercing the yolk sac. This is an area situated 
close to the heart. To prevent triggering any inflammatory response, the needle 
broke through the yolk sac circulation valley only once. After injection, the needle 
was swiftly removed from the larvae. After completing one slide worth of larvae 
the fish were gently rinsed off with 1X E3 medium without methylene blue, to a 
clean petri plate filled with 1X E3, no methylene blue. After injections, the fish 
were looked at under stereo fluorescent Leica MZ10F microscope (bright field 
and GFP filter) to check the quality of injections. Any fish damaged or accidentally 








Figure 2.5 Schematic diagram of larva showing the site of microinjection 
with C. neoformans/C. gattii. The region injected is between two bright green 
continuous lines. The bright green dashed line with an arrowhead denotes the direction 




































2.7.5.4 High content imaging method 
Infected zebrafish were anesthetised by immersion in 0.0168 % tricaine in 1X E3 
and mounted in agar channels for imaging. Channels were made by adding 200 
μl of 1% agar (Sigma Aldrich, UK, Cat. No. 05039) in 1X E3 containing 0.0168 % 
tricaine into glass-bottomed, 96-well plates (Porvair Sciences, UK, Cat. No 
215006). Channels were cut in cooled agar using GelX4 tips. Mounted embryos 
were imaged on a Nikon Ti-E with a CFI Plan Apochromat λ 10X, N.A.0.45 
objective lens, a custom built 500 μm Piezo Z-stage (Mad City Labs, Madison, 
WI, USA) and using Intensilight fluorescent illumination with ET/sputtered series 
fluorescent filters 49002 and 49008 (Chroma, Bellow Falls, VT, USA). Images 
were captured with Neo sCMOS, 2560 × 2160 Format, 16.6 mm x 14.0 mm 
Sensor Size, 6.5 μm pixel size camera (Andor, Belfast, UK) and NIS-Elements 
(Nikon, Richmond, UK) using the following settings: 1. GFP, filter 49002, 10 ms 
exposure, gain 4 2. mCherry, filter 49008, 10 ms exposure, gain 4. Each zebrafish 
was imaged as three contiguous fields of view that were assigned from bright-
field images. 80 z sections, 5 μm apart, were captured in each channel and each 
position in that order. Each biological repeat contained 40 infected zebrafish, with 
3 multi-channel z stacks per fish. The microscope was enclosed in a humidified, 
28°C, environmental chamber (Okolabs, Pozzuoli, Italy). After imaging larvae 
were recovered in fresh E3 and returned to a new numbered 96-well plate 
(Bojarczuk et al., 2016). 
2.9 Preparation of C. gattii culture for mice infections 
C. gattii strains (R265 wild-type (wt) and R265 GFP14) were cultivated as in the 
Cryptococcal strains cultivation section. Culturing and counting was the same as 
described in Preparation of the C. neoformans/ culture prior to injection. The dose 
used, 5x104 in 50 µl PBS was chosen upon previous experiments with an intra 
tracheal dose (surgical) of 1x104 in 50 µl PBS (Guillot, Carroll, Homer, et al., 2008) 
and an intranasal dose of 5x104 in 25 µl PBS (Wiesner et al., 2015). The volume 
of 50 µl seemed to be better as its larger size is more affected by gravity; this 




1x106 cfu/ml was made up in PBS and 50 µl of this suspension was used for mice 
infections. The strains were placed on ice and carried to the Biological Services 
Unit (BSU). 
2.10 Zebrafish survival assay 
 
Zebrafish embryos that had undergone cryptococcal injection were subjected to 
survival analysis. Zebrafish larvae were checked every 24 hours for their survival 
or mortality. This was assessed by presence or absence of heartbeat. All 
zebrafish larvae used in experiments were under 5.2 days post fertilisation (dpf). 
Statistical analysis was performed as described in the Statistical analysis.  
2.11 Disposal of zebrafish and microbiological waste 
 
Zebrafish that had undergone either injection or drug treatment were disposed of  
just before reaching 5.2 dpf. These are classed as non-procedure and were 
disposed through bleaching (SLS, UK, Cat. No. CLE0300). The initial 
concentration of the bleach starts off at 100% but gets diluted as more fish and 
E3/aquarium water is added. The bleaching is preceded by anaesthesia in 
0.0168% tricaine. In the case of Cryptococcus challenged zebrafish, 1% virkon 
(Sigma Aldrich, UK, Cat. No. Z692158) made up in distilled water was applied to 
plates. These were sealed and disposed through infectious waste.  
Microbiological agar plates were sealed as soon as possible after use and 
disposed through infectious waste. Individual small volume cultures (<10 ml) 
were inactivated with 1% virkon 
2.12 Statistical analysis 
Statistical analysis was performed as described in the results and figure legends. 
Graphing and statistical analysis was performed in GraphPad Software Prism 
(version 7.04; La Jolla, California USA). 




All data sets were investigated for normal or not normal distribution. This was 
achieved by analysing frequency distribution (histograms) and investigating 
whether the mean was equal to the mean, which is true in normally distributed 
data (Peacock and Peacock, 2011). If the data is not normally distributed then 
nonparametric methods should be used. This was the case for the majority of 
data in this thesis. There was one case of data transformation to obtain normal 
distribution. This was done by using the log transformation. 
 
T-tests: Mann-Whitney t-tests were used to test data arising from separate 
individuals (unpaired data) when data are not normally distributed. Mann-Whitney 
is a nonparametric test, which does not depend on the assumption that values 
were sampled from normal distributions. The test was to compare whether there 
is a difference in the dependent variable (“effect “of the “cause” independent 
variable) for two independent groups. The test compares if the distribution of the 
dependent variable is the same for the two groups and therefore from the same 
population. Mann-Whitney test ranks all of the data and then compares the sum 
of the ranks for each group to determine whether the groups are the same or not 
(Peacock and Peacock, 2011) 
 
Survival analysis: The Log-Rank Mantel-Cox test was used to compare the trend 
of survival between different populations. This test compares the whole curve for 
each group. The null hypothesis is that there is no tendency for survival time to 
be shorter in one group that the other (Peacock and Peacock, 2011). 
 
Linear regression: Line of best fit for data points. R2 is a measure of goodness-
of-fit of linear regression. The value (between 0 and 1) represents the percentage 
of points which line on the line, i.e. 1 represents 100% of all points lying exactly 
on the line with no scatter (Peacock and Peacock, 2011). 
In reverse migration assay, a line of best fit was used to compare the difference 
in slopes. To test whether the slopes were significantly different, Prism calculated 




prior the site of injury were removed for the figure clearness. Only the P value 
was kept.  
 
Analysis of variance: One-way ANOVA (and nonparametric) was used to 
determine the difference of mean ranks between two or more groups, when the 
data were not normally distributed. Kruskal-Wallis test was used for unpaired data 
at different time-points. Friedman test was used for paired repeated measures. 
Following nonparametric ANOVA, Prism calculated  Dunn’s post-test. An ordinary 
One-way ANOVA cannot have been used as the assumptions for it are normal 
distribution and equal standard deviation in each group (Peacock and Peacock, 
2011). 
Two-way analysis of variance, namely repeated measures (RM) two-way ANOVA 
for paired subjects was used to determine the difference of means between two 
groups, with one variable. Sidak’s post-test was added to this to compare each 
mean to the other mean at time-points tested. Two-way ANOVA assumes that 
replicates are sampled from normal distributions. The data were not normally 
distributed. However, the two-way ANOVA was performed because the 
assumption of normal distribution is not too important with large samples. The 
sample size was large in phenotypic array experiments. RM two way-ANOVA 















Chapter 3: Cryptococcus neoformans intracellular proliferation and 
capsule size determines early macrophage control of infection  
3.1 Introduction 
3.1.1 The importance of C. neoformans, interactions with macrophages and 
the polysaccharide capsule 
C. neoformans was first described as a human pathogen in 1894 after isolation 
from a sarcoma-like lesion in the infected female’s tibia (Busse, 1894). The 
fungus is recognised as a serious, worldwide public health concern. It is a major 
pathogen of the immunocompromised, especially AIDS patients. C. neoformans 
is the causative agent of cryptococcosis, a disease that primarily affects HIV 
immunosuppressed individuals and manifests in meningoencephalitis in these 
patients (reviewed by (Zaragoza, 2019)). The most recent estimate of global 
disease burden includes over 200 000 cases of cryptococcal meningitis resulting 
in over 180 000 deaths. Cryptococcal meningitis causes 15% of AIDS-related 
deaths globally. 73% of meningitis cases occur in sub-Saharan Africa 
(Rajasingham et al., 2017). In healthy individuals, C. neoformans infection is 
usually self- resolving. 
In most cases, the infection begins in the lungs, where the first cells encountered 
by cryptococci are alveolar macrophages or dendritic cells (reviewed by (May et 
al., 2016)). The population of macrophages that live within the lung alveolar 
airspaces is predominant cell type within the alveolus (reviewed by (Fels and 
Cohn, 1986)). In bronchoalveolar lavage (BAL) fluid of HIV patients the numbers 
of alveolar macrophages is significantly lower as compared to non-HIV 
individuals (Mwale et al., 2017). Thus, they are at risk of developing 
cryptococcosis. C. neoformans is also associated with other 
immunocompromised groups such as solid transplant patients. These patients 
also have reduced alveolar macrophages count (Bray et al., 1992). 
Macrophages respond to changes in their cytokine microenvironment. Briefly, 




exposure to a specific stimulus ((Davis et al., 2013), reviewed by (Wager and 
Wormley, 2014)). C. neoformans is more efficiently killed by M1 than M2 
polarised macrophages. M2 (alternatively activated) macrophages cannot 
contain C. neoformans replication (Osterholzer, Surana, et al., 2009; Zhang et 
al., 2009) while M1 (classically activated) macrophages have antifungal activity 
(Wormley et al., 2007; Hardison et al., 2010; Kamuyango, 2017).  
In recent years, researchers have demonstrated that in experimental mice 
pulmonary infection C. neoformans elicits Th2 response and activation of 
alternative macrophages (Huffnagle et al., 1998; Osterholzer, Surana, et al., 
2009; Hardison et al., 2010). Actually, both types of cytokines, Th1 and Th2 are 
produced in the lungs during infection but the Th1 predominance is required for 
the clearance (Hoag et al., 1995, 1997; Wormley et al., 2007). Th2-type immune 
responses are associated with exacerbation of disease whereas Th1-type 
immune responses with resistance to cryptococcosis (reviewed by (Mukaremera 
and Nielsen, 2017)). Cytokine expression in C. neoformans-infected lungs 
changes from Th2 towards Th1 profile over several weeks during infection (Arora 
et al., 2011). As described, Th1 is required for the clearance as the protection 
against Cryptococcus is associated with M1 or classically activated 
macrophages. In CNS the clearance is possible due to Th1 cytokines and 
chemokines (Huffnagle and McNeil, 1999; Buchanan and Doyle, 2000). 
Macrophage-Cryptococcus interactions have gained great importance among the 
scientific community because they are the dominant phagocytic cell that interacts 
with the pathogen. As described in section 1.2.3 Virulence of Cryptococcus, the 
fungus can grow within the host macrophages (intracellular proliferation) or use 
them for efficient dissemination (escape via non-lytic vomocytosis, cell lysis). 
Moreover, Cryptococcus can be laterally transferred from one macrophage to 
another. An interesting facet is a latent phase. It is thought that the majority of 
cryptococcosis cases result from reactivation from latency in instances where 
severe immune system defect had occurred long before the diagnosis (Garcia-




bloodstream and across the blood brain barrier gives an idea how Cryptococcus 
can stay latent (Chrétien et al., 2002; Charlier et al., 2009).  
This complex interaction between Cryptococcus and macrophages is illustrated 












Figure 3.1 Schematic interaction of Cryptococcus with macrophages. A opsonic, B non-opsonic phagocytosis. Adapted from 
(Ma, 2009).
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C. neoformans is associated with soil and pigeon excreta (Hagen et al., 2015). 
Since virulence is usually maintained as a result of selection, the origin of the 
virulence is difficult to interpret (reviewed by (Steenbergen and Casadevall, 
2003)). Whatever the evolutionary path for C. neoformans virulence is, it is 
doubtful that the virulence involved a selection through a vertebrate host 
(Johnston and May, 2013). It is likely that cryptococcal virulence originated due 
to environmental selective pressure (Casadevall et al., 2003).  
C. neoformans virulence factors include a polysaccharide capsule. The capsule 
was widely described in section 1.2.3 Virulence of Cryptococcus. Briefly, it 
provides a physical barrier and confers biochemical and immunological 
properties. It is characterised by a dynamic plasticity that enables adaptation to 
the host environment for prolonged survival (Cordero et al., 2011). During 
mammalian infection, the capsule increases in size (Feldmesser et al., 2001). 
3.1.2 The need for the development of a new integrated model of 
cryptococcosis 
Innate immunity and especially macrophages are significantly involved in the 
response to cryptococcosis (reviewed by (Campuzano and Wormley, 2018)). The 
interaction between Cryptococcus and the host immune system is highly 
complex. The interaction between Cryptococcus and macrophages is an 
established model system for investigation of cryptococcal virulence. Human 
cases of cryptococcosis caused by acapsular strains are not common (Farmer 
and Komorowski, 1973). At the time of my appointment to the Johnston lab, 
previous estimates showed C. neoformans caused meningoencephalitis, 
primarily in the immunocompromised resulting in approximately one million cases 
and 600 000 deaths annually (Park et al., 2009). At the time the aim of my work 
was formulated, the existing clinical, in vitro cell biology data on host-pathogen 
interaction as well as in vivo data did not permit the simultaneous study of host 
and pathogen factors that determine disease progression and outcome in vivo. 
As stated in the thesis aims, at the time, there was no model, which would enable 
to track macrophages and cryptococci in the entire body of a living vertebrate. 
Therefore, there was a need to extend the range of existing models to study 
immunity to cryptococcal infection. Zebrafish appeared to be ideally suited to 
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become the model of cryptococcosis. This was due to for a few key reasons: 
zebrafish being a vertebrate, embryos transparency, similarity of immune system 
to mammals, a high genetic homology and high fecundity, genetic manipulation 
and imaging potential (reviewed by (Goldsmith and Jobin, 2012; Renshaw and 
Trede, 2012)). It was noted that other animal species could serve as a model, 
too. However, only the zebrafish has the potential for in vivo subcellular resolution 
imaging in the entire body of a living vertebrate, allowing the interpretation of cell 
biology data in the context of the whole disease and organism. In addition, 
zebrafish are easily bred and infected making large-scale studies possible that 
will give power to complex correlations of host and pathogen disease 
determinants (reviewed by (Van Der Sar et al., 2004)) at a scale not possible in 
other vertebrates. In addition zebrafish are proven models of human disease 
(reviewed by (Dooley and Zon, 2000; Lieschke and Currie, 2007)), immune cell 
(Renshaw et al., 2006; Colucci-Guyon et al., 2011), infection biology (Tobin et al., 
2010; Volkman et al., 2010; Adams et al., 2011) and are also used in drug 
discovery (reviewed by (MacRae and Peterson, 2015)).  
At the time the hypothesis that this organism can serve as an experimental model 
of cryptococcosis was evidenced by the fact that these animals have been used 
successfully to study fungal pathogens (Brothers et al., 2013; Herbst et al., 2015).  
Unquestionable advantages of the zebrafish are low costs of their maintenance, 
high fecundity and short generation time of only three months, thus zebrafish are 
more preferable than mice. As mentioned, zebrafish immunity is similar to that of 
humans. They possess both adaptive (humoral and cellular) and innate 
components, the latter including macrophages, neutrophils, TLRs, complement 
factors and cytokines and their signalling molecules (reviewed by (Lieschke and 
Currie, 2007; Goldsmith and Jobin, 2012)). However, it is important to note the 
limitations of the zebrafish immunity model. Due to most zebrafish licences 
allowing the studies until day 5 post fertilisation, the adaptive immunity is missing 
from infection models. Thus, translating findings from zebrafish research to 
humans might be difficult, although studying the innate immunity provides a good 
basis to understand human innate immunity. Another factor could be the fact that 
zebrafish are maintained at 28°C, not 37°C. 28°C is not the human body 
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temperature pathogens have evolved to infect at. This should be taken into 
consideration when interpreting data. On the other hand, C. neoformans seems 
to infect such a wide range of animal species with different thermoregulation 
(Malik et al., 2011) and therefore, it is likely that pathogenesis does not depend 
on the host body temperature. 
3.1.3 The development of a new integrated model of cryptococcosis and 
commentary on resulting publication (Bojarczuk et al., 2016) 
A model of the early events following dissemination of C. neoformans was 
essential to improve our fundamental understanding of the behaviour of 
phagocytes during infection. Thus, I started with the question of developing a 
zebrafish model of cryptococcosis. At the time the aim of my work was formulated 
our understanding of cryptococcosis used to be based on either in vitro analysis 
of interactions between cryptococci and isolated mammalian cells or in vivo studies in 
murine or leporine hosts. Despite the wealth of in vitro or in vivo studies on C. 
neoformans, there was no direct in vivo data on disease progression. The 
limitations of the past studies included 1) the difficulties in interpreting studies 
using isolated macrophages in the context of the progression of infection, and 2) 
the use of high resolution imaging in understanding immune cell behaviour during 
animal infection. Consequently, an animal in vivo model was required to unravel 
how the infection causes diseases in humans. A larval zebrafish model of C. 
neoformans infection with microinjections into the yolk sac circulation valley at 48 
hpf was proposed (Bojarczuk et al., 2016). 
One might argue that the zebrafish infection model had existed before my 
(Bojarczuk et al., 2016) publication. This is true. There are publications of (Tenor 
et al., 2015; Davis et al., 2016), which employ the zebrafish model of C. 
neoformans infection. In (Tenor et al., 2015) microinjections were done into 
caudal vein at 48 hpf, whereas the work of (Davis et al., 2016) utilised intravenous 
and hindbrain inoculations at 28 hpf. However, I started my work in 2012 and 
published in 2016, whereas the other groups published earlier. Still, at time of the 
manuscript preparation there was an in vivo model including macrophages 
interactions but it only partially addressed my question of macrophages role and 
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behaviour during the course of infection (Tenor et al., 2015). The publication of 
(Tenor et al., 2015) was cited in mine (Bojarczuk et al., 2016). The work of (Davis 
et al., 2016) was not mentioned in mine because the final version of the 
manuscript had been completed.  
As described, following uptake, internalised Cryptococcus can be destroyed or is 
able to survive and replicate. It can be transferred between macrophages laterally 
or exit non-lytically via vomocytosis. I wanted to investigate if these interactions 
were conserved in the zebrafish. The recapitulation of these events was essential 
to prove the zebrafish meets the criteria to become a model of infection. I 
successfully reported these interactions in the zebrafish embryo (cryptococcal 
internalisation by macrophages, lateral transfer and cryptococcal cell death, all 
unpublished) before setting the experiments in (Bojarczuk et al., 2016).  
As mentioned, the capsule grows during mammalian infection. The work on 
capsule in the zebrafish model (Bojarczuk et al., 2016) was possible upon 
evidencing the capsule growth during zebrafish infection (the initial data 
unpublished). 
 
This chapter is based on a publication published in a multidisciplinary journal 
Scientific Reports (Bojarczuk et al., 2016). Here, I presented the zebrafish model 
of C. neoformans infection and studied macrophage-cryptococcal cell 
interactions.  
My work in the publication reports: 1) a method for the live quantification of 
macrophage behaviour in response to C. neoformans infection, thus the 
establishment of a high-content imaging method in a zebrafish model of 
cryptococcosis that permits the detailed analysis of macrophage interactions with 
C. neoformans during infection; 2) the majority of cryptococci are intracellular 
after twenty-four hours post infection; 3) intracellular proliferation drives 
increased numbers of cryptococci at twenty-four hours post infection and this is 
linked with vomocytosis. The work of others in the publication demonstrates that: 
1) macrophages are essential for the early control of cryptococcal fungemia; 2) 
cryptococci that are phagocytosed within two hours have small polysaccharide 
capsules that are absent from the fungal cell population twenty-four hours post 
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infection; 3) enlargement of capsules of initial fungal burden limits phagocytosis 
and restricts macrophage control of cryptococci. The following figures in the 
publication are mine: Supplementary Data S1, Supplementary Fig. S1, 
Supplementary Fig. S2, Supplementary Fig. S2, Supplementary Movie S1, Fig. 1 
a-g, Fig. 2 a, Fig. 3 a-f, Fig. 4 a-f, Fig. 5 a-b. 
From the results, it is clear that macrophages are critical for control of  
C. neoformans and a failure of macrophage response is not the limiting defect in 
fatal infections. 
The present study confirmed the findings about phagocytosis prevention very 
early in infection and that increasing numbers of cryptococci are driven by 
intracellular proliferation. Macrophages preferentially phagocytose cryptococci 
with smaller polysaccharide capsules and the capsule size increases dramatically 
over twenty-four hours of infection, a change that is sufficient to limit further 
phagocytosis. The results found clearly support the hypothesis that differences in 
cryptococcal capsule size are sufficient to define the limitation of phagocytosis 
(Bojarczuk et al., 2016). 
3.2 The publication Cryptococcus neoformans intracellular proliferation 
and capsule size determines early macrophage control of infection 
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                                                   Table 3.1 Supplementary Data Set 1-macrophage response data set 
 
 







Table 3.1 (continued) 





In 2015 and 2016, three independent studies established the zebrafish embryo 
as a model for cryptococcal infection (Tenor et al., 2015; Bojarczuk et al., 2016; 
Davis et al., 2016). 
I provided a zebrafish model of C. neoformans infection using larvae mounted in 
a 96-well format for repeat imaging at day 0, 1, 2 and 3 post infection taking 
advantage of the zebrafish embryo’s potential for high-throughput imaging and 
analysis. However, there are two other peer-reviewed publications reporting 
zebrafish-Cryptococcus infection models (Tenor et al., 2015; Davis et al., 2016). 
As mentioned in this thesis, the work of Tenor et al. was cited in my publication. 
The work of Davis et al. was not because their publication was published later 
than mine. It is surprising that the authors of (Davis et al., 2016) did not cite my 
work. 
One could ask how my model is better or different than of the others. Firstly,  
I established a model by microinjecting the pathogen at 48 hpf into the yolk sac 
circulation valley to produce a systemic infection. Tenor et al. injected at 48 hpf 
and into the caudal vein (Tenor et al., 2015), which also produces the same effect. 
However my experience shows it is not possible to inject the dose they used, i.e. 
10 to 20 nl (Tenor et al., 2015) because the standard dose is never greater than 
1 nl. Moreover, the caudal vein is too hard to inject into at 48 hpf, perhaps 
narrower and deeper and would require a wider needle than the ones used for 
bacteria. I believe this would disrupt the caudal vein. In addition, at 1 dpi many 
fish die from the infection (Bojarczuk, unpublished). Thus, I specifically used the 
circulation valley as the entry point for Cryptococcus and a wide needle due to 
cryptococcal cells being bigger in size than bacteria. 
In contrast, microinjections described in (Davis et al., 2016) do not provide any 
information about their volumes but only mention the dose of 150 and 250 
cryptococcal cells per larva. Intravenous or hindbrain inoculations were 
performed at 28 hpf (Davis et al., 2016). 
However, the work of the three publications (Tenor et al., 2015; Bojarczuk et al., 
2016; Davis et al., 2016) establishes a connection among zebrafish becoming a 
tool to explore cryptococcosis. Studies in zebrafish have shown that ablation of 
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macrophages leads to high fungal burden and reduced survival (Bojarczuk et al, 
2016; Tenor et al, 2015) underlining the fact that macrophages are essential for 
protecting zebrafish from cryptococcal disease progression. I showed it in 
clodronate liposomes experiment, whereas Tenor at al. by morpholino 
knockdown. These results corroborate the findings of others in mice (Monga, 
1981; Osterholzer, Milam, et al., 2009). My work and of Tenor et al.  
provided validation for multiple aspects of macrophage parasitism by  
C. neoformans that have previously been characterised in vitro. For example,  
C. neoformans replicates intracellularly (Figure 2C in (Tenor et al., 2015) and 
Figure 4 in (Bojarczuk et al., 2016)) in zebrafish macrophages in vivo (Tenor et 
al., 2015; Bojarczuk et al., 2016), which is in line with previous findings in vitro 
(Ma et al., 2006; Voelz et al., 2009). I also agree with the dose-dependent 
mortality shown by Tenor et al. as I reported the same response with 
stratifications of my injections (Figure 2A in (Tenor et al., 2015) and Figure 2A in 
(Bojarczuk et al., 2016)). Also, Tenor et al. (2015) and I have shown that the  
C. neoformans polysaccharide capsule enlarges during infection by 
macrophages in vivo (Figures 2E-G in (Tenor et al., 2015)) and Figures 5H-J in 
(Bojarczuk et al., 2016)). Therefore both publications concluded that the 
increased capsule was sufficient to induce uncontrolled fungal growth leading to 
the host death. However, since I showed that intracellular proliferation is the 
principal factor driving the shift in the proportion of cryptococci that were 
intracellular at 24 hpi (Bojarczuk et al., 2016), I cannot agree with the findings 
that phagocytic fate of C. neoformans yeast cells at 13 hpi was due to 
phagocytosis (Tenor et al., 2015). Instead, I believe it was due to the intracellular 
proliferation (Bojarczuk et al., 2016). 
To test the robustness of the zebrafish model for mammalian virulence 
determinants-infections of a number of Cryptococcus mutants were performed 
(Tenor et al., 2015). My work (Bojarczuk et al., 2016) demonstrated that infection 
with the cap59 mutant resulted in zero mortality over 72 hours of infection despite 
using a dose that caused greater than 50% mortality in the parental H99 strain 
(Figure 5B). Instead, the infection with an acapsular mutant of Cryptococcus in 
(Tenor et al., 2015) resulted in 80% survival (Figure 3A) and similar fungal burden 
to a wild-type cryptococcal strain (Figure 3B). This highlights the role of the 
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capsule. It seems convincing that compromised capsule results in a similar fungal 
load and a high survival of the host. In this aspect, these two publications 
supplement each other.  
The publication of Davis et al. (2016) should also be discussed. It validates 
previous findings that vomocytosis occurs in vivo (Figure 4A in (Bojarczuk et al., 
2016), Figure 5A in (Davis et al., 2016)) and that C. neoformans establishes an 
infection in zebrafish that eventually disseminates to the brain (Figure 1I in  
(Davis et al., 2016) and Figure 5A in (Tenor et al., 2015)). This is in line what  
I could see in my experimental zebrafish. I never quantified this response. 
However, based on my observations and the findings of (Tenor et al., 2015;  
Davis et al., 2016), I believe that zebrafish can also be used to study brain 
invasion. The publication of Davis et al. (2016) deserves a special appreciation 
due to the fact of working with spores. Namely, since desiccated yeast or spores 
are believed to be infectious propagules (Mitchell and Perfect, 1995; Velagapudi 
et al., 2009; Walsh et al., 2019), it is dangerous to work with spores. In addition, 
yeast were also used as infectious particles and recognised models (Tenor et al., 
2015; Bojarczuk et al., 2016) are most practical at using yeast cells. However,  
I would challenge the publication of Davis et al. (2016) in one aspect, namely it is 
not assuring that the findings regarding spores are truly representative of H99 
virulence (serotype A) as generated spores were from serotype D strains, which 
are less virulent than serotype A, which was used by (Bojarczuk et al., 2016) and 
(Tenor et al., 2015). Thus, the previously described low mortality of wild-type 
larvae from either spores or yeast of this background, even at the highest 
inoculum (Figure 1B) (Davis et al., 2016) is likely to result from the use of the less 
virulent serotype D. In contrast, yeast cells of the hyper virulent H99 (serotype A) 
strain killed the larvae at moderate inoculum as reported previously (Tenor et al., 
2015; Bojarczuk et al., 2016). The publication of Davis et al. (2016) is otherwise 
novel, i.e. employs endothelial cells showing the lodging of Cryptococcus inside 
the brain vasculature (Figure 1I) and these cells are a temporary niche for survival 
(Figure 4B). It is also interesting that similarly to Tenor and colleagues, this group 
also investigated neutrophils role in cryptococcosis. It is surprising, given 
macrophages are the dominant cells engaged in the response to cryptococci 
(reviewed by (Mansour et al., 2014; Rudman et al., 2019)). In 2000, Marta 
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Feldmesser and colleagues wrote that the macrophage was the primary 
phagocytic cell at all times of infection in mice, but neutrophils also ingested yeast 
(Feldmesser et al., 2000). I also showed macrophages were essential for control, 
as their depletion had a catastrophic effect on any restriction of fungal burden, 
even when neutrophil numbers were unaffected (Bojarczuk et al., 2016). In fact, 
(Tenor et al., 2015) confirmed it in zebrafish using a transient knockdown of the 
Spi-1 transcription factor. However, David and colleagues using IFR-8 knockout 
zebrafish, showed at the initial infection of the mutant that neutrophils were better 
killers of the pathogen at the initial infection than macrophages were (Figure 2D) 
(Davis et al., 2016). Thus, perhaps the role of neutrophils might be undermined 
in the Cryptococcus field. 
With acknowledging the work of (Tenor et al., 2015; Davis et al., 2016), it is my 
zebrafish model of cryptococcosis (Bojarczuk et al., 2016) that is cited the most 
in comparison to the other two. Up to August 2020 it was cited 95 times, whereas 
(Tenor et al., 2015) was cited 48 and (Davis et al., 2016) 16 times.  
In addition, an elegant review exists, which compares all three established 
models and which highlights the novelty of my publication (Rosowski et al., 2018). 
In terms of how my work uniquely contributed to the field, the answer lies in many 
facts. I pioneered novel approaches to studying cryptococcosis using an 
experimental zebrafish model, which demonstrated for the first time how the early 
interactions with macrophages determined the outcome of infection. I established 
the model by injections facilitated by the use of Polyvinylpyrrolidinone (PVP), 
0.5% Phenol Red in PBS (PVP is a polymer that increases the viscosity of the 
injection fluid and prevents settling of microbes in the injection needle (Spaink et 
al., 2013). This is really useful and time-saving in order to obtain very high 
accuracy injections with a speed of up to 300 embryos per hour in my case and 
the use of PVP was not described by other two groups (Tenor et al., 2015; Davis 
et al., 2016). In addition, only my method of high content imaging of the whole 
zebrafish allows data collection for day 0 and three consecutive days. Thus the 
same infections across an extended time period days can be quantified in the 
context of the whole organismal response. This was not described by others 
(Tenor et al., 2015; Davis et al., 2016). Next, although Tenor’s group showed 
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intracellular proliferation in vivo (Figure 2C), they did not consider this event when 
stating that macrophages rapidly phagocytosed the majority of C. neoformans 
cells following injection (Figure 1B) (Tenor et al., 2015). Cryptococcal intracellular 
proliferation should always be taken in consideration in the field as there is a 
distinct difference between completed phagocytosis and intracellular 
proliferation. Next, I was the first to demonstrate vomocytosis in vivo. Previously, 
this was shown indirectly in mice via flow cytometry (Nicola and Robertson, 
2011). This work gave rise to a follow-up publication wherein I am the fourth 
author. Using my model of cryptococcosis the authors show that reducing ERK5 
activity in vivo stimulates vomocytosis and results in reduced dissemination of 
infection thereby introducing ERK5 as a potential target for the future 
development of vomocytosis-modulating therapies (Gilbert et al., 2017). In 
addition, my model has benefitted other projects in the Johnston lab. For 
example, it was used by three BMedSci students whose theses are not published 
and hence not cited in this paragraph. However, I can state the model was used 
by e.g. Richard Hotham, a co-author of (Bojarczuk et al., 2016) and (Gibson et 
al., 2018) to show dissemination of cryptococci to the swim bladder, somites and 
brain. It also formed a basis for work on mycophenolate mofetil (MMF). This work 
was further carried on by another BMedSci student, Rory Gibson and resulted in 
a pre-printed publication (Gibson et al., 2018). The model was also used by 
another BmedSci student, Katherine Miller, who hypothesised that increased 
capsule size in vitro will result in an increased susceptibility to infection in 
zebrafish due to a decrease in rate of phagocytosis. This is published in 
(Bojarczuk et al., 2016). The model was used by a few Johnston’s PhD students, 
too. For instance, in her thesis, Dr Josie Gibson used it to investigate autophagy 
(Gibson, 2017) and in a pre-printed publication to get insight into blood vessel 
occlusion by C. neoformans (Gibson et al., 2020). I am a second author of this 
work. Another PhD student, now Dr Hamid Fehri used my initial imaging data sets 
to develop automatic algorithms that can analyse different types of cells and their 
relations in the image to increase analysis efficiency (Fehri, 2018). External 
collaborations also based on my model and this resulted in publications. For 
instance the aforementioned publication (Gilbert et al., 2017). Another example 
of exploiting the model is a publication on eicosanoids produced by C. 
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neoformans to support intracellular proliferation within macrophages and 
subsequent promotion of pathogenesis (Evans et al., 2019). The model has also 
been optimised for high-throughput drug screening (unpublished, Christopher 
Donaldson, PhD student) or to mimic the mechanisms that cause this increase in 
intracranial pressure (unpublished, Jacqui Chalakova, PhD student).  
As the research carries on not only in the Johnston lab, but worldwide it is clear 
the model will be used to enable new ways to diagnose, prevent or cure human 
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Chapter 4: Characterisation of a virulence and growth defect in 
Cryptococcus gattii strain R265 with a genomic defect following GFP 
transformation 
4.1 Introduction 
Until 1949 C. neoformans had been considered as homogeneous species. This 
view changed after revealing four serotypes on the base of the antigenic 
properties of its polysaccharide capsule (reviewed by (Kwon-Chung and Varma, 
2006). There is an ongoing debate regarding the lineages and nomenclature of 
C. neoformans/C. gattii species complex mainly between the two-species 
concept (Kwon-Chung and Varma, 2006; Bovers et al., 2008; Ngamskulrungroj, 
Gilgado, et al., 2009; Hagen et al., 2015). The genomes of C. neoformans and C. 
gattii are similar in 85–90% (Kavanaugh et al., 2006). However, these two species 
are distinguishable in many ways. For instance, a morphological difference exists 
in basidiospores. C. neoformans forms rough-walled oblong to elliptical, whereas 
C. gattii produces rod shaped basidiospores with smooth walls (reviewed by 
(Kwon-Chung et al., 2014)). In terms of metabolics, C. neoformans is not as 
efficient as C. gattii in the utilisation of D-amino acids ((Chang et al., 2015), 
reviewed by (Watkins et al., 2017)). However, both species have one common 
feature. They are both the etiologic agents of cryptococcosis. The disease results 
apparently from the accident inhalation of fungal cells. 
4.1.1 Comparison of C. neoformans and C. gattii geographical distribution 
C. neoformans and C. gattii present numerous differences in geographical 
distribution. C. neoformans has been mainly isolated from avian droppings, e.g. 
pigeons, canaries (Swinne-Desgain, 1975; Criseo et al., 1995) or eagles 
(Caicedo et al., 1999)). C. neoformans var. grubii (serotype A) has a global 
distribution, occurring in avian excreta and some tree hollows, whereas C. 
neoformans var. neoformans (serotype D), also found in avian guano, prevails 
mainly in Europe ((Dromer, Mathoulin, Dupont and Laporte, 1996; Dromer, 
Mathoulin, Dupont, Letenneur, et al., 1996); reviewed by (Mitchell and Perfect, 
1995; Maziarz and Perfect, 2016)). 
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C. gattii (serotypes B and C), is endemic in tropical and subtropical regions and 
associated with many tree species, especially Eucalyptus trees (reviewed by 
(Ellis and Pfeiffer, 1990; Hagen and Boekhout, 2010; Hagen et al., 2015)). 
However, this view has changed due to the outbreak on Vancouver Island in 1999 
that represents moderate climate. 
4.1.2 Comparison of C. neoformans and C. gattii infection 
Comparison of C. neoformans and C. gattii infections was widely reviewed in 
Chapter 1. To summarise, the immune competence is a factor in cryptococcosis. 
C. neoformans mainly causes infections in profoundly immunosuppressed 
patients whereas C. gattii received attention because of devastating illness in 
immunocompetent individuals (reviewed by (Chen et al., 2014)). A survey of 
(Chen et al., 2000) conducted on Australians and New Zealanders during 1994–
1997 identified that out of 312 episodes of cryptococccosis, C. neoformans 
caused 265 and C. gattii 47. C. neoformans was identified in 209 
immunocompromised of which 133 were AIDS positive. C. gattii was found in 41 
immunocompetent hosts. This supports the trend of C. neoformans being a major 
pathogen of the immunocompromised, especially AIDS patients and C. gattii of 
immunocompetent. 
Cryptococcus is thought to enter the body through the lungs. Pulmonary disease 
is a primary manifestation of both species in apparently immunocompetent 
patients (Kerkering et al., 1981; Lui et al., 2006; Yang et al., 2006). In the study 
of Australian patients between 1993 and 2000 (Jenney et al., 2004) the C. gattii 
infections mostly occurred in immunocompetent patients presenting with 
pulmonary lesions. Another retrospective study of C. gattii infected patients 
hospitalised between 1999–2007 in British Columbia also demonstrated lung 
cryptococcomas in patients without HIV/AIDS (Galanis and MacDougall, 2010).  
Central nervous system manifestations result from the dissemination from the 
lung. C. neoformans shows neurotropism and its major target is the central 
nervous system. A recent in vitro model of the human blood-brain barrier (BBB) 
of (Vu et al., 2014) revealed that invasion of the CNS by C. neoformans requires 
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a secreted fungal metalloprotease. However, the trend is that C. neoformans 
targets CNS whereas C. gattii, the lungs. This was also confirmed in a mouse 
aspiration inhalation model (inhalation method). C. neoformans, H99 killed by 
brain infection while C. gattii by lung infection, in both BALB/C and C57BL/6 
strains (Ngamskulrungroj, Chang, Sionov, et al., 2012). In the study R265 wt was 
more virulent than H99 wt in C57BL/6 but the virulence of the strains was similar 
in BALB/C survival assay. Both strains manifested in high pulmonary fungal 
burdens. However, the lungs fungal burden was significantly higher in mice 
challenged with R265 wt as compared to H99 wt. Leukocyte infiltrations in the 
R265 wt lungs infected mice were significantly lower than in H99 wt infected lugs 
in both early and late time-points (Ngamskulrungroj, Chang, Sionov, et al., 2012). 
Previous study demonstrated that C. neoformans did not but C. gattii inhibited 
neutrophil migration in vitro (Zhao Ming Dong and Murphy, 1995). Thus, it is likely 
that R265 wt induces a pulmonary immunosuppression. Indeed, all of the C. gattii 
strains including R265 wt triggered a less protective inflammatory response in 
C57BL/6 mice by suppressing neutrophil migration to the infection sites. The 
immune response of C57BL/6 mice to R265 wt was weak, as pro-inflammatory 
and protective Th1 cytokines were not produced in the lungs whereas H99 wt 
elicited their production. A strong inflammatory immune response might 
contribute to the host protection (Cheng et al., 2009). However, since Th1 
cytokines were measured at day 7 and 14 during infection with the prevalence of 
them being produced at day 7 this suggests that early Th1‐type immune response 
might be required for protection against cryptococcosis. This data is congruent 
with findings of (Angkasekwinai et al., 2014), who also observed the same pattern 
of Th1 cytokines in the lungs of C57BL/6 mice measured on day 7 only. H99 wt 
induced a greater Th1 response than R265 wt (Angkasekwinai et al., 2014). This 
suggests that Th1-type response is needed for the clearance of the pathogen and 
that C. gattii infection dampens Th1 response, which results in the impaired ability 
of the host to mount protective immunity against R265 wt. Studies in mice, 
zebrafish and humans demonstrated some efficacy to induce anti-cryptococcal 
host response by administration of Th1-type cytokines (Joly et al., 1994; Graybill 
et al., 1997; Kamuyango, 2017). Treatment of both C. neoformans H99 wt and C. 
gattii R265 wt with Th1 cytokines activates anti-cryptococcal functions of 
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macrophages (Voelz et al., 2009). On the other hand, Th1 response is pro-
inflammatory and when exaggerated, it might be disadvantageous to the host.  
Interestingly, other groups show that C. neoformans triggers Th2 response in 
mice, which is not protective (Hoag et al., 1997; Chen et al., 2008; Osterholzer, 
Surana, et al., 2009; Wiesner et al., 2015). Treatment with Th2 cytokines inhibits 
anti-cryptococcal functions of macrophages (Voelz et al., 2009). Th2 response 
can also be detrimental to the host. For instance, IL-13, the Th2 cytokine 
produced during C. neoformans infection causes an allergic reaction presenting 
with lung eosinophilia, goblet cell metaplasia and elevated mucus production 
(Müller et al., 2007). Thus, Th1/Th2 balance is essential for both cryptococci and 
host survival.  
C. gattii recently emerged as the causative agent of cryptococcosis in otherwise 
healthy individuals. R265 represents the highly virulent VGIIa Vancouver Island 
outbreak genotype. H99 was the most intensively studied strain of C. neoformans 
worldwide. R265 and H99 strains have similar virulence in A/J mice whereas in 
C57BL/6 R265 is less virulent than H99 in an intranasal inoculation model (Cheng 
et al., 2009). This is not in line with the study of (Ngamskulrungroj, Chang, Sionov, 
et al., 2012) in spite of the same dose used. Nevertheless, the recent research 
has employed KN99 (C. neoformans). This is due to H99 having acquired 
mutations of two genes that made it more virulent owing to being extensively 
cultured in the lab (Morrow et al., 2012; Janbon et al., 2014), thus not being 
representative of wild-type C. neoformans. KN99 is a mating type α, congenic 
strain in the H99 genetic background (Nielsen et al., 2003). KN99 behaves a lot 
more like the original H99. KN99 is the strain used in this present chapter. 
The literature lacks R265 and KN99 alongside survival studies. Only one 
publication has shown prolonged survival of mice challenged with R265. 
However, there was 100% mortality for both strains 4 days apart (Specht et al., 
2017).  
4.1.3 C. gattii R265 and hypothesis 
Recently, increased attention has been drawn to C. neoformans sibling species,  
C. gattii. This is due to an outbreak of a fatal fungal disease caused by a highly 
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virulent lineage of C. gattii. Before 1999 C. gattii was never reported to cause a 
disease in Vancouver (Fyfe et al., 2008) and was also rarely reported previously 
from Canada (Kwon-Chung and Bennett, 1984). In 1999 an outbreak occurred on 
Vancouver Island and since then has spread the Canadian mainland and into the 
USA causing outbreaks in otherwise healthy people. According to Centres for 
Disease Control and Prevention, 218 cases were reported during 1999 – 2007 in 
British Columbia, Canada (Galanis and MacDougall, 2010) and 96 cases 
between 2004–2011 in the USA Pacific Northwest (Harris et al., 2011). The 
majority of cases in the USA come from Oregon, Washington, and California 
(Harris et al., 2013). This means C. gattii has spread and expanded to temperate 
zones. The Vancouver Island major outbreak strain is VGIIa, and this molecular 
type is significantly more virulent in mice than other molecular types of C. gattii 
(Kidd et al., 2004; Fraser et al., 2005; Byrnes et al., 2010). The C. gattii R265 
VGIIa strain is a hyper virulent clinical isolate from the Vancouver outbreak. The 
outbreak has almost exclusively affected immunocompetent patients. The 
underlying mechanism of R265 virulence in immunocompetent individuals 
remains unexplained, and little is known regarding C. gattii growth and 
mechanism of infection. 
I hypothesised that C. gattii growth assessment in the zebrafish model of 
cryptococcosis will reveal the cause of its virulence.  
This chapter reports a systemic investigation of the virulence R265, KN99 in the 
zebrafish model of infection (Bojarczuk et al., 2016). It is acknowledged that the 
model does not involve lungs but it fits with the aim of studying virulence and the 
early events following dissemination of cryptococci. I found that R265 was more 
virulent and this was confirmed in a mammalian model. To find a possible 
explanation of its virulence, genome sequencing and metabolic profiling were 
used. C. neoformans and C. gattii, aside from the differences mentioned at the 
beginning of this introduction, are also significantly different in their ability to utilise 
carbon (Bennett et al., 1978) or nitrogen sources (Lee et al., 2011; 
Ngamskulrungroj, Chang, Roh, et al., 2012). Thus, I hypothesised R265 might 
present with a unique metabolic profile. 




4.2.1 Cryptococcus gattii R265 infection results in decreased host survival 
than C. neoformans strain KN99 in a zebrafish model 
To identify the utility of zebrafish to study C. gattii virulence, C. gattii R265 and  
C. neoformans KN99 were compared side by side. Following injection of 48 hpf 
zebrafish larvae with 1000 cfu of R265 wt or KN99 wt strains, R265 wt infection 
resulted in 11.1 % survival (Figure 4.1). In contrast, the survival was >6 fold higher 
for larvae injected with KN99 wt (66.7%; Figure 4.1). This delivered significantly 
different results as compared to studies in mice, wherein the survival curves for 
KN99 wt and R265 wt were nearly identical (Specht et al., 2017).  
Phagocyte-Cryptococcus interactions are important to investigate disease 
progression. To facilitate methods for assaying virulence, a GFP version of R265 
was needed and has been previously described. In vitro, R265 GFP14 showed 
no difference in growth in rich media, under stress conditions and in macrophages 
compared to the parental strain (Voelz et al., 2010). However, there are no 
reports of using it in vivo. To determine whether the GFP insertion had an effect 
on virulence, nacre zebrafish larvae were injected in the same manner as in the 
survival assay between KN99 wt and R65 wt. The injection of C. gattii R265 wt 
resulted in 23.3% survival. In contrast, the survival was >3 fold higher for larvae 
injected with GFP-tagged C. gattii R265 GFP14 and was 76.7% (Figure 4.2).  
The unexpected finding signalled the need for additional studies regarding KN99 
wt and KN99 GFP in order to find out whether GFP insertion influenced its 
virulence. No previous research has investigated KN99 GFP and KN99 wt 
alongside in survival assays in vivo. Therefore, several studies have almost 
exclusively focused on either KN99 wt (Nielsen et al., 2003) or KN99 GFP 
(Gibson et al., 2018). The direct comparison revealed there was no significant 
difference between KN99 wt and KN99 GFP (Figure 4.3). Both strains resulted in 
the same survival rate of 66.7%. 




Figure 4.1 Survival of nacre zebrafish larvae at 3 dpi is increased with  
C. neoformans KN99 wt as compared to C. gattii R265 wt. injected. Zebrafish 
injected with with 1000 cfu of R265 wt or KN99 wt in 10% PVP, 0.5% phenol red in PBS. 
R265 wt is more virulent than KN99 wt. P value calculated using Log-Rank Mantel-Cox 
test; n=12 larvae per group in 3 independent experiments.    
                  
                                                
Figure 4.2 Survival of nacre zebrafish larvae at 3 dpi is increased with  
C. gattii R265 GFP14 strain as compared to C. gattii R265 wt. Zebrafish injected 
with 1000 cfu of R265 GFP14 or R265 wt in 10% PVP, 0.5% phenol red in PBS.  
P value calculated using Log-Rank Mantel-Cox test; n=10 larvae per group in 3 
independent experiments  
                        
Figure 4.3 Survival of nacre zebrafish larvae at 3 dpi injected with  
C. neoformans KN99 wt or KN99 GFP strains is identical. Zebrafish injected 
with 1000 cfu of KN99 wt or KN99 GFP in 10% PVP, 0.5% phenol red in PBS. KN99 wt 
and KN99 GFP are equally virulent. P values were calculated using Log-Rank Mantel-
Cox test; n=12 larvae per group in 3 independent experiments 
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The analysis of zebrafish survival led to the following conclusions: 1) R265 wt 
was more virulent than KN99 wt; 2) GFP insertion to KN99 did not have an effect 
on virulence when compared to KN99 wt 3) GFP insertion to R265 had an effect 
on virulence as R265 GFP was attenuated when compared to its isogenic strain 
R265 wt. 
4.2.2 R265 GFP14 is avirulent in C57BL/6 mice  
Next, to determine whether R265 GFP14 was attenuated in a mammalian host, 
C57BL/6 mice were utilised in the intranasal model of infection. Mice survival 
assay revealed that animals infected with R265 GFP14 had 100% survival 
(Figure 4.4). In contrast, all mice challenged with R265 wt succumbed by 20 dpf. 
The survival of mice infected with R265 wt was in line with previous studies 

























Figure 4.4 Survival of C57BL/6 mice infected with R265 GFP14 is 100%. 6-8 
weeks old female mice infected intranasally with R265 wt or R265 GFP14. Inoculum 




                                                             
1 The work was done with the help of Carl Wright and Jessica Willis, research technicians 
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4.2.3 R265 GFP14 has lost six genes deleted during generation of the GFP-
tagged derivative of R265 
From the results obtained in both larval zebrafish and murine models, it was clear 
that fluorescent C. gattii strain had impaired pathogenesis. It was therefore 
hypothesised that GFP randomly inserted into R265 strain (Voelz et al., 2010) 
caused changes in the R265 parental strain genome which would be indicative 
to some degree as to why R265 GFP14-infected mice and zebrafish larvae 
showed a high survival rate. R265 wt and R265 GFP14 were whole genome 
sequenced (Farrer et al., 2016) but their sequences were not compared in this 
study. Therefore, R265 wt and R265 GFP14 were compared for differences that 
might explain altered virulence seen for R265 GFP14. The sequencing revealed 
that R265 GFP14 appeared to have a region deleted in chromosome 1 before 
WM276 genome position (22116-30690) and R265 wt (32307-42262). This is 
equivalent to 32 kb deletion when R265 GFP14 and R265 wt reads were mapped 
to the R265 wt assembly. This resulted in the loss of six genes: CGB_A0010C, 
CGB_A0020C, CGB_A0030W, CGB_A0040C, CGB_A0050W and 
CGB_A0060W (Figure 4.5). All of them have been found in C. gattii reference 
strain WM276 (D’Souza et al., 2011). Following sequencing, the next step must 




































Figure 4.5 Diagrammatic representation of genome sequencing differences 
between C. gattii strains R265 wt and R265 GFP14. (A) The R265 wt and R265 
GFP14 assemblies comparison to a reference genome C. gattii WM276 with the 
chromosomes concatenated together. (B) Alignment of contig 1 from C. gattii strains, 
WM276, R265 wt and R265 GFP14. (C) The missing region of R265 GFP14 but present 
in R265 wt is equivalent to ~32 kb. The black dashed lines indicate a different kb scale 
of 4 kb or 10 kb.  
2 
                                                             
2 Analysed with Dr Roy Chaudhuri in the Department of Molecular Biology and 
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4.2.4 In silico analysis of function of six genes deleted during generation 
of the GFP-tagged derivative of R265 
 
An obvious question arose: What are the functions of the deleted genes? Below 
the genes are characterised according to the available literature and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) and a brief description of genes 
deleted in R265 GFP14 is shown in Table 4.1. 
CGB_A0010C xenobiotic-transporting ATPase, putative 
KEGG; (Kanehisaa and Goto, 2000; Kanehisa, 2019; Kanehisa et al., 2019)) 
describes xenobiotic-transporting ATPase protein as an enzyme that catalyses 
the translocation of other compounds according to the following scheme: ATP + 
H2O + xenobiotic[side 1] = ADP + phosphate + xenobiotic[side 2]. It is an ABC-
type (ATP-binding cassette) xenobiotic transporter (KEGG). ABC transporters 
have ATP-binding cassettes which power the transporter by binding and 
hydrolysing ATP (reviewed by (Davidson and Chen, 2004)). The ATP-binding 
cassette (ABC) transporters are a family of transporter proteins that are 
responsible for drug resistance by pumping a variety of drugs out of the cytoplasm 
at the expense of ATP hydrolysis (reviewed by (Choi, 2005)). Since exporter-type 
ABC transporters are expressed in all species and importer-like are found in 
prokaryotes only (reviewed by (Locher, 2009)) it is plausible that C. gattii converts 
the energy gained from ATP hydrolysis into trans-bilayer movement of substrates 
out of the cytoplasm. 
CGB_A0020C glucose 1-dehydrogenase, putative 
Glucose 1-dehydrogenase performs reaction: D-glucose + NAD(P)+ = D-glucono-
1,5-lactone + NAD(P)H + H+. This enzyme has similar activity with either NAD+ 
or NADP+. It participates in the pentose pathway (KEGG). 
CGB_A0030W racemase, putative 
Racemase changes the L into D or S into R conformation of amino acids (KEGG) 
thus enabling their use in different metabolic pathways. 
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CGB_A0040C rhamnosidase B, putative      
Rhamnosidase B performs hydrolysis of terminal, non-reducing beta-L-rhamnose 
residues in beta-L-rhamnosides. Since C. neoformans grows on L-rhamnose 
(Schmeding et al., 1984), it is suggested that this enzyme is involved in rhamnose 
utilisation.  
CGB_A0050W hypothetical protein CNB05730 is not characterised. 
CGB_A0060W hypothetical protein CNB05720-only information about predicted 
domains exist.  
Virulence is of the greatest importance for the survival of the pathogen within a 
host. The term “hyper virulent” often describes a strain that exhibits a significant 
increase in virulence compared to either the parental wild-type strain or related 
strains within the same species (reviewed by (Bliven and Maurelli, 2012)). R265 
wt is such a strain. While investigating a strain virulence, gene loss and resulting 
phenotypes related to the virulence are very often studied. A question arises-how 
the gene/genes loss could impact R265 GFP14 virulence in vivo? Thus, the 
critical issue really is to pay attention to Cryptococcus expression profiles under 
various conditions. For instance, Fan et al. observed that genes encoding 
membrane transporters for nutrients, general metabolism, and oxidative stress 
response were upregulated in the presence of macrophages (Fan et al., 2005). 
A recent publication of Farrer and colleagues also paid attention to expression 
profiles of C. gattii in vitro without macrophages and ex vivo post co-incubation 
with BMDMs. Transcriptome sequencing revealed that lineage VGII, to which 
R265 wt belongs, is transcriptionally divergent from non-VGII lineage. Moreover, 
the total number of differentially expressed gene changed (either up- or 
downregulation) for isolates ex vivo but not in vitro. One of the genes upregulated 
ex vivo was ABC transporter gene CNBG_4708, an ortholog in  
C. gattii R265 to a gene of known function in C. neoformans H99 (Farrer et al., 
2018). Interestingly, one of the genes deleted in R265 GFP14 is CGB_A0010C 
with conserved ABC domain. This suggests that although the exact function of 
this deleted gene remains unknown, it is possible that it has a role in cryptococcal 
virulence. However, in comparison to the parental strain R265 wt, it is known that 
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R265 GFP14 does not have a different ability to grow in macrophages even 
though it has lost its genes (Voelz et al., 2010). Only, when in vivo the virulence 
of R265 GFP14 changed and in the current study this strain is attenuated in 
zebrafish and mice when compared to R265 wt. 
It is also interesting to note that phenome-based functional analysis of the  
C. neoformans transcription factor (TF) mutant library showed differences in 
virulence in vitro versus in vivo. Specifically, there are genes whose deletions 
cause, for example, reduced virulence in mice and at the same time enhanced 
virulence in vitro in YPD at 30°C or 37°C in the means of growth, differentiation, 
stress responses, antifungal resistance and virulence-factor production (Jung et 
al., 2015). This may explain some genes loss could impact virulence in vivo. 
However, this might also relate to thermotolerance, which is discussed in section 
4.3.1 Temperature and thermotolerance. The same suggestion appeared in 
(Yang et al., 2017), which referred to the study of (Jung et al., 2015). Indeed, 
CNB05770 encoding xenobiotic-transporting ATPase in C. neoformans var. 
neoformans JEC21 (Loftus et al., 2005), an ortholog of CGB_A0010C deleted in 
R265 GFP14, is induced at 37°C in vitro in YPD suggesting that a conserved 
transcriptional program is used by the fungus to alter gene expression during 
stressful conditions (Kraus et al., 2004). By contrast, CNAG_04096 encoding 
racemase in C. neoformans var. grubii H99, a gene deleted in R265 GFP14, is 
repressed in vitro after internalisation by phagocytic cells (Derengowski et al., 
2013). CNAG_02587 encoding rhamnosidase in C. neoformans var. grubii H99 
(NCBI server), which is deleted in R265 GFP14, is also downregulated in vitro at 
37 °C in YPD (Kmetzsch et al., 2011). 
These findings further support the idea of changing gene expression levels under 
various conditions. This phenomenon is seen in other pathogenic fungi, e.g. 
Aspergillus fumigatus or C. albicans. Virulence associated genes are expressed 
at significantly higher levels during invasive infection than in vitro for A. fumigatus 
(Gravelat et al., 2008). As for C. albicans, differences between in vivo biofilm 
expression data and previously reported from in vitro models, including 
alterations in metabolism and carbohydrate processing, could be due to the 
continuous availability of nutrients from host serum and the incorporation of the 
host-pathogen interaction (Nett et al., 2011).  
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This cast a new light on the fluorescent C. gattii strain. R265 GFP14 was 
attenuated in vivo, in both zebrafish and mice, possibly due to the loss of six 
genes deleted during generation of the GFP-bearing transgenic C. gatti. This 
mutation in the R265 GFP14 caused by GFP insertion was not only specific to 
fish pathogenesis, but also to mice. This suggested that these six genes were 
important for in vivo virulence in both animal models, independent of the growth 
conditions previously tested (Voelz et al., 2010). Therefore, the GFP strain was 
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Table 4.1 List of genes deleted in R265 GFP14  




1. ABCG_PDR_domain2; Second 
domain of the pleiotropic drug 
resistance-like (PDR) subfamily G of 
ATP-binding cassette transporters 
2. ABCG_PDR_domain1; First 
domain of the pleiotropic drug 
resistance-like subfamily G of ATP-
binding cassette transporters 
3. 3a01205; Pleiotropic Drug 
Resistance (PDR) Family protein 
4. ABC2_membrane; ABC-2 type 
transporter 
5. PDR_CDR; CDR ABC transporter 
6. ABC_trans_N; ABC-transporter 
extracellular N-terminal 





protein) reductase; Validated 
2. NADB_Rossmann; Rossmann-fold 
NAD(P)(+)-binding proteins 
CGB_A0030W      racemase, putative 
 
1. RK15440; L-rhamnonate 
dehydratase; provisional 
2. MR_like_2; Mandelate racemase 
(MR)-like subfamily of the enolase 
superfamily, subgroup 2. 
CGB_A0040C      rhamnosidase B, 
putative 
1. Bac_rhamnosid; Bacterial alpha-L-
rhamnosidase 
2. Bac_rhamnosid_N; Alpha-L-
rhamnosidase N-terminal domain 




not indicated on NCBI 




1. Zn_clus; Fungal Zn(2)-Cys(6) 
binuclear cluster domain 
2. fungal_TF_MHR; fungal 
transcription factor regulatory middle 
homology region 
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4.2.5 C. gattii R265 GFP14 does not grow in the zebrafish  
 A previously developed zebrafish model of cryptococcosis (Bojarczuk et al., 
2016) was used to determine how the transgenic R265 GFP14 cryptococcal cells 
were attenuated in zebrafish, as suggested in survival assays. My zebrafish 
model of cryptococcosis (Bojarczuk et al., 2016) provided a highly tractable 
system to study cryptococcal interactions with the innate immune cells such as 
macrophages.  
Tg(mpeg1:mCherryCAAX)sh378 (Bojarczuk et al., 2016) (expressing fluorescent 
marker mCherry under the control of the macrophage-specific mpeg1 promoter) 
zebrafish larvae were injected at 48 hpf with 100 cfu of R265 GFP14 strain into 
the yolk sac circulation valley (Figure 2.5).  
It was hypothesised that the observed extended survival in zebrafish challenged 
with R265 GFP14 was due to macrophages efficiently phagocytosing the 
pathogen followed by intramacrophage killing of cryptococci (and further 
possibilities discussed below).  
R265 GFP14 did not grow in any of the analysed infected zebrafish (Figure 4.6). 
In order to gain an insight into a complex process of phagocytosis, the intracellular 





   
211 
  
Figure 4.6 R265 GFP14 does not grow in any of the analysed infected 
zebrafish. (A) Progression of infection within individual zebrafish infected with 100 cfu 
of R265 GFP14. Cryptococci injected in 10% PVP, 0.5% phenol red in PBS into 48 hpf 
Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae.; n=20 per group in 3 independent 
experiments; in each repeat 7, 6 and 7 larvae were used. Data presented as connecting 
lines only. (B) The number of R265 GFP14 cryptococci decreases over time. R265 
GFP14 injected in 10% PVP, 0.5% phenol red in PBS into 2 dpf (48 hpf) 
Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae. P values presented as One-way 
ANOVA (and nonparametric) in Friedman test with Dunn’s multiple comparisons; data 
presented as connecting lines (A) and dot plot with mean ±standard deviation (B).  
 
 
Figure 4.7 The number of extracellular cryptococci is lower than the number 
of intracellular cryptococci at 48 and 72 hpi. Due to nonparametric distribution of 
intra- and extracellular numbers of cryptococci, the data was log10(x+1) transformed. This 
allowed for two-way ANOVA analysis. The number of extracellular cryptococci is lower 
than the number of intracellular cryptococci at 48 and 72 hpi. R265 GFP14 injected in 
10% PVP, 0.5% phenol red in PBS into 2 dpf (48 hpf) Tg(mpeg1:mCherryCAAX)sh378 
zebrafish larvae; n=20 per group in 3 independent experiments; in each repeat 7, 6 and 
7 larvae were used . P values presented as RM two-way ANOVA with Sidak’s post-test; 
data presented as interleaved scatter plot with mean ±standard deviation.  
A B 
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The results led to the conclusion that the number of extracellular cryptococci at 
48 and 72 hpi was lower than the number of intracellular cryptococci at these 
time-points. The applicability of these new results were then tested separately to 
investigate the changes in each portion of cryptococci between the experimental 
time-points. 
First, the number of intracellular cryptococci was plotted (Figure 4.8). There were 
no significant differences between the experimental time-points.  
The number of extracellular cryptococci declined over time with significant 
differences at 48 and 72 hpi as compared to 2 hpi (P <0.0001 at both time-points) 
(perhaps phagocytosed and killed) (Figure 4.9).  
Next, the effectiveness of macrophages during phagocytosis was investigated. 
This was achieved by calculating the percentage of phagocytosed cryptococci, 
the number of infected macrophages and phagocytic index.  
The percentage of phagocytosed cryptococci was obtained as the number of 
intracellular (engulfed) cryptococci divided by the total number of cryptococci at 
a given time-point (Figure 4.10). It should be noted, that the phagocytosis 
percentage can apply only to the first time-point. After this time-point, 
phagocytosis might represents different cryptococcal fates, e.g. vomocytosis, 
growth within macrophages. Thus, phagocytosis at time-points other than the first 
one is described as the percentage proportion of intracellular cryptococci. The 
highest proportion of intracellular cryptococci engulfed by macrophages occurred 
at 72 hpi (Figure 4.10, P=0.0045). The last time-point was surprisingly significant 
considering only 50% of internalised cryptococci at 2 hpi. This suggested a small 
increase in the proportion of intracellular cryptococci over time. It also highlighted 
that little is known about the R265 GFP14 capsule. The capsule is the most 
important virulence factor of C. neoformans and it prevents phagocytosis (see 








Figure 4.8 The number of intracellular cryptococci does not change 
throughout the course of infection. R265 GFP14 injected in 10% PVP, 0.5% 
phenol red in PBS into 2 dpf (48 hpf) Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae; 
n=20 per group in 3 independent experiments; in each repeat 7, 6 and 7 larvae were 
used. P values presented as One-way ANOVA (and nonparametric) in Friedman test 
with Dunn’s multiple comparisons; data presented as scatter plot with mean ±standard 
deviation.  
  
Figure 4.9 The number of extracellular cryptococci declines over the time 
of infection. R265 GFP14 injected in 10% PVP, 0.5% phenol red in PBS into 2 dpf (48 
hpf) Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae. n=20 per group in 3 independent 
experiments; in each repeat 7, 6 and 7 larvae were used. P values presented as One-
way ANOVA (and nonparametric) in Friedman test with Dunn’s multiple comparisons; 
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To investigate whether the percentage proportion of intracellular cryptococci is 
due to a greater number of macrophages phagocytosing R265 GFP14, the 
number of infected macrophages was calculated (Figure 4.11). No significant 
differences were found throughout the experiment. This suggests that the rate of 
cryptococci engulfment by macrophages is steady over the course of infection. 
To investigate how many cryptococci there were per macrophage, the phagocytic 
index (PI) was calculated. The rate of phagocytosis defined as the ingestion of 
particular number of cryptococci by one macrophage (but not phagocytosis 
expressed as the percentage proportion of intracellular cryptococci) was similar 
between time-points with the exception of 48 hpi. At 2 hpi, PI appears to be non-
significantly higher than all other time-points, but it is significantly higher than 48 
hpi (P=0.0036) (Figure 4.12). There is not much difference overall and this small 
trend might be expected as more free cryptococcal cells would be present in the 
zebrafish at earlier time-points. Over time more was phagocytosed (Figure 4.10), 
and since some will survive within the macrophages and some will be killed the 
PI appears relatively constant.  
Collectively, the results appeared to suggest a distinctive course of infection. To 
present this interesting case, a model of R265 GFP14 infection progression was 
proposed (Figure 4.38, see Discussion section 4.3.3.3 C. gattii R265 GFP14 does 
not grow in the zebrafish). 
So far, the above results revealed that a transgenic insertion mutant of the VIO 
type strain R265 GFP14 was attenuated both in zebrafish and in mice. A deletion 
equivalent to 32 kb was identified in the GFP genome, which might be associated 
with better fish and mice survival as compared with its isogenic R265 wt. Given 
the involvement of the six genes deleted in the GFP strain, in metabolite related 
processes, it was hypothesised that R265 GFP14 had an altered ability to adapt 
to the host environment. 
 
 






Figure 4.10 The percentage proportion of intracellular R265 GFP14 
cryptococci is the greatest at 72 hpi. R265 GFP14 injected in 10% PVP, 0.5% 
phenol red in PBS into 2 dpf (48 hpf) Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae 
n=20 per group in 3 independent experiments; in each repeat 7, 6 and 7 larvae were 
used. P values presented as One-way ANOVA (and nonparametric) in Friedman test 
with Dunn’s multiple comparisons; data presented as scatter plot with mean ±standard 
deviation. 
      
 
Figure 4.11 The number of infected macrophages does not change over the 
course of infection. R265 GFP14 injected in 10% PVP, 0.5% phenol red in PBS into 
2 dpf (48 hpf) Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae n=20 per group in 3 
independent experiments; in each repeat 7, 6 and 7 larvae were used. P values 
presented as One-way ANOVA (and nonparametric) in Friedman test with Dunn’s 
multiple comparisons; data presented as scatter plot with mean ±standard deviation.  




Figure 4.12 Phagocytic index (PI) is relatively constant throughout the 
course of infection. R265 GFP14 injected in 10% PVP, 0.5% phenol red in PBS into 
2 dpf (48 hpf) Tg(mpeg1:mCherryCAAX)sh378 zebrafish larvae; n=20 fish in total from 3 
repeats. P values presented as One-way ANOVA (and nonparametric) in Friedman test 
with Dunn’s multiple comparisons; data presented as scatter plot with mean ±standard 
deviation. 
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4.2.6 R265 GFP14 shows a growth deficit in the minimal medium 
Based on the hypothesis that R265 GFP14 had a decreased ability to adapt to 
the host environment, it was predicted that the fungus would show a growth 
deficit. Therefore, its growth in rich and minimal media was measured. The rich 
medium was YPD, commonly used in laboratories for Cryptococcus cultivation. 
This rich medium contains 1% yeast extract, 2% peptone and 2% glucose 
(Ngamskulrungroj, Himmelreich, et al., 2009) in distilled water. The minimal 
medium is also made up in distilled water and contains potassium phosphate 
monobasic, magnesium sulphate, glycine, thymine and glucose with the sugar 
contribution at 0.27% (Zaragoza et al., 2010). The minimal medium does not 
inhibit C. neoformans growth in vitro (Araujo et al., 2012). Assuming an altered 
ability to the environment, it was hypothesised that these two C. gattii strains 
would grow at different rates. It was predicted that R265 GFP14 would exhibit 
lower growth rate in the minimal medium, which supplies less nutrients than the 
rich one, although still containing glucose as the sole source of carbon. The 
experiment was initially designed to grow cryptococci for 24 hours following the 
common procedure. However, due to not observing any changes after this time 
period, it was decided to grow the cultures for 48 hours. The R265 GFP14 strain 
had a deficit in growth in the minimal media in comparison to R265 wt (Figure 
4.13). The result suggested the possibility of similar conditions in vivo in zebrafish 
larvae. Therefore, a growth deficit in the minimal media potentially represented 
attenuation in vivo. The implication of this finding was that R265 GFP14 might 
have metabolic defects resulting from the loss of the aforementioned six genes 
deleted during random genomic integration of GFP construct. However, it should 
be mentioned, that the findings from Figure 4.13 are subject to at least two 
limitations. First, due to growing the strains as separate cultures and not knowing 
their initial concentrations, it was not possible to plot the data on the same graph: 
day 0- two cultures of R265 wt and two of R265 GFP14 were set up, day 1- two 
R265 wt samples were mixed with each other and the same applied to two R265 
GFP14 mixed with each other to obtain the required concentration of cells, day 
2- the samples were counted in 1ml of PBS but no difference was observed. 
Therefore, the cells were grown for one more day and on day 3, counts were 
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plotted on two separate graphs, representing either R265 wt R265 GFP14 counts 
in rich and minimal media. In retrospect, a protocol refinement would be that on 
day 1, the three samples should be made at the same concentration. The growth 
data could then be plotted on the same graph and this would answer whether the 
isogenic strain grows equally well in YPD/ minimal media.  
It seems the second limitation might be the use of haemocytometer, where there 
is the possibility that dead cells are counted. Some researchers use OD instead 
when counting Cryptococcus (Bielska et al., 2018; Maurya et al., 2018). However, 
this technique also has limitations, e.g. spectrophotometers with different optical 
configurations give different OD values for the same culture. 






Figure 4.13 The R265 GFP14 strain had a deficit in growth in the minimal 
media in comparison to R265 wt. Neither YPD nor minimal medium has an effect 
on R265 wt (A) while R265 GFP14 has a significant deficit in growth in minimal media in 
vitro (B).The number of cells counted at 48 hours post inoculation; n=9 per group in 3 
independent experiments. P values presented are Mann-Whitney test; data presented 
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4.2.7 C. gattii R265 GFP14 exhibits different use of carbon sources 
R265 GFP14 showed a difference when cultured in YPD and minimal media. To 
investigate differences in the cellular metabolic pathway(s) and identify 
differences between the R265 GFP14 and R265 wt, a phenotypic metabolic 
profiling approach (Bochner et al., 2011) was adapted. It is important to 
understand which metabolic pathways are activated or deficient and could 
potentially be manipulated to achieve anti-cryptococcal protection. For 
characterisation of potential carbon substrates utilisation and identification of the 
specific differences in substrates metabolism, cryptococcal cells were tested in 
an OmniLogTM Phenotype Microarray system. 96-well phenotype microarray 
plates (PM1, Technopath) were used. This technology enables the unveiling of 
new functions of genes by concurrently testing mutants for a large number of 
phenotypes (Bochner et al., 2001; Bochner, 2003). The protocol was done as 
described previously (Zhou et al., 2003; Nielsen et al., 2005). This was the first 
time PM1 metabolic panel was performed in C. gattii. Due to protocol 
optimisation, a large number of experiments were excluded from the analysis. 
Thus, only two were selected and considered preliminary. 
PM1 array is a novel screening approach to identify substrates that had 
significantly different NADH production in the R265 GFP14 compared to R265 
wt. PM1 set is a 96 well plate assay with each well containing either R265 wt or 
R265 GFP14 and a different metabolite serving as a source of carbon. This 
experimental design allows for testing a unique phenotype or cell function. The 
analysis allows strain phenotypes to be quantitatively measured over a 36 hour 
time period based on colour change in each well. Cryptococcal cells are 
combined with a tetrazolium dye that absorbs electrons produced by yeast cell 
respiration. Reduction of the tetrazolium dye D yields a purple colour. The colour 
reaction indicates that the inoculated cells are actively metabolising a substrate 
in the well, producing NADH, while the lack of colour change implies that the cells 
are not able to utilise the substrate. Representative images of dye D colour 
changes with R265 wt and R265 GFP14 after 36 hours of incubation for two 
repeats are presented in Figure 4.14. Representative images of kinetic traces 
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Figure 4.14 Representative images of the redox dye D colour changes. (A) 
R265 wt and (B) R265 GFP14 in the first run and (C) R265 wt and (D) R265 
GFP14 in the second run after 36 hours of incubation. 
3 
                                                             
3 The data was obtained with the help of Dr Scott Allen, Senior Non-Clinical 
Fellow in SITraN, The University of Sheffield  




Figure 4.15 Representative images of kinetic traces. (A) R265 wt and (B) 
R265 GFP14 in the first run and (C) R265 wt and (D) R265 GFP14 in the 




                                                             
4 The data was obtained with the help of Dr Scott Allen, Senior Non-Clinical 
Fellow in SITraN.  
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To identify the substrates in question for further kinetic analysis data from the two 
screens were firstly analysed by focusing on the last time-point of each 
experiment, this was the 36th hour. Thus, the starting point for the analysis was 
the creation of end-point metabolic profile at 36 hours (Figure 4.16) for all of 
metabolites. This did not give a true reflection of the kinetics. However, it provided  
an idea as to which metabolites to analyse in terms of kinetics. For all metabolites, 
the background (negative control) was removed in order to normalise data. The 
end-point profile identified a number of potential substrates candidates. The 
graph provided information only about data distribution but not statistical 
significance. In order to justify statistical differences, kinetic response curves 
were generated for each metabolite and two-way ANOVA was performed.  
In the majority of cases, the lag phase was observed, which lasted around 1005 
minutes, with a range of 810 minutes and 1065 minutes. While it was tempting to 
remove the lag phase data, on a final note it was decided to keep it for 
completeness of the assay.  
It is not understood why R265 GFP14 showed higher metabolic activity than the 
wild-type during the lag phase. The inoculum concentration was determined by 
transmittance, i.e. conveniently measured from inoculum fluid tubes with the 
original Biolog turbidimeter. The meter was adjusted to 100% on each inoculated 
tube just prior to cell addition. Cells were then added mixed uniformly from top to 
bottom of the tube. On occasions, where the transmittance was too high, dilutions 
were made. The highest dilution was proximately 1:3. However, the most frequent 
dilutions were at proximally 1:2. This might mean that the different cultures might 
have been at different stages of growth phase. Taking into account the time spent 
on the carriage of samples from The University of Sheffield building to SiTRAN 
and plates preparation in the latter building, this time might have resulted in the 
average time from one second to one third of the experimental time in the Biolog 
plate reader to be spent on the adjusting to adapting to growth conditions (lag 
phase). 
Converting the negative values was applied both to the wild-type and the GFP 
strains. The negative well value (A01) was removed from all the other values on 
the plate to normalise for background and then any negative values were 
converted to zero. This was done because the negative values are a measure of 
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the background metabolism in the cells on any given day. This will be different on 
different days and different runs. If normalisation is not done by removing the 
negative values, then there is no certainty that any increases or decreases in 
metabolism seen on a run to run basis are not just down to the cells being more 
or less active on that day. Many assays use this approach as this is a way to 
remove background variation seen in cells, buffers etc. (Bochner et al., 2011; 
Allen et al., 2019). Therefore, it is unlikely to lose any increase in NADH 
measurement. Another issue which remains is reproducibility. This issue is solved 
through a replication study, which must be completely independent and generate 
identical findings. To ensure reproducibility, the same protocol and software were 
used. In both runs data obtained looked similar. 
In the initial screen, sixty-six compounds were identified as positive hits, reflecting 
P values <0.05 for genotype and time factors as well as genotype-time 
interaction. All the substrates showed a significant difference overall between 
R265 wt and R265 GFP14 (using two-way ANOVA) and a significant difference 
at one time-point or more (Sidak’s post-test analysis). However, only twenty-one 
kinetic graphs (graphing reaction of NADH production as a function of substrate 
metabolism) showed real kinetic traces. These were identified as hits (Figure 
4.17-37). 








Figure 4.16 The end-point metabolic profile at 36 hours for all of metabolites. Data presented as column bars with mean ±standard 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.17 NADH production kinetics in R265 wt and R265 GFP14 with D-
xylose. R265 wt (magenta) and R265 GFP14 (green). NADH production was measured 
using an OmniLogTM Phenotype Microarray plate reader taking CCD Camera Units 
readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were substracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value=0.0071. For all 
multiple comparisons, see Table 4.2 (Appendix 1). 
 
Figure 4.18 NADH production kinetics in R265 wt and R265 GFP14 with D-
mannose. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 min over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value=0.0006. For all 
multiple comparisons, see Table 4.3 (Appendix 1).  
 
 




Figure 4.19 NADH production kinetics in R265 wt and R265 GFP14 with 
tricarballylic acid. R265 wt (magenta) and R265 GFP14 (green). NADH production 
was measured using a OmniLogTM Phenotype Microarray plate reader taking CCD 
Camera Units readings every 15 minutes over a 36 hours period. Data presented as 
mean with standard error, for R265 wt and R265 GFP14 in duplicate. Background values 
(from a negative control) were subtracted from raw data values and any negative values 
were converted to zero for normalisation. To detect differences in NADH production 
between R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was 
performed. Interaction P value <0.0001, time P value<0.0001, genotype P value= 
0.0044. For all multiple comparisons, see Table 4.4 (Appendix 1). 
 
Figure 4.20 NADH production kinetics in R265 wt and R265 GFP14 with L-
lyxose. R265 wt (magenta) and R265 GFP14 (green). NADH production was measured 
using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera Units 
readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value=0.0098. For all 
multiple comparisons, see Table 4.5 (Appendix 1). 
 
 




Figure 4.21 NADH production kinetics in R265 wt and R265 GFP14 with D, 
L-malic acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0033. For all 
multiple comparisons, see Table 4.6 (Appendix 1). 
 
Figure 4.22 NADH production kinetics in R265 wt and R265 GFP14 with 
bromosuccinic acid. R265 wt (magenta) and R265 GFP14 (green). NADH production 
was measured using a OmniLogTM Phenotype Microarray plate reader taking CCD 
Camera Units readings every 15 minutes over a 36 hours period. Data presented as 
mean with standard error, for R265 wt and R265 GFP14 in duplicate. Background values 
(from a negative control) were subtracted from raw data values and any negative values 
were converted to zero for normalisation. To detect differences in NADH production 
between R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was 
performed. Interaction P value <0.0001, time P value<0.0001, genotype P value= 
0.0168. For all multiple comparisons, see Table 4.7 (Appendix 1). 
 
 




Figure 4.23 NADH production kinetics in R265 wt and R265 GFP14 with L-
asparagine. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0185. For all 
multiple comparisons, see Table 4.8 (Appendix 1). 
 
Figure 4.24 NADH production kinetics in R265 wt and R265 GFP14 with 
sucrose. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0003. For all 
multiple comparisons, see Table 4.9 (Appendix 1). 
 
 




Figure 4.25 NADH production kinetics in R265 wt and R265 GFP14 with L-
lactic acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0005. For all 
multiple comparisons, see Table 4.10 (Appendix 1) 
 
Figure 4.26 NADH production kinetics in R265 wt and R265 GFP14 with 
citric acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0027. For all 
multiple comparisons, see Table 4.11(Appendix 1). 
  
 




Figure 4.27 NADH production kinetics in R265 wt and R265 GFP14 with 
fumaric acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0018. For all 
multiple comparisons, see Table 4.12 (Appendix 1). 
 
 
Figure 4.28 NADH production kinetics in R265 wt and R265 GFP14 with 
acetic acid. R265 wt and R265 GFP14. NADH production was measured using a 
OmniLogTM Phenotype Microarray plate reader taking CCD Camera Units readings every 
15 minutes over a 36 hours period. Data presented as mean with standard error, for 
R265 wt and R265 GFP14 in duplicate. Background values (from a negative control) 
were subtracted from raw data values and any negative values were converted to zero 
for normalisation. To detect differences in NADH production between R265 wt and R265 
GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. Interaction P value 
<0.0001, time P value<0.0001, genotype P value= 0.0059. For all multiple comparisons, 
see Table 4.13 (Appendix 1). 





Figure 4.29 NADH production kinetics in R265 wt and R265 GFP14 with 
pyruvic acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0429. For all 
multiple comparisons, see Table 4.14 (Appendix 1).  
 
Figure 4.30 NADH production kinetics in R265 wt and R265 GFP14 with m-
tartaric acid. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0072. For all 
multiple comparisons, see Table 4.15 (Appendix 1).  
 




Figure 4.31 NADH production kinetics in R265 wt and R265 GFP14 with 
Tween 40. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0088. For all 
multiple comparisons, see Table 4.16 (Appendix 1). 
 
Figure 4.32 NADH production kinetics in R265 wt and R265 GFP14 with 
Tween 80. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0059. For all 
multiple comparisons, see Table 4.17 (Appendix 1). 
 




Figure 4.33 NADH production kinetics in R265 wt and R265 GFP14 with α-
ketoglutaric acid. R265 wt (magenta) and R265 GFP14 (green). NADH production 
was measured using a OmniLogTM Phenotype Microarray plate reader taking CCD 
Camera Units readings every 15 minutes over a 36 hours period. Data presented as 
mean with standard error, for R265 wt and R265 GFP14 in duplicate. Background values 
(from a negative control) were subtracted from raw data values and any negative values 
were converted to zero for normalisation. To detect differences in NADH production 
between R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was 
performed. Interaction P value <0.0001, time P value<0.0001, genotype P value= 
0.0061. For all multiple comparisons, see Table 4.18 (Appendix 1).  
 
 
Figure 4.34 NADH production kinetics in R265 wt and R265 GFP14 with 
glucuronamide. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0451. For all 
multiple comparisons, see Table 4.19 (Appendix 1).  
 




Figure 4.35 NADH production kinetics in R265 wt and R265 GFP14 with 
methyl pyruvate. R265 wt (magenta) and R265 GFP14 (green). NADH production 
was measured using a OmniLogTM Phenotype Microarray plate reader taking CCD 
Camera Units readings every 15 minutes over a 36 hours period. Data presented as 
mean with standard error, for R265 wt and R265 GFP14 in duplicate. Background values 
(from a negative control) were subtracted from raw data values and any negative values 
were converted to zero for normalisation. To detect differences in NADH production 
between R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was 
performed. Interaction P value <0.0001, time P value<0.0001, genotype P value= 
0.0387. For all multiple comparisons, see Table 4.20 (Appendix 1).  
 
Figure 4.36 NADH production kinetics in R265 wt and R265 GFP14 with L-
serine. R265 wt (magenta) and R265 GFP14 (green). NADH production was measured 
using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera Units 
readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0149. For all 








Figure 4.37 NADH production kinetics in R265 wt and R265 GFP14 with D-
fructose. R265 wt (magenta) and R265 GFP14 (green). NADH production was 
measured using a OmniLogTM Phenotype Microarray plate reader taking CCD Camera 
Units readings every 15 minutes over a 36 hours period. Data presented as mean with 
standard error, for R265 wt and R265 GFP14 in duplicate. Background values (from a 
negative control) were subtracted from raw data values and any negative values were 
converted to zero for normalisation. To detect differences in NADH production between 
R265 wt and R265 GFP14, RM two-way ANOVA, with Sidak’s post-test was performed. 
Interaction P value <0.0001, time P value<0.0001, genotype P value= 0.0333. For all 
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R265 GFP14 showed increased NADH production in all twenty-one substrates.  
Table 4.23 (see Appendix 2) shows the hits organised by the highest number of 
significant comparisons. It is noteworthy, that PM microplates were originally 
designed mostly for E. coli, but also included carbon sources for other 
microorganisms. The substrates include many categories of carbon 
sources. They can be categorised both structurally and functionally. For PM1 
used in this study the hits can be organised as follows: amino acids (L-
asparagine, L-serine), monosaccharides aldoses (D-xylose, D-mannose, L-
lyxose), disaccharides (sucrose), diacid sugars (m-tartarte), substituted 
monosaccharides (glucuronamide), fructose/mannose metabolism (D-fructose), 
Krebs cycle metabolites (succinate, acetate, α-ketoglutarate, citrate, fumarate), 
glycolysis metabolites (pyruvate) and miscellaneous (bromosuccinic acid, Tween 
40, Tween 80, methyl pyruvate, tricarballylate). D, L malate remained 
unclassified. D-malate is involved in butanoate metabolism whereas L-malate in 
Krebs cycle (personal communication, Biolog technical support). L-form is 
naturally occurring, whereas a mixture of L- and D-malic acid is produced 
synthetically (Brittain, 2001). L-lactic acid falls in propanoate metabolism, 
according to Biolog.  
4.2.8 Conclusions  
In this chapter, larval zebrafish and mice survival provided a firm conclusion about 
R265 GFP14 virulence attenuation. It was proposed that the attenuation was 
associated with the loss of six genes deleted during generation of the fluorescent 
derivative of R265 wt. Analysis of macrophage-cryptococcal cell interactions 
suggested a distinctive course of infection with many alternative fates of 
cryptococci. To present this interesting case, a model of R265 GFP14 infection 
progression was proposed (see Discussion). R265 GFP14 had a growth deficit 
when cultured in the minimum media as compared with the rich one. This 
suggested the possibility of similar conditions in vivo in zebrafish larvae and 
possibly metabolic defects likely resulting from the loss of the aforementioned six 
genes deleted during random genomic integration of GFP construct. Therefore, 
a metabolic screening was approached to identify differences in the metabolic 
pathway(s) differences between the R265 GFP14 and R265 wt. This aspect of 
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the research suggested that R265 GFP14 exhibited different use of carbon 
sources and confirmed the R265 GFP14 was more efficient at substrate 
assimilation. The main conclusion that can be drawn is that there is a metabolic 
difference between R265 wt and R265 GFP14.  
4.3 Discussion 
 
VGII molecular type of C. gattii has drawn more attention than any other 
molecular type because it was the cause of the Canadian outbreak (Kidd et al., 
2004). Here I have shown that C. gattii R265 wt molecular type VGII is more 
virulent in a zebrafish model of infection than KN99 wt, which is of genotype VNI 
background (Nielsen et al., 2003). However, insertion of GFP reduced virulence 
of R265 in zebrafish and mice. The GFP14 mutant was unable to increase in 
number in zebrafish and I concluded that it had an in vivo growth defect. Using 
an in vitro minimal media growth assay, I found that GFP14 was less able to grow 
supporting my conclusion from the zebrafish studies. To understand this growth 
defect I tested the metabolic activity of R265 GFP14 compared to R265 wt.  
I found that there was evidence of increased oxidative phosphorylation activity in 
the GFP14 mutant but could not conclude how this resulted in decreased growth 
during infection of zebrafish (discussed below). Concurrently, I found that there 
was a 6 gene deletion in the GFP14 R265 mutant and attempted to understand 
how this deletion resulted in decreased virulence. My experiments have not 
answered this question yet and at this stage I cannot conclude how the genotype 
of the GFP14 mutant results in reduced virulence. 
R265 infection resulted in decreased host survival than KN99 in a zebrafish 
model. This is an important finding as there has been little interest in such 
comparisons in vivo. In addition, my finding corroborates the findings of the small 
amount of previous work investigating this question (Thompson et al., 2012). 
While GFP insertion to KN99 did not influence the virulence of KN99 GFP, the 
insertion of GFP into R265 resulted in severe attenuation in zebrafish and mice. 
R265 strains genome sequencing revealed that R265 GFP14 lost six genes 
deleted during generation of the GFP-tagged derivative of R265. It was 
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hypothesised that the loss of these six genes accounted for the loss of virulence 
and that the genes are important in R265 wt pathogenesis.  
To investigate how the virulence was attenuated in the host, R265 GFP14 was 
analysed in a zebrafish model of macrophage and cryptococcal cell interactions 
that permits analysis at a cellular level in vivo, non-invasively and over the course 
of infection (Bojarczuk et al., 2016). It appeared that the infection with R265 
GFP14 is the process of simultaneous killing of previously phagocytosed 
cryptococci with the internalisation of new cryptococci, which were previously 
extracellular. However, R265 GFP14 did not grow in any of the analysed infected 
zebrafish and the overall number of cryptococci was significantly reduced at the 
end of infection. Considering the involvement of the six genes deleted in the GFP 
strain, in metabolite related processes, it was hypothesised that R265 GFP14 
had reduced ability to adapt to the host environment. Thus, it was predicted that 
the fungus would show a growth deficit. Therefore, both R265 wt and R265 
GFP14 were tested for growth in rich and minimal media. R265 GFP14 failed to 
grow in minimal media suggesting the presence of an unrecognised auxotrophic 
phenotype (Dymond, 2013). This has been observed several times for 
Cryptococcus previously: C. neoformans mutant for LYS9 gene (encoding 
saccharopine dehydrogenase) that failed to grow in YNB lysine-deficient medium 
and was avirulent in mice (Kingsbury et al., 2004), C. neoformans mutant for 
methionine synthase gene (MET6) that lost viability when starved of methionine 
plus avirulent in mice (Pascon et al., 2004). However, without being able to 
confirm the supplemental nutrient required, and given the lack of a causative 
gene, confirming autotrophy is not possible. While an uncharacterised autotrophy 
is a possible explanation for the growth defect, the lack of specific nutrient is not 
the only explanation. Other possible phenotypes would be an inability to utilise 
the nutrients present (lack of transporter or enzyme), failure to remove waste 
products from the cell, misregulation of cell growth/division signalling and 
machinery or non-growth response to the environment (e.g. energy used for 
capsule production instead of replication). To investigate some of these 
possibilities metabolic profiling of both strains using a phenotype microarray (PM) 
technology was performed. This demonstrated that the strains differed in terms 
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of carbon utilisation, which might shape the host-pathogen interface. Most 
publications make an impression that carbon must be obtained in large quantities 
from the environment and in the context of infection in order to sustain 
biosynthetic processes (reviewed by (Ene et al., 2014; Ries et al., 2018)). 
Interestingly, the loss of both hexokinases in C. neoformans results in the inability 
to utilise glucose. The loss of both hexokinases together, but not single deletions, 
results in reduced virulence in mice (Price et al., 2011). This means that virulence 
and metabolism of microorganisms are uniquely interlinked. Phenotypic and 
virulence changes that result from changes in the genome are discussed below 
(see The mechanism of R265 GFP14 attenuation in vivo). 
 
4.3.1 Temperature and thermotolerance  
Broad thermotolerance is a widely studied aspect of cryptococci that is 
recognised as being an important part of their ability to cause infection in 
mammals and an important factor in the use of different experimental models.The 
ability to withstand relatively hot or cold conditions might be important for the 
outcome of R265 infection. There is no hard evidence in this present study that 
temperature is a factor. This is because the R265 GFP14 virulence phenotypes 
are similar in zebrafish maintained at 28°C (UK Home Office regulations) with the 
temperature of water controlling the zebrafish body and in mice that have the 
body temperature of about 37°C (Refinetti and Menaker, 1992). However, it might 
be that R265 GFP14 has reduced temperature stress tolerance.  
Interestingly, in vitro, R265 GFP14 showed no difference in growth in rich (YPD) 
media, under stress conditions, proliferation in macrophages or in vomocytosis 
rates compared to the parental strain (Voelz et al., 2010). However, in the 
publication of (Voelz et al., 2010) all stress conditions as well as proliferation and 
vomocytosis were investigated at 37°C only whereas growth rates at both 25°C 
and 37°C. My thorough analysis of the figure representing growth at 25°C and 
37°C in YPD in (Voelz et al., 2010), leads to an interesting observation. I agree 
that there were no differences in the growth between R265 wt and R265 GFP14 
strains at neither 25°C nor 37°C. However, a considerable difference in the 
growth rate can be seen between both the temperatures, which was not 
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addressed in the paper. R265 wt and R265 GFP14 grew worse at 25°C in 
contrast to 37°C. It is interesting that in the growth experiments, the variation 
expressed as standard error of the mean, was quite significant between the 
temperatures. At 37°C, the variation was much more pronounced than at 25°C 
for both strains. R265 GFP14 appeared with very small error bars at both 
temperatures when compared to other strains tested. Therefore, it would be of 
significant interest to test growth of R265 and R265 GFP14 under stress at 
different temperatures. This could be a temperature difference affect or it may be 
a combinatorial stress effect and therefore it would also be of interest to combine 
different stresses as would be present in the animal models used. 
 
4.3.2 GFP insertion 
4.3.2.1 GFP insertion effect on the course of infection 
During infection, the interplay between host and pathogen are investigated to 
assess how host-pathogen interactions at a cellular level take place and to 
understand how the outcome of infection is determined (e.g. Bojarczuk et al., 
2016). To facilitate faster analysis of cryptococcal intracellular parasitism and aid 
assaying virulence, a fluorescent version of a pathogen was needed. In addition, 
a match between non-fluorescent and fluorescent strain in terms of virulence has 
to be demonstrated before its use in infection experiments. Therefore, zebrafish 
larvae were tested in a survival assay to evaluate whether the GFP insertion had 
an effect on virulence. The findings of extended survival of zebrafish challenged 
with R265 GFP14 were unexpected and suggested there might have been a 
difference between R265 wt and R265 GFP14, speculated to be associated with 
the GFP insertion. Therefore, I aimed to establish whether GFP insertion 
influenced the virulence of KN99 wt. No study to date has examined KN99 wt and 
KN99 GFP wt alongside in vivo in a survival assay. Thus, only KN99 wt can be 
discussed in this aspect. In my study, both strains resulted in the same rate of 
survival. This was broadly in line with findings of (Gibson, 2017) wherein the 
KN99 wt injection into zebrafish resulted in 90% survival. The slight difference in 
the survival curves for KN99 wt infected zebrafish might have resulted from the 
zebrafish strain used. In my study nacre was used, whereas AB was used in 
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(Gibson, 2017). The zebrafish data also revealed a difference in response to the 
R265 wt and R265 GFP14, which was surprising for isogenic strains. 
Many bacterial and fungal strains have GFP markers, which does not affect their 
virulence. The following are examples of comparisons of virulence between GFP 
strains and their non-GFP isogenic strains: bacteria in planta Xantomonas 
PXO99GFP (Han et al., 2008); in vivo C. neoformans H99 from the May lab 
(Voelz et al., 2010) versus H99 GFP generated by (Voelz et al., 2010) (Bojarczuk, 
unpublished), KN99 GFP (Gibson et al., 2018) versus KN99 (Nielsen et al., 2003) 
(this present study Chapter 4 in section 4.2.1). Other examples include in vivo 
bacteria Staphylococcus aureus SH1000 pMV158-GFP versus SH1000 (Dr 
Tomasz Prajsnar, the University of Sheffield, unpublished) as well as in planta 
comparison of GFP-labelled fungi Aspergillus to its parental strain (Rajasekaran 
et al., 2008). Actually, the literature is not evident in side-by-side comparisons of 
fluorescently tagged microorganisms to their isogenic non-fluorescent strains in 
terms of virulence. Instead, many concentrate rather on growth comparisons in 
vitro, e.g. growth of GFP-labelled E. coli O157:H7, Salmonella enteritidis, Listeria 
innocua, Listeria monocytogenes versus the growth of parental strains (Ma et al., 
2011) or R265 GFP strains versus R265 wt (Voelz et al., 2010).  
Until recently, there were only two cases of published evidence that addition of a 
fluorescent protein to a genome of a microorganism produced a different 
phenotype (D’Souza et al., 2011; Upadhya et al., 2017). The authors of (Upadhya 
et al., 2017) found no differences in growth of Cryptococcus KN99 mCherry in 
rich or nutrient deprived media, capsule inducing medium, stress conditions such 
as cell wall stressors, oxidative or nitrosative stress. However, there was a small 
increase in survival time of 19 days post infection (dpi) with KN99 mCherry 
expressing construct (KN99mCH) as compared to 16 dpi with KN99 wt 
suggesting that GPF insertion could have an impact on the outcome of survival 
assays and virulence. Nonetheless, the authors of (Upadhya et al., 2017) argued 
that the extended survival of mice with KN99mCH attributed to its slower growth 
in vivo, when mice were co-infected with KN99 wt, likely due to high expression 
of mCherry or due to genomic changes. However, it remains unknown whether 
the KN99mCH genome was sequenced for other mutations, which may be an 
alternative reason. The study of (D’Souza et al., 2011) also produced results 
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which corroborated the findings of my experiments. A number of WM276 GFP C. 
gattii strains were tested in virulence assays and only WM276 GFP2 conferred 
avirulence in infected C57BL/6 mice via intratracheal route with 1x105 cfu. This 
was explained for changes in chromosome 11 of the transformant. This region 
contained 24 genes, including a putative invertase gene (CGB_K4300C), 
mutation of which conferred a raffinose auxotrophy. However, mutations 
elsewhere in the WM276gfp2 genome might account for the virulence defect. This 
suggests that the GFP in C. gattii in itself is not an issue, and instead, that the 
avirulent phenotype seen with zebrafish and mice is related to changes to the 
genome associated with the GFP insertion, i.e. six genes deletion, instead of GFP 
itself.  
 
4.3.2.2 GFP insertion site 
The transformation of C. gattii resulted in homologous integration of plasmid DNA 
asserting mitotically stable integration (Varma et al., 1992). The homologous 
recombination was achieved by using Saccharomyces cerevisiae machinery, 
which assures nearly 100% homologue (Orr-Weaver et al., 1981). The GFP 
expression was stable in vitro after re-streaking and growing at 25°C and 37°C 
as well as under stress conditions at 37°C. This implied stable ectopic integration 
within the genome (Voelz et al., 2010). The creators of R265 GFP14 were unable 
to identify the GFP integration site following PCR and sequencing (Voelz, 2010). 
However, my analysis specified the integration site being on chromosome 1 
replacing the first six genes. While there are now some ways in which to target 
insertion of GFP markers in the cryptococcal genomes these are still uncommon 
and were not performed in this case. Random integration carries the risk of the 
formation of inserted and deleted regions around the site of integration. It is very 
rare that insertion causes a significant change. However, in R265 GFP14, GFP 
insertion removed ~32 kb from early in chromosome 1. From this deletion there 
was no clear candidate for the cause of avirulence (discussed below). Given the 
previous study that demonstrated chromosomal changes following GFP insertion 
into C. gattii strain WM272 (D’Souza et al., 2011) and that chromosomal changes 
have been shown in C. neoformans during the response to fluconazole 
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(Altamirano et al., 2017), I would suggest that genome sequencing of 
cryptococcal strains with insertions is to be recommended as there may be 
changes more frequently than is currently recognised. 
4.3.3 Virulence  
4.3.3.1 Virulence of R265 wt and KN99 wt in a zebrafish model of infection  
The study set out with the aim of assessing the virulence of C. gattii strain R265 
(an isolate from the ongoing Vancouver Island Outbreak, VIO) (Kidd et al., 2004) 
in the zebrafish. The first question in this study sought to determine the difference 
in the virulence between C. gattii R265 wt and C. neoformans KN99 wt (Nielsen 
et al., 2003) (according to the old nomenclature serotype B, genotype VGIIa and 
serotype A background, genotype VNI background respectively). This is 
important to consider, as previous comparisons of systemic infection with these 
strains in vivo were not evident in the literature. Furthermore, understanding if 
virulence of an outbreak strain is increased in comparison to other lab strains 
would be beneficial to ensure research and treatment are developed to the 
correct efficacy. 
 
Subcutaneous infection in C57BL/6 mice gave almost identical lethal infections 
caused by 1x104 cfu of R265 wt or KN99 wt (33 and 29 days post infection (dpi), 
respectively) (Specht et al., 2017). However, systemic infection in zebrafish 
demonstrated a large difference in survival between R265 wt and KN99 wt 
suggesting C. gattii was more virulent. The zebrafish data with inoculation of 
1x103 CFU agrees with data of (Thompson et al., 2012) obtained from a mouse 
(ICR) brain infection model with 2X103 CFU inoculation. C. gattii strain used was 
06-3908, serotype C, genotype VGIIa. This C. gatti strain, 06-3908 similarly to 
R265, is likely to be more virulent in mice than other molecular types of C. gattii 
because it represents VGIIa. VGIIa is described as the most virulent in mice (Kidd 
et al., 2004; Fraser et al., 2005; Byrnes et al., 2010). C. neoformans used by 
Thompson et al was USC1597 of serotype A, genotype VNI, thus it is similar to 
the background of KN99 wt used in my study. Others have shown that survival 
significantly deteriorates with VGIIa compared to VNI in Drospophila 
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melanogaster study with 5x103 cells inoculated through the thorax (Thompson et 
al., 2014). However, it is not clear which VGIIa and VNI strains were used in the 
publication. Overall, it is clear that different cryptococcal strains exhibit altered 
virulence, which depends on the specific strains and infection models used. 
Nonetheless, the zebrafish data shows that C. gattii R265 wt infection results in 
decreased host survival than C. neoformans strain KN99 wt, which is broadly in 
line with the small amount of literature in this area (Thompson et al., 2012). 
4.3.3.2 Avirulence of R265 GFP14 in a mouse model of infection  
The zebrafish study completed in this study on R265 GFP14 and its isogenic 
strain R265 wt highlighted differences in virulence. Thus, to investigate whether 
these results were applicable in a mammalian system a mouse model using the 
C57BL/6 strain was the most commonly used for studying cryptococcosis 
(Ngamskulrungroj, Chang, Sionov, et al., 2012; Sionov et al., 2015; Wiesner et 
al., 2015). There was a large difference in survival of mice between the R265 wt 
and R256 GFP14 with infection with the mutant strain resulting in no mortality. 
The virulence of the R265 wt here was similar to published studies. For example, 
(Specht et al., 2015) also showed deadly infection in C57BL/6 strain succumbing 
at 29 dpi, 28dpi (Ngamskulrungroj, Chang, Sionov, et al., 2012) and 20 dpi 
(Upadhya et al., 2016) with the CBA/J strain. 
4.3.3.3 C. gattii R265 GFP14 does not grow in the zebrafish  
A high mortality rate with R265 wt in my zebrafish study, led to further interaction 
with macrophage investigations in vivo to assess disease progression. For this 
purpose, a fluorescent version was needed along with an assessment of both 
strains virulence. A florescent strain highlights its utility for elucidation of host-
pathogen interactions. Due to the availability of R265 GFP14, being the best 
amongst other GFP mutants generated by (Voelz et al., 2010), this particular 
strain was chosen for planned experiments. Surprisingly, the zebrafish infection 
with R265 GFP14 did not cause the same high level of mortality as R265 wt, 
suggesting that the GFP insertion was reducing virulence of the strain.  
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The extended survival in zebrafish challenged with R265 GFP14 raised a 
hypothesis of macrophages more efficiently phagocytosing the pathogen and 
macrophage killing of cryptococci (than wt). Therefore, the first question in the 
following zebrafish experiments series sought to determine whether R265 GFP14 
survives in the host. The number of cryptococci was significantly lower at each 
time-point when compared to 2 hpi. This suggested efficient killing by 
macrophages. However, the number of cryptococci was not significantly different 
between 24, 48 and 72 hpi and appeared to be maintained at the same level. No 
one has examined intramacrophage killing for R265 GFP14. While intracellular 
proliferation rate and phagocytosis were assayed in macrophages (Voelz et al., 
2010), they do not directly represent the rate of death. Moreover, it was difficult 
to interpret such results without the context of intracellular and extracellular 
numbers, which are indicative of phagocytosis process. The analysis revealed 
that the number of extracellular cryptococci was lower than the number of 
intracellular cryptococci only at 48 and 72 hpi suggesting phagocytosis and 
possibly extracellular portion becoming a pool of intracellular cryptococci. 
Changes within an individual portion of cryptococci unveiled that the number of 
intracellular cryptococci was rather static. Interestingly, between 2 and 24 hpi  
intracellular proliferation is eminent in zebrafish infection with C. neoformans and 
this restrains phagocytosis (Bojarczuk et al., 2016). By contrast, extracellular 
cryptococci dropped rapidly at 24, 48 and 72 hp when compared to 2 hpi. 
However, the comparison between 24, 48 and 72 hpi showed no difference 
somewhat suggesting stabilisation and plateau. Hence, it could be hypothesised 
that the infection included continuous uptake of extracellular portion and killing of 
internalised cryptococci. This explains the maintenance of intracellular portion. It 
is possible that this continuation of somewhat stabilised intracellular cryptococci 
is an effect of replication inside macrophages. The dominance of killing by 
macrophages seems more realistic since the total number of cryptococci is 
reduced at the end of the experiment. However, this study cannot discern 
intracellular proliferation, and use of time-lapse microscopy may help.  
The mechanism of macrophage killing is not known for the R265 GFP14. It could 
be through the host reactive oxygen species (ROS) generated by macrophages. 
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It might be that host ROS do not facilitate intracellular survival. The opposite was 
seen for R265 wt (Voelz et al., 2014). However, since the killing undoubtedly 
facilitates phagocytosis and this process is an essential function of the immune 
system, the latter became the primary matter of interest.  
Interestingly, in vitro, percent phagocytosis by J774 macrophages (Voelz et al., 
2009) of the GFP mutant (33%) showed no difference when compared to its 
parental strain (38%) (Voelz et al., 2010). In vitro J774 study of (Hansakon et al., 
2019) showed a significantly decreased phagocytic uptake of R265 wt at 2 hpi 
analysed by the  (Sabiiti et al., 2014) method when compared to C. neoformans. 
This publication focused attention on the cumulative comparison of 18 C. gattii 
and 23 C. neoformans strains but it drew up the possibility of R265 wt being not 
readily phagocytosed by macrophages. Perhaps the R265 GFP14 is favoured in 
terms of the phagocytic uptake. Unfortunately, due to practical reasons, this study 
was limited to the GPF strain only. It would be preferable to perform all of the 
host-pathogen interactions experiments in the zebrafish model with the use of the 
reference strain R265 wt. An apparent limitation of using R265 wt is the lack of 
fluorescent tag. Thus, the visualisation is limited and recognition of intracellular 
cryptococci straitened. 
It became apparent that after infection of cryptococci, wherein the numbers of 
intracellular and extracellular cryptococci were similar, an immune response was 
initiated. To present this interesting case, a model of R265 GFP14 infection 
progression was proposed (Figure 4.38). Considering the fundamental 
assumptions of the model, all effects observed during the course of infection, 
were assigned to macrophages. Nonetheless, it was acknowledged that 
extracellular numbers could be phagocytosed by different cells of innate immunity 
in zebrafish.  
 
 





Figure 4.38 Diagrammatic representation of proposed model of R265 GFP14 
infection progression in zebrafish larvae. R265 GFP14 cells (yellow) within 
macrophages (purple) are intracellular. R265 GFP14 cells (green) outside macrophages 
are extracellular. Newly internalised cryptococci are brown. One cryptococcal cell 
represents 10 cfu. 
 
Based on the results it is likely, that the infection with R265 GFP14 is the process 
of simultaneous killing of previously phagocytosed cryptococci with the 
internalisation of new cryptococci, which were previously extracellular. The 
number of extracellular cryptococci significantly decreased over time likely due to 
the uptake by macrophages and subsequent phagocytosis. Although there were 
no significant differences between the numbers of infected macrophages, the 
possibility of unviable cryptococci containment cannot be excluded. 
Concomitantly, those cells that had been phagocytosed, might have been killed 
as suggested by the reduced numbers of total cryptococci injected. Again, there 
is no proof confirming R265 GFP14 cell death but the killing seems to be the best 
explanation considering the dropping numbers of injected cryptococci and the 
number of intracellular cryptococci remaining similar at all stages of infection. 
Therefore, my results indicate that C. gattii R265 GFP14 is attenuated in 
zebrafish because it is efficiently phagocytosed and killed by macrophages.  
4.3.4 Analysis of phenotypes produced by R265 wt and R265 GFP14 
 
The phenotypic analysis in this study revealed 21 potential substrate differences. 
The most surprising aspect of the analysis lies in the fact that the wild-type strain 
did not appear to use these compounds to generate NADH. R265 GFP14 
appeared to use Krebs substrate (acetate, α-ketoglutatarate, citrate, fumarate, 
malate), but R265 wt did not. Tags for functions in the tricarboxylic acid cycle 
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(TCA) known as the Krebs cycle, have been found for C. neoformans (Hu et al., 
2008). These included aconitase, malate dehydrogenase, isocitrate 
dehydrogenase, malic enzyme or fumarase (all putative) (Hu et al., 2008). A 
comparison of the genome sequences of C. gattii WM276 and C. neoformans 
JEC21 shows that the WM276 has these genes (all putative) (D’Souza et al., 
2011). Although there are some minor chromosomal rearrangements, the 
majority of chromosomes are collinear between WM276 and R265 wt (D’Souza 
et al., 2011). Aforementioned TCA related genes found in WM276 are present in 
R265 wt (D’Souza et al., 2011). Thus it is assumed they are also present in R265 
GFP14 because they are located on chromosomes other than chromosome 1 in 
R265 wt (D’Souza et al., 2011) and some other genes important in the Krebs 
cycle locate on region of chromosome 1 that is assumed to be unaltered in R265 
GFP14. This introduces a question: Why did R265 not seem to use Krebs 
substrates? What came to mind first was the fact that the plates were sealed. 
This is the only difference in comparison to other growth experiments in this 
thesis. Biolog plates were sealed to prevent a false positive reaction where dye 
is reduced by gas exchange with the air. Therefore, the plates were sealed for 
the 36 hours of the phenotypic experiments. Theoretically, the use of a sealing 
film can affect availability of oxygen. Since gases are constantly consumed and 
produced by cellular and metabolic reactions, a functional gas exchange 
mechanism exists to keep oxygen and carbon dioxide at a healthy level. In 
aerobic organisms, gas exchange is essential for respiration, which involves the 
uptake of oxygen and release of carbon dioxide. In the case of sealing therefore 
the possibility of impaired gas exchange exists, which might lead to carbon 
dioxide accumulation if cells use up oxygen. In other words the sealing might 
impair the results. Any sealed system may be prone to carbon dioxide cell injury 
but this would then be detected in a positive control (in my study glucose, data 
not shown as glucose was not a hit compound) and death resulting in no colour 
change would be seen. Both R265 and R265 GFP14 had colour changes for 
glucose. Therefore, it is rejected that the sealing impaired the results. However, 
this well had less colour change for R265 wt than for R265 GFP14, which was 
suspicious and might suggest altered physiological conditions (discussed later).  
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In contrast, there is no evidence of anaerobic degradation by yeast of  
α-ketoglutarate, citrate, acetate or fumarate in yeast. In this light, it is now 
reasonable to think that R265 wt simply did not perform Krebs cycle from acetate, 
α-ketoglutarate, citrate or fumarate. This can be supported by no growth on citrate 
for C. gattii serotype B (Chaskes et al., 2008). However, a contradictory finding 
of the growth of C. neoformans var. gatti serotype B on this substrate was 
reported by (Lazéra et al., 1998). Isocitrate lyase is required for growth on acetate 
plates (Rude et al., 2002). The gene encoding isocitrate lyase is present in the 
R265 wt on chromosome 9 (D’Souza et al., 2011) and it would be tempting to 
suggest that acetate could be used for energy. There is also evidence for acetic 
acid assimilation by C. albidus (Li et al., 2015) and growth of C. neoformans H99 
on acetate (Hu et al., 2008). Moreover, generally C. neoformans serotypes B and 
C assimilate fumaric acid (Bennett et al., 1978). Interestingly, there were two 
serotype B isolates which failed to assimilate L-malic acid and they also failed to 
assimilate fumaric acid in the study of (Bennett et al., 1978). However, it is not 
known which of B serotype were the ones that did not utilise the compound in the 
publication of (Bennett et al., 1978). In addition, assimilation tests are not 
informative of the pathway by which carbon source is used and perhaps they 
mean assimilatory mechanisms and not catabolic pathways. For instance, citrate 
can be metabolised via the glyoxylate cycle reactions, which then suggests 
anabolism. Perhaps this is a case for the R265 wt. 
In regards to malate, the literature proposes, e.g. malate anaerobic fermentation 
by Saccharomyces bailli through the malic enzyme (Kuczynski and Radler, 
1982). R265 wt has a gene encoding this enzyme and is located on chromosome 
8 (putative) (D’Souza et al., 2011). Therefore, there is a possibility for malate to 
be fermented by R265 wt. The issue in this present assay is that D, L malate was 
tested. As described in the result section, L-form is naturally occurring, whereas 
a mixture of L- and D-malic acid is produced synthetically (Brittain, 2001). Thus, 
it is unknown, whether the mixture would have been taken up, even to proceed 
with fermentation. Although fermentation cannot be excluded as the means of 
energy source, it has to be rejected in this present assay because it occurs in the 
complete absence of oxygen. 
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More recently, some preliminary respirometry has suggested that R265 wt 
respiration is abnormal. Oxygen consumption rate was measured, i.e. routine 
oxygen consumption, oxygen consumption not linked to ATPase function, 
maximum respiration and non-mitochondrial oxygen consumption. Routine 
oxygen consumption is measured in an oxygen-saturated solution in the 
respirometry chamber before any drugs are added and after cell suspension 
when stable oxygen flux reading appears. When this is achieved, respiration-
modulating drugs are added. To measure oxygen consumption not linked to 
ATPase function (leak respiration), triethyltin bromide (TET) is added (Duvenage 
et al., 2019). In the leak respiration state, proton translocation through the ATP 
synthase is thus inhibited by TET, which blocks protons moving through the ATP 
synthase (complex V) and this causes protons to accumulate in the 
intermembrane space. This increase inhibits electrons moving along the chain. 
So the change in oxygen consumption observed after TET addition tells how 
much electron transport is coupled to the movement of protons through the 
ATP synthase, which in turn tells how much it is coupled to ATP production (as 
movement of protons through the ATP synthase is what drives ATP 
production). In other words, following TET addition protons may enter the 
mitochondrial matrix only by diffusion, therefore termed leak respiration giving an 
assessment of how well electron transport is coupled to ATP production (personal 
communication with Dr Campbell Gourlay, University of Kent and Dr Lucian 
Duvenage, University of Cape Town). The maximum respiration is also called 
maximal electron transport chain capacity (uncoupled respiration) and measured 
when carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) is added 
(Duvenage et al., 2019). This means electron flow through the complex I-IV is not 
limited by the bottleneck of oxidative phosphorylation (i.e. the action of ATP 
synthase). The maximum respiration is usually higher than the routine (personal 
communication with Dr Lucian Duvenage, University of Cape Town). Non-
mitochondrial respiration is measured by addition of classical respiration 
inhibitors, i. e. antimycin A (complex III) and/or potassium cyanide (complex IV) 
(Duvenage et al., 2019). The leftover oxygen consumption after antimycin/ 
cyanide addition is the non-mitochondrial respiration as no electron transport is 
taking place. However, it is still possible for an organism to contain an oxidase 
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that is fully resistant to the inhibitor used. R265 wt possess an alternative 
oxidase gene (AOX1) (D’Souza et al., 2011) and the oxidase has to be inhibited, 
too. Aox1 can be inhibited with salicylhydroxamic acid SHAM (Duvenage et al., 
2019). The respiratory work of Dr Gourlay (unpublished) suggested that R265 
respires at mitochondria but little of this respiration is coupled to ATP 
production. This was based on the observation that the leak respiration and 
routine were similar suggesting that the ETC and the oxygen consumption are 
not linked to ATP production at the ATP synthase. Normally oxygen 
consumption decreases after TET addition (personal communication with Dr 
Lucian Duvenage). Since the ratio between routine and leak respiration levels 
(respiratory control ratio) indicates how much the ETC is linked to ATP 
production, or how coupled respiration is (Duvenage et al., 2019), it might be that 
respiration is not well coupled to ATP production in R265 wt strain. In addition, 
the leak control ratio described as the ratio of leak and the maximum capacity of 
ETC was very high for R265 wt as compared to other isolates tested. This 
suggests R265 wt is less efficient at obtaining ATP from oxidative 
phosphorylation. The maximal of ETC capacity (uncoupled respiration) was the 
highest as compared to routine, leak and non-mitochondrial respiration. However, 
it cannot be concluded at this stage that R265 wt might not be performing the 
Krebs cycle at all. This is because the measurement with FCCP (an uncoupler) 
disrupts the mitochondrial membrane potential and results in uninhibited electron 
flow through the ETC. Thus, it only shows how close to maximum capacity the 
organism is respiring. However, the non-mitochondrial respiration value for 
R265 wt was about 50% of the routine respiration (the total respiration under 
normal conditions). Together with the conclusion of R65 wt respiration at 
mitochondria not coupled to energy production, it seems plausible to think that 
the strain will need to rely on fermentation to produce the energy it needs for 
growth. Alternatively, it might be that R265 wt are dysfunctional in terms of ATP 
production and a good proportion of respiration occurs at alternative oxidase 
(Aox1). Aox1 allows respiration and functioning of the TCA cycle when the ETC 
is disturbed (Lambers, 1982; Huh and Kang, 1999). AOX1 is important for C. 
neoformans virulence as mice infected with aox1 mutant had increased survival 
as compared to those infected with H99 (Akhter et al., 2003). Alternative 
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oxidase is not coupled to the proton gradient generation across the mitochondrial 
membrane and thus is not very well coupled to ATP production. This means that 
alternative oxidase produces less ATP than classical oxidative phosphorylation 
(Helmerhorst et al., 2002). Interestingly, R265 wt preliminary data with alternative 
oxidase inhibitor, (SHAM) suggests that it is resistant to alternative oxidase 
inhibition. This suggests R265 does not need the classical respiration and 
alternative respiration is a still functional pathway enabling the TCA cycle. 
Although there is no hard evidence in the respirometry that R265 wt does not 
perform Krebs cycle, this possibility cannot be rejected in my phenotypic array. 
Given that respiration behaviour could change depending on experimental 
condition, it is possible that in the PM1 assay, the non-mitochondrial respiration 
is much higher than the total respiration, which would suggest the fungus does 
not use the oxygen and the oxidative phosphorylation does not occur. 
Experiments investigating fermentation should be performed. This would give a 
clue about its capacity to upregulate the TCA cycle/oxidative phosphorylation if 
the respirometry profile changes (further discussed in section 6.2 Assessment of 
C. gattii virulence in zebrafish and mice). To conclude, all the three options are 
possible: fermentation, alternative respiration and the impeded TCA cycle in 
R265 wt. Experiments proposed to investigate these events are proposed in this 
chapter in section 4.3.7.3 Future work in respect to metabolic profiling of R265 
and R265 GFP14. 
In contrast, I believe my data suggests that R265 GFP14 utilised acetate, α-
ketoglutarate, citrate, fumarate and D, L malate in the Krebs cycle. Acetate can 
enter the TCA cycle in the form of acetyl-CoA. A direct conversion of acetate to 
acetylo-CoA does not produce NADH (KEGG). This occurs via Acetate-CoA 
ligase (KEGG), present in R265 wt on chromosome 1 (D’Souza et al., 2011). It is 
likely that R265 GFP14 strain possesses this enzyme as the region of Acetate-
CoA ligase gene location is not affected in this strain. Further reactions of the 
Krebs cycle then yield NADH in R265 GFP14 but not for the wild-type. Direct α-
ketoglutarate utilisation is not evident in the cryptococcal literature. Α-
ketoglutarate enters the TCA and yields NADH via α-ketoglutarate 
dehydrogenase action converting α-ketoglutarate into succinyl-CoA. R265 wt 
encodes the α-ketoglutarate dehydrogenase gene (putative) that is located on 
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chromosome 2 (D’Souza et al., 2011) and therefore predicted to be unaltered in 
R265 GFP14. Thus, it is reasonable to think that R265 GFP14 can incorporate α-
ketoglutarate into the TCA given that this region of the chromosome 2 was not 
disrupted by the GFP insertion. Citrate must be converted by aconitase that 
performs two reactions. First, a conversion of citrate to cis-aconitate and second, 
cis-aconitate to isocitrate. The analysis of (D’Souza et al., 2011) confirms 
aconitase gene on chromosome 4 (putative). Thus, it is predicted this gene 
remains present in the GFP strain given that this region of the chromosome was 
not disrupted by the GFP insertion. Further reactions of the TCA yield NADH, e.g. 
conversion of D-isocitrate to α-ketoglutarate by the action of isocitrate 
dehydrogenase, predicted to be encoded on chromosome 9 (D’Souza et al., 
2011), which is unaltered in R265 GFP14. Fumarate can be converted in the TCA 
to malate via fumarase hydratase. The encoding gene is located on chromosome 
3 (D’Souza et al., 2011), thus this gene should be present in R265 GFP14. 
Although this reaction is reversible, once yielding NADH and in the reverse order 
NAD+, once fumarate is incorporated to the Krebs, it will lead to another NADH 
producing reactions, e.g. conversion of malate to oxaloacetate. This occurs 
through malate dehydrogenase. R265 wt encodes the malate dehydrogenase 
gene. It is located on chromosome 6 (D’Souza et al., 2011), which is not affected 
in this study. Thus, it is assumed that R265 GFP14 also encodes this gene. 
Therefore, it is assumed that R265 GFP14 used both fumarate and malate in the 
TCA. In the case of R265 wt, as mentioned, there is no alternative degradation 
of fumarate. Malate could be fermented via the malic enzyme in R265 wt but 
fermentative conditions are ruled out in this present study because fermentation 
requires the absence of oxygen and this condition is rejected. 
Pyruvate enters the cycle after conversion into acetyl-CoA by the pyruvate 
dehydrogenase, which is an oxidative process wherein NADH is produced. The 
pyruvate dehydrogenase gene is present in R265 wt on chromosome 1(D’Souza 
et al., 2011). Although this chromosome is altered in R265 GFP14, this gene 
occupies position on an intact remaining region. Therefore, it is plausible to think 
that R265 GFP14 incorporated this substrate via pyruvate dehydrogenase. 
Suggested fermentative mode of energy acquisition for the wild-type could 
convert pyruvate anaerobically to lactate by the action of lactate dehydrogenase, 
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which oxidises NAD+ to NADH (KEGG database). Indeed, R265 wt possess gene 
encoding thus enzyme and it is located on chromosome 11 (D’Souza et al., 2011). 
If fermentation were taking place, this is difficult to assess in this assay, as 
fermentation would replenish NAD+ from the NADH produced in glycolysis.  
Pyruvate discussion raises an opportunity to discuss methyl pyruvate, which was 
one of the hits in the Biolog assay. Methyl pyruvate is a novel metabolic activating 
agent for mitochondria that seems to provoke a slight or transient increase in 
ROS production in tumour cells (Nishida et al., 2014). It should be a substrate for 
the TCA cycle since it is pyruvic acid derivative. In pancreatic β cells represented 
as mitochondria it did not relate to mitochondrial ATP production (Lembert et al., 
2001; Duffer et al., 2002) although produced more NAD(P)H than pyruvate 
(Duffer et al., 2002). The NAD(P)H cannot be separated spectrally from NADH 
autofluorescence and the measured autofluorescence is always a mixture of both 
NADPH and NADH when measured as NAD(P)H (Blacker and Duchen, 2016). 
Therefore, the publication was not conclusive in terms of NADH levels.  
Methyl pyruvate initiates depolarisation of β cells (Lembert et al., 2001) and this 
results in the opening of voltage-dependent Ca2+ channels, and influx of Ca2+ is 
the main trigger for insulin secretion (MacDonald and Wheeler, 2003). The 
increase in the protonic potential is accompanied by a rise in ROS production 
(Korshunov et al., 1997). In order to keep ROS at harmless, levels cofactors such 
as NADH and NADPH play essential roles. NADH generates ATP via catabolism, 
during which ROS are generated, whereas NADPH is needed for anabolism and 
protects the cell from the oxidative stress. In the aspect of the relationship 
between the oxidative stress regulation and the central carbon metabolism under 
oxidative stress condition, NADH concentration must be reduced, while NADPH 
level must be increased (reviewed by (Shimizu and Matsuoka, 2019)).  
It might be that methyl pyruvate exerts or exacerbates harmful oxidative stress. 
ROS are produced mainly by mitochondria (reviewed by (Turrens, 2003; 
Kowaltowski et al., 2009; Murphy, 2009). To keep a steady-state control over 
ROS production, aerobic organisms have evolved a complex array of defensive 
systems to eradicate ROS and return to physiological conditions (reviewed by 
(Birben et al., 2012; Panieri and Santoro, 2016)). It is known that to help protect 
against the destructive effects of ROS, Cryptococcus produces, e.g. superoxide 
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dismutase (SOD) enzyme production (Cox et al., 2003) that converts superoxide 
into sodium peroxide, which is further converted to water by glutathione 
peroxidase or catalase. The last two enzymes are also produced by the fungus 
((Missall et al., 2005) and (Giles et al., 2006), respectively). Paradoxically,  
C. gattii R265 wt uses host ROS to induce an intracellular survival and 
proliferation within macrophages. The use of apocynin, which blocks host ROS, 
reduces growth of R265 wt. The R265 GFP14 was not assessed for apocynin 
effect (Voelz et al., 2014). Generally, under stress, mitochondrial tubular 
morphology results from mitochondrial fusion (reviewed by (Youle and van der 
Bliek, 2012)). This has been observed both in C. neoformans under hydrogen 
peroxide treatment (Chang and Doering, 2018) and in C. gattii R265 wt (Voelz et 
al., 2014). The fusion has been found to protect from cell death (Sugioka et al., 
2004; Chaudhari and Kipreos, 2017). The tubular morphology was observed for 
both R265 wt and R265 GFP14 after engulfment by macrophages (Voelz et al., 
2014). Various ROS are produced within the phagosome and cause oxidative 
damage. Therefore, engulfment by macrophages mimics the oxidative stress 
within a phagosome.  
Although the reaction to host ROS is peculiar, one aspect of own ROS generation 
in terms of central metabolism has not been considered. As mentioned, ROS are 
mainly produced by mitochondria, specifically at electron transport chain (ETC) 
((reviewed by (Murphy, 2009; Brand, 2010)). In order to minimise the oxidative 
stress and ROS production, the amount of electron flux through ETC gets 
decreased by repressing the respiratory chain enzymes and reducing NADH 
production at the TCA cycle (or e.g. by activating the glyoxylate pathway). This 
means that TCA cycle activity is repressed (reviewed by (Shimizu and Matsuoka, 
2019)). Considering that R265 wt did not appear to perform Krebs cycle, I believe, 
that if methyl pyruvate induces ROS, TCA would be suppressed anyway and 
NADH would be minimised. Perhaps this is a case for R255 wt. Moreover, methyl 
pyruvate might induce strong oxidative stress in the R265 wt leading to 
intracellular ROS accumulation. It might be that ROS build up compromises 
membrane integrity. This was shown in vitro in R265 wt by fluconazole treatment. 
It led to accumulation of ROS, which correlated with compromised cryptococcal 
membrane integrity (Peng et al., 2018). In addition, it might be that under methyl 
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pyruvate a tubular mitochondrial morphology is induced as demonstrated by 
hydrogen peroxide treatment in R265 wt (Voelz et al., 2014). Given that tubular 
yeast are non-proliferative (Voelz et al., 2014), the effect observed in my present 
study might be combined and R265 wt is in a somewhat metabolic latent phase. 
If methyl pyruvate action is through ROS, it is not understood why R265 GFP14 
utilised this substrate. 
Alternatively, methyl pyruvate might not be linked with detrimental ROS 
generation but with TCA cycle. As mentioned, pyruvate enters the cycle after 
conversion into acetyl-CoA by the pyruvate dehydrogenase complex (KEGG). 
Perhaps methyl pyruvate does not enter the TCA in R265 wt and a fermentive 
mode of energy acquisition would be suggested if not for the fact that the assay 
rejects anaerobic conditions required for fermentation. It could be argued that it 
is not possible by Cryptococcus to ferment pyruvate as the procces is associated 
with alcohol production and there is no evidence for alcohol production in the 
cryptococcal field. However, an attention to pyruvate metabolism by  
C. neoformans has been drawn recently. The analysis of biofilms formed by  
C. neoformans showed that lactoylglutathione lyase is up-regulated suggesting 
pyruvate is likely to be used in energy metabolism via lactate metabolism (Santi 
et al., 2014).  
A suggested non-mitochondrial respiration for R265 wt, shown by the abolished 
TCA cycle, can also be supported by the fact that Tween 40 and Tween 80 were 
not metabolised. The mechanism of Tween 80 utilisation was suggested for 
Pseudomonas aeruginosa (Ohkawa et al., 1979). It involves its outer membrane 
esterase, which has a preference for long-chain fatty acids. Mutants that do not 
have esterase activity do not grow on Tween 80 as a sole carbon source. 
Microorganisms that express esterase activity produce a halo zone around 
colonies due to crystals of the calcium salt of the fatty acid released by lipolysis 
(Sierra, 1957). This suggests a possible role of the esterase in the utilisation of 
fatty acids from Tween. Lipase (a subclass of esterase) activity was assessed for 
both C. neoformans and C. gattii (Hagen et al., 2015). Interestingly, lipase 
activities, tested using Tweens 40 and 80, showed variable reactions among the 
various species in the study of (Hagen et al., 2015). Furthermore, temperature 
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appeared to be a factor. Importantly, the activity for R265 was higher at 25°C than 
at 37°C. My assay was established at 30°C (Nielsen et al., 2005) and the 
response to Tweens was lost for the wild-type R265. It would be of interest to test 
Tweens in an overnight growth assay using the Kurtzman method (Kurtzman et 
al., 2011). This method tests the ability of yeast to grow on a particular carbon 
source. The test can be done on either solid or liquid media. The liquid media is 
considered more reliable due to better substrates availability. Therefore, yeast 
nitrogen broth (YNB) (Kurtzman et al., 2011) is recommended for growth in 
Tweens. Nonetheless, the data for R265 GFP14 strain in Tweens suggests a fatty 
acids metabolism pathway. Presumably, their degradation, suggested by lipolysis 
in (Hagen et al., 2015) and NADH formation in my study. Fatty acid degradation 
leads to the formation of acetyl-CoA in the final step termed β-oxidation, the entry 
molecule for the Krebs cycle. Β-oxidation yields NADH and is well known to 
perform in aerobic conditions. It remains obscure, why R265 wt utilised Tweens 
at 25°C and at 37°C in (Hagen et al., 2015). The publication of (Hagen et al., 
2015) regarding C. neoformans and C. gattii used a method of (Sierra, 1957) 
using peptone agar plates with each of the Tweens. It is harder to grow on plates 
in comparison to liquid media. It is concluded that incubation time for Tweens was 
3-4 weeks because grow patterns on different carbon sources in (Hagen et al., 
2015) was investigated using the method of (Kurtzman et al., 2011), which 
typically applies up to 4 weeks incubation. This yields a conclusion of a possible 
adaption of R265 wt to utilise compounds by long incubations in the study of 
(Hagen et al., 2015). Therefore, as mentioned, it would be recommended to 
repeat the growth in YNB. Although R265 wt respiration is suggested non-
mitochondrial, perhaps the fungus can still use other enzymatic pathways in the 
mitochondria. This might by the case, as at the end of phenotypic experiment in 
this present study, some readings appear, e.g. for Tween 40. 
In addition, the assay revealed that lactate was used by R265 GFP14. It is 
possible to gain NADH from this compound by the action of L-lactate 
dehydrogenase (KEGG). As for R265 wt, it might be that acetate was utilised in 
the propanoate metabolism. 
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All the reviewed phenotypic data so far indicates significant differences in 
metabolic requirements. There is one more aspect to discuss related to use of 
sugars. Most fungi favour assimilation of sugars because their catabolism via 
glycolysis and respiration is energetically favourable (reviewed by (Ene et al., 
2014)). In addition, it is known that C. neoformans requires a glycolytic pathway 
for disease but not for persistence (Price et al., 2011). Blocking glycolysis at the 
entry point by deleting two hexose kinases resulted in decreased fungal 
persistence in the rabbit CSF model and attenuated the virulence in the murine 
inhalation model of cryptococcosis. Blocking the carbon exit by the deletion of 
pyruvate kinase enhanced the persistence in the lungs in the inhalation model 
without causing the disease. The removal of pyruvate kinase led to severely 
decreased persistence in the rabbit CSF (Price et al., 2011). Therefore, glycolysis 
seems to be important in cryptococcal pathogenesis. Thus, one could argue that 
R265 wt should perform glycolysis. It is tempting to conclude that R265 wt did not 
perform glycolysis in the Biolog assay. The data for glucose for R265 wt is 
negative (not shown). Considering that C. neoformans grows at 2% and 0.06% 
of glucose in YPD in vitro (Williams and del Poeta, 2011), it is expected for R265 
wt to grow in the Biolog assay because the concentration of glucose in this 
present study was 0.4% equating to 22 mM. The cells were added to the well in 
YNB supplemented with histidine, uracil and leucine to satisfy auxotrophic 
requirements for growth. After supplementing YNB medium with amino acids, 
which are supplements for corresponding auxotrophic markers commonly 
present in Saccharomyces laboratory, the pH of the medium was adjusted to 5.4, 
in agreement with the manufacturer’s instructions. IFY-0 was the inoculating fluid, 
which is non-nutritive and is supplemented with ammonium sulphate, potassium 
phosphate dibasic, potassium phosphate dibasic and magnesium sulphate. 
Since, the YNB with acidic pH was the medium, wherein cryptococci were 
suspended, and the cells were added to the microplates as the last, it might be 
they had been acidified. It is acknowledged that cryptococci grow in culture 
medium at acidic pH (Levitz et al., 1997). This gives it a survival advantage in the 
phagolysosome. It is also acknowledged that fungi have mechanisms to regulate 
intracellular pH and to maintain this pH homeostasis in response to environmental 
changes. For instance, fungal vacuolar proton-translocating ATPase (V-
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ATPases) couple hydrolysis of ATP to proton transport and therefore are 
important in establishing pH gradients (reviewed by (Orij et al., 2011)) by pumping 
protons out of the cytosol (Martínez-Muñoz and Kane, 2008). R265 wt possess a 
Vacuolar (H+)-ATPase subunit (putative) on chromosome 4 (D’Souza et al., 
2011) with V-type ATPase domain (NCBI). Still, the incubation in acidic medium 
can have an effect on the intracellular pH of a cell.  
It is possible that YNB medium affected the intracellular pH of R265 wt. Some 
media contain unwanted weak acids or weak-acid buffers are added. Lowering 
the pH in these media results in these compounds protonation and therefore 
induces a weak-acid stress that lowers the intracellular pH of the cell (Orij et al., 
2009). The YNB contains folic acid, which in the review of (Gazzali et al., 2016) 
is described as a weak acid. At acidic pH, a substantial fraction of weak acid gets 
protonated. This form easily passes the plasma membrane because it dissolves 
in the membrane. In the neutral cytosol, most of the weak acid dissociates. This 
leads to intracellular proton and anion release. Both the proton and the anion can 
exit the cell at the cost of ATP. The low pH of the medium causes the anions to 
re-associate with protons outside the cell and they diffuse back through the 
membrane. This might cause a constant drain on the cells energy reserves 
(reviewed by (Orij et al., 2011)). The ability of weak acids to acidify the cytosol 
was considered as the main contributor to growth inhibition (Krebs et al., 1983).  
In addition, the rate limiting enzyme of glycolysis, phosphofructokinase, is 
sensitive to small changes in pH in the physiological range, a high pH increasing 
its activity (Trivedi and Danforth, 1966). Perhaps in the Biolog assay R265 wt 
does not grow well, phosphofructokinase is impeded and therefore glycolysis is 
hampered. It would be useful in the future to run an overnight growth experiment 
in the Biolog media (IFY-0, YNB and a combination of both) as well as an 
overnight growth experiment in the concentration of glucose from the Biolog 
assay but in trying a different medium. This would answer whether the Biolog 
assay allows cryptococci growing in glucose.  
In addition, R265 wt did not use fructose, sucrose or mannose, although catabolic 
pathways for these do not involve NADH production but eventually lead to 
glycolysis. If glycolysis did not occur for the wild-type when incubated in glucose, 
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this would explain the lack of other sugars utilisation for energy. To check if 
glycolysis is performed, pyruvate, the product of glycolysis, could be measured 
using, e.g. a fluorometric assay described by (Zhu et al., 2010) or available 
commercially pyruvate assay.  
The sugars, fructose, glucose, sucrose, mannose, are also fermentable to 
alcohol. This process is anaerobic and thus should not occur in my experiments. 
However, in some yeasts the Crabtree effect can occur repressing respiration by 
the fermentation pathway in aerobic conditions (De Deken, 1966) but 
Cryptococcus is Crabtree-negative. In contrast to related sugars, xylose is not 
fermentable. For instance, S. cerevisiae is considered unable to efficiently 
metabolise xylose to alcohol, and thus, a lot of research has engineered this yeast 
to allow xylose consumption and alcoholic fermentation (reviewed by (Patiño et 
al., 2019)). Some of the suggested reasons for the impaired ability to alcohol 
fermentation are low xylose reductase and xylose dehydrogenase activities (Batt 
et al., 1986) and cofactor imbalance in the xylose reductase/xylitol 
dehydrogenase pathway (reviewed by (Hou et al., 2017)). However, even without 
proceeding to fermentation, both pathways (the xylose reductase and xylitol 
dehydrogenase) produce D-xylulose (KEGG). My study shows increased NADH 
production for both R265 wt and R265 GFP14 strain with D-xylulose. However, a 
larger increase was seen for the GFP stain. This suggested the reduction of D-
xylose to xylulose. This occurs in two steps. Xylose is converted to xylitol via 
xylose reductase and xylitol converts into xylulose via xylitol dehydrogenase. The 
second reaction yields NADH. Interestingly, the analysis of (D’Souza et al., 2011) 
indicated the absence of xylose reductase gene. However, aldo-keto reductase 
was assessed in the R265 wt on chromosome 11 (D’Souza et al., 2011). Since 
aldo-keto reductases are a family of proteins that include xylose reductase, it 
might be that assessed by (D’Souza et al., 2011) aldo-keto reductase fulfils a 
function of xylose reductase. Moreover, xylitol dehydrogenase gene was also 
assessed in R265 wt on chromosome 3 (D’Souza et al., 2011). The locations of 
these enzymes are intact in the R265 GFP14. Therefore, it seems plausible to 
propose that both strains can degrade D-xylose. It is, however unexplained, why 
R265 GFP14 was more efficient. On a final note on sugars: glucose, fructose, 
sucrose and xylose supported growth of C. gattii NIH isolates 198 and 444 which 
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are of B serotype (Chaskes et al., 2008). A publication of (Hagen et al., 2015) 
describes specifically xylose utilisation by R265 wt. Xylose is proved to be 
assimilated by C. neoformans from the pentose pathway (Cherniak, O’Neill, et 
al., 1998). This pathway is anabolic so cannot be indicated by the Biolog assay. 
This encourages reflection that assimilation or utilisation of a substrate does not 
necessarily have to support NADH production. Another example of the confusing 
utilisation/assimilation term is the utilisation of sucrose. There is evidence the 
sugar is utilised by Cryptococcus. In the study of (Vimercati et al., 2016) a Biolog 
assay was used at 10°C after 4 days in the dark, but it is not known which strain 
was used. In (Benham, 1956) sucrose utilisation in C. neoformans was assessed 
by Wickerham’s method (Wickerham, 1951) for carbon assimilation by  
C. neoformans was used, which employs 25°C and up to 24 days incubation. The 
publication of (Hagen et al., 2015) regarding C. neoformans and C. gattii used a 
method of (Kurtzman et al., 2011) at 25°C after 3-4 weeks of incubation. All of 
the methods were growth based. Thus, they rather indicate growth than NADH 
production. It also suggests a possible adaption to utilise substrates by long 
incubations. For example, malic acid is generally utilised by C. gattii serotype B 
in the mean of growth in media at 2 or 5 days (Bennett et al., 1978). In my assay, 
the wild-type R265, serotype B did not use the substrate as a source of energy. 
This raises many questions, e.g. would it be used if the experiment was longer? 
It could be as some increasing readings appeared at about 32 hours. As 
mentioned long incubation times may lead to an adaption to utilise compounds.  
4.3.5 The mechanism of R265 GFP14 attenuation in vivo  
From the results obtained in both larval zebrafish and murine models, the most 
striking observation was that fluorescent C. gattii strain R265 GFP14 had 
impaired pathogenesis. It was therefore possible to hypothesise that the random 
GFP insertion into R265 wt strain (Voelz et al., 2010) changed to some degree 
the R265 parental strain genome which resulted in a high survival of the animals. 
Genome sequencing revealed that region missing in R265 GFP14 was equivalent 
to 32 kb on R265 wt on chromosome 1, resulting in the loss of six genes (see 
results chapter). All of them have been found in C. gattii reference strain WM276 
(D’Souza et al., 2011). Subsequent experiments compared R265 wt with R265 
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GFP14 showed that these two strains exhibited different use of carbon sources 
and R265 GFP14 was more efficient at the substrates assimilation suggesting a 
metabolic difference between R265 wt and R265 GFP14. 
Gene loss and virulence 
 
The hypothesis of attenuated virulence linked to genes deletion is strongly 
supported by the evidence from the study of (D’Souza et al., 2011). Genome 
hybridisation studies revealed that C. gattii fluorescent strain WM276 GFP2 had 
a missing region of ~75 kb. The deletion knocked out 24 genes in chromosome 
11 and caused a virulence defect in C57BL/6 mice. The genes included a number 
of putative sugar transporters and glycosyl hydrolases, which are of paramount 
importance and Cryptococcus lacking these genes cannot utilise, for example, 
raffinose sugar. This was explained by the deletion of the invertase gene 
(D’Souza et al., 2011) since invertase hydrolyses raffinose to melibiose and 
fructose (Doudoroff, 1945). Therefore, it was speculated that the deletion of six 
genes in my study might have detrimental consequences in the fungal growth. 
The growth, metabolism and virulence are interlinked. Although the literature 
regarding these six genes is not evident, it is possible that they have a function 
in R265 wt metabolism and therefore in virulence. For instance, R265 GFP14 
does not have a gene encoding racemase (analysed with the help of Dr 
Choudhury). According to (D’Souza et al., 2011), this gene is termed alanine 
racemase. Interestingly, alanine racemase gene knock-out attenuates the 
pathogenicity of bacterium Aeromonas hydrophila in BALB/c mice and carp fish 
(Liu et al., 2019).  
It is difficult to explain R265 GFP14 gene/genes loss in the context of virulence 
loss, but it might be related to the concept of antivirulence. Sporadically, certain 
genes must be inactivated or deleted for full expression of the pathogen 
phenotype to occur. These genes are described as antivirulence genes (reviewed 
by (Bliven and Maurelli, 2012)). This is supported by the fact that R265 GFP14 
does not have a different ability to grow in macrophages in comparison to the 
parental strain R265 wt, even though it has lost its genes (Voelz et al., 2010). In 
addition or alternatively, it seems important that Cryptococcus expression profiles 
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under various conditions play a role in its virulence. This clue was provided in the  
Results section. Moreover, gene deletion in a pathogen might improve host 
immune response. For instance, one of the genes deleted in R265 GFP14 is 
rhamnosidase (CGB_A0040C), described as putative. In many teleost fish, 
rhamnose-binding lectins are involved in immune responses (via complement) 
(Gao et al., 2018). It could be that rhamnosidase in the wt strain hydrolyses 
rhamnose-binding lectins and thereby attenuates the host innate immune 
response while the opposite occurs in the GFP mutant.  
 
Gene loss, virulence and metabolism 
 
Gene deletion can be also linked with metabolism. For instance, the loss of both 
hexokinases in C. neoformans results in the inability to utilise glucose. The loss 
of both hexokinases together, but not single deletions, results in reduced 
virulence in mice (Price et al., 2011). In reviewing the literature, carbon utilisation 
was found to be associated with the continued survival of host- restricted 
pathogens. Carbon is crucial for pathogenic fungi to grow and persist within a 
host (reviewed by (Ene et al., 2014)). Both the pathogen and infected host 
compete for the same nutrients trying to influence the behaviour of the other 
(reviewed by (Passalacqua et al., 2016)). I concentrated on carbon sources to 
investigate the differences between R265 wt and R265 GFP14 since pathogenic 
fungi have evolved different carbon assimilation profiles that presumably reflect 
their different niches (reviewed by (Ene et al., 2014)).  
This work found evidence of increased oxidative phosphorylation activity in the 
GFP14 mutant. It is not understood how gene deletion results, virulence results 
in vivo translate to phenotypic results. However, it is likely that R265 wt might not 
perform the TCA cycle because the inoculation fluid was not rich in iron and TCA 
and oxidative phosphorylation C. gattii genes are abundantly expressed when 
iron is available in the culture medium but not in iron replete medium (Crestani et 
al., 2012). This means that iron reduction affects the mitochondrial function in  
C. gattii. This is interesting as iron limitation increases the capsule size 
(Vartivarian et al., 1993). Given both CO2 and low iron influence capsule size, this 
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is even more interesting because these conditions mimic some situations that 
Cryptococcus encounters during lung infection (Zaragoza, Rodrigues, et al., 
2010). R265 wt grew worse than R265 GFP14 in the mice lungs personal 
communication, Jacob Rudman, a PhD student in the Johnston lab), which 
suggests that R265 wt might not perform TCA cycle either in vivo nor in PM1 
arrays probably due to iron limitation. However, with the knowledge that R265 wt 
has an impaired oxidative phosphorylation, it is even harder to interpret the 
phenotypic data. It might be that the difference with GFP mutant might be that it 
is more stressed in PM1 assay and so it tries to activate mitochondria. This might 
result in greater metabolic flexibility with respect to carbon utilisation and 
metabolic adaptation but this prevents its flourish, likely due to the inability to 
activate the right pathway. It is not clear what the possible functions for these 
genes are and my PM1 array did not answer this question due to the fact of 
dealing with multiple knock-out mutation in the R265 GFP14. This also 
demonstrates that the proposed differences in the TCA cycle utilisation between 
R265 and R265-GFP cannot be brought to the level of six genes in total or a 
single gene. An apparent limitation of the phenotypic assay turned out to be its 
designed strength, i.e. the idea of testing a single gene under a number of 
nutritive conditions. The array can be used to directly assay the effects of genetic 
changes on cells, especially gene knock-outs, but not in the situation of testing 
the genes function while not knowing at all what the genes are involved in (the 
six genes are not fully characterised and 5 of them have domains predicted). 
Thus, while getting evidence of impaired oxidative phosporilation, it is difficult to 
draw clear conclusions, which of the genes is involved in this process. Single 
knock-outs in the wt followed by PM1 arrays would help to find gene function as 
phenotypes are the expression of genotypes and reveal gene function when a 
single gene is investigated under several conditions (Bochner, 2003). 
Additionally, sequence similarity search should be performed with basic local 
alignment search tool (BLAST). This will answer if gene/genes are found in other 
organisms and will facilitate protein function prediction. No study to date has 
examined R265 metabolism per se. I believe that cryptococci can only establish 
an infection when able to acquire usable food sources. However, the literature 
regarding the preferences to fuel itself is not evident in vitro or in vivo for 
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Cryptococcus. R265 wt is VGIIa type strain from the Vancouver Island outbreak. 
Cryptococcosis caused by this molecular type presents with pulmonary disease  
in humans (Galanis et al., 2009; Harris et al., 2011) and mice infected with R265 
wt die from extensive pulmonary infection (Ngamskulrungroj, Chang, Sionov, et 
al., 2012). R265 wt grew better in the lungs of mice infected in this present study 
whereas R265 GFP14 had impaired growth in the lungs and resulted in 100% 
animal survival (personal communication, Jacob Rudman, a PhD student in the 
Johnston lab). A comparison of previously described serial analysis of gene 
expression (SAGE) libraries from C. neoformans cells grown in YNB and low ion 
media with SAGE on cells recovered by bronchoalveolar lavage (BAL) from mice 
lungs at 8 and 24 hours after infection revealed significant differences in gene 
expression. For example, tags for genes encoding the TCA cycle enzymes 
aconitase and succinate dehydrogenase were elevated in the lung libraries. 
However, tags representing three other TCA cycle enzymes, namely isocitrate 
dehydrogenase, malic dehydrogenase and fumarase were lower in the lung 
libraries than in one or both of the in vitro libraries. Importantly, a tag for the gene 
encoding phosphoenolpyruvate carboxykinase (PCK1), which controls the only 
irreversible step in gluconeogenesis, was higher in both in vivo libraries at 8 and 
24 hours post infection. PCK1 elevation implies glucose limitation during early 
infection (Hu et al., 2008). The authors suggested that murine pulmonary infection 
represents a nutrient-limiting environment for invading C. neoformans (Hu et al., 
2008). This is supported by the fact that the secretions from respiratory airways 
have a very low glucose concentration in healthy individuals (<0.05 mM) (Philips 
et al., 2003). In addition, the tags for genes encoding glycolytic functions including 
glucose-6-phosphate isomerase and phosphoglycerate mutase were relatively 
low in the lung libraries. Moreover, in vitro analysis indicated that the expression 
of hexose transporter (HXT1) was dramatically higher at 0.2% glucose compared 
to 2% glucose. This suggests that HXT1 has a role in glucose sensing in low 
glucose availability (Hu et al., 2008). However, the tag for PCK1 was increased 
in the SAGE analysis of pulmonary infection (Hu et al., 2008), but not in vitro in 
macrophage internalised cryptococcal cells (Fan et al., 2005). This suggests that 
in the publication of (Hu et al., 2008) cryptococci might not have been internalised 
and a difference between the pulmonary infection and the intracellular 
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environment might exist which leads to a different metabolism mode. 
Phagocytosis induces genes involved in lipid degradation and fatty acid 
catabolism but does not induce gluconeogenesis genes (Fan et al., 2005). The 
SAGE analysis and phagocytosis data of (Fan et al., 2005) suggest that 
Cryptococcus displays different metabolic profiles depending on the in vivo or in 
vitro infection whether it is internalised or not. It means that in vitro and in vivo 
conditions might exert different energy acquisition modes. Thus, in my present in 
vitro study, R265 wt might not be performing TCA cycle. Instead, fermentation is 
suggested. Equally, it might be performing gluconeogenesis, which is the reverse 
of glycolysis and it is an anabolic process, thus NADH cannot be elevated. A 
switch from glycolysis to gluconeogenesis occurs in yeast. For example, in 
response to nutrient starvation, Candida albicans shifts from glycolysis to 
gluconeogenesis. This is seen as an adaptation to enable the host invasion and 
pathogenesis by C. albicans (Mayer et al., 2013). Thus it is possible that R265 
GFP14 could not adapt to in vivo conditions and that a potential for differential 
metabolic requirements across fungal pathogens exist. This might depend on the 
host niche occupied by each species and the models used to test each mutant 
(reviewed by (Ries et al., 2018)). Althought fungi experience a variety of micro-
environmental conditions in vivo and the ability to adapt to and thrive under 
several carbon conditions is critical for virulence (Barelle et al., 2006), far too little 
attention has been paid to in vivo versus in vitro experiments such as to genes 
expression of fungi that are metabolically active during host infection or in vitro 
conditions that simulate mammalian environments. Therefore, I cannot 
understand why in vitro/in vivo phenotypes are different. I was hoping to obtain 
some clearer conclusions form PM1 phenotypic array that would point out to a 
single gene, but was unfortunate and the experiment has its limitation. It became 
apparent that a significant inconvenience was multiple knock-out mutation of the 
R265 GFP14. I do not think there is a simple answer to a question how gene 
deletion translates into virulence or how could the R265-GFP strain exhibit 
greater metabolic flexibility with respect to carbon utilisation or how could this in 
turn result in impaired virulence. Currently it is not known if the TCA cycle 
utilisation always determines the cryptococcal triumph and which carbon sources 
have to be obtained in which quantities from the environment and in the context 
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of infection. Tags for functions in the tricarboxylic acid cycle (TCA) known as the 
Krebs cycle, have been found for C. neoformans (Hu et al., 2008). These 
included, e.g. aconitase, malate dehydrogenase, isocitrate dehydrogenase, malic 
enzyme or fumarase (all putative) (Hu et al., 2008). A comparison of the genome 
sequences of C. gattii WM276 and C. neoformans JEC21 shows that the WM276 
has these genes (all putative) (D’Souza et al., 2011). Aforementioned TCA 
related genes found in WM276 are present in R265 wt (D’Souza et al., 2011). 
Thus it is assumed they are also present in R265 GFP14 because they are 
located on chromosomes other than chromosome 1 in R265 wt (D’Souza et al., 
2011) and some other genes important in the Krebs cycle locate on region of 
chromosome 1 that is assumed to be unaltered in R265 GFP14. It is not 
understood if it will be the genes listed by (Hu et al., 2008) or by (Crestani et al., 
2012) that guarantee the TCA performance or if the six genes deletion incites the 
cycle, with a concomitant phenotype suppression. I do not know how gene 
deletion resolves virulence but there is an opportunity to understand it in the 
future (see Future work and Major experiments to bring Chapter 4 towards a 
publication).  
4.3.6 Future work  
 
4.3.7.1 Genetic work in R265 wt and animal survival assay 
It is acknowledged that the hypothesis of deleted genes being important for 
virulence in animal models may raise further questions about the actual number 
of genes having an impact on the outcome of infection with R265 GFP14. For 
example, this phenotype may be caused by a single gene deletion. Thus, a further 
study with more focus on the genes is suggested. Particularly, single gene knock- 
outs in the R265 wt independently to identify whether the same phenotype seen 
with the GFP strain in zebrafish/mice would be reproduced. This should be 
confirmed by survival assays. Ideally, the goal would be to identify just one gene 
responsible for the high zebrafish/mice survival as seen with the GFP strain. It 
would appear that it would be the one of those six that had an effect. Of course, 
if that was unsuccessful, combinations of genes should also be tried.  
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However, it should be noted that in eukaryotic organisms gene positioning on a 
chromosome is known to affect its expression (Wilson et al., 1990). This 
phenomenon is also seen in prokaryotes. Expression of a reporter gene cassette, 
comprised of E. coli lac promoter driving expression of GFP, varies by ∼300-fold 
depending on its precise location on the chromosome (Bryant et al., 2014). 
Genomes are not organised randomly. Gene positioning has remained 
unchanged throughout evolution, which points to a functional role for positioning 
in genome activity and homeostasis (reviewed by (Takizawa et al., 2008)). Thus, 
gene positioning will be important for fungi, too. Therefore, the rescue of the 
phenotype seen with the R265 GFP14 might not be obtained, unless the gene/s 
are located in positions indicated in the R265 parental strain. An important 
question is also whether the downstream genes might be altered, not just the 
missing ones. In addition, if one of the missing genes is a regulatory, it might alter 
the function of others. Alternatively, another interesting experiment for the future 
would be with R265 GFP14 and rescuing the phenotype by reintroducing 
gene/few genes or all of those six genes (depending on the outcome of the 
above-mentioned study) with keeping the GFP in. If the virulence defect persists, 
this might be rather related to alternative gene/genes positioning than GFP 
having an effect on virulence.  
4.3.7.2 Genes function 
Revealing functions of genes and proteins encoded is one of the major 
challenges of molecular biology. Amino acid sequence determines protein 
structure and the structure shapes the protein function. Proteins sharing a similar 
sequence often have similar functions, even in distantly related organisms 
(reviewed by(Pearson and Sierk, 2005)). This means that orthologues proteins 
(the same protein in a different species) will perform similar functions. Therefore, 
sequence similarity search should be performed with basic local alignment 
search tool (BLAST). This will answer if gene/genes are found in other organisms 
and will facilitate protein function prediction. However, they might not be found by 
BLAST in other organisms as only sequenced strains show up in BLAST. This 
might be the case for hypothetical proteins CNB05730 and CNB05720 as they 
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are uncharacterised. These two genes characterisation might be a challenge 
since no information about them is available.  
The genes might appear fungi specific. Therefore, they could be drug targeted. 
The genes, however, should be investigated in detail. For example, protein 
domains function should be characterised because their annotation is an 
alternative approach to sequence similarity searches. By convention, domains 
are defined as conserved, functionally independent protein sequences. They 
have specific functions, e.g. binding to a specific molecule or catalysing a 
reaction. Therefore, they are used for predicting the functions of whole proteins. 
Because the event of speciation occurred so long ago, it is accepted that a 
domain from different species will have similar function in Cryptococcus. Domain 
characterisation is also important in another aspect. Protein domains serve as 
drug targets (Wang et al., 2012) and so possibly R265 wt could be drug targeted. 
It would be interesting to know if the genes deleted whilst GPF-tagged R265 
generation have a defect in virulence. The identified genes should be searched 
for their role in Cryptococcus. For example, the study of (Martinez and 
Casadevall, 2007) suggested that polysaccharide matrix includes rhamnose. 
According to KEGG database, α-L rhamnosidase utilises an inverting mechanism 
of hydrolysis, releasing β-L-rhamnose. Thus, it is possible that rhamnosidase 
deleted in R265 GFP14, is involved in the formation of the capsule (a key 
virulence factor).  
The proteins encoded by the genes deleted in R265 GFP14 might also be 
important in a wide range of metabolic processes. Thus, the genes/proteins 
should be searched in metabolic and cellular/molecular processes, e.g. with the 
KEGG database or (Hoffman-La Roche Ltd, 2014).  
It would also be interesting to screen patients’ samples and strains to find out if 
gene/genes correlate with patients’ outcome/disease severity. As for the 
Vancouver Island outbreak strain, the gene/s could be compared to both non-
outbreak C. gattii and C. neoformans. It could be that non-outbreak strains do not 
have the gene/genes and therefore are less virulent than the outbreak ones.  
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As discussed, the defect in virulence with R265 GFP14 is linked to transformation 
event. Interestingly, in vitro transformation can change chromosome sizes in  
C. neoformans (Toffaletti and Perfect, 1997). In JEC21 the karyotype variations 
are due to the presence of transposons (5% of its genome) (Loftus et al., 2005). 
Karyotype differences were found under infection in mice (Fries et al., 1996) and 
associated with phenotypic switching in rats (Fries et al., 1999). Moreover, the 
genome plasticity was suggested to be a risk of reinfection (Brandt et al., 1996). 
Variations were also demonstrated in C. gattii genome sequences of the VGI and 
VGIIa genotypes of C. gattii. The changes also applied to chromosome copy 
numbers and ploidy in C. gattii isolates displaying fluconazole heteroresistance 
(D’Souza et al., 2011). To conclude, my study also shows karyotype change and 
therefore a change in the R265 GFP14 virulence resulting in impaired ability to 
overcome the natural defences of a host in zebrafish/ mice models. It was 
therefore assumed that those six genes were important for virulence. The genes 
were accordingly considered as targets in R265 infection. They can be potentially 
involved in human infection. For this reason, the R265 GFP14 was pursued.   
4.3.7.3 Future work in respect to metabolic profiling of R265 wt and R265 
GFP14 
R265 wt and R265 GFP14 present with a metabolic difference in the Biolog 
assay. It is not understood whether R265 GFP14 presents with metabolic 
adaptation in this present study. At the same time, it cannot be concluded the 
R265 GFP14 does not have a metabolic defect. It does as indicated by impaired 
growth in the minimal medium in my study. It could also be that the R265 wt 
displays a metabolic defect in this present assay. As described, the sealing of 
plates preventing gas exchange might be an unexplained factor. It is also possible 
that in the Biolog assay the R265 wt did not grow and thus presented with 
interesting phenotypes. Further work is required to investigate whether the strain 
grows in the assay. As mentioned, the strains should be tested in an overnight 
growth assay in the substrates pulled out in the screen. Another concentration of 
glucose should be tested, too. The growths should be done in the Biolog media 
and different media should be tried. In addition, dye D and other dyes should be 
tested alongside. Apparently, dyes are all reduced to form a purple colour, but 
    
273 
 
the redox threshold at which they are reduced is different. The order of reduction 
power is: A>B>F>D>H>G, where A is most difficult to reduce and G most easily 
reduced. Recent communication with the company revealed that in the presence 
of a few positives, dye G should be tried (personal communication with Biolog). 
At the same time, it is not known what the dye D does to C. gattii cells and 
information about this dye is considered proprietary. It is possible that for R265 
wt dye D is hard to reduce or dye D introduces latency in the R265 wt. Previous 
studies reported that some tetrazolium based dyes caused toxicity to microbes 
(Ullrich et al., 1996). The only reason for dye D selection in my study, was a 
strong recommendation from Dr Barry Bochner, CEO of Biolog and the author of, 
e.g. (Bochner et al., 2001; Bochner, 2003; Bochner et al., 2011).   
The Biolog assay should be repeated after checking all aforementioned 
parameters and reassuring the cells grow in the assay. If the same effect is seen, 
i.e. that a virulent R265 wt strain appears not to be performing Krebs, this should 
by supported by testing for the TCA occurrence in vitro. This can be done with, 
for example, TCA cycle metabolism assay kits by Merck. Additionally, 
respirometry work including the R265 GFP14, should be undertaken. 
Respirometry should include such parameters as routine mitochondrial 
respiration, leak respiration, non-mitochondrial oxygen consumption, maximum 
mitochondrial respiration rate and leak control ratio. Dr Gourlay has done this in 
R265 wt but the data is preliminary. Thus, more repeats are needed. Interestingly, 
the non-mitochondrial respiration value was about 50% of the total respiration, so 
R265 wt mitochondria are consuming oxygen. However, this is not coupled to 
energy production and so it seems R265 wt might rely on fermentation to produce 
energy. This implies that R265 wt might not need to perform Krebs cycle. 
Moreover, it may be that a good proportion of respiration is occurring at Aox1. 
R265 wt has Aox1 encoding gene on chromosome 2 (D’Souza et al., 2011). It 
may be that Aox1 is consuming the oxygen and this should be further tested in 
future. The preliminary data suggest that R265 wt respires through Aox1 because 
it consumes oxygen when Aox1 is inhibited with SHAM. To check if fungi respire 
through Aox1, AOX1 gene knock- out should be done in R265 wt and R265 
GFP14. 
    
274 
 
Alternative respiration and fermentation yield less energy than a classical 
respiration. Thus, R265 wt might be less efficient in energy production. 
Interestingly, depending on carbon sources availability, some bacteria that 
encode all of the enzymes for respiration, with its high energy yield, switch to less 
energy but faster fermentation (reviewed by (Passalacqua et al., 2016)). It is 
acknowledged that yeast is eukaryote whereas bacteria are prokaryotes. 
However, it is possible that Cryptococcus might ferment. Although the literature 
characterises Cryptococcus as an aerobe (Odds et al., 1995), fermentation has 
been suggested as this mode of energy acquisition for H99 C. neoformans (Santi 
et al., 2014). Thus, it would be useful to feed R265 in vitro with glucose and 
measure fermentation products, e.g. lactic acid in a fluorometric lactate assay. 
4.3.7.4 Linking data to assess why deleted genes are important for R265 wt 
virulence  
The PM technology utilised in my study anticipated the effects of loss of gene 
function to provide a linkage between genotype and phenotype. The idea was to 
compare isogenic pairs of R265 wt and R265 GFP14 strains to directly assay for 
the cellular effects of loss of gene function (Bochner et al., 2001). It became 
apparent that a significant inconvenience was multiple knock-out mutation of the 
R265 GFP14. The array is designed to investigate a single gene under several 
growth conditions and this study deals with six genes. Therefore, single gene 
knock-outs in R265 wt should be performed (described in 1.7.1) and followed by 
the PM1 screen. It has to be highlighted that the data from phenotypic screen can 
be mostly accurate for in vitro conditions as other microbial phenotypes might be 
expressed when the microbe interacts with an animal (Bochner, 2003). 
Characterisation of deleted proteins is recommended. It would involve purification 
from in vitro. I would propose investigation of proteins structure. Protein structure 
is evolutionarily more conserved than sequence. It is believed that structural 
information provides a solution for many of the remaining proteins (reviewed by 
(Skolnick and Fetrow, 2000; Kinoshita and Nakamura, 2003)). This would require 
nuclear magnetic resonance (NMR) spectroscopy or x-ray crystallography for 
determination of the three-dimensional structures. Since the function of proteins 
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are not defined in this study and protein function is directly dependent on its three 
dimensional structure, it would be beneficial to determine their structure.  
Another approach would be to find binding partners to each of the six proteins of 
interest. This would require making six different His-tagged R265 recombinants 
in order to perform a silver stain, which followed by mass spectrophotometry 
would reveal binding partners. In addition, if a protein is predicted to have an 
enzymatic activity (three of the deleted proteins are enzymes, namely glucose 1-
dehydrogenase, racemase and rhamnosidase), enzymatic assays could be 
performed to identify they substrates and pathways, which they might be involved 
in. Because the phenotypes in this study might change, when cryptococci interact 
with an animal, protein purification could be also be done in vivo. However, this 
would be very difficult. Alternatively, quantitative polymerase chain reaction 
(qPCR) could be performed, e.g. on cryptococci grown in different metabolic 
substrates and cells extracted from in vivo infection. This would show a particular 
gene expression and identify if a gene is important in vitro or in vivo. At the same 
time working back from phenotypic data should be done. From the array, 
enzymes should be searched that use the 21 substrates. This is how the data 
from the sequencing element of R265 wt versus R265 GFP14, knock-out genes 
in zebrafish, protein characterisation and proteins revealed from PM arrays could 
be linked to assess why the six (or one or a few) are important in R265 
pathogenesis. 
 
4.3.7 Major experiments to bring Chapter 4 towards publication 
 
To bring this chapter towards publication I believe additional work has to 
be performed. In this chapter I focused on C. gattii that is the cause of an ongoing 
outbreak on Vancouver Island, which has subsequently spread to mainland 
Canada and the USA. This was linked to the general question I asked when 
appointed to the Johnston lab- how Cryptococcus causes a disease. This 
question was really important as the literature is not evident as to how it causes 
a disease and what is the difference between C. neoformans and C. gattii in this 
aspect? The literature is not evident in terms of how C. gattii causes a disease 
and what the difference between them two species in this aspect is.  
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I characterised a virulence and growth defect in R265 GFP14 with a genomic 
defect following GFP transformation hoping to reveal why the wild-type is virulent. 
Unfortunately, I did not fully answer the question, how C. gattii causes a disease. 
What can be concluded is that the lost six genes are important for virulence in 
fish and mice. These results warrant additional experiments or analyses that 
could help answer the research question more fully. In the discussion I described 
potential experiments that can be carried out in future. Here I provide the sum of 
crucial work before seeking publication. The main objective to answer the main 
question, i.e. how R265 wt causes a disease, would be to create a derivative 
fluorescent strain that is equally virulent as R265 wt in used animals, e.g. an 
mCherry version of R265. Since the R265 GFP14 has an altered genome (32 kb 
deletion) as compared to the parental strain, other transformants created at the 
time of R265 GFP14 generation (Voelz et al., 2010) should be genome 
sequenced. If there is one that does not have an altered genome, it should be 
used in macrophages-cryptococci interactions assay. However, the work 
dedicated R265 GFP14 is meaningful and highlights the deleted six genes’ 
importance in cryptoccocal virulence. Thus, the work should be focused on those 
genes. The identified genes should be searched for their role in Cryptococcus. 
For instance, a publication of (Martinez and Casadevall, 2007) proposed that 
polysaccharide matrix includes rhamnose. According to KEGG database, α-L 
rhamnosidase utilises an inverting mechanism of hydrolysis, releasing β-L-
rhamnose. Thus, it is possible that rhamnosidase deleted in R265 GFP14, is 
involved in the formation of the key virulence factor-the capsule. On that note, 
one of the genes upregulated ex vivo in lineage VGII, to which R265 wt belongs, 
was ABC transporter gene CNBG_4708, an ortholog to a gene of known function 
in C. neoformans H99 (Farrer et al., 2018). Since one of the genes deleted in 
R265 GFP14 is CGB_A0010C with conserved ABC domain, it might be that the 
gene is upregulated in vivo in zebrafish and mice in my current study in R265 wt 
and contributes to virulence. In addition, BLAST similarity search should be done 
to answer if those genes are found in other organisms and this will facilitate 
protein function prediction. Protein domains function should be characterised 
because their annotation is an alternative approach to sequence similarity 
searches. This will all lead to a new knowledge about R265 wt candidate 
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virulence genes, which have been listed by me and thereby about its virulence in 
general. 
With regard to intermediate goals referring to work on the GFP strain and trying 
to explain why the genes loss could impact virulence in vivo, they can be divided 
into a few themed experiments: GFP insertion, virulence in the zebrafish, and 
metabolic profiling of R265 wt and R265 GFP14.  
With regard to GFP insertion, I do not have evidence that it is not the GFP that 
causes avirulence in zebrafish or mice. Only an experiment with the same knock-
outs in the wild-type would inform if the GFP in itself is defective. Future 
investigations should also focus on other R265 GFP strains generated by (Voelz 
et al., 2010) to determine if GFP insertion has changed their virulence. Since a 
GFP construct was made with the use of actin promoter, making another C. gattii 
GFP strain attached to alternative promoters and comparing the virulence of the 
existing strain would answer if the promoter can cause virulence defect.  
With regard to the virulence in zebrafish, the dominance of killing by 
macrophages over the intracellular proliferation is supported by significant 
decrease in the number of total cryptococci and in the dropping extracellular 
numbers in the latest stages of infection. However, this study cannot discern 
intracellular proliferation, and use of time-lapse microscopy may help as it was 
done in (Bojarczuk et al., 2016). Alternatively, removing extracellular portions of 
the pathogen and counting the number cryptococci at all time-points would prove 
the event of intracellular proliferation. It is not feasible to do so in vivo in 
comparison to in vitro, e.g. with gentamycin but fluconazole could be a good 
choice. What cannot be left unattended is the role of macrophages in R265 
wt/R265 GFP14. It might be that in vivo macrophages are not the dominant cells 
combating the infection. Therefore, an experiment with clodronate should be 
done as in (Bojarczuk et al., 2016). 
Deciphering the principles as to how pathogenic yeast adapt their metabolism to 
a specific host microenvironment is critical for understanding cryptococcal 
pathogenesis. Cryptococcus senses the nutritional composition during the course 
of an infection. Therefore, metabolomic microarrays were exploited. It became 
apparent that this experiment had limitations. A significant inconvenience was 
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multiple knock-out mutation of the R265 GFP14. Thus, single knock-outs in the 
wild-type should be done and then phenotypic arrays performed. For example, 
deleting the first gene only that amongst six is already removed, would allow clear 
conclusion of this gene function because the array would preferably point towards 
specific cellular pathway and biological function. Meanwhile, without single 
knock-outs, growth experiments for the wild-type R265 and R265 GFP14 in hit 
substrates would be extremely useful in determining if they are needed for 
replication. This is because metabolic assays might not accurately represent 
changes in cell growth as they do not quantify cell proliferation. From this it would 
be easier to draw clear conclusions whether or not R265 wt performs Krebs cycle 
in vitro in phenotypic array settings. This was the main issue in the phenotypic 
work. R265 GFP14 appeared to use Krebs substrate, but R265 wt did not. I even 
suggested fermentation. Most definitely Krebs functions during fermentation, e.g. 
in S. cerevisiae grown in glucose there is a reduced growth rate and biomass 
when the gene PDA1, which is part of the pyruvate-dehydrogenase (PDH) 
complex that yields acetyl-CoA in the mitochondrial matrix, is disrupted (pyruvate 
+ NAD+ + CoA → acetyl-CoAmit + NADH + H+ + CO2). This tells us that even a 
crabtree positive yeast will use the cycle when it is fermenting in aerobic 
conditions. A problem is that even in S. cerevisiae the interface between 
glycolysis and TCA is not fully defined (van Rossum et al., 2016). It is not known 
what R265 wt does and how this relates to virulence. Thus, TCA cycle metabolism 
assay kits should be tried in vitro. Unfortunately there is no method to measure 
TCA cycle of microbial cells in vivo. SAGE on cryptococci recovered from the 
lungs of infected mice with a special attention to SAGE tags for genes encoding 
predicted functions in the TCA could be done. Transcriptome sequencing (RNA-
seq) comparisons of in vitro results from kits to ex vivo (zebrafish) TCA 
associated genes expression levels should give a clue as to whether the wild-
type is likely to perform fermentation. However, nutrient availability has an impact 
on expression of virulence genes. Hence, transcriptome sequencing (RNA-seq) 
comparisons of cells grown in vitro in Krebs related substrates to ex vivo 
(zebrafish) Krebs associated genes expression levels should give a clue as to 
whether the wild-type is likely to perform the cycle. In turn, nutrient availability has 
an impact on expression of virulence genes. This is important knowledge as the 
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TCA cycle has a central role in the regulation of energy regulation and 
metabolism. It is essential yeast cells have to have Krebs (or some partial Krebs 
cycle) activity. Yeast cells that are just fermenting or have no mitochondrial DNA 
are still running the Krebs cycle to support production of metabolites and certain 
amino acids. The data obtained from respirometry suggests that R265 must get 
ATP from another mechanism and so it is likely to be fermenting, too. If the final 
product from glucose utilisation kit is pyruvate, then glycolysis is successful. If the 
final product is ethanol, then this indicates fermentation. In addition, testing the 
growth on non-fermentable media (yeast peption glycerol) should be done. If a 
strain relies mostly on fermentation and does not use oxidative phosphorilation 
much then it would grow poorly on such media. Again, there is no technique to 
measure fermentation of microbes in vivo. SAGE on cryptococci recovered from 
the lungs of infected mice with special attention to SAGE tags for genes encoding 
predicted functions in fermentation could be done. Transcriptome sequencing 
(RNA-seq) comparisons of in vitro results from kit to ex vivo fermentation 
associated genes expression levels should also give a clue whether the wild-type 
is likely to perform fermentation. Additionally, transcriptome sequencing (RNA-
seq) comparisons of cells grown in vitro in fermentation related substrates to ex 
vivo (zebrafish) fermentation associated genes expression levels. It has to be 
acknowledged that R265 wt might behave differently in vitro and in vivo. This 
might be due to the continuous availability of nutrients from host serum and the 
incorporation of the host-pathogen interaction (Nett et al., 2011). The underlying 
mechanism of C. gattii virulence is still unclear. However, I believe that not only 
known virulence factors determine cryptococcal virulence, but also variations in 
metabolic functions. It is very likely that differences in metabolic adaptation 
contribute to observed differences in pathogenicity and clinical outcome 
regarding Cryptococcus complex. Table 4.24 lists the most crucial experiments 
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Table 4.24 The summary of core experiments to bring Chapter 4 towards 
manuscript publication 
research question core experiments for Chapter 4 to be 
submitted for publication 
How does R265 wt cause a disease?     generation of a derivative fluorescent 
strain that is equally virulent as R265 wt 
in animals used (zebrafish, mice) or  
genome sequencing of other 
transformants created by (Voelz et al., 
2010) to find the one that does not have 
an altered genome; to be used in 
macrophages-cryptococci interactions 
assay in zebrafish and time-lapse 
microscopy as in (Bojarczuk et al., 2016) 
using an unaltered genome fluorescence 
R265 derivative 
Are macrophages important during 
cryptocococal infection in zebrafish?   
zebrafish infection assay without 
macrophages using an unaltered 
genome fluorescence R265 derivative 
Do cryptococci proliferate intracellularly 
in macrophages in zebrafish? 
time-lapse microscopy as in (Bojarczuk 
et al., 2016) using an unaltered genome 
fluorescence R265 derivative 
Are macrophages important during 
cryptocococal infection in zebrafish?   
zebrafish infection assay without 
macrophages using R265 GFP14 
Do cryptococci proliferate intracellularly 
in macrophages in zebrafish? Does the 
six genes loss impact cryptococcal 
behaviour when in macrophages? 
time-lapse microscopy as in (Bojarczuk 
et al., 2016) using R265 GFP14 
Is GFP defective itself to cause 
avirulence in mice and virulence 
attenuation in zebrafish? 
six gene knock-outs in the wild-type 
R265 and survival assays in 
mice/zebrafish 
What are the functions of genes deleted 
in R265 GFP14=what are the functions 
of genes present in R265 wt? 
BLAST similarity search, protein domains 
characterisation 
What is each gene function?  single knock-outs in the wild-type 
followed by phenotypic array  
Does R265 wt rely on Krebs cycle? Does 
it perform Krebs cycle mostly in vitro or in 
vivo? 
 
in vitro TCA cycle metabolism assay kit 
followed by SAGE on cryptococci 
recovered from the lungs of infected mice 
with a special attention to SAGE tags for 
genes encoding predicted functions in 
the TCA and followed by transcriptome 
sequencing (RNA-seq) comparisons of 
cells grown in vitro in Krebs related 




Chapter: 5 Mycophenolate mofetil increases inflammation resolution in 
zebrafish via neutrophil apoptosis 
5.1 Introduction 
My zebrafish model of cryptococcosis (Bojarczuk et al., 2016) has been exploited 
in a number of studies (Gibson, 2017; Gibson et al., 2017, 2018; Gilbert et al., 
2017; Kamuyango, 2017; Fehri, 2018; Evans et al., 2019). One of these studies 
was to investigate the role of mycophenolate mofetil (MMF) during C. neoformans 
infection in vivo in my zebrafish model (Gibson et al., 2018). This study focused 
on macrophages, the key cells required for clearing cryptococcal infection 
(Feldmesser et al., 2000; Tenor et al., 2015; Bojarczuk et al., 2016). MMF had a 
distinct and specific effect on macrophages, in the absence of lymphoid cells and 
this resulted in an increased macrophage cell death (Gibson et al., 2018).This is 
in line with the hypothesis of MMF capable of the direct modulation of innate 
immune system as MMF was shown to decrease circulating neutrophil counts 
(Von Vietinghoff et al., 2010) or infiltration of macrophages (Jiang et al., 2012). In 
contrast there was no difference in neutrophil numbers (Gibson et al., 2018). 
However, this was in the absence of a neutrophil insult (as neutrophils do not 
appear to respond to cryptococci, as discussed above) and I wanted to ask if the 
same effect occured in neutrophils in the situation of neutrophilic responses. To 
test whether the induction of neutrophil cell death occurs under MMF treatment, 
I used a well described zebrafish inflammation model (Renshaw et al., 2006).  
I hypothesised MMF would cause enhanced apoptosis in neutrophils during the 
resolution of inflammation following tissue injury.  
5.1.1 Mechanism of MMF on lymphocytes and other effects on other cells 
Mycophenolate mofetil (MMF) is an immunosuppressant and potent anti-
proliferative agent against lymphocytes commonly used following organ 
transplant. Lymphocytes proliferation has to be supressed as graft rejection is 
primarily mediated by these cells. MMF is a morpholinoethylester prodrug of 
mycophenolic acid (MPA) (Lee et al., 1990) and non-competitive reversible 
inhibitor of inosine-5’-monophosphate dehydrogenase (IMPDH) (Smak Gregoor 
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et al., 2000). In humans there are two isoforms, IMPDHI and IMPDHII (Collart 
and Huberman, 1988; Natsumeda et al., 1990). While the former is widely 
expressed in resting lymphocytes (Natsumeda et al., 1990), the latter is 
abundantly produced in activated lymphocytes, shown by Epstein Barr Virus 
transformation (Nagai et al., 1992; Alfieri et al., 1994). IMPDHII is also fivefold 
more susceptible to inhibition by MMF than IMPDHI (Syntex laboratories in 
collaboration with (Allison and Eugui, 2005)). It is believed the inhibition of IMPDH 
occurs after inosine monophosphate (IMP) and NAD+ binding, after hydride 
transfer, and after NADH release (Fleming et al., 1996).  
The IMPDH enzyme is essential for de novo purine synthesis pathway that 
generates a nucleotide precursor-deoxyguanosine triphosphate (dGTP) and 
purine nucleoside-guanosine triphosphate (GTP) for DNA synthesis (Allison and 
Eugui, 1996) (Figure 5.1). However, despite decades of research, it is not known 
which isoform of IMDPH is crucial for de novo purine pathway. Previous studies 
have rather focused on demonstrating the inhibitory effect of the IMPDH enzyme. 
Treatment of phytohaemagglutinin (PHA) mitogen activated human leukemic T-
lymphocytic cells and mononuclear cells with MPA resulted in significant GTP 
and dGTP depletion (Allison and Eugui, 1993). The effect was reversed by adding 
guanine or guanosine or deoxyguanosine (Allison et al., 1991; Allison and Eugui, 
1993). The first two efficiently restored GTP levels with lesser effect on dGTP 
restoration; deoxyguanosine however, efficiently recovered dGTP (Allison et al., 
1991). Addition of adenosine or deoxyadenosine did not restore DNA synthesis 
(Allison et al., 1991; Allison and Eugui, 1993). Inhibition of DNA synthesis in 
lymphocytes was shown by the incorporation of thymidine 3H-[dThd] (Allison and 
Eugui, 1993), to arrest cells throughout S phase (Cohn et al., 1999), thus 
inhibiting DNA replication. This was predominantly due to the depletion of dGTP. 
Lymphocytes exclusively rely on de novo pathway (Allison et al., 1977) while 
other cells use additional salvage pathways. Therefore it is believed the principal 
effect of MMF suppression is on lymphocytes (Allison and Eugui, 2000) by 
blocking the source of dGTP and GTP from de novo guanosine nucleotide 
synthesis (Allison and Eugui, 1993) (Figure 5.1). However inhibition of 
promonocytic cell lines proliferation was also demonstrated (Eugui et al., 1991). 
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Notably, amongst PHA stimulated primary lymphocytes and monocytes, only 
neutrophils did not have depleted GTP (Allison and Eugui, 1993). GTP is also 
required for neopterin synthesis by monocytes activated with IFNγ (Wachter et 
al., 1989), produced by activated T-cells. Since neopterin is indicative of a pro-
inflammatory immune status, it could be that MMF might supress macrophage 
mediated cell damage (Allison and Eugui, 1993). 
MMF also leads to apoptosis in monocytic U937 (Cohn et al., 1999; Allison and 
Eugui, 2000; Andrikos et al., 2005) and THP-1 cell lines (Cohn et al., 1999). A 
recent study using K562 leukemic cells on how MMF induces apoptosis, found it 
was due to GTP drop. This augmented accumulation of pro-apoptotic factor p21 
in the cell nuclei and led to cell death (Meshkini et al., 2011).  
It has been previously demonstrated with another IMPDH drug mizoribine, that 
GTP depletion in human peripheral blood T cells arrested the movement of cells 
from G1 to S phase of the cell cycle. The conclusion arose from unaffected initial 
steps of T cell activation measured by G1 phase genes expression and cell cycle 
analysis revealing decreased numbers of cells in S, G2, and M phases, measured 
by DNA content in flow cytometry (Turka et al., 1991). The similar arrest is also 
seen in MPA treated lymphocytic (MOLT-4) and monocytic cell lines (THP-1 and 
U937) where cells progressed through G1 but accumulated in S phase (Cohn et 
al., 1999). MMF treatment also promotes monocyte differentiation (Waters et al., 
1993). In vitro studies indicate MPA reduces the proliferative capacity of cell lines 
(promyelocytes HL60 and promonocytes U937), but also promotes differentiation 
of monocytes to macrophages (Waters et al., 1993). The latter effect was shown 
with the restricted production of pro-inflammatory cytokine IL-β, which is 
associated with monocytes and augmented production of IL-1 receptor 
antagonist (IL-1RA), which is associated with macrophages (Waters et al., 1993).  
In contrast, the differentiation of monocytes to dendritic cells is impaired with 
MMF, also affecting the maturation of immature monocyte-derived dendritic 
primary cells (Colic et al., 2003). Proliferation of IC-21 macrophages has also 
been suppressed by MPA. The effect was reversed by the addition of guanosine, 
suggesting this mechanism is GTP-dependent (Jonsson and Carlsten, 2002). 
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5.1.2 MMF effects on glycosylation and adhesion 
 
Adhesion of lymphocytes is required for mounting an immune response including 
migration to the sites of infection or inflammation (reviewed by (Dustin et al., 
2004)). The same applies to leukocytes (reviewed by (Ley et al., 2007)). In the 
context of transplanted grafts, lymphocytes and leukocytes can discourage organ 
rejection. MMF inhibits IMPDH, which prevents DNA synthesis in T and B cells 
because they lack the ability to generate purines through the alternative salvage 
pathway. It is speculated that MMF suppresses the expression of adhesion 
molecules thereby decreasing the recruitment of lymphocytes and monocytes 
into sites of inflammation and graft rejection (Allison and Eugui, 2000)). However, 
an adhesion phenotype was only shown in vitro, wherein the number of adhering 
T cells was lower and the expression of some adhesion endothelial receptors was 
reduced (Blaheta et al., 1998). Rats biopsies after induced renal failure and MMF 
treatment show lower numbers of lymphocytes and macrophages as well as 
reduced expression of some lymphocyte/monocyte adhesion molecules  
(Romero et al., 1999). Thus, one possible explanation for reduced 
macrophages/lymphocytes might be inhibited adhesion. However, these 
publications did not account for, e.g. apoptosis of cells once they arrive for 
example.  
MMF also has important roles in glycosylation. GTP is needed to transfer 
carbohydrates to glycoproteins during glycosylation. Due to guanosine depletion 
through MMF action the transfer of fucose- and mannose to glycoproteins serving 
as adhesion receptors- is impeded. This was demonstrated by measuring the 
expression of mannose on the surface of human peripheral blood lymphocytes, 
using a specific lectin for terminal mannose. MMF significantly reduced available 
mannose for lectin binding (Allison and Eugui, 1993). This also implies the 
depleted GTP source affects the glycosylation process by which glycoproteins 
are formed. Since some glycoproteins, such as selectins, are adhesion molecules 
involved in rolling steps of leukocytes to sites of inflammation (Ley, 2002), it is 
hypothesised that loss of adhesion might be the mechanism by which MMF 
decreases the recruitment of those cells to inflammation sites (Allison and Eugui, 
    
285 
 
2000). In contrast, there is some evidence MMF does not hinder glycosylation of 
T cells, as there is no effect on the binding of either fucose or mannose-specific 
lectins (Jepson et al., 2000). There have been conflicting reports concerning the 
ability of MMF to affect either endothelial or lymphoid cell adhesion molecules. In 
vivo, the expression of lymphocyte function-associated antigen adhesion 
molecule (LFA-1) was reduced whereas no effect was seen with endothelium 
associated molecules Intercellular Adhesion Molecule 1 (ICAM-1) and VCAM-1 
(Heemann et al., 1996). Contrary to this, in vitro endothelial adhesion molecules 
VCAM-1 , E-selectin and P-selectin were downregulated (Blaheta et al., 1998). 
Moreover, protein glycosylation occurs in the lumen of the endoplasmic reticulum 
(ER) and the Golgi, and requires GTP for the movement from the first organelle 
to the other. This trafficking, therefore, might be impaired (Allison and Eugui, 
2000).  
MMF reduces the adhesion of human monocytes to human umbilical vein 
endothelial cells (HUVECs) shown in immunocytochemistry assay. It also inhibits 
the expression of intercellular adhesion molecule (ICAM-1) and Major 
Histocompatibility Complex (MHC-II) in primary monocytes stimulated with LPS, 
measured through mean fluorescence intensity. Moreover, MMF treated primary 
monocytes do not adhere to E-selectin. It was suggested these effects could be 
beneficial in acute spinal cord injury. In these conditions migration of 
macrophages might be deleterious promoting pro-inflammatory action (Glomsda 
et al., 2003).  
It has been suggested that MMF downregulates expression of adhesion 
molecules involved in leukocytes recruitment through IL-1RA production and pro-
inflammatory cytokines. The IL-RA antagonist inhibits IL-1 that induces the 
expression of adhesion factors (Waters et al., 1993). In the blood of stable renal 
transplant patients treated with MMF and LPS, the production of pro-inflammatory 
IL-1β, TNFα, IL-6 and IL-10 cytokines was supressed. In addition, MMF alone 
significantly reduced TNFα (Weimer et al., 1999). Thus MMF might be beneficial 
in inhibiting chronic graft rejection, where immunological destruction described by 
gradual and progressive deterioration of the graft is often linked to persistent 
inflammation and occurs after the first few months of transplantation. 
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Taken together, by suppressing glycosylation and antagonising the expression of 
adhesion molecules MMF decreases the recruitment of lymphocytes and 
monocytes into sites of inflammation and graft rejection. It might also contribute 
to reduced pro-inflammatory cytokines production and increased IL-RA, which 
again might be a factor in the suppressed production of adhesion molecules, seen 


















Figure 5.1 Purine biosynthesis pathways including the de novo pathway 
and salvage pathway, showing the central position of inosine 
monophosphate (IMP) and point of action for MPA (mycophenolic acid). 
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5.1.3 Side effects of MMF described in clinical studies 
MMF has known side effects. For instance, a case study reported MMF might 
cause neutrophil dysplasia described as nuclear hypolobulation and abnormal 
clumping of nuclear chromatin. In this case, the neutrophil abnormality preceded 
the development of neutropenia (Banerjee et al., 2000). There are also reports of 
acute inflammatory syndrome in a kidney transplant patient with characteristics 
such as fever and oligoarthritis appearing within one week of increasing the MMF 
dosage. After MMF withdrawal, all complaints disappeared within 48 hours 
(Hochegger et al., 2006). The syndrome was also reported after introduction of 
MMF in patients with Wegener's granulomatosis and resolved after MMF 
withdrawal (Maes, 2002). In both reports it was hypothesised that this syndrome 
might be due to a paradox, pro-inflammatory reaction of PMNs. 
MMF in combination with cyclosporine prevents graft versus host disease 
(GVHD) in bone marrow transplantation due to diminishing the risk of mucositis, 
and causes faster neutrophil engraftment (Bolwell et al., 2004). However, the 
latter effect has been recently contradicted in cord blood transplantation 
(Okamura et al., 2011). This study, however, reported on MMF in combination 
with tacrolimus. Thus, it could be that the effect depends on calcineurin inhibitor 
or graft type.   
Common side effects of MMF include gastrointestinal and bone marrow 
suppression (leukopenia and thrombocytopenia) (reviewed by (Sollinger, 
2004)) and viral infections (Filler et al., 2003). 
5.1.4 MMF in autoimmunity  
Autoimmunity is described as an immune response leading to reaction with self 
antigen. MMF is used in autoimmunity: vasculitis, systemic lupus erythematosus, 
Wegener’s granulomatosis (Filler et al., 2003), bowel disease (Tan and 
Lawrance, 2009), immune-related pulmonary fibrotic conditions: interstitial lung 
disease in systemic sclerosis (Ueda et al., 2018), sarcoidosis (Hamzeh et al., 
2014) and other inflammatory conditions; e.g. myasthenia gravis (Heatwole and 
Ciafaloni, 2008), dermatomyositis (Orvis et al., 2009). Autoimmunity results from 
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abnormal lymphocyte recognition of self-antigens. In many cases, this results in 
autoantibody production. Abnormal monocyte count is also a hallmark of 
autoimmunity and unresolved inflammation. MMF causes apoptosis in monocytic 
lineages and inhibits the differentiation of monocytes to DCs (references in 
Mechanism of MMF on lymphocytes and other effects on other cells). In this 
context, it is believed that MMF has an anti-inflammatory effect because it affects 
both the adaptive and innate immune systems. Indeed, the literature suggests 
that MMF is an anti-inflammatory drug. For instance, in a mouse model of acute 
lung injury induced by lipopolysaccharide (LPS), MMF impedes the influx of 
neutrophils and reduces pro-inflammatory TNFα and IL-1β levels (Beduschi et 
al., 2013). On another note, those cytokines were measured in the pleural cavity 
by enzyme-linked immunosorbent assay (ELISA) with monoclonal- specific 
antibodies for each cytokine. Therefore, it is not known which cells produced 
them. 
In lung ischemia–reperfusion injury, when oxygen supply to the lung is limited 
and followed by a period of reperfusion (reviewed by (Weyker et al., 2013)), MMF 
sequestrated neutrophils, where accumulation was assessed by reduced MPO 
content in lung parenchyma (Farivar et al., 2005). This was further explained by 
attenuated levels of activator protein 1 (AP-1) and early growth response 1 (EGR-
1)- factors that transcriptionally regulate ICAM-1 (van de Stolpe and van der 
Saag, 1996; Yan et al., 2000), critical to leukocytes recruitment . Moreover, it has 
been suggested that the attenuation of AP-1 and EGR-1 could partially mediate 
reduced cytokine-induced neutrophil chemoattractant (CINC) and chemokine-
monocyte chemoattractant 1 (MCP-1) (Farivar et al., 2005). However, the role of 
MCP-1 in neutrophil recruitment is debatable and the generalised anti-
inflammatory effect of MMF could be due to MCP-1 not affecting neutrophils 
(Balamayooran et al., 2011).  
5.1.5 MMF’s pharmacokinetics 
MPA has been isolated from several species of Penicillium moulds (Clutterbruck 
et al., 1932) and firstly tested against IMPDH II activity in vitro in a LS culture line 
derived from mouse L fibroblasts (Franklin and Cook, 1969). In humans, 
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recommended therapeutic range of MMF falls between 1.0–3.5 µg/ml through 
serum or plasma levels (equivalent of 3.125 μM -10.9 μM, respectively) (Tredger 
et al., 2004). Orally dosed MMF is promptly absorbed from the gastrointestinal 
tract, followed by a presystemic deesterification to become MPA, the active 
portion. Administered intravenously, MMF’s plasma concentration, both in 
healthy and renal insufficiency patients, decreases significantly whereas MPA 
concentration rises reaching its maximum peak within 1 hour (Bullingham et al., 
1998). MPA is glucuronidated to the inactive 7-O-mycophenolic acid glucuronide 
(MPAG) and the active acyl glucuronide (AcMPAG) (Ting et al., 2008). Over 90% 
of MMF is excreted in the urine, mainly as MPAG. In healthy patients 97% of MPA 
and 82% of MPAG bind to serum albumins (Bullingham et al., 1996, 1998). In 
renal insufficiency unbound MPA might be increased while the total circulating 
drug level is in the therapeutic range (Smak Gregoor et al., 1998). Since only 
unbound MPA dictates the drug’s immunosuppressive action on IMPDH (Nowak 
and Shaw, 1995), factors influencing albumins binding can alter the effect of MPA 
(Jeong and Kaplan, 2006). In stable renal graft recipients, the unbound MMF 
fraction is consistent (Kaplan et al., 1999), doubled in delayed graft situations 
(Shaw et al., 1998) and significantly increased in renal insufficiency (Kaplan et 
al., 1998). In the first situation albumin concentration was not altered, in the 
second and third, decreased. It has been suggested the declined albumin could 
be due to renal dysfunction per se or by counteraction for albumin binding by 
MPAG (Kaplan et al., 1999).  
In addition, MPA encounters enterohepatic circulation (Figure 5.2) and reaches 
its secondary peak in plasma between 6-12 hours post intravenous or oral dosing 
(Bullingham et al., 1998; Jeong and Kaplan, 2006). This is concluded from MPAG 
excretion in bile as the recirculated metabolite and recirculation maximum in 
plasma being MPA (Bullingham et al., 1998). However, renal conditions do not 
mirror free MPA levels. Thus MMF dosage has to be thoroughly monitored 
(Kaplan et al., 1999). Nevertheless, MMF is widely used in renal diseases and 
many other post transplant treatments. 
 
 









Figure 5.2 Pharmacokinetics of MMF after oral administration. MMF 
undergoes pre-systemic deesterification into MPA, then gets metabolised to its 
glucuronide forms, MPAG and AcMPAG, by different isoforms of 
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5.1.6 Azathioprine (AZA) 
AZA is an alternative to MMF anti-proliferative agent acting on lymphocytes 
inhibiting de novo purine and DNA synthesis. In vivo AZA is converted non-
enzymatically to 6-mercapturine (6MP) (Chan et al., 1990) or purine base 
hypoxanthine (Wright et al., 2004) (Figure 5.3). Three enzymes compete to 
metabolise 6MP: thiopurine S-methyltransferase (TPMT), xanthine oxidase (XO) 
and hypoxanthine guanine phosphoribosyltransferase (HPRT) (Yatscoff et al., 
1998; Warner et al., 2018) (Figure 5.3). 6MP metabolism involves three 
competing pathways. The first one is the breakdown to inactive 6-thiouric acid 
(6TU) excreted in the urine, the second is through methylation into 
methylmercaptopurine (MeMP), which inhibits de novo purines pathway, and the 
last one is degradation of 6MP into thioinosine monophosphate (TIMP), also 
known as 6-thioinosic acid (6TA). The last is catalysed by monophosphate 
dehydrogenase (IMPDH) into 6-thioguanine monophosphate (TGMP), which, via 
kinases, is converted into 6-thioguanine nucleotides (6TGN) via purine salvage 
pathway (Simsek et al., 2017; Warner et al., 2018). 
The 6-TGTP nucleotides suppress Rac1 GTPase and finally induce T-cell 
apoptosis. This occurs when lymphocytes are co-stimulated with CD28 (Tiede et 
al., 2003) known to enhance T cell proliferation, which is associated with the 
stimulation of T cell receptor (TCR) via activation of Bcl-xL (cell survival gene) 
(Noel et al., 1996). The blockade of Rac1 activation is mediated via binding of 
azathioprine-generated 6-TGTP nucleotides instead of GTP. The blockade of 
Rac1 target genes such as MEK, NF-κB, and Bcl-xL leading to a mitochondrial 
pathway of T cell apoptosis (Tiede et al., 2003). The inhibition of Rac1 also 
encourages apoptosis of monocyte derived osteoclasts (Fukuda et al., 2005). 
The mechanism of this event is unknown. However, it is suggested that it might 
be due to compromised binding of the αvβ3 osteoclast integrin to its immobilised 
ligand, which promotes a programmed death (Fukuda et al., 2005; Zhao et al., 
2005; Croke et al., 2011). TGN become incorporated into DNA and inhibit its 
synthesis (Allison, 2005), whereas MeMP nucleotides inhibit de novo purine 
synthesis by blocking the first enzyme of de novo purine biosynthesis; 
amidophosphoribosyltransferase (PRPP) (Wright et al., 2004; Bowne et al., 
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2009). In addition, TIMP is not a substrate for adenylosuccinate synthetase, the 
first enzyme of adenine nucleotides formation from IMP (Parker, 2009) and 6MP 
depletes adenine nucleotides, even to a greater extent than TGN (Dayton et al., 
1992). Thus, AZA inhibits adenosine nucleotide more than guanosine nucleotide 
formation. The opposite is true of MMF (Allison and Eugui, 2005). AZA also 
inhibits to some extent ATP and GTP de novo biosynthesis through methyl 
thioinosine monophosphate (MeTIMP) generation (Cara et al., 2004; Petit et al., 
2008). MMF primarily inhibits GTP in de novo purine synthesis. However, it also 
affects ATP levels since in the purine synthesis the first fully formed purine 
nucleotide IMP can be converted either to adenosine monophosphate (AMP) or 
guanosine monophosphate (GMP) nucleotides. It was demonstrated in human 
peripheral blood lectin-stimulated primary lymphocytes that ATP levels were 
diminished as compared to monocytes and neutrophils (Allison and Eugui, 1993). 
The direction of the pathway is controlled by the level of the respective nucleotide.  
An excess of GTP will lead to the synthesis of AMP with the opposite being the 
case when ATP levels are higher (King, 2017). Reduced levels of ATP was found 













   









Figure 5.3 AZA metabolic pathway. Orange depicts Rac1 binding of 6-TGTP to finally induce T-cell apoptosis. Adapted from (Chan et 
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5.1.7 MMF versus AZA 
MMF inhibits DNA synthesis through interfering with GTP synthesis (Figure 5.1). 
AZA and its metabolite 6-thioguanine are two compounds that block DNA 
synthesis by incorporating thioguanine nucleotides into DNA (Figure 5.3). MMF 
results in a cellular depletion of GTP (Jagodzinski et al., 2004) by directly blocking 
the synthesis of GMP (Allison and Eugui, 1993) achieved by inhibiting IMPDH 
needed for de novo IMP pathway. 
Thus, with MMF treatment GMP can only be generated via the salvage pathway 
increasing the competition for GMP (mainly from nucleotide synthesis) and 
resulting in overall GTP depletion. By contrast, in lymphocytes, AZA allows GMP 
generation and therefore GTP restoration and its downstream products. This is 
achieved by depletion of cellular ATP through de novo IMP pathway. 6-
thioguanine however, will predominantly block DNA synthesis (Gibson et al., 
2018).  



























Figure 5.4 Biochemical pathways of AZA and MMF. Adapted from (Chan et al., 1990; Allison and Eugui, 1993; Wright et al., 2004; 
Simsek et al., 2017; Warner et al., 2018).  
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5.1.8 Conclusions, hypothesis and the research model 
As described, a great deal of research on MMF has been conducted on 
lymphocytes, thus in the presence of the adaptive immunity. Therefore, it is not 
informative of direct effects of neutrophils. A large body of work also included 
monocytes and macrophages, but MMF’s direct effects on neutrophils are less 
clear. 
Considering the effectiveness of MMF, which is given for inflammatory conditions, 
the question has arisen if MMF might have a direct effect on neutrophils 
independent of lymphoid factors as neutrophils are critical in inflammatory 
disease. They are the most numerous type of white blood cell in human peripheral 
blood. Under normal conditions, leukocytes travel in the centre of blood vessels. 
Within the sites of inflammation, the vessels are dilated and the consequent faster 
blood flow enables neutrophils to interact with vascular endothelium. During an 
inflammatory response the induction of adhesion molecules on the endothelium 
within the infected/inflamed tissue along with induced changes on adhesion 
molecules expressed by leukocytes, recruits circulating leukocytes (recruitment 
of inflammatory cells was described in section 1.6.1.1.2). 
Neutrophils recruited at the infection/inflammation site are considered to be a 
hallmark of inflammation (Donnelly and Haslett, 1992). As opposed to other cells 
of innate immunity, neutrophils undergo a complex migration from the vascular 
lumen to the tissues and in this context, they are the first cells to arrive to the 
infection/wound site (Voisin and Nourshargh, 2013). Under normal 
circumstances, neutrophils are not recruited to the inflamed site until 
approximately 6 hours after initiation of the inflammatory response (Serhan and 
Savill, 2005). In this respect, neutrophils are essential to exert host-defence 
actions in tissues.  
Work from the Johnston group demonstrated that the total number of neutrophils 
is not reduced after treatment with MMF in unmanipulated or Cryptococcus 
infected Tg(mpx:GFP)i114 zebrafish larvae (which lack adaptive immunity) 
(Gibson et al., 2018). This is in line with ex-vivo, -rodent work which also indicates 
neutrophil production was not altered (Allison and Eugui, 2000). 
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However, in the clinic MMF is given in the context of existing inflammation. 
Therefore, I hypothesised that MMF would have a direct effect on neutrophil 
function during neutrophil inflammation. To address this hypothesis, I proposed 
to test MMF in the zebrafish model of neutrophilic inflammation where innate 
immunity operates without functional adaptive immunity (Renshaw et al., 2006). 
In this model, neutrophilic inflammation is induced by injury to the zebrafish tail. 
The model enables assessment of the ability of compounds to modulate 
neutrophilic inflammation in vivo (Loynes et al., 2010). Using this model, I have 
demonstrated that MMF treatment results in reduced neutrophil numbers and 
induces neutrophil apoptosis during the resolution of a neutrophilic inflammatory 
response, which is beneficial. I also tested if AZA can reduce the number of 
neutrophils following inflammatory insult. AZA does not replicate the effect 
observed with MMF. 
5.2 Results 
5.2.1 Neutrophilic inflammation is reduced with MMF treatment 
To test the hypothesis that MMF has a direct effect on neutrophil function, the 
zebrafish tail transection assay of neutrophilic inflammation was used (Figure 
2.2). In this model, an injury to the tailfin (Figure 2.2) induces a robust 
inflammatory response, with distinct phases of neutrophil recruitment peaking at 
approximately 6 hpi (Renshaw et al., 2006; Gray et al., 2011). At 12 hpi 
inflammation resolution is not entirely complete (Renshaw et al., 2006), but by 24 
hpi it largely is (Renshaw et al., 2006); by 48 hpi recruited neutrophil numbers 
return to baseline (Gray et al., 2011). Each phase can be easily monitored by 
imaging GFP-expressing neutrophils. 
To observe the effect of MMF on the recruitment of neutrophils to the site of injury, 
zebrafish larvae were exposed to pharmacological agents immediately post-
wounding. MMF demonstrated a small reduction in the number of neutrophils at 
6 hpi, indicating that MMF inhibits the recruitment of neutrophils in this early 
phase of inflammation (Figure 5.5A), which is characterised by the rapid 
accumulation of immune cells. Inhibition of neutrophils recruitment with 
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SP600125 (c-Jun N-terminal kinase inhibitor, positive control) had a larger effect 
on recruitment compared to MMF (P<0.0001, P=0.0495, respectively).  
To test the effect of MMF on resolution, MMF was applied at 4 hpi when 
recruitment of neutrophils was maximal. By 4 hpi, the number of neutrophils at 
the wound site approaches the expected peak value (Renshaw et al., 2006) and 
the effect of drugs on the resolution phase of neutrophilic inflammation can be 
studied. Thus, at 4 hpi, larvae that had recruited comparable numbers of 
neutrophils (30-40) were subsequently treated and neutrophil counts undertaken 
at 6 hpi and 24 hpi. Interestingly, at 2 hpt (6 hpi) there was no effect on further 
neutrophil recruitment (Figure 5.5B). MMF neither augmented neutrophil 
numbers at 6 hpi, nor prevented the further recruitment. While there was no 
significant difference between controls and the MMF treated group at 6 hpi 
(Figure 5.5B), MMF reduced the number of neutrophils remaining at the wound 
site during the resolution phase of inflammation at 24 hpi (Figure 5.5C). Increased 
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Figure 5.5 MMF accelerates resolution of neutrophilic inflammation in vivo. 
(A) Number of neutrophils at the site of injury at 6 hpi is reduced with MMF treatment. 
Compounds added at the time of injury (B) MMF does not alter neutrophil recruitment at 
6 hpi (2 hours after compounds addition). (C) By 24 hpi (20 hours after compounds 
addition) number of neutrophils at the site of injury is reduced in MMF treated group; 
n=18 per group in 3 independent experiments; in each repeat 6 larvae were used per 
treatment per time-point. P values presented as One-way ANOVA (and nonparametric) 
in Kruskal-Wallis test with Dunn’s multiple comparisons; data presented as dot plot with 
mean ±standard deviation; DMSO (vehicle control), MMF (compound of interest) and the 
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To find the relative contribution of recruitment and resolution in the decrease in 
neutrophilic inflammation with MMF treatment, the percentage change in the 
number of neutrophils at the site of injury in the same zebrafish between 6 and 
24 hours was calculated (Figure 5.6). MMF treatment resulted in a more than 2-
fold reduction in the proportion of neutrophils at the site of injury between 6 and 
24 hours (P=0.0003). These results confirm that reduced inflammation with MMF 
treatment was due to increased resolution. However, it became apparent that 
MMF might be influencing early, but not later stages of neutrophil recruitment 
during the course of inflammatory response, where the neutrophil numbers 
usually peak at 6 hpi. However, during the resolution phase of inflammation, the 
6 hpi time-point remains unaffected and a significant reduction is seen by 24 hpi.  
To test whether the reduction in neutrophil recruitment on treatment with MMF 
may have been due to a decrease in the total number of neutrophils, the total 
number of neutrophils was compared. Representative images of larvae treated 
with DMSO and MMF after 6 and 24 hours of incubation are presented in Figure 
5.7. No difference in the total number of neutrophils between treatments was 
found either at 6 (Figure 5.8A) or 24 hpt (Figure 5.8B) as described previously 
(Gibson et al., 2018). Since the whole-body total neutrophil count was assessed 
in the absence of any inflammatory stimulus, this supported the hypothesis that 
MMF acts specifically on activated neutrophils participating in the inflammatory 
response as shown in the recruitment and resolution experiments.  
 
 





Figure 5.6 MMF results in a more than 2-fold reduction in the proportion of 
neutrophils at the wound site between 6-24 hpi (2 and 20 hours after compounds 
administration, respectively). Percentage change in number of neutrophils at the site of 
injury calculated by extracting the number of neutrophils at 24 hpi from the number at 6 
hpi and dividing by number at the first time-point, 6 hpi; n=18 per group in 3 independent 
experiments; in each repeat 6 larvae were used per treatment per tme-point. P values 
presented as One-way ANOVA (and nonparametric) in Kruskal-Wallis test with Dunn’s 












































Figure 5.7 Representative images of larvae treated with DMSO and MMF 
after 6 and 24 hours of incubation. Scale bars are 100 µm. 
 
DMSO bright field after 6 hours of 
incubation 
DMSO GFP after 6 hours of incubation 
DMSO merge after 6 hours of 
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DMSO merge after 24 hours of incubation 
MMF bright field after 6 hours of 
incubation 
MMF GFP after 6 hours of incubation 
MMF merge after 6 hours of incubation 
MMF bright field after 24 hours of incubation 
MMF GFP after 24 hours of incubation 
MMF merge after 24 hours of incubation 





Figure 5.8 MMF has no effect on the total number of neutrophils. MMF does 
not alter the total number of neutrophils after (A) 6 hours incubation or (B) after 24 
hours incubation; n=17-18 per group in 3 independent experiments; in each repeat 6, 
6, 5 larvae were used in DMSO group at 6hpi whereas 6, 6, 6 larvae were used in MMF 
group at 24 hpi. P values presented are Mann-Whitney test; data presented as dot plot 
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Neutrophil recruitment, although necessary in the first stage of inflammation, 
might be a direct cause of chronic conditions. Known anti-inflammatory drugs 
inhibit neutrophil recruitment (Hasçelik et al., 1994), consistent with results seen 
in both the recruitment and resolution assays (Figure 5.5). In the recruitment 
experiment, MMF blocked neutrophil recruitment with a small, but significant 
effect. In the resolution assay, MMF failed to alter numbers of neutrophils at sites 
of injuries at 6 hpi. In contrast, a significant drop in neutrophil numbers is seen by 
24 hpi. The percentage resolution of the neutrophilic component of the 
inflammatory response shows a significant increase in the resolution. In this light, 
these findings provide a basis to believe MMF has anti-inflammatory and pro-
resolution properties, which is accentuated by the fact that there is no effect on 
the whole body count in the absence of any inflammatory factor (Figure 5.8). 
 
5.2.2 AZA does not replicate the effect of MMF treatment on neutrophilic 
inflammation 
As previously described, AZA is also a lymphoid cell anti-proliferative agent. AZA 
was tested due to its application in a number of inflammatory conditions, e.g. 
Crohn’s disease or ulcerative colitis (Fraser, 2002), which are also managed with 
MMF (Appel et al., 2005). Both MMF and AZA interfere with DNA synthesis, but 
via distinct mechanisms act at distinct points (Figure 5.4). Here, AZA was used 
to distinguish whether the results seen following MMF treatment are specific to 
its mechanism, as AZA is one of few drugs also involved in the inhibition of de 
novo purine synthesis.  
In contrast to MMF, AZA did not affect recruitment or resolution of neutrophils 
from wound sites (Figure 5.9A-C). Similar to MMF, no change in total neutrophil 








Figure 5.9 AZA does not accelerate the resolution of neutrophilic 
inflammation. (A) AZA has no effect on neutrophil recruitment at 6 hpi (2 hours after 
compounds addition); n=24 per group in 4 independent experiments; in each repeat 6 
larvae were used per treatment (B) AZA has no effect on neutrophil recruitment at 24 hpi 
(20 hours after compounds addition); n=24 per group in 4 independent experiments; in 
each repeat 6 larvae were used per treatment (C) AZA has no effect on the recruitment 
of neutrophils at 6 hpi (compounds addition immediately after injury); n=24 in 4 
independent experiments; in each repeat 6 larvae were used per treatment. P values 
presented as One-way ANOVA (and nonparametric) in Kruskal-Wallis test with Dunn’s 










Figure 5.10 AZA has no effect on the total number of neutrophils. AZA does 
not affect the total number of neutrophils after (A) 6 hours incubation or (B) after 24 hours 
incubation; n=28 per group in 3 independent experiments; in each repeat 10,10, 8 in 
DMSO treatment whereas 10, 9, 9 larvae were used in AZA group at both 6 hpi and 24 
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5.2.3 Reverse migration is not the mechanism by which MMF accelerates 
inflammation resolution in vivo 
It was first reported that neutrophils can exit inflammatory sites via a phenomenon 
of reverse migration over a decade ago (Tharp, 2005; Buckley et al., 2006; 
Mathias et al., 2006). There are many modes to this migration, including reverse 
luminal crawling, reverse abluminal-to-luminal transendothelial migration, reverse 
abluminal crawling, and reverse interstitial migration. In general, the term 
describes the general concept of retrograde neutrophil migration (Nourshargh et 
al., 2016). The event has become accepted as a mechanism of neutrophil 
removal from the site of inflammation and of inflammation resolution. Neutrophils 
migrating away from the site of inflammation have been reported both in 
mammalian systems (Buckley et al., 2006) and zebrafish (Mathias et al., 2006; 
Elks et al., 2011; A. L. Robertson et al., 2014). The study of reverse migration 
could therefore identify novel means of modulating inflammation and thereby 
make an important contribution to counteracting negative effects of chronic 
inflammatory diseases. 
As previously stated, the number of neutrophils at 6 hpi was not altered following 
MMF treatment for 2 hours. However, their number was attenuated after 20 hours 
of treatment indicating reduced neutrophilic inflammation. To assess neutrophil 
behaviour after 6 hpi, a well-established assay of neutrophil reverse migration 
(Elks et al., 2011; A. L. Robertson et al., 2014), which uses optimised 
photoconversion (Dixon et al., 2012), was performed on mpx:Kaede larvae 
(Figure 2.4, Figure 5.11). Fluorescence time-lapse imaging of photo-converted 
neutrophils at the site of injury was performed. Results indicated larvae 
challenged with MMF had unaltered reverse migration of neutrophils from the 
wounded site (Figure 5.12). This suggests the retrograde migration is not the 
mechanism by which neutrophils are cleared from the wound site. Moreover, 
while there were different numbers of neutrophils at the site of injury with MMF, 
there was no difference in the number or rate of neutrophils leaving the site of 
injury (Figure 5.12). Given there was no difference in reverse migration, another 
mechanism of neutrophils clearance was considered, apoptosis.  
 





Figure 5.11 Representative images of mpx:Kaede larvae DMSO and MMF 
treated larvae at 0 and 8 hours post photoconversion (hpc). At 4 hpi the larvae 
with recruited neutrophils were treated with MMF or the DMSO control. At 6 hpi larvae 
were mounted and neutrophils at the site of injury were photo-converted from green to 
red. Larvae were imaged for 8 hours. The number of red neutrophils that migrated away 
from the site of injury into the anterior and posterior region to the circulatory loop was 
measured. Blue dashed line indicates the posterior region of the tail in which neutrophil 
recruited to the site of injury were photo-converted. Yellow box indicates the anterior 
region of the tail where reverse migration was assessed. Scale bars represent 100 µm. 
Blue dashed line indicates the posterior region of the tail in which neutrophil recruited to 
the site of injury were photo-converted. Yellow box indicates the anterior region of the 
tail where reverse migration was assessed. Scale bars represent 100 µm.  
 





Figure 5.12 MMF does not promote reverse migration in vivo. Reverse 
migration was assessed by counting neutrophils in the posterior and anterior region to 
the circulatory loop. The region of interest was at the anterior of the tail and this data set 
was extracted to plot the number of photoconverted neutrophils leaving the area of 
transection. Data presented as points with connecting line with error bars. Points are the 
mean and the standard deviation of n=17 (DMSO) or n=18 (MMF) animals from 3 
biological repeats; in each repeat 6, 6, 5 in DMSO group and 6, 6, 6 larvae were used in 
MMF group. Difference in slope assessed by linear regression analysis with P=0.52 
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5.2.4 MMF induces neutrophil apoptosis in the tail injury model  
Apoptosis is crucial for neutrophil functional shutdown, their clearance and timely 
resolution of inflammation (Haslett, 1992; Kebir and Filep, 2013). Apoptosis has 
been well documented as a clearance mechanism (Savill et al., 1989; Grigg et 
al., 1991; Cox et al., 1995). Given there was no difference in reverse migration, 
apoptosis as another possible mechanism of neutrophil removal was tested. To 
assess for apoptosis-inducing properties of MMF, TUNEL staining in vivo at 12 
hpi (an intermediate stage of inflammation resolution) was performed on injured 
2 dpf mpx:GFP larvae (Figure 2.3, Figure 5.13). The number of apoptotic 
neutrophils (double mpx:GFP and TUNEL positive cells) in MMF treated larvae 
revealed a >2-fold increase in neutrophil apoptosis (Figure 5.14). 
These findings suggest MMF promotes resolution of inflammation in the tail injury 
model through apoptosis. The difference in the percentage of apoptotic 
neutrophils between control (>1%) and MMF-treated (>2%) groups although 
being small, is comparable to rates of detectable apoptosis in patients with 
inflammatory conditions (Matute-Bello et al., 1997) and agrees with differences 
in neutrophil numbers measured at 24 hpi.  
Furthermore, at 12 hpi, the ideal time-point for assessing the resolution stage of 
inflammation (an intermediate stage of inflammation resolution (Loynes et al., 
2010)), there was a significant difference in the number of neutrophils at the site 
of injury with MMF (Figure 5.15), accentuating apoptosis contribution to reduced 
neutrophils numbers. To test for a difference between DMSO and MMF, the 
neutrophil number was calculated in the same fish, used in apoptosis assay. As 
expected, the number of neutrophils at 12 hpi was significantly different between 
treated groups (Figure 5.15) (P=0.0103). This result suggests the reduction in 
neutrophils numbers seen by 24 hpi in the resolution assay begins much earlier 
within the reduction being already statistically significant at 12 hours. 
 





Figure 5.13 Representative images of mpx:GFP zebrafish fixed and stained 
12 hpi for colocalisation of neutrophil (FITC-TSA) and apoptotic (TUNEL) 
markers. Dual staining for neutrophil and apoptosis markers provides biochemical 
confirmation of neutrophil apoptosis during resolution of neutrophilic inflammation in 
mpx:GFP zebrafish at 12 hpi. Yellow are apoptotic neutrophils (white arrowheads) that 
are double-positive (positive for green neutrophil- FITC-TSA specifically labels the Mpx 
protein green and positive for red apoptotic markers- TUNEL labels the Nick-ended DNA 
fragments red (rhodamine) when a cell undergoes apoptosis). Images are extended 
focus of 15 sections in the Z dimension with 5.37 µm z step. Scale bars represents 100 
µm. 





Figure 5.14 MMF increases neutrophil apoptosis at the site of inflammation. 
MMF treatment results in a >2-fold increase in neutrophil apoptosis at the site of injury 
at 12 hpi. 139 vehicle treated and 161 MMF treated mpx:GFP larvae from 3 independent 
experiments; in each repeat 27, 70, 42 in DMSO group and 48, 73, 40 larvae were used. 
P value presented is Mann-Whitney test; data presented as column graph bars with 
mean ±standard deviation.  
 
 
Figure 5.15 MMF reduces the number of neutrophils at the site of injury at 
12 hpi. 139 vehicle treated and 161 MMF treated animals from three biological repeats; 
in each repeat 27, 70, 42 in DMSO group and 48, 73, 40 larvae were used The number 
of mpx:GFP zebrafish larvae is high as this data is obtained from larvae assayed with 
apoptosis staining. P value presented is Mann-Whitney test; data presented as box and 
whiskers with 5-95 percentile. 
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Finally, to investigate whether inhibition of neutrophil cell death was sufficient to 
reverse the increased inflammation resolution identified with MMF, a pan-
caspase inhibitor Z-VAD was used. The effect of MMF on neutrophil numbers 
was reversed by the addition of Z-VAD, confirming MMF induces caspase-
dependent cell death, and the effect of MMF was reversed at both 6 and 24 hours 
(Figure 5.16A-B). This indicates that preventing neutrophil cell death was 















Figure 5.16 The effect of MMF is reversed with Z-VAD at both 6 and 24 hpi. 
Z-(A) Z-VAD blocks the effect of MMF at 6 hpi (2 hours after compounds administration); 
n=18 per group in 3 independent experiments; in each repeat 6 larvae per treatment 
were used (B) Z-VAD blocks the effect of MMF at 24 hpi (20 hours after compounds 
addition); n=14-18 per group in 3 independent experiment; in each repeat 6 larvae in all 
groups were used; at 24 hpi in DMSO, MMF, Z-VAD 6 larvae were used in each repeat 
whereas 5, 5, 4 in MMF+Z-VAD group. P values presented as One-way ANOVA (and 
nonparametric) in Kruskal-Wallis test with Dunn’s multiple comparisons; data presented 
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5.3 Discussion  
 
5.3.1 The dose of MMF used in the study 
 
The experiments in my study aimed to determine that MMF would have a direct 
effect on neutrophil function during neutrophil inflammation. To test this 
hypothesis, I used the well-described zebrafish model of neutrophilic 
inflammation (Renshaw et al., 2006).   
The dose used in the study was 0.5 µM. One could ask how the dose was chosen.  
As described in Chapter 2 regarding the dose chosen for the zebrafish study, 
when zebrafish embryos are given 1.5 μM mycophenolic acid from fertilisation, 
intersegmental blood vessel formation is revoked. The dose of 0.9 μM 
significantly reduces blood vessel formation (Wu et al., 2006). A study looking at 
liver transplant patients treated with MMF, demonstrated mycophenolic acid 
concentrations in the body ranges from 1.5 μM up to 22 μM (Dasgupta et al., 
2013). Target therapeutic range for liver recipients is between 1.0–3.5 µg/ml 
(equivalent of 3.125 μM -10.9 μM, respectively) (Tredger et al., 2004). In liver 
transplantation 1 or 1.5 g twice daily of MMF is the standard protocol. Target 
dose, when combined with cycloslosporine, falls between 3 μM to 11 μM (Shaw 
et al., 2007). Recommendations obtained online from drugs.com confirm the 
dose for hepatic transplantations and describe the dose for renal and cardiac of 
1.5 g daily (https://www.drugs.com/dosage/mycophenolate-mofetil.html). 
It was not be possible to use therapeutic doses of MMF considering angiogenic 
inhibition in zebrafish. Therefore, to minimise these effects it was decided to treat 
zebrafish with 0.5 µM. Richard Hotham, a former BMedSci student in the 
Johnston lab, did the establishment of this dose. Other doses were also tested in 
zebrafish survival assays. This level of drug was thought to still be likely to cause 
effects in macrophages because concentrations between 0.1 μM and 1 μM of 
mycophenolic acid caused apoptosis in monocytes in vitro (Cohn et al., 1999). 
The dose selected was representative of therapeutic blood stream concentrations 
of MMF in humans. 
At the same time it is acknowledged the dose response could have been done in 
the zebrafish tail transection assay to find the lowest dose that gives the required 
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effect. However, this would mean that the zebrafish would be tested under 
conditions where the inflammation is reduced but the immunosuppressive effect 
might also be reduced. This was not the aim of the experiment. I wanted the 
zebrafish to be immunosuppressed. Only such conditions would be informative 
of the real effects and the mechanism MMF exerts when the zebrafish is 
immunosuppressed. Thus, the safe dose of 0.5 µM was used. This also suggests 
that finding the lowest dose that reduces neutrophilic inflammation in patients 
could be beneficial for them when the immunosuppression is not required. 
5.3.2 Neutrophilic inflammation is reduced with MMF treatment 
Here I have shown MMF treatment results in neutrophil cell death by apoptosis 
in vivo, thereby reducing neutrophilic inflammation. Neutrophil apoptosis, not 
reverse migration, is the mechanism by which MMF promotes neutrophilic 
inflammation resolution. Reduced neutrophil numbers are beneficial in terms of 
the generalised anti-inflammatory effect of MMF. 
MMF is widely used and is the mainstay of post-transplant management triple 
immunosuppression (Vincenti, 2003). Introduced first in 1995, MMF is preferred 
over AZA due to a lesser risk of acute graft rejection when used in a combined 
therapy (Knight et al., 2009; Muntean and Lucan, 2013). It is also commonly used 
prior to transplantations in combination with other immunosuppressants 
(Maamoun et al., 2010), replacement regimen (Banerjee et al., 2000), in chronic 
diseases, e.g. Crohn’s (Neurath et al., 1998), chronic hepatitis (Nogueras et al., 
2005), in renal complications and autoimmune conditions (Appel et al., 2005); or 
as a primary treatment in interstitial lung disease (Volkmann et al., 2017). All of 
these patients are characterised by one common factor being an inflammatory 
insult. However, research on the specific effects of MMF on neutrophils have 
been scarce and thus this study was proposed to test possible mechanisms of 
MMF engagement in neutrophil function.  
Immune-modifying agents were identified previously using the zebrafish in vivo 
model of neutrophilic inflammation (Loynes et al., 2010). Roscovitine and 
pyocyanin (inducers of human neutrophil apoptosis (Usher et al., 2002; Rossi et 
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al., 2006)) led to reduced neutrophil numbers at the wound (Loynes et al., 2010). 
The model also identified a number of compounds that accelerated inflammation 
resolution in a preliminary screen, of which half had known anti-inflammatory 
properties (Loynes et al., 2010). Another zebrafish compound screen revealed 
the mechanism of action of tanshinone IIA (A. L. Robertson et al., 2014), known 
to have anti-inflammatory activity (Fan et al., 2009, 2016). This model of 
spontaneously resolving neutrophilia enables the identification of compounds that 
alter recruitment of neutrophils or escalate inflammation resolution. Therefore, 
the use of this zebrafish model in these studies allows one to reveal an off-target 
effect of MMF on neutrophil function as MMF specifically targets lymphocytes. 
This is particularly informative in elucidating the role of neutrophils during the 
inflammatory response during MMF treatment. 
As described previously in the Tg(mpx:GFP)i114 zebrafish model, neutrophils are 
recruited to the injury site and their numbers approach peak levels at 
approximately 6 hpi (Renshaw et al., 2006). At this time-point, MMF was found to 
reduce neutrophil numbers. There were three plausible explanations for this 
decrease. 1) Given the finding that MMF increased neutrophil apoptosis, it is 
possible that with MMF treatment apoptosis occurs earlier than at 12 hpi and 
therefore a reduction in neutrophils is already seen at 6 hpi; 2) MMF has been 
reported to reduce levels of CINC, a neutrophil pro-inflammatory chemotactic 
mediator in a rodent model of lung perfusion injury, therefore MMF may directly 
reduce neutrophil numbers at the site of injury (Farivar et al., 2005); 3) 
Myelosuppression, which is known to be a major complication, despite MMF’s 
greatly favourable side-effect profile (Keown et al., 1996), could play a role.  
Granulopoiesis in adult vertebrates or humans occurs in the bone marrow (Perry, 
1971); in adult zebrafish this process occurs in the kidney, a site considered 
equivalent to haematopoietic human bone marrow (Lieschke et al., 2001; 
Crowhurst et al., 2002). However, in zebrafish larvae, neutrophils develop at 18-
24 hpf in the yolk sac mesoderm (Bennett et al., 2001), between 24-30 hpf in 
intermediate cell mass (Crowhurst et al., 2002) and possibly in ventral venous 
plexus >30 hpf (Willett et al., 1999). Zebrafish larvae used in the experiment were 
always aged 48 hpf and their neutrophils are human homologues. Therefore, it 
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could be that MMF supresses granulopoiesis in zebrafish. Potentially production 
of granulocytes is linked with neutropenia caused by MMF (Shapiro et al., 1999; 
Nogueras et al., 2005), possibly by inhibiting IL-17 as shown in mice treated with 
MMF (Von Vietinghoff et al., 2010). This defect could also explain the finding. 
However, MMF-induced neutropenia in patients occurs typically after two to three 
months of treatment (Banerjee et al., 2000; Budde et al., 2004) and perhaps 
longer treatment and multiple zebrafish recruitment experimental time-points 
would reveal the neutropenic impact of MMF on neutrophil recruitment. However, 
inhibited myelopoesis would not be in agreement with the whole body findings, 
which will be discussed later. Also, another aspect of the recruitment result 
cannot be ignored. My finding suggests MMF might exert neutrophil-targeted  
anti-inflammatory activity, which would be in line with broadly defined anti-
inflammatory properties in mice (Durez et al., 1999; Monguilhott Dalmarco et al., 
2011; Beduschi et al., 2013) and would explain why MMF is clinically widely used 
in inflammatory conditions.  
MMF treatment also showed a pro-resolution activity by accelerating 
inflammation resolution through reducing the numbers of neutrophils at the site 
of injury in the resolution phase. While neutrophil counts at the injury site could 
be taken at various experimental time-points, the key concept of the experimental 
design of the resolution assay is to select those injured larvae that have recruited 
comparable numbers of neutrophils to the wound by 4 hpi without any treatment. 
By 4 hpi, the number of neutrophils at the wound site approaches the expected 
peak value (Renshaw et al., 2006) and the effect of drugs on the resolution phase 
of neutrophilic inflammation can be studied. The first time-point being 6 hpi that 
is equal to 2 hpt indicated no changes between MMF and the control. This 
suggests that either two hours treatment is not enough time for the drug to enter 
the zebrafish system and no change in neutrophils accumulation was observed, 
or this simply is the pharmacological pattern in zebrafish. At 12 hpi the number of 
neutrophils at the wound site is significantly reduced, although data was gained 
from a different set of fish (from the apoptosis assay). The number of neutrophils 
by 24 hpi was strikingly lowered, indicating MMF promotes inflammation 
resolution. Moreover, the relative contribution of recruitment and resolution in the 
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decrease in neutrophilic inflammation with MMF treatment expressed as the 
percentage change in the number of neutrophils at the site of injury confirmed 
that reduced inflammation with MMF treatment was due to increased resolution. 
In addition, MMF did not cause any changes in neutrophil numbers when 
uninjured fish were tested, suggesting MMF acts on neutrophils engaged in the 
inflammatory response. As already stated, the total number of neutrophils assay 
is informative of haematopoiesis. Many drugs may have a negative effect on the 
haematopoietic system and peripheral blood cells (Lubran, 1989).Therefore total 
body counts determine if drugs alter haematopoiesis in the absence of any 
inflammatory stimulus. Thus, if a drug increases or decreases neutrophil 
recruitment/persistence at the wound site, following injury or infection, it can be 
ruled out that the fish have more or less neutrophils due to a change in their 
production. In this context, MMF did not affect that process. However, MMF might 
have influenced the global fish development during which at a certain point 
haematopoesis begins. Due to the timing of the whole body neutrophil count 
experiment, which lasted 24 hours, it was not possible to detect obvious changes 
in development often leading to distinguishable phenotypes such as oedema and 
curled tails (Kok et al., 2015). It is possible that after 5 dpf, larvae can show 
developmental abnormalities, thereby supporting the hypothesis of MMF 
affecting global development and thus haematopoiesis. There are reasons to 
doubt this explanation of inhibited haematopoiesis as the number of neutrophils 
in the whole body count assay was not altered. It is also possible that 
haematopoiesis might have been accelerated but global development hampered. 
However, this is not shown due to the experiment limitation.  
Clinical data shows the administration of MMF in combination with tacrolimus can 
result in thrombocytopenia (Mourad et al., 2001) and leukopenia (Hao et al., 
2008). The incidence of leukopenic adverse effects caused by MMF is lower as 
compared to AZA when these immunosuppressants are given in combination 
with cyclosporine and corticosteroids (Eisen et al., 2005). Thus, it becomes 
difficult to assess whether the adverse effects result only from MMF treatment. 
The differences in the incidence of haematological toxicity might arise from the 
additionally applied immunosuppressives and other factors such as the possibility 
of genetic predisposition (Jacobson, 2011; Sobiak et al., 2013). In contrast, the 
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findings demonstrated MMF in conjuction with calceneurin inhbitors did not cause 
leukopenia or thrombocytopenia (Sobiak et al., 2013), Therefore, it is difficult to 
draw a clear conclusion of MMF’s effect on haematopoesis. The apparent 
discrepancy seems not to influence MMF use after haematopoietic cell 
transplantation (Giaccone et al., 2005).  
5.3.3 AZA does not replicate the effect of MMF treatment on neutrophilic 
inflammation 
Thiopurines (generated by AZA) were tested in my study for their ability to 
influence neutrophil inflammation following inflammatory insult. No effect on total 
neutrophil numbers or resolution of neutrophils at the site of injury was found. 
However, some patients cannot take AZA due to a genetic predisposition. The 
mechanism of AZA induced leukopenia is not clear, but there is a recognised host 
genetic component with several polymorphisms identified (Weinshilboum and 
Sladek, 1980). AZA is a prodrug that is metabolised both enzymatically and non-
enzymatically to form thioguanine nucleotides. The polymorphisms associated 
with AZA neutropenia are in genes that regulate thiopurine deactivation, 
metabolism and repair of thiopurine mediated DNA damage (Weinshilboum and 
Sladek, 1980; Colombel et al., 2000; H. S. Kim et al., 2016; Yang et al., 2016). 
For instance, mutations of thiopurine S-methyltransferase (TPMT) result in 
increased 6-thioguanine nucleotides (6TGNs) concentrations, putting patients at 
risk of developing bone marrow suppression (Ansari et al., 2002; Lennard, 2002). 
Thus, mutations in TPMT is a factor for casual AZA-induced leukopenia (S.-K. 
Yang et al., 2014). High RBC TGNs have been also linked to severe leukopenia 
(Lennard et al., 1984). More than 20% of patients have AZA discontinued 
because of adverse events, most commonly due to bone marrow suppression 
induced leukopenia (H. S. Kim et al., 2016). In this present study, AZA was tested 
independently of the genetic predisposition to severe myelosuppression resulting 
in leukopenia. Perhaps this is the reason for not observing reduced neutrophils 
numbers in zebrafish.  
It is interesting that one nucleotide antagonist (MMF) alters neutrophil numbers, 
while another not (AZA). AZA requires conversion to its active metabolite (6MP) 
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in order to function in the inhibition of purine synthesis (Berenbaum, 1971). AZA 
releases 6MP in vivo and the metabolic products derived from the 6MP are the 
same as those formed from 6MP, when only 6MP is tested (Elion et al., 1961, 
1963). It seems that conversion of AZA to 6MP differs from species to species 
(e.g. in rhesus monkeys to the extent of 15% (Ding and Benet, 1979), 88% in 
humans (Nielsen et al., 2001)). Therefore, 6MP levels should be checked in 
zebrafish to evaluate AZA efficacy. This may provide an insight into the absence 
of systemic neutropenia in my studies. 
5.3.4 MMF induces neutrophil apoptosis in the tail injury model  
MMF significantly reduced numbers of neutrophils in the resolution stage of 
inflammation and TSA/TUNEL staining in vivo identified an increase in the 
percentage of apoptotic neutrophils at the site injury at the intermediate time of 
inflammation resolution. Using the pan-caspase inhibitor Z-VAD to inhibit 
apoptosis, the effect of MMF was reversed, demonstrating that preventing 
neutrophil cell death was sufficient to reverse neutrophilic inflammation resolution 
due to MMF. 
Circulating neutrophils are short-lived with the half-life of 8 hours (Dancey et al., 
1976), which increases several fold upon entry into infected or inflamed tissues 
(Edwards et al., 2004). At sites of inflammation they first generate signals to 
amplify inflammatory recruitment, and at the late stages of healing they secrete 
signals to dampen inflammation (Nathan, 2006). Successful resolution of 
inflammation depends on timely removal of neutrophils to prevent further spillage 
of their cytotoxic content and thus limit neutrophil pro-inflammatory potential. 
Aged neutrophils commit suicide in the absence of pro-inflammatory mediators 
ahead of their removal by macrophages, while those not involved in inflammation 
undergo spontaneous apoptosis. Neutrophils also undergo apoptosis during 
tissue healing. Programmed cell death of neutrophils and their histotoxic contents 
is therefore a prerequisite of resolution of inflammation (Savill et al., 1989)  
 
Using TSA/TUNEL staining in fixed larvae it was demonstrated that there was a 
significant increase in the percentage of apoptotic neutrophils at the wound site 
   
323 
  
at 12 hpi with MMF treatment. Moreover, at 12 hpi, there was a significant 
difference in the number of neutrophils at the site of injury with MMF, likely due 
to occurrence of apoptosis. The magnitude of the difference between the two 
groups is small, likely due to measuring early in the assay. Combined with the 
previous results of reduced numbers of neutrophils during the resolution phase 
of inflammation, at 24 hpi and the experiment with Z-VAD where inhibition of 
apoptosis is sufficient to remove the effect of MMF, it was concluded that the 
effect at a single 12 hpi time-point is biologically meaningful. This conclusion is 
also supported by the previously published work of others using this and related 
models: e.g. in larvae treated with compounds once inflammation was already 
established, at 6 hours hpi and their effects on neutrophil number assessed at 12 
hpi, 4-chromanone at 1 µM showed a reduction described as 1.5-fold (Robertson 
et al., 2016). In another zebrafish study, pyocynin, a profound inducer of 
neutrophil apoptosis in human and mouse models (Usher et al., 2002; Allen et 
al., 2005) showed a >1-fold reduction in neutrophils numbers at 12 hpi (Loynes 
et al., 2010). Considering, the total number of neutrophils following 24 hours 
treatment revealed no difference and MMF increased the percentage of 
apoptosis, it is believed apoptosis was specific to activated neutrophils 
participating in the inflammatory response. This general idea could be tested by 
activation of neutrophils via different means (e.g. pro-inflammatory cytokines) in 
the presence and absence of MMF. 
As described, apoptosis was assessed by TSA/TUNEL. Cells undergoing 
apoptosis are typically characterised by rapid and dynamic alterations of the 
cytoskeleton, leading to membrane protrusions and altered motility patterns 
typical of apoptosis (Elliott and Ravichandran, 2016). Although in my study the 
blebbing was not investigated, the typical shrunken and rounded morphology of 
an apoptotic neutrophil was observed, which corroborated studies of others 
(Majewska et al., 2000; Nagaoka et al., 2008) and neutrophils in vivo (Loynes et 
al., 2010).  
The event of apoptosis, biochemically confirmed with TSA/TUNEL, demonstrated 
that >2% of detectable neutrophils were apoptotic. The 2-fold increase in 
neutrophil apoptosis with MMF treatment suggests the pro-resolution properties 
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of the drug. Perhaps this visible neutrophil effect was scored less than 3%, but it 
is still consistent with numbers from mammalian models and disease states 
(Howie et al., 1994; Matute-Bello et al., 1997) and seen in zebrafish (Elks et al., 
2011). The percentage of detectable apoptotic reported in zebrafish is always 
small, e.g. DMSO 1.6% vs isopimpinellin 3.3% (Robertson, 2013) or DMSO 0.7% 
vs tanshinone IIA 1.5% (A. L. Robertson et al., 2014) or DMSO 1% vs 3.5% 
nedocromil (Robertson et al., 2016). Thus, from other work, the >2-fold increase 
in neutrophil apoptosis with MMF treatment can be still considered to be 
biologically significant. It should be noted that detecting apoptosis reflects the 
equilibrium between the development of apoptosis and phagocytosis of apoptotic 
neutrophils, e.g. by macrophages (Matute-Bello et al., 1997). Thus it is possible 
that low numbers of apoptotic neutrophils could be associated with a shorter life-
span due to patrolling macrophages rapidly phagocytosing apoptotic cells (Savill 
et al., 1989). Furthermore, it is technically challenging to quantify total neutrophil 
apoptosis with the TSA/TUNEL assay as larvae are fixed at specific time-points; 
more detailed analysis using live reporters/dyes would provide a clearer answer 
on this point. Capturing efferocytosis would doubly confirm apoptosis.  
It would also be interesting to show that MMF alone or in combination with 
inflammatory cytokines induces neutrophil apoptosis in vitro to confirm the direct 
action of MMF. Neutrophil trafficking is regulated by cell adhesion molecules. The 
movement of leukocytes is facilitated by adhesive pairing between, for example, 
β integrin on neutrophils with its endothelial ligand ICAM-1 (Lomakina and 
Waugh, 2009). Apoptotic neutrophils show reduced expression of L-selectin 
ligand. However CD11b/ CD18 and CD11c/CD18 integrins are expressed at 
increased levels (Dransfield et al., 1995). MMF may suppress adhesion of 
neutrophils to epithelium, since the study of Laurent et al. found that MMF 
impeded attachment of human monocytes to endothelial cells and laminin 
(Laurent et al., 1996). This is consistent with what has been found in the previous 
study of (Huang et al., 2005). They showed that MMF suppressed both mRNA 
and surface levels of the TNFα-induced neutrophil adhesion molecule ICAM-1 
and decreased TNFα-mediated adhesion of neutrophils to endothelial cells (it is 
known that TNFα induces the increased expression of leukocytes integrin ligands 
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for ICAM-1 (reviewed in (Nourshargh et al., 2010)). Future studies could fruitfully 
explore potential loss of adhesive properties of neutrophils in vivo under MMF 
treatment.  
Another promising finding was that the number of neutrophils at the site of 
inflammation was reduced by MMF treatment alone, reflecting a blockade of 
recruitment or an induction of neutrophil apoptosis. The effect of MMF on 
neutrophil number was reversed by the addition of an irreversible dipeptide 
caspase inhibitor, Z-VAD, confirming MMF induces caspase-dependent cell 
death.  
In vivo studies show that Z-VAD is effective in inhibiting apoptosis and death in a 
rodent model of TNFα induced apoptosis in liver parenchymal cells during 
endotoxemia (Jaeschke et al., 2000). Its efficacy is confirmed in intravenous  
(i. v.) administration in three rodent models of apoptosis: anti-Fas-induced liver 
failure, transient focal brain ischemia/reperfusion, and myocardial ischemia 
(MCI)/reperfusion (Yang et al., 2003). The Yang’s findings also corroborated anti-
apoptotic properties of Z-VAD in vitro in HeLa S3 (the third clone isolated and 
propagated from an immortal cell line HeLA and the letter S in honour of physician 
and scientist Dr. Florence Rena Sabin) and Jurkat (immortal T lymphocytes) cell 
lines.  
Human polymorphonuclear neutrophils (PMNs) undergo a spontaneous 
apoptosis associated with translocation of the BCL-2–like protein BAX (internal 
regulator of cells-fate) to the mitochondria and subsequent caspase-3 activation. 
However, PMNs treated with Z-VAD show inhibited caspase-3 activation and 
apoptosis, but not BAX movement (Maianski, 2002). Another study showed a 
relationship between induced pulmonary apoptosis of PMNs by inhalation of 
Escherichia coli (E. coli) and attenuated lung injury with tetrapeptide Z-VAD 
(Sookhai et al., 2002). In ischemia–reperfusion (I/R) treated with aerosolised 
opsonised dead bacteria and Z-VAD intratracheally five minutes prior to 
reperfusion, the rate of pulmonary PMN apoptosis was similar to that of the I/R 
normal saline control group (Sookhai et al., 2002). 
The findings of Yang, Maianski and Sookhai formed the basis for the hypothesis 
of Z-VAD delayed neutrophils apoptosis thus delaying normal resolution of 
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inflammation. This was tested by the Renshaw lab using in vivo zebrafish model 
of neutrophilic inflammation (Renshaw et al., 2006). Z-VAD delayed the 
resolution of inflammation in that model. This was shown by  neutrophils numbers 
not being reduced at the wound site at 24 hpi when Z-VAD was added post 
recruitment (at 4 hpi) leading to the question of caspase-dependent apoptosis 
determining the neutrophil lifespan during inflammation. In the total number of 
neutrophil assay without inflammatory stimulus-an increase in total neutrophil 
count suggested a role for caspase activity in the neutrophil lifespan regulation. 
The direct link to neutrophil apoptosis was however shown in another study of 
theirs (Loynes et al., 2010). Z-VAD delayed the resolution of inflammation when 
added after recruitment, and inhibited apoptosis shown by a reduced count of 
apoptotic neutrophils stained with FITC-TSA and TUNEL at 12 hpi. 
Therefore, Z-VAD was selected in MMF study as an agent delaying inflammation 
of resolution as proven to be the most potent one as compared to bacterial 
lipopolysaccharides endotoxin (LPS), a stable synthetic cyclic adenosine 
monophosphate analog (dbcAMP) or several caspase inhibitors (Loynes et al., 
2010). 
As Z-VAD prevents neutrophil cell death, the compound was also used to test if 
MMF’s action can be reversed. According to the zebrafish literature, the dose of 
100 µM was used. 
As described, Z-VAD inhibits caspases through irreversibly binding to the 
catalytic site of caspase proteases (Slee et al., 1996) and therefore inhibits 
apoptosis in many cell types. Thus, it was suspected that Z-VAD would have a 
greater effect in elevating neutrophil numbers present at the injury site at the later 
time-point. This would have been in line with zebrafish findings, as when Z-VAD 
was added post recruitment, less apoptotic neutrophils were observed at the 
wound site (Loynes et al., 2010). As stated, Z-VAD is a pan-caspase inhibitor and 
caspases are implied in both extrinsic and intrinsic pathways of apoptosis. 
Extrinsic signalling is mediated by the activation of death receptors by 
extracellular ligands. Intrinsic, or mitochondrial, apoptosis is mediated by noxious 
stimuli including UV, chemotherapeutic drugs or lack of the growth factor 
signalling pathways. There are two classes of caspases – initiators, which 
promote apoptosis by cleaving and activating other caspases, and effectors, that 
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begin the cellular changes apoptosis associated. The intrinsic pathway is 
associated with initiator caspase -9; extrinsic with initiator caspases -8 and -10; 
both use executioner caspase -3, -6, -7 (Janeway et al., 2012a). Another 
classification provides caspases apoptosis (caspase-3, -6, -7, -8, and -9 in 
mammals) and inflammation (caspase-1, -4, -5, -12 in humans and caspase-1, -
11, and -12 in mice)- associated (Mcilwain et al., 2015). As Z-VAD inhibits 
caspase-1, it is therefore thought not to be a trigger of apoptosis but more an 
enzyme that cleaves IL-1β to stimulate pro-inflammatory cytokines (Sun and 
Scott, 2016). In addition, caspases -3, -6, -7, -8, and -9 are also inhibited (Yang 
et al., 2003). On the grounds of the above, it is speculated in my study, MMF 
causes apoptosis by activation of those five aforementioned caspases. This is 
partially in agreement with delaying resolution of inflammation by caspases-3, 
and -9, and to a lesser extent with -8, tested in zebrafish model of inflammation 
(Loynes et al., 2010). This might support a role for intrinsic apoptosis in 
inflammation resolution in this model, and would be in accordance with data from 
human neutrophils data (Murphy et al., 2003; Maianski et al., 2004). 
In summary, my data indicate that MMF induces apoptosis in vivo and the result 
casts a new light on MMF mechanism of action in the absence of adaptive 
immunity. 
Finally, my data, and the clinical evidence for use of MMF in inflammatory 
disease, suggest that neutrophils may be a de facto target for MMF. Recently, 
methotrexate, another chemotherapy drug used as an anti-inflammatory agent, 
has been identified as new inhibitor of the JAK/STAT pathway (Thomas et al., 
2015). Methotrexate is classically an inhibitor of the folate pathway, via 
dihydrofolate reductase inhibition, but its novel JAK/STAT activity may represent 
a significant proportion of its anti-inflammatory effect. Recently JAK/STAT has 
been demonstrated to be important in the development and resolution of 
inflammation (Shea and Murray, 2008). In vivo in the mouse model of 
experimental lupus nephritis, MMF reduced the level of pro-inflammatory 
cytokines with almost the same efficacy as CP-690,550, a JAK3 inhibitor (Ripoll 
et al., 2016) which inhibits pro-inflammatory cytokines. Thus, my study 
demonstrates a specific effect of MMF on neutrophil apoptosis and highlights the 
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need for better mechanistic understanding of MMF action specifically and 
immunosuppressive treatment in general (Bojarczuk and Johnston, 2017).  
5.3.5. Summary and future 
 
The aim of this project was to investigate whether MMF frequently used in the 
treatment of autoimmune, inflammatory conditions and following organ transplant 
has a direct effect on neutrophil function. To address this hypothesis, the 
zebrafish model of neutrophilic inflammation was employed, where innate 
immunity operates without functional adaptive immunity. This study arose from 
the work of former BMedSci students (Richard Hotham, Rory Gibson), who 
investigated the modulation of innate immunity focusing on macrophages by 
MMF in the zebrafish model of cryptococcosis. As it has been suggested that 
some of MMF’s clinical effect might be via modulation of innate immune cell 
function, e.g. macrophages (Shah et al., 2010; von Vietinghoff et al., 2011),  
I concentrated on another innate immune cell type, the neutrophil, during an 
inflammatory insult which fits with the idea of prescribing MMF in neutrophilic 
autoimmunity or inflammatory conditions.  
Neutrophils were initially investigated in vivo. However, it is interesting to discover 
whether the effect of MMF is confirmed in vitro using human neutrophils. My 
intention was to collaborate with Dr Lynne Prince (Department of Infection, 
Immunity & Cardiovascular Disease) to detail the immunology of MMF in PMN 
isolated from human peripheral blood. For example, an interesting way to 
investigate MMF effects in vitro is to determine the percentage of apoptosis with 
increasing doses of MMF alongside AZA (e.g. at concentrations of 2.5, 5,10, 25, 
50 µM) to see if MMF and AZA have any effect on neutrophil apoptosis in a 
‘resting state’ i.e. without stimulating the cells. It is also a subject of interest to 
determine the percentage apoptosis with stimuli such as GM-CSF and TNFα, 
which are present in a site inflammation. GM-CSF and TNFα prolong neutrophil 
lifespan (Cowburn et al., 2002). Their addition to MMF is indicative of neutrophils 
still undergoing apoptosis and thereby the question of MMF overcoming the 
effects of these two stimuli could be answered. Roscovitine in contrast has the 
opposite effect on neutrophils (Rossi et al., 2006) so the following research 
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question could be answered: does MMF in conjunction with roscovitine 
accelerate the apoptosis further? In vitro experiments on human neutrophils have 
been completed and the data should be integrated with zebrafish data in the new 
version of mycophenolate manuscript submitted for publication. 
The following is the summary of the in vitro work on MMF and human neutrophils 
and its relevance to the in vivo work. 
A question arose whether in vivo apoptosis data was biologically meaningful 
given the difference in the percentage of apoptotic neutrophils between control 
and MMF-treated groups being small (2-fold change). Also, a putative role of 
MMF in neutrophil cell death seemed interesting as it might be highly beneficial 
in some diseases with dysregulated neutrophil cell death, e.g. lupus nephritis (Wu 
et al., 2017). The present in vitro study was designed to determine the effect of 
MMF on human neutrophils to find support for in vivo work in the zebrafish model 
of inflammation to claim it has a direct effect on neutrophil apoptosis.  
We could show that MMF showed a 3-fold increase in the number of apoptotic 
human neutrophils, equating to nearly 20% apoptosis. In contrast, AZA did not 
have any effect on apoptosis enhancement. Both MMF and AZA interfere with 
DNA synthesis, but via distinct mechanisms act at distinct points (Figure 5.4). 
Experiments performed on human neutrophils, similarly to in vivo work used AZA 
to distinguish whether the results seen following MMF treatment were specific to 
its mechanism. AZA did not have any effect on neutrophil apoptosis in vitro in the 
‘resting’ state, i. e. without stimuli. This is an important finding in the 
understanding of the difference in the mechanism of action between MMF and 
AZA. This aspect of results of the in vitro study indicates that MMF can induce 
apoptosis without inflammatory insult highlighting it is an inducer of neutrophil 
apoptosis. In addition, is able to induce inflammation resolution in my zebrafish 
study that includes inflammatory insult. AZA does not replicate MMF treatment 
neither in vitro, nor in vivo suggesting that the differences in the mechanism of 
action between MMF and AZA are responsible for neutrophil apoptosis in vitro 
and in vivo. This finding is the most critical piece of information answering my 
research question that was made into a hypothesis in the thesis aims: 
immunosuppression with MMF does have an effect on neutrophils. 
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Some earlier in vitro studies indicated that mycophenolate decreases GTP levels 
in human lymphocytes and monocytes with an anti-proliferative result. MMF 
significantly depleted GTP in human lymphocytes and monocytes but not in 
neutrophils shown by restoration of GTP in the first two cell types after guanosine 
addition (Allison and Eugui, 1993). However, the authors did not account for the 
fact that GTP can also be replenished from ATP, which is produced from 
inosinate as it is GTP. This is the branch point in the synthesis of AMP and GMP. 
Prior research also showed that mycophenolate increases apoptosis in 
monocytic (THP-1 and U937) cell lines (Cohn et al., 1999). A question arose if 
human neutrophils undergo apoptosis as a result of GTP depletion. When 
guanosine was added to the cultures, the MMF’s effect on apoptosis was 
abrogated, showing that the effect was due to guanosine depletion, i.e. MMF 
induces guanosine-dependent cell death.  
The interaction with known apoptotic signalling pathways was also investigated 
in human neutrophils. TNFα or GM-CSF were used to inhibit apoptosis and then 
MMF was added to pre-treated cells. By contrast, roscovitine was used to induce 
apoptosis followed by MMF addition. MMF did not reverse the effect of GM-CSF 
or TNFα at any concentration used, but the stimuli reversed the pro-apoptotic 
effect of MMF. However, with roscovitine, which is pro-apoptotic, the effect was 
greatly enhanced at the highest concentration of MMF used, equating to a 3.5-
fold change. In vivo I identified a small but significant >2-fold effect on increase 
in neutrophil apoptosis with MMF treatment. This was without inducing apoptosis. 
In vitro, after apoptosis induction, this effect was greater and can be described 
as synergistic. At this stage it is not understood which signalling pathways or 
mechanisms are involved in the control and coordination of neutrophil apoptosis 
under MMF and stimuli treatments (the mechanism of roscovitine is not known). 
Several questions remain unanswered at present. In the zebrafish model of 
inflammation MMF had a protective role, i.e. increased the resolution of 
inflammation. Thereby, to support a proposal that MMF has anti-inflammatory and 
pro-resolution properties as speculated in the zebrafish work, it would be ideal to 
repeat one of the key experiments in human neutrophils, namely the resolution 
assay. It is not possible to do so in vitro but LPS could be used to induce 
inflammation and then apoptosis enhancement with MMF measured. It is worth 
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noting that anti-inflammatory effects and pro-resolving effects do not totally 
overlap. Anti-inflammation mainly describes an inhibitory action while pro-
resolving functions specify certain processes, e.g. apoptosis or efferocytosis. In 
either case, the end point is inflammation inhibition, but only pro-resolving 
mediators truly enable resolution. The mechanism of action of anti-inflammatory 
drugs inhibiting some specific pathways and pro-resolving drugs anticipated to 
start off a plethora of actions might be completely different. Therefore, there is a 
mechanistic difference between inhibiting specific mediators, which can be 
detrimental for tissue, and activating cellular processes preventing tissue 
damage. This vision has fostered the concept that pro-resolving-based therapies 
will promote both anti-inflammatory and pro-resolution actions, differing from 
traditional anti-inflammatory agents that solely inhibit key pro-inflammatory 
mediators (reviewed by (Sugimoto, Sousa, et al., 2016)). Moreover, pro-resolving 
molecules have been recently described as exerting “mild-to-moderate actions” 
(reviewed by (Perretti et al., 2015; Sugimoto, Sousa, et al., 2016)). Perhaps MMF 
is a potential resolution agent since it might have not blocked the anti-apoptotic 
actions of TNFα or GM-CSF and it caused apoptosis both in vitro in this current 
study and in vivo in my zebrafish work. Aforementioned experiment with LPS 
would confirm MMF’s pro-resolving effects in the means of enhancing apoptosis 
of inflamed neutrophils and their phagocytosis by macrophages. The 
measurement of neutrophil apoptosis should be done as before by cytospin 
analysis and efferocytosis could be quantified by the recently established anxA5- 
pHrodo tool (Stöhr et al., 2018). 
In summary, our study has shown that MMF both accelerates apoptosis of human 
neutrophils in vitro by depleting GTP and facilitates resolution of neutrophil-
dependent inflammation in vivo. The data supports the investigation of MMF as 
a potential therapeutic agent for the treatment of neutrophil mediated 
inflammatory diseases. This is import due to the fact that apoptotic neutrophil 
itself is an important anti-inflammatory stimulus to other cells involved in the 
inflammation resolution (reviewed by (Fox et al., 2010)). The in vitro data supports 
the idea that my in vivo MMF data is biologically significant and we would not 
have found this if we did not use the zebrafish model to begin with (personal 
communication with Dr Lynn Prince and Bethany Hughes).  
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The MMF manuscript was uploaded to bioRxiv preprint server three years ago. 
Here I have updated the results with in vitro data that is yet to be included in a 
new manuscript.
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Chapter 6: Overall discussion and future work 
6.1 The zebrafish model of C. neoformans infection 
There are many systems in which to study cryptococcosis. However, the main 
question or issue to be addressed when developing a model of a disease, is to 
be able to emulate the biological phenomenon of interest for a disease occurring 
in humans (reviewed by (Swearengen, 2018)). From this point of view, models of 
non-biological origin, such as computer or mathematical models, will always be 
less attractive. In vitro systems, although meaningful, will not reproduce in vivo 
conditions. Thus, for infectious diseases, animal models are generally required. 
This is due to the fact that in many cases the disease might be lethal and therefore 
human subjects cannot be used in research. In addition, a model has to be well 
characterised and understood, i.e. similarities and differences in the physiology 
between animals and humans have to be incorporated into the goals of the study 
(reviewed by (Swearengen, 2018)). Nonetheless, over the years, the zebrafish 
has come to the forefront of biomedical research including human infectious 
diseases (reviewed by (Van Der Sar et al., 2004; Sullivan and Kim, 2008; Tobin 
et al., 2012; Varela et al., 2017; Torraca and Mostowy, 2018).  
There is good conservation of the immune system between humans and 
zebrafish. The zebrafish immune system contains macrophages, neutrophils, 
lymphocytes, eosinophils, dendritic cells and NK cells (Renshaw and Trede, 
2012) and all of these are found within vertebrate immune systems. Pathogen 
sensing occurs through PRRs as in vertebrates (Jault et al., 2004).  
C. neoformans is primarily attacked through innate immune cells, especially by 
macrophages (Feldmesser et al., 2000). The study of the innate immune 
response to C. neoformans is not confounded by adaptive arm because innate 
and adaptive immune systems develop at different rates. The innate cells develop 
at day one and during the initial 4 days, the zebrafish exhibit no adaptive markers 
and does not fully develop until 3 weeks ((Herbomel et al., 1999), reviewed by 
(Sullivan and Kim, 2008)). Genome analysis shows that zebrafish share many 
orthologous genes, and even conserved synteny, with mammals. Zebrafish are 
vertebrates and thus evolutionarily closer to humans than are, for example, the 
fruit fly and the nematode, and they are easier to work with and to study than 
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mice (reviewed by (Van Der Sar et al., 2004)). The use of any model host requires 
a trade-off towards asking new experimental questions. For example, the 
zebrafish immune system is highly similar to humans (reviewed by (Lieschke and 
Trede, 2009)). However, there are differences in the adaptive immune response 
where sites of maturation differ (reviewed by (Tobin et al., 2012)) and there is 
also some evolutionary divergence in TLR signalling. In zebrafish, as opposed to 
mammals, LPS is not sensed by zebrafish TLR4 (Sepulcre et al., 2009). However, 
this does not seem an issue in the context of Cryptococcus that lacks LPS. 
Another pitfall and problem of zebrafish infection models is, for example, a lack 
of cell markers. In zebrafish there is almost a complete lack of monoclonal 
antibodies against surface markers of cells of the immune system (reviewed by 
(Van Der Sar et al., 2004)). There are distinct anatomical differences between 
zebrafish and mammals (using gills instead of lungs for gas exchange, 
haematopoiesis in the anterior kidney instead of bone marrow, lack of discernible 
lymph nodes, and a different reproductive system) (reviewed by (Tobin et al., 
2012)). Of note, I did not intend to model the likely route of human infection of a 
very low inoculum into the alveolar space but the route of infection directly related 
to the aim of studying the early events following dissemination of C. neoformans 
(Bojarczuk et al., 2016). Another drawback is that due to differential immunity 
development rates and the fact that most zebrafish work is done under the age 
of 5.2 days, there are no adaptive markers in such an infection model. Therefore 
translating data from zebrafish studies to humans is difficult, despite providing the 
opportunity and basis for a human study starting point. For instance, human 
macrophages also operate in a context with the adaptive immunity, which might 
affect my findings from my model of zebrafish cryptococcosis, i.e. it is known 
Cryptococcus is readily taken when opsonised, for example, with complement or 
antibodies (Levitz et al., 1991; Shapiro et al., 2002). In adult zebrafish, the 
infection would have been cleared due to the action of lymphocytes and 
antibodies. In fact, when I was doing preliminary grant experiments in the 
Johnston lab, I injected Cryptococcus intramuscularly into 4 week old fish (about 
200 cfu). Within 8 days there was no single fluorescent cryptococcal cell 
(Bojarczuk, unpublished). This means that in the immunocompetent, an efficient 
immune response will eliminate most of the inhaled cryptococci. Nonetheless, the 
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model is one of innate immunity to Cryptococcus and the most practical at that 
because the innate seems the most rapid and efficient response to microbial 
exposure (reviewed by (Trede et al., 2004)). The other issue is that due to the 
lack of the adaptive arm, zebrafish are exposed to environmental pathogens and 
care must be taken during husbandry. Temperature of zebrafish incubation might 
be a factor. Zebrafish and their natural pathogens exist at 28°C, whereas many 
pathogens of humans are only infectious at 37°C (reviewed by (Meeker and 
Trede, 2008)). However, since C. neoformans appears to infect such a wide 
range of animal species, with very different thermoregulation, it is likely that 
pathogenesis is not dependent of host body temperature (Malik et al., 2011). As 
reviewed here, some zebrafish limits can be turned into advantages. What has 
not been mentioned in the cryptococcal-zebrafish field is that although hundreds 
of embryos in a single day can be subjected to experiments, it is challenging to 
deal with such fragile animals. For example, on the day of Cryptococcus injection 
into embryos, hundreds of them have to be dechorionated beforehand. This is 
time-consuming. The injections into yolk sac do not produce systemic infections 
and therefore more challenging protocol had to be implemented. There is indeed 
tremendous concern about the route of infection. Local injections include the yolk 
sac, or body cavities, such as the hindbrain ventricle and otic vesicle. Other 
compartments include subcutaneous, intramuscular, or the notochord. 
Intravenous injections for establishing a rapid systemic infection are performed 
into the caudal vein blood island or duct of Cuvier (reviewed by (Torraca and 
Mostowy, 2018)). My model relies on injections into the yolk sac circulation valley, 
which also produces a systemic infection (Bojarczuk et al., 2016). This was to 
study the early events following dissemination. The pathogen administration 
route depends highly on the infection type to be achieved and the goal of a study. 
For example, hindbrain, otic vesicle or intramuscular injections allow investigating 
immune cell recruitment, whereas the notochord is inaccessible to immune cells 
(reviewed by (Torraca and Mostowy, 2018)). My analysis of host pathogen 
interactions was only possible due to zebrafish embryo transparency. This allows 
for high resolution imaging. The imaging, in turn can be done non-invasively in 
real-time enabling data collection in a fairly short time. This is the biggest 
advantage of this system as a model of experimental cryptococcosis. The whole 
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fish can be imaged and this cannot be obtained in the case of other animals. Of 
note, when possible, it is recommended to use nacre background zebrafish to 
avoid pigment interference during real-time imaging. The visual data collected 
from imaging can be translated into quantitative data. Using infected embryos 
mounted in a 96-well format for repeat imaging at various stages of infection, I 
developed a high content imaging methodology that permits a full analysis of 
cryptococcal and macrophage cell interactions during infection (Bojarczuk et al., 
2016). There were additional challenges regarding imaging and image analysis: 
mounting embryos in agar for imaging required optimising a tool for carefully 
manipulating larvae using an eyelash glued to a pipette tip (undescribed in 
(Bojarczuk et al., 2016)). Calculating and implementing the number and thickness 
of z sections, as well as how many fields of view, to capture the whole larvae took 
much optimisation to be able to collect reliable and complete data. Image analysis 
was completed manually and included a number of checks for double counting if 
cryptococci were intracellular in macrophages. 
 
Animal models became tools for research in human infectious diseases and they 
contributed substantially to unravelling the physiopathology of infection and host-
pathogen interactions. Guidance for ‘humane experimental technique’ is 
described by the UK’s National Centre for the Replacement, Refinement and 
Reduction of Animals in Research (NC3Rs), which is responsible for supporting 
animal experimentation in the UK through the application of the core principles 
termed 3Rs (reviewed by (Singh, 2012)). The NC3Rs’ strategy is to advance the 
3Rs by focusing on their scientific impacts and benefits. The NC3Rs’ objectives 
are advantages of my model. Replacement refers to methods which avoid or 
replace the use of animals. In terms of replacement alternatives it is not possible 
to replace the zebrafish with inanimate systems, such as computer simulations. 
Zebrafish already serve as relative replacements because they replace more 
sentient animals, such as higher vertebrates, and they are accepted to have a 
lower potential for pain perception. 
In regards to reduction, namely methods which minimise the number of animals 
used per experiment, the number of animals previously calculated from published 
studies (Loynes et al., 2010; Elks et al., 2011; A. L. Robertson et al., 2014) to 
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obtain sufficient data to answer the research questions. There is also a practice 
to maximise the information obtained per fish and thus a potential limit or 
avoidance of the subsequent use of additional animals. In addition, I also used 
an imaging method enabling longitudinal studies in the same animals. 
In terms of refinement, which refers to methods minimising animal suffering and 
improving welfare, I used an appropriate anaesthetic regime for pain relief. 
Tricaine was used for infection or imaging purposes. In addition, I did not cause 
much pain and suffering, which would have been caused using other models, e.g. 
mice. At the same time I could identify within-host processes that would have 
been identified in other animals with an emphasis on the identification of host-
pathogens interactions in real time, which is not possible in other models. 
The welfare of zebrafish used was assured from the time the fish were born until 
their death. Any potential adverse effects and the times of pain or distress were 
monitored by Named Animal Care and Welfare Officers (NACWOs) and aquarium 
staff. In addition, The University of Sheffield acts under the Scientific Procedures 
Act 1986.  
 
The role for modelling in supporting public health has progressively expanded 
since the first Cryptococcus isolation from a sarcoma-like lesion of a female 
patient’s tibia (Busse, 1894). Animal models have been used in experimental 
research to increase human knowledge about this pathogen. My zebrafish model 
has contributed substantially to unravelling the physiopathology of 
cryptococcosis. In regards to the publication (Bojarczuk et al., 2016), I 
demonstrated for the first time how the early interactions with macrophages 
determined the outcome of infection. I confirmed that in the zebrafish a 
phenomenon observed in mammalian infection, i.e. the polysaccharide capsule’s 
growth, is recapitulated. This change was observable between 2 and 24 hours 
post infection (hpi). Early in infection, at 2 hpi, the intracellular cryptococci had 
significantly smaller capsule radius as compared to the extracellular portion. The 
measurement was done by immunofluorescence labelling of the capsule and 
staining of the cell wall immediately prior to infection and followed by live imaging 
of injected zebrafish with labelled capsule/cell wall (Bojarczuk et al., 2016). At 24 
hpi, fixed tissue was immunolabelled. The comparison between 2 and 24 hpi 
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revealed that by 24 hpi, the  cryptococcal capsule was significantly enlarged 
(Bojarczuk et al., 2016). At 24 hpi a different technique was used as changes in 
the capsule could not be observed live in the same way, i.e. upon replication the 
staining would have been lost. However, what could be done is perform the same 
experiment and perform in vivo immunolabelling, which permits observation 
under truly physiological conditions (reviewed by (Progatzky et al., 2013)). 
Alternatively, at 24 hpi the zebrafish could be fixed and the capsule labelled. This 
would allow for measuring the size of the capsule for both intra- and extracellular 
portions in order to investigate the dynamics between those two cryptoccoal 
fractions. The next step could be also testing whether the capsule thickness 
changes once inside a macrophage in vivo. This has never been investigated in 
vivo. It is acknowledged that there are different fates following the uptake by 
macrophages (e.g. vomocytosis, lateral transfer, death), but it would be 
interesting to measure the capsule radius before a particular event occurs. In vivo 
immunolabeling and live imaging/electron microscopy could be utilised. 
   
C. neoformans is a clinically important opportunistic pathogen of humans. Here,  
I exploited a transparent zebrafish model of cryptococcosis to address 
mechanistic questions relevant to human primary immune response dynamics. 
My high-content imaging method in a zebrafish model of cryptococcosis 
(Bojarczuk et al., 2016) might have many applications to impact human health. 
For instance, it can be used in chemical screening for novel biological and 
therapeutic discovery related to cryptococcosis. Zebrafish are used for this 
purpose (A. L. Robertson et al., 2014; Wiley et al., 2017); reviewed by (Bowman 
and Zon, 2010; Rennekamp and Peterson, 2015)). A multi-well plate screen could 
point to anti-cryptococcal molecules. The whole libraries could be tested as well. 
The exemplary libraries to be tested could be Tocris Bioscience, Sigma Lopac 
and John Hopkins. They are collections of biologically active compounds that 
have proven pharmacological activity against certain targets. Thus after 
investigating fungal burdens and finding hits, the pathways involved could be 
investigated. Drug targets between zebrafish and humans are conserved 
(reviewed by (Wiley et al., 2017)). Thus, compounds screening can lead to the 
identification of candidate substances that can be further examined in pre- and 
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clinical trials to target cryptococcal infection. This could lead to therapeutics 
development. The recent work of (Kamuyango, 2017) supports this. IFNγ 
injection promoted the clearance of cryptococcal infection in a modified version 
of my model, i.e. in an intramuscular zebrafish infection model in the absence of 
T cells (Kamuyango, 2017). This suggests that IFNγ treatment could be beneficial 
in the immunocompromised. This antifungal effect was also observed in a mouse 
model of pulmonary infection with C. neoformans engineered to produce IFNγ. 
This C. neoformans strain was avirulent in mice and the Th1-type anti-
cryptococcal response was stimulated (Wormley et al., 2007). Th1 response 
induction extends mice survival (Decken et al., 1998). This is important because 
C. neoformans stimulates Th2 response, which is not protective in mice (Wiesner 
et al., 2015). In contrast, in vitro, treatment with IFNγ results in no change in 
fungistatic capacity (Voelz et al., 2009). This clearly emphases that the use of the 
animal model is better suited for observing the overall effects. However, despite 
a wide range of advantages in using mice, the zebrafish offers significant 
advantages over higher vertebrates such as rapid development, ease of imaging 
in real time, fast procreation and cost benefits. This enables a significant progress 
in a project.  This means that zebrafish provides a variety of advantages including 
the identification of disease-modifying molecules (reviewed by (Gehrig et al., 
2018)). 
Testing a range of compounds could be done using the yolk sack infection model 
to represent a disseminated infection. For example, TLR agonists could be 
tested. This would be seen as a drug treatment (by injection or dissolve in E3 
water). Some were tested by (Kamuyango, 2017) and yielded good results. The 
idea would be to initiate the immune response and enhance phagocytosis. It is 
known that an opsonic phagocytosis in the presence of an antibody is the most 
effective in the clearance of the pathogen (Levitz et al., 1991; Shapiro et al., 
2002). Complement works well as an opsonin when there is no antibody (Levitz 
and Tabuni, 1991) but phagocytosis could be enhanced by the presence of TLR 
agonists when antibodies are not included. I would use the zebrafish model 
without the adaptive immunity and thus no antibodies involvement. If we could 
enhance the innate response to confine Cryptococcus, the chances for quicker 
clearance would increase. The innate responses are recognised to occur first as 
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there will be, for example, circulating neutrophils and tissue macrophages that 
would have the first interactions. Adaptive responses will take more time, but if 
Cryptococcus is the pathogen, for which there is immune memory, the reaction 
will be quick as it will match to a circulating antibody and trigger a large response. 
If the immune system is naïve to Cryptococcus, it will take longer as, for example,  
antigen presentation in lymph nodes has to take place. In both cases, naïve and 
experienced immunity, the enhancement of innate responses is beneficial. This 
means that details of appropriate immunostimulation can be identified that could 
be advantageous in improving the outcome of cryptococcosis and will lead to 
cryptococcal clearance. 
The model can be pushed forward and modified. An adult model of cryptococcal 
infection can be developed. Due to a wide range of zebrafish transgenic lines 
availability, it would be possible to investigate adaptive responses and innate-
adaptive crosstalk against the pathogen. Many projects could arise from the adult 
system. Although mice data relate to the adaptive immunity, mice cannot be 
imaged in vivo in real time to show host–pathogen interactions. The new adult 
zebrafish model could utilise localised injections in the swim bladder. The swim 
bladder is highly similar in structure and the precursor to the mammalian lung 
(Robertson et al., 2007; Winata et al., 2009). The bronchial epithelial cells of the 
upper airway and the alveolar epithelial cells of the lower airway are likely to be 
the first host cells that Cryptococcus engage with (reviewed by (Taylor-Smith, 
2017)). Given that this pathogen involves the lungs and clinical manifestations 
range from asymptomatic pneumonia to severe acute respiratory distress 
syndrome (ARDS) (Pappas, 2001; Orsini et al., 2016), it would be worth 
establishing an adult model of this organ infection to show similarities between 
swim bladder cryptococcosis in the transparent zebrafish and cryptococcal 
infection at the mammalian epithelium. This work could involve NF-κB activation, 
induction of NF-κB-dependent pro-inflammatory genes and an investigation into  
whether neutrophils or macrophages protect against death in the adult zebrafish 
swim bladder infection. This would examine the roles of particular cell types and 
molecular pathways involved in protection against Cryptococcus.  Pulmonary 
involvement is not only one of the characteristics of cryptococcosis. There is also 
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CNS involvement, which is the cause of the greatest mortality among patients. 
Raised intracranial pressure in cryptococcal meningitis seen in patients is thought 
to be responsible for the high mortality of this group. Moreover, the disruption of 
blood brain barrier (BBB) and choroid plexus (CP) has been proposed as a 
mechanism for the raised intracranial pressure (Loyse, Wainwright, et al., 2013). 
Thus, it would be of interest to establish a model of cryptococcal meningitis (CM). 
This would have to be done in unprotected zebrafish as the hindbrain is more 
accessible for injections. In fact, I was involved in the creation of a transgenic 
zebrafish model for the in vivo study of the blood and choroid plexus brain barriers 
using claudin 5. The gene claudin 5a is the zebrafish orthologue highly expressed 
in the BBB and CP barriers and demonstrates the conservation of the BBB and 
CP between humans and zebrafish (Van Leeuwen et al., 2017). Thus, there is a 
tool to investigate CM at many angles, e.g. to answer the question whether 
cryptococcal cell and capsule interactions with blood brain barrier and choroid 
plexus correlate with the pathology of CM. This would be to identify potential new 
therapies for cryptococcal meningitis that will reduce intracranial pressure. 
Another idea as to how my model can be used to impact human health is to show 
a protective activation of T cells including CNS. I proved in the zebrafish model 
that macrophages alone cannot clear cryptococcal infection in vivo (Bojarczuk et 
al., 2016). This was shown in mice (Wozniak et al., 2011), which supports the 
zebrafish utility. At the same time no research to date has investigated how 
cryptococci are cleared in a healthy immune system, when lymphocytes are 
involved. Therefore, I would propose an adult model of infection. For instance, by 
using Tg(cfms:GFP)sh377 (Dee et al., 2016) (labelling macrophages with GFP) and 
injecting C. neoformans strain, KN99 mCherry, could demonstrate how 
cryptococci are cleared. Indeed, my unpublished, preliminary data demonstrated 
that AB adult zebrafish, from 4 weeks post fertilisation, efficiently clear a somite 
infection with C. neoformans using a relatively small dose of 150 cells. This would 
be exactly the same experiment I performed in (Bojarczuk et al., 2016) or in this 
thesis with R265 GFP14. To investigate the cross-talk between lymphocytes and 
macrophages as well as cryptococcoci, a cross between Tg(cd4-1:mCherry) 
(Dee et al., 2016) and Tg(cfms:GFP)sh377 (Dee et al., 2016) could be done. I would 
be interested in tracking T helper cells during cryptococcal infection, as they are 
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important in immunity. When their pool becomes depleted, e.g. due to HIV 
infection or in a result of immunosuppression, the host is susceptible to infections. 
I would be also interested in tracing macrophages as their role is significant, 
which was highlighted in this thesis many times. CD4 mcherry labels both T-cells 
and CD4+ expressing macrophages but in the case of the resulting line, 
macrophages will be labelled by cfms+CD4+ and cfms+CD4-. There will be also 
CD4+cfms- that correspond to T helper cells, cfms+ (macrophages/ 
monocyte/DCs) and a proportion of the CD4- cfms-. The issue might be the choice 
of cryptococcal strain to be used as so far in the planned experiment would 
involve GFP or mCherry cell population. Since the available cryptococcal strains 
are also labelled with GFP or mCherry, the work would involve, for example, 
turquoise strain generation using the Tol2 Kit Gateway system (Kwan et al., 
2007). To conclude, zebrafish offer a unique opportunity to study the mechanisms 
of immunity to infection using non- invasive in vivo imaging of fluorescent immune 
system markers/reporters. To date, this has been performed almost exclusively 
in larval models of innate immunity. However, my preliminary data on adult 
zebrafish demonstrate that imaging host and pathogen interactions in adult 
zebrafish during cryptococcal infection is highly tractable. 
To summarise, I provided an animal model creating an indispensable tool for 
basic and applied research to enable study of disease development in vivo. My 
model has benefitted other projects in the Johnston lab. For example, it was used 
by three BMedSci students; i. e. Richard Hotham, Rory Gibson and Katherine 
Miller. Their theses are not published and hence not cited in this section. The 
model was used by Richard Hotham, a co-author of (Bojarczuk et al., 2016) and 
(Gibson et al., 2018) to show dissemination of cryptococci to the swim bladder, 
somites and brain. It also formed a basis for work on mycophenolate mofetil 
(MMF). This work was further carried on by another BMedSci student, Rory 
Gibson and resulted in a pre-printed publication (Gibson et al., 2018). The model 
was also used by Katherine Miller, who worked on the capsule with the 
hypothesis that its increased size in vitro will result in an increased susceptibility 
to infection in zebrafish due to a decrease in rate of phagocytosis. This is 
published in (Bojarczuk et al., 2016). The model was used by a number of former 
PhD students in the Johnston lab, too. For example, Dr Josie Gibson used my 
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model to investigate autophagy (Gibson, 2017). She also used it in a pre-printed 
publication, wherein I am a second author. This was to investigate blood vessel 
occlusion by C. neoformans (Gibson et al., 2020). Next, Dr Hamid Fehri used my 
initial imaging data sets to develop automatic algorithms that can analyse 
different types of cells and their relations in the image to increase analysis 
efficiency (Fehri, 2018). My model was also exploited in collaborative projects to 
address perplexing questions relating to this pathogen. For instance, we found 
that reducing the extracellular receptor kinase ERK5 activity in vivo stimulates 
vomocytosis and results in reduced dissemination of infection (Gilbert et al., 
2017). Next, Dr Robert Evans found that prostaglandin E2 was sufficient to 
promote growth of Δplb1 and Δlac1 independent of host PGE2 production, in vitro 
and in vivo in zebrafish (Evans et al., 2019). The model has also been optimised 
for high-throughput drug screening (unpublished, Christopher Donaldson, PhD 
student) or to mimic the mechanisms that cause this increase in intracranial 
pressure (unpublished, Jacqui Chalakova, PhD student).  
A fungal infection in vivo model and above all, the high-resolution imaging of the 
whole animal in understanding immune cell behaviour during animal infection, is 
the novelty that can provide an excellent contribution in helping to prevent and 
treat cryptococcal disease. Hopefully, these findings will go towards widening our 
understanding of this pathogen and how it causes disease to ultimately improve 
therapy in humans. These data would not have been found in higher vertebrates, 
e.g. mice due to real-time imaging limitations. Some of these data could have 
been found in cell lines. For instance, vomocytosis of C. neoformans and C. gattii 
expulsion was reported in macrophages cell lines (Alvarez and Casadevall, 2006; 
Ma et al., 2006; Alvarez et al., 2008), primary murine macrophages (Alvarez and 
Casadevall, 2006), primary birds macrophages (Johnston et al., 2016) and 
primary human macrophages (Alvarez and Casadevall, 2006; Alvarez, et al., 
2009). However, given that pathogen’s behaviour in vitro and in vivo might be 
different due to incorporation of the host-pathogen interaction, in vivo work is 
required. This is to show recapitulation of in vitro established physiopathological 
events or to find new behavioural differences. Having the zebrafish model, which 
interlocks vertebrate immunity, ease of imaging and genetic tractability, makes 
the research on cryptococcosis possible to expand. C. neoformans work 
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including the model (Bojarczuk et al., 2016) was published in Scientific Reports 
and describes the complex interplay between the host and pathogen. A critical 
challenge will be to develop novel treatments. This requires a better 
understanding of both host-pathogen interplay and a relationship of the model to 
the human disease termed cryptococcosis. Thus, the future work was proposed. 
6.2 Assessment of Cryptococcus gattii virulence in zebrafish and mice 
 
The experiments in my study aimed to determine the virulence of C. gattii R265 
wt, which has recently emerged as a pathogen of immunocompetent individuals. 
This strain is a clinical isolate from an ongoing outbreak on Vancouver Island 
(VIO) (Kidd et al., 2004). Previous work has shown VIO C. gatti strains survive 
and replicate in vitro in macrophages at a greater rate than non-outbreak strains 
and their ability to replicate in macrophages is associated with virulence in a 
mouse model of infection (Voelz et al., 2014). Previous studies have also 
demonstrated that VIO type strain R265 wt and its transgenic insertion mutant 
R265 GFP14 show normal growth in macrophages in vitro (Voelz et al., 2010). 
However, despite a large body of work conducted in vitro and in mice on R265, 
the mechanism underlying its pathogenicity, growth requirements and 
mechanism of infection remained unknown. To identify the utility of zebrafish to 
study C. gattii virulence, first C. gattii R265 wt and C. neoformans KN99 wt were 
compared side by side. A series of survival experiments gave interesting findings 
including that GFP insertion to R265 had an effect on virulence as R265 GFP14 
was attenuated when compared to its isogenic strain R265 wt. This was also 
confirmed in mice. Interestingly, R265 GFP14 grew worse than R265 wt in the 
mammalian lungs. It is generally accepted that the primary target organ for C. 
gattii is the lungs (Ngamskulrungroj, Chang, Sionov, et al., 2012). As mentioned 
in Chapter 4 Discussion, the serial analysis of gene expression (SAGE) analysis 
and phagocytosis data of (Fan et al., 2005) suggest that Cryptococcus displays 
different metabolic profiles depending on the experimental settings. Different 
profiles are obtained during in vivo or in vitro infections. This means that in vivo 
and in vitro conditions might exert different energy acquisition modes. Here  
I hypothesise that during cryptococcosis in mice used in this thesis, R265 wt 
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might have performed the TCA whereas R265 GFP14 might have not. Although 
the secretions from respiratory airways have a very low glucose concentration in 
healthy individuals (<0.05 mM) (<0.00009 %) (Philips et al., 2003), the presence 
of glucose cuases in Crabtree-negative fungi to up-regulate the pyruvate 
dehydrogenase complex, i.e. most of the carbon flows into the Krebs cycle 
(reviewed by (Ene et al., 2014)). Some tags for function in the TCA cycle are 
elevated in the SAGE analysis on C. neoformans cells recovered from lungs of 
infected mice (Hu et al., 2008). Therefore, to prove the TCA functioning during 
R265 wt infection in mice used in my study, I would infect the animals with R265 
wt and R265 GFP14, isolate RNA and perform SAGE on cells recovered from the 
lungs. I would specifically look at the following SAGE tags for genes encoding 
predicted functions in the TCA (aconitase, succinate dehydrogenase, malate 
dehydrogenase, isocitrate dehydrogenase, malic enzyme, fumarase) (Hu et al., 
2008). I propose to investigate these genes described for C. neoformans by (Hu 
et al., 2008) because C. gattii would have these genes (D’Souza et al., 2011). 
Alternatively, qPCR could be done to check the expression of those genes.  
I would do the same experiment for cells recovered from the PM1 microarray 
assay run in the settings described using methodology described Chapter 2. This 
would confirm if R265 wt in the phenotypic array performed the TCA cycle. 
Another experiment with the same objective would be to employ a TCA cycle 
metabolism assay. 
In the phenotypic array, it became apparent that there was less signal for the 
glucose well. The well had less colour change for R265 wt than for R265 GFP14. 
Therfore, one could ask if R265 wt performed glycolysis. Apart from the 
experiments proposed in Chapter 4 discussion regarding that issue, I would 
suggest SAGE on cells recovered from PM1 assay. I would specifically focus on 
the following SAGE tags for genes encoding predicted functions in glycolysis: 
fructose 1,6-biphosphate aldolase, phosphofructokinase, hexokinase, enolase, 
glucose-6-phosphate isomerase, phosphoglycerate mutase (Hu et al., 2008). 
Alternatively, qPCR could be done.  
However, it is possible that in my PM1 assay, the cells were nutrient-starved. In 
response to nutrient starvation, Candida albicans shifts from glycolysis to 
gluconeogenesis (Mayer et al., 2013). Perhaps R265 wt shifts too and NADH 
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elevation cannot be observed since gluconeogenesis is anabolic. Thus I would 
also apply the SAGE with an attention to phosphoenolpyruvate carboxykinase 
(PCK1) (Hu et al., 2008) or qPCR. 
The respirometry work performed by Dr Gourlay (unpublished) suggested that 
R265 wt is less efficient at obtaining ATP from oxidative phosphorylation. It is not 
known whether R265 wt in my metabolic array performed oxidative 
phosphorylation or the strain relies on fermentation. To answer these questions, 
the following test could be run. The strains (R265 wt and R265 GFP14) should 
be grown on non-fermentable media, e.g. yeast extract peptone glycerol 
(Turcotte et al., 2010) agar (YPGA) versus yeast extract peptone dextrose agar 
(YPDA) as a control. Potassium cyanide and SHAM should be added to the 
plates. The former blocks the classical respiration but might induce alternative 
oxidase. Thus SHAM should be added (Duvenage et al., 2019). If a strain relies 
mostly on fermentation and does not use oxidative phosphorylation much, then it 
would grow poorly on YPGA in the presence of ETC drugs. 
The alternative oxidase function in both strains (R265 wt and R265 GFP14) and 
how it contributes to the overall respiration still remains unresolved. The 
respirometry conducted by Dr Gourlay showed resistance to Aox inhibition by 
SHAM which might suggest that Aox levels are very high in R265 wt. In 
discussion in Chapter 4, I proposed AOX1 gene knock-out to confirm this. 
However, this could also be done with knock-down of AOX1. Respirometry should 
then be done including both knock-out/knock-down and R265 wt, other VIO 
strains (Voelz et al., 2014), R265 GFP14 and other GFP strains generated by 
(Voelz et al., 2010). This could be also done by immunoblotting (Western blot) 
with the strains listed above. To find out whether the same alternative oxidase 
phenotype occurs in the PM1 assay, R265 wt and R265 GFP14 as well as aox1 
mutants, other VIO strains (Voelz et al., 2014) and other GFP strains in R265 
background (Voelz et al., 2010) should be run in the metabolic assay. Then cells 
recovered from the hit wells described in Chapter 4’s Result section should be 
tested by immunoblotting and these results compared to Western blot 
respirometry results. As suggested, R265 metabolic profile might be flexible 
depending on the in vivo or in vitro conditions and nutrients provided. However, I 
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hypothesise that even in vitro results might vary depending on nutrients provided. 
The respirometry includes YPD with 2% glucose (111 mM) (Duvenage et al., 
2019) whereas glucose in PM1 procedure is at 0.4% (22 mM) (personal 
communication with Biolog). Thus, this well should be included in the experiment 
for alternative oxidase profiling. The concentration of substrates as the sole 
source of carbon remains unknown, although within the range of 2-20 mM 
(personal communication with Biolog). It might be that the respirometry profile 
changes depending on the nutrient and its concentration.  
The fact that SHAM effectively inhibits the Aox1 in R265 wt suggests the 
alternative respiration pathway is still functional. However, it is not known whether 
alternative respiration is prevalent in the respirometry or in my PM1 assay. It is 
not known whether the fungus switches to alternative respiration or fermentation.  
It is not clear whether C. gattii favours alternative respiration over fermentation 
and vice versa. Indeed, I speculated in the results in Chapter 4 that R265 wt might 
ferment and as mentioned above it is resistant to alternative oxidase inhibition. A 
lot of questions could be raised, e.g. if fermentation takes place, can alternative 
respiration and the Krebs cycle co-exist? A problem is that even in  
S. cerevisiae the interface between glycolysis and the TCA is not fully defined 
(van Rossum et al., 2016). The following diagram represents cellular respiration 
(Figure 6.1).






Figure 6.1 A simplified diagram of cellular respiration. I, II, III, IV and V 
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The case is complicated as yeast cells have to have Krebs (or some partial Krebs 
cycle) activity. Yeast cells that are just fermenting or have no mitochondrial DNA 
should still run the Krebs cycle to support production of, for example, metabolites 
and certain amino acids. At the same time, the respirometry suggests that R265 
wt must get ATP from another mechanism and so it is likely to be fermenting 
(communication with Dr Gourlay). Therefore, experiments to investigate 
fermentation phenotype would confirm whether R265 wt is able to ferment. 
Actually, this could also be confirmed by measuring pyruvate and ethanol. If the 
final product from glucose is pyruvate, then glycolysis is successful. If the final 
product is ethanol, then this indicates fermentation. Concomitantly, investigation 
of the genes that should be upregulated if Krebs cycle occurs would indicate if 
R265 wt or R265 GFP14 runs the cycle. In addition, AOX1 expression would also 
inform if the yeast switches to the alternative respiration mode and thereby 
produces less energy. All options are possible because Cryptococcus has broken 
out of the opportunistic box and has become a primary pathogen of humans. 
The analysis of macrophages-cryptococci interactions assayed in the zebrafish 
model of cryptococcosis (Bojarczuk et al., 2016) was performed using R265 
GFP14. This was done to evaluate how the strain was attenuated. It is clear that 
R265 wt should be investigated above all. This is the VIO outbreak strain and 
therefore one could argue this should be done primarily. Unfortunately, this strain 
is not fluorescent and all analysis from macrophage data set would be very 
difficult. In contrast, in (Bojarczuk et al., 2016), the data was obtained using H99 
GFP strain. This was possible because I ensured there was a match in the 
zebrafish survival between non-fluorescent and fluorescent strain in terms of 
virulence before proceeding with fluorescent strain experiments (unpublished). 
Since the R265 GFP14 has an altered genome (32 kb deletion) as compared to 
the parental strain, other transformants created at the time of R265 GFP14 
generation (Voelz et al., 2010) should be genome sequenced. If there is one that 
does not have an altered genome, it should be used in macrophages-cryptococci 
interactions assay.  
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To summarise, I discovered there are six genes related to R265 wt virulence, 
which could be exploited to target infection. Of note, if R265 GFP14 will ever be 
studied in the mammalian host, the researchers should be aware that the 
conclusions drawn from their studies will not be representative for its isogenic 
strain, R265 wt. My C. gattii work will be publishable upon completion of proposed 
experiments in the discussion section relating to Chapter 4 of my thesis. 
6.3 Mycophenolate mofetil (MMF) increases inflammation resolution in 
zebrafish via neutrophil apoptosis 
I demonstrated that MMF reduces the number of neutrophils in zebrafish during 
an inflammatory insult. Despite previously unexplained mechanism of action in 
the means of neutrophils, MMF has been prescribed in inflammatory conditions. 
The examples include: sarcoidosis (Kouba et al., 2003), inflammatory eye 
disease (Thorne et al., 2005; Hornbeak and Thorne, 2015), pulmonary fibrosis 
(Tzouvelekis et al., 2011) or systemic lupus erythematosus (Pisoni et al., 2005). 
MMF is also promising in the interstitial lung disease (Fischer et al., 2013). 
Neutrophils are implicated in the pathology of many diseases, e.g. chronic 
obstructive pulmonary disease (reviewed by (Hoenderdos and Condliffe, 2013)), 
rheumatoid arthritis (reviewed by (Cecchi et al., 2018)) or Behçet’s disease 
(Rifaioglu et al., 2014). Given, that neutrophil products are involved in the tissue 
damage seen in a range of inflammatory diseases, in a range of organs, including 
the lung (Haslett, 1999), MMF could be beneficial in neutrophil-related 
inflammatory diseases, e.g. in chronic obstructive pulmonary disease(COPD). 
Clinical trials comparing azathioprine (AZA) and MMF have been conducted on 
patients with lung allograft (Palmer et al., 2001) and estimated MMF efficacy was 
similar to AZA. However, those trials have never been performed in patients 
without grafting factor. Only such trials would estimate MMF efficacy in COPD 
and other related neutrophilic diseases. 
What emerges from this project is that the zebrafish model of inflammation 
(Renshaw et al., 2006) enables not only the study of pharmaceutical agents 
modulating inflammation (Loynes et al., 2010) but testing immunosuppressants 
on their role on neutrophils. It would be interesting to test other 
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immunosuppressive drugs used in inflammation, e.g. cyclophosphamide. This 
immunosuppressant is used in scleroderma lung disease (Kowal-Bielecka et al., 
2005). For instance cyclophosphamide reduces the neutrophilic component in 
idiopathic pulmonary fibrosis (O’Donnell et al., 1987). Cyclophosphamide is used 
post transplantation and is able to induce apoptosis in T cells (Al-Homsi et al., 
2015) but its mechanism is not well described in the literature, especially in the 
context of modulating neutrophils it is not clear.  
To summarise, MMF is used for a wide range of autoimmune and inflammatory 
conditions, but little was known about its direct effects on neutrophils. This could 
broaden the drug’s use influencing public health.  
MMF manuscript (Bojarczuk and Johnston, 2017) was revised in The Journal of 
Immunology in 2017 and reviewers gave favourable reports, but raised some 
critical points that will require amendments to the manuscript. We are now in the 
process of making amendments. 
6.4 Thesis summary 
I developed a model of zebrafish model of cryptococcosis (Bojarczuk et al., 2016).  
I have shown that both host and pathogen factors, important in immunity and 
virulence can be identified using this model. The model was also well suited to 
expand on the virulence of VIO strain, R265. I have identified that a transgenic 
insertion mutant of the VIO type strain R265 (R265GFP14) cannot be a 
representative of R265 wt as it has 32 kb deletion resulting in the loss of six genes 
important in zebrafish and mice virulence. R265 wt and R265 GFP14 differ 
significantly in terms of pathogenesis and metabolism. This suggests the 
virulence of R265 wt lies in the genes deleted in R265 GFP14 and they could be 
exploited to target infection.  
The study on susceptibility to cryptococcal infection in my model of 
cryptococcosis (Bojarczuk et al., 2016) with an immunosuppressant 
mycophenolate mofetil (MMF) (Gibson et al., 2018) led to MMF testing in 
inflammation set up (Renshaw et al., 2006). This confirmed that MMF is a potent 
anti-inflammatory agent and I revealed its mechanism of action on neutrophils 
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through apoptosis. I proved that zebrafish are an effective system to study 
Cryptococcus invasiveness and a great tool to immunosuppressant testing. 




Table 4.2 Sidak’s multiple comparisons test with D-xylose 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 0.0004 
15 >0.9999 585 0.0002 
30 >0.9999 600 0.0001 
45 0.9748 615 0.0007 
60 >0.9999 630 <0.0001 
75 0.9025 645 <0.0001 
90 0.9991 660 0.003 
105 0.321 675 <0.0001 
120 0.5795 690 0.0001 
135 0.1971 705 <0.0001 
150 0.4865 720 <0.0001 
165 0.0634 735 0.0003 
180 0.0634 750 <0.0001 
195 0.0089 765 0.0001 
210 0.0465 780 <0.0001 
225 0.0043 795 <0.0001 
240 0.0021 810 0.0014 
255 0.0245 825 0.9998 
270 0.0339 840 0.1971 
285 0.0176 855 0.0855 
300 0.0855 870 >0.9999 
315 0.0089 885 0.0062 
330 0.0004 900 <0.0001 
345 0.0004 915 <0.0001 
360 0.0014 930 0.947 
375 0.0125 945 >0.9999 
390 0.0014 960 <0.0001 
405 0.0176 975 <0.0001 
420 0.0043 990 >0.9999 
435 0.0125 1005 <0.0001 
450 0.0004 1020 >0.9999 
465 <0.0001 1035 >0.9999 
480 0.0001 1050 0.9991 
495 0.001 1065 0.1143 
510 <0.0001 1080 <0.0001 
525 <0.0001 1095 <0.0001 
540 <0.0001 1110 <0.0001 
555 0.001 1125 <0.0001 
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Table 4.2 (continued) 
1140 <0.0001 1710 0.001 
1155 <0.0001 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 <0.0001 1755 0.0004 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 0.0021 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 <0.0001 1830 0.0014 
1275 <0.0001 1845 0.0004 
1290 <0.0001 1860 0.0001 
1305 0.0001 1875 0.0002 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 0.0014 
1380 <0.0001 1950 0.001 
1395 0.0003 1965 0.0002 
1410 <0.0001 1980 0.0043 
1425 <0.0001 1995 0.0007 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 0.0007 
1500 <0.0001 2070 0.0021 
1515 0.0001 2085 0.1971 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 0.0634 
1560 <0.0001 2130 0.003 
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Table 4.3 Sidak’s multiple comparisons test with D-mannose 
 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 0.054 
15 >0.9999 585 0.5519 
30 >0.9999 600 0.0053 
45 >0.9999 615 0.2019 
60 >0.9999 630 0.0004 
75 >0.9999 645 0.0002 
90 >0.9999 660 0.1075 
105 >0.9999 675 0.001 
120 >0.9999 690 0.012 
135 >0.9999 705 0.012 
150 >0.9999 720 0.012 
165 >0.9999 735 0.5519 
180 >0.9999 750 0.5519 
195 >0.9999 765 0.2019 
210 >0.9999 780 0.0002 
225 >0.9999 795 0.0259 
240 >0.9999 810 0.0259 
255 >0.9999 825 0.5519 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.2019 
315 >0.9999 885 <0.0001 
330 0.5519 900 <0.0001 
345 0.9187 915 <0.0001 
360 0.9855 930 0.0002 
375 0.5519 945 >0.9999 
390 0.9187 960 <0.0001 
405 0.999 975 <0.0001 
420 0.9855 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 0.012 1020 >0.9999 
465 0.0259 1035 >0.9999 
480 0.3511 1050 0.0053 
495 0.7636 1065 <0.0001 
510 0.1075 1080 0.0002 
525 <0.0001 1095 <0.0001 
540 0.0023 1110 <0.0001 
555 0.054 1125 0.0004 
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Table 4.3 (continued) 
1140 <0.0001 1710 <0.0001 
1155 0.001 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 0.0004 1755 <0.0001 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 <0.0001 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 <0.0001 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.4 Sidak’s multiple comparisons test with tricarbalyllic acid 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 0.2391 570 0.999 
15 0.0025 585 0.7913 
30 0.0174 600 0.999 
45 0.6967 615 0.9998 
60 0.8704 630 0.9998 
75 0.0507 645 0.929 
90 0.2391 660 0.987 
105 0.0709 675 >0.9999 
120 0.0981 690 >0.9999 
135 0.134 705 0.3958 
150 0.7913 720 0.987 
165 0.0709 735 0.987 
180 0.987 750 >0.9999 
195 0.0709 765 0.999 
210 0.1804 780 0.987 
225 0.929 795 0.3958 
240 0.5941 810 0.9666 
255 0.929 825 <0.0001 
270 0.6967 840 <0.0001 
285 0.999 855 <0.0001 
300 0.9666 870 <0.0001 
315 0.9666 885 <0.0001 
330 0.7913 900 <0.0001 
345 0.929 915 <0.0001 
360 0.7913 930 <0.0001 
375 0.3109 945 <0.0001 
390 0.5941 960 <0.0001 
405 >0.9999 975 <0.0001 
420 0.9959 990 <0.0001 
435 0.999 1005 <0.0001 
450 0.929 1020 <0.0001 
465 >0.9999 1035 <0.0001 
480 >0.9999 1050 <0.0001 
495 0.999 1065 <0.0001 
510 0.0358 1080 0.0251 
525 0.3958 1095 0.0037 
540 0.3958 1110 <0.0001 
555 0.999 1125 0.0017 
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Table 4.4 (continued) 
1140 <0.0001 1710 <0.0001 
1155 0.0011 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 <0.0001 1755 <0.0001 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 <0.0001 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 <0.0001 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.5 Sidak’s multiple comparisons test with L-lyxose 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 0.0013 570 <0.0001 
15 <0.0001 585 <0.0001 
30 <0.0001 600 <0.0001 
45 <0.0001 615 0.0001 
60 <0.0001 630 <0.0001 
75 <0.0001 645 <0.0001 
90 <0.0001 660 <0.0001 
105 <0.0001 675 <0.0001 
120 <0.0001 690 <0.0001 
135 <0.0001 705 <0.0001 
150 <0.0001 720 <0.0001 
165 <0.0001 735 <0.0001 
180 <0.0001 750 0.0042 
195 <0.0001 765 <0.0001 
210 <0.0001 780 <0.0001 
225 <0.0001 795 <0.0001 
240 <0.0001 810 <0.0001 
255 <0.0001 825 >0.9999 
270 <0.0001 840 >0.9999 
285 <0.0001 855 >0.9999 
300 <0.0001 870 >0.9999 
315 <0.0001 885 >0.9999 
330 <0.0001 900 >0.9999 
345 <0.0001 915 >0.9999 
360 <0.0001 930 >0.9999 
375 <0.0001 945 >0.9999 
390 <0.0001 960 >0.9999 
405 <0.0001 975 >0.9999 
420 <0.0001 990 >0.9999 
435 <0.0001 1005 >0.9999 
450 <0.0001 1020 >0.9999 
465 <0.0001 1035 >0.9999 
480 <0.0001 1050 >0.9999 
495 <0.0001 1065 >0.9999 
510 <0.0001 1080 <0.0001 
525 <0.0001 1095 <0.0001 
540 <0.0001 1110 <0.0001 
555 <0.0001 1125 <0.0001 
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Table 4.5 (continued) 
1140 <0.0001 1710 0.8743 
1155 <0.0001 1725 0.1516 
1170 <0.0001 1740 0.4651 
1185 <0.0001 1755 >0.9999 
1200 <0.0001 1770 0.8199 
1215 <0.0001 1785 >0.9999 
1230 <0.0001 1800 0.1516 
1245 <0.0001 1815 0.9724 
1260 <0.0001 1830 >0.9999 
1275 0.0003 1845 >0.9999 
1290 0.0001 1860 0.9724 
1305 <0.0001 1875 >0.9999 
1320 <0.0001 1890 0.2295 
1335 <0.0001 1905 0.9938 
1350 <0.0001 1920 0.8743 
1365 0.0013 1935 >0.9999 
1380 0.0042 1950 >0.9999 
1395 0.1516 1965 >0.9999 
1410 0.0018 1980 >0.9999 
1425 0.0056 1995 >0.9999 
1440 0.0002 2010 >0.9999 
1455 0.0056 2025 >0.9999 
1470 0.013 2040 0.9992 
1485 0.0024 2055 >0.9999 
1500 0.0099 2070 >0.9999 
1515 0.3343 2085 >0.9999 
1530 0.013 2100 0.9502 
1545 0.013 2115 >0.9999 
1560 0.1873 2130 >0.9999 
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Table 4.6 Sidak’s multiple comparisons test with D, L-malic acid 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 0.0051 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.0569 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 0.0002 
375 >0.9999 945 >0.9999 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 0.0003 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 0.0323 
540 >0.9999 1110 0.0051 
555 >0.9999 1125 0.0097 
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Table 4.6 (continued) 
1140 0.3858 1710 <0.0001 
1155 0.0569 1725 <0.0001 
1170 0.0007 1740 <0.0001 
1185 0.0007 1755 <0.0001 
1200 0.0003 1770 <0.0001 
1215 0.0003 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 0.0007 1815 <0.0001 
1260 <0.0001 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 0.0014 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.7 Sidak’s multiple comparisons test with bromosuccinic acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 0.8885 
240 >0.9999 810 >0.9999 
255 >0.9999 825 <0.0001 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 <0.0001 
315 >0.9999 885 <0.0001 
330 0.8885 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 <0.0001 
375 >0.9999 945 <0.0001 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 <0.0001 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 <0.0001 
465 >0.9999 1035 <0.0001 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 <0.0001 
510 0.8885 1080 0.465 
525 0.8885 1095 0.142 
540 >0.9999 1110 0.0005 
555 0.9602 1125 0.0536 
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Table 4.7 (continued) 
1140 0.6195 1710 <0.0001 
1155 0.8885 1725 <0.0001 
1170 0.0002 1740 <0.0001 
1185 0.0183 1755 <0.0001 
1200 0.0104 1770 <0.0001 
1215 0.0032 1785 <0.0001 
1230 0.0104 1800 <0.0001 
1245 0.0536 1815 <0.0001 
1260 0.0536 1830 <0.0001 
1275 0.0058 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 0.0885 1875 <0.0001 
1320 0.0017 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 0.0001 1920 <0.0001 
1365 0.0032 1935 <0.0001 
1380 0.0058 1950 <0.0001 
1395 0.0001 1965 <0.0001 
1410 0.0005 1980 <0.0001 
1425 0.0001 1995 <0.0001 
1440 0.0001 2010 <0.0001 
1455 0.0005 2025 <0.0001 
1470 0.0058 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.8 Sidak’s multiple comparisons test with L-asparagine 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 0.9997 585 >0.9999 
30 0.9987 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 0.8342 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 0.9955 765 0.9987 
210 >0.9999 780 0.9997 
225 >0.9999 795 0.7578 
240 >0.9999 810 0.9876 
255 >0.9999 825 0.9876 
270 >0.9999 840 0.3281 
285 >0.9999 855 0.0018 
300 >0.9999 870 0.9987 
315 >0.9999 885 0.0074 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 0.6712 
375 >0.9999 945 >0.9999 
390 0.9997 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 0.4897 
495 >0.9999 1065 0.4048 
510 >0.9999 1080 <0.0001 
525 0.9955 1095 <0.0001 
540 0.9997 1110 <0.0001 
555 >0.9999 1125 <0.0001 
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Table 4.8 (continued) 
1140 <0.0001 1710 0.0006 
1155 <0.0001 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 <0.0001 1755 0.0002 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 0.0001 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 <0.0001 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 <0.0001 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.9 Sidak’s multiple comparisons test with sucrose 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 0.4577 
15 >0.9999 585 0.0326 
30 >0.9999 600 0.8108 
45 >0.9999 615 0.6398 
60 >0.9999 630 0.0087 
75 >0.9999 645 >0.9999 
90 >0.9999 660 0.9839 
105 >0.9999 675 0.3009 
120 >0.9999 690 0.9982 
135 >0.9999 705 0.0603 
150 >0.9999 720 0.3009 
165 >0.9999 735 >0.9999 
180 >0.9999 750 0.6398 
195 0.4577 765 0.4577 
210 >0.9999 780 0.4577 
225 >0.9999 795 0.1079 
240 >0.9999 810 >0.9999 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 0.3009 900 >0.9999 
345 0.9839 915 >0.9999 
360 0.9839 930 >0.9999 
375 0.9295 945 >0.9999 
390 0.6398 960 >0.9999 
405 >0.9999 975 >0.9999 
420 0.9839 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 0.0021 1020 >0.9999 
465 0.0087 1035 >0.9999 
480 0.3009 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 0.0087 1080 0.3009 
525 0.001 1095 0.0603 
540 0.1079 1110 0.0005 
555 0.9982 1125 0.0087 
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Table 4.9 (continued) 
1140 0.0171 1710 <0.0001 
1155 0.0171 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 0.0021 1755 <0.0001 
1200 0.0005 1770 <0.0001 
1215 0.0087 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 0.0043 1815 <0.0001 
1260 0.4577 1830 <0.0001 
1275 0.0021 1845 <0.0001 
1290 0.0005 1860 <0.0001 
1305 0.001 1875 <0.0001 
1320 0.0043 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 0.0171 1920 <0.0001 
1365 0.0087 1935 <0.0001 
1380 0.0021 1950 <0.0001 
1395 0.0326 1965 <0.0001 
1410 0.0021 1980 <0.0001 
1425 0.0087 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 0.0603 2025 <0.0001 
1470 0.0326 2040 <0.0001 
1485 0.0087 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 0.0021 2085 <0.0001 
1530 0.0326 2100 <0.0001 
1545 0.0043 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.10 Sidak’s multiple comparisons test with L-lactic acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 <0.0001 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 <0.0001 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 <0.0001 
375 >0.9999 945 0.5586 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 0.8918 
555 >0.9999 1125 >0.9999 
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Table 4.10 (continued) 
1140 0.9959 1710 <0.0001 
1155 0.9709 1725 <0.0001 
1170 0.3799 1740 <0.0001 
1185 0.8918 1755 <0.0001 
1200 0.1405 1770 <0.0001 
1215 0.8918 1785 <0.0001 
1230 0.0788 1800 <0.0001 
1245 0.9709 1815 <0.0001 
1260 0.0112 1830 <0.0001 
1275 0.0006 1845 <0.0001 
1290 0.0027 1860 <0.0001 
1305 0.2384 1875 <0.0001 
1320 0.0006 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 0.0006 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 0.0003 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.11 Sidak’s multiple comparisons test with citric acid 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 0.3639 585 0.9695 
30 0.659 600 0.9933 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 0.0381 645 0.9933 
90 >0.9999 660 0.9992 
105 0.0381 675 >0.9999 
120 0.3639 690 >0.9999 
135 0.5051 705 0.3639 
150 0.9695 720 >0.9999 
165 0.9089 735 0.9992 
180 >0.9999 750 >0.9999 
195 0.1631 765 0.659 
210 0.1032 780 0.9933 
225 0.9089 795 0.659 
240 >0.9999 810 >0.9999 
255 0.659 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 0.8018 870 >0.9999 
315 >0.9999 885 >0.9999 
330 0.2488 900 >0.9999 
345 0.659 915 >0.9999 
360 0.3639 930 >0.9999 
375 0.3639 945 >0.9999 
390 0.659 960 >0.9999 
405 >0.9999 975 >0.9999 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 0.8018 1020 >0.9999 
465 0.9695 1035 >0.9999 
480 0.9089 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 0.0129 1080 0.659 
525 0.0635 1095 0.9695 
540 0.3639 1110 0.0002 
555 >0.9999 1125 0.3639 
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Table 4.11 (continued) 
1140 0.0073 1710 <0.0001 
1155 0.0012 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 <0.0001 1755 <0.0001 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 0.0003 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 0.0003 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.12 Sidak’s multiple comparisons test with fumaric acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 0.3521 
240 >0.9999 810 >0.9999 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 >0.9999 900 >0.9999 
345 >0.9999 915 >0.9999 
360 >0.9999 930 >0.9999 
375 >0.9999 945 >0.9999 
390 >0.9999 960 >0.9999 
405 >0.9999 975 >0.9999 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 >0.9999 1080 0.821 
525 >0.9999 1095 0.0009 
540 >0.9999 1110 <0.0001 
555 >0.9999 1125 0.0001 
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Table 4.12 (continued) 
1140 0.0389 1710 <0.0001 
1155 0.0163 1725 <0.0001 
1170 <0.0001 1740 <0.0001 
1185 <0.0001 1755 <0.0001 
1200 <0.0001 1770 <0.0001 
1215 <0.0001 1785 <0.0001 
1230 <0.0001 1800 <0.0001 
1245 <0.0001 1815 <0.0001 
1260 0.0003 1830 <0.0001 
1275 <0.0001 1845 <0.0001 
1290 <0.0001 1860 <0.0001 
1305 <0.0001 1875 <0.0001 
1320 <0.0001 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 <0.0001 1920 <0.0001 
1365 <0.0001 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 <0.0001 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.13 Sidak’s multiple comparisons test with acetic acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 0.2666 
270 >0.9999 840 0.0016 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.0915 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 0.0069 
375 >0.9999 945 >0.9999 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 0.0016 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 >0.9999 
555 >0.9999 1125 >0.9999 
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Table 4.13 (continued) 
1140 >0.9999 1710 <0.0001 
1155 >0.9999 1725 <0.0001 
1170 >0.9999 1740 <0.0001 
1185 >0.9999 1755 <0.0001 
1200 >0.9999 1770 <0.0001 
1215 >0.9999 1785 <0.0001 
1230 0.9624 1800 <0.0001 
1245 0.9996 1815 <0.0001 
1260 >0.9999 1830 <0.0001 
1275 0.1911 1845 <0.0001 
1290 0.0915 1860 <0.0001 
1305 0.5969 1875 <0.0001 
1320 0.0408 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 0.001 1920 <0.0001 
1365 0.0043 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 <0.0001 1965 <0.0001 
1410 <0.0001 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 0.0002 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.14 Sidak’s multiple comparisons test with pyruvic acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 0.8893 
30 >0.9999 600 0.9994 
45 >0.9999 615 0.9981 
60 >0.9999 630 0.9994 
75 >0.9999 645 0.9579 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 0.9951 
135 >0.9999 705 0.8388 
150 >0.9999 720 0.9888 
165 0.9998 735 0.9579 
180 >0.9999 750 >0.9999 
195 0.9981 765 0.9981 
210 >0.9999 780 0.4916 
225 >0.9999 795 0.4916 
240 >0.9999 810 0.9771 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 >0.9999 900 >0.9999 
345 >0.9999 915 >0.9999 
360 0.9998 930 >0.9999 
375 >0.9999 945 >0.9999 
390 >0.9999 960 >0.9999 
405 >0.9999 975 >0.9999 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 0.9994 1020 >0.9999 
465 0.9998 1035 >0.9999 
480 >0.9999 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 0.6385 1080 0.5644 
525 0.7786 1095 0.2485 
540 0.8388 1110 0.0532 
555 >0.9999 1125 0.4221 
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Table 4.14 (continued) 
1140 0.134 1710 <0.0001 
1155 0.166 1725 <0.0001 
1170 0.0066 1740 <0.0001 
1185 0.0532 1755 <0.0001 
1200 0.0194 1770 <0.0001 
1215 0.0087 1785 <0.0001 
1230 0.0087 1800 <0.0001 
1245 0.0087 1815 <0.0001 
1260 0.0416 1830 <0.0001 
1275 0.0003 1845 <0.0001 
1290 0.0087 1860 <0.0001 
1305 0.0114 1875 <0.0001 
1320 0.0114 1890 <0.0001 
1335 0.0037 1905 <0.0001 
1350 0.0114 1920 <0.0001 
1365 0.0149 1935 <0.0001 
1380 0.0037 1950 <0.0001 
1395 0.0021 1965 <0.0001 
1410 0.0016 1980 <0.0001 
1425 0.0021 1995 <0.0001 
1440 0.0002 2010 <0.0001 
1455 0.0028 2025 <0.0001 
1470 0.0016 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 0.0001 2070 <0.0001 
1515 0.0003 2085 <0.0001 
1530 0.0012 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.15 Sidak’s multiple comparisons test with m-tartaric acid 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 0.9957 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 0.9996 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 0.0317 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 >0.9999 900 0.9957 
345 >0.9999 915 0.5013 
360 >0.9999 930 >0.9999 
375 >0.9999 945 0.9957 
390 >0.9999 960 >0.9999 
405 >0.9999 975 0.5013 
420 >0.9999 990 0.6633 
435 >0.9999 1005 0.5013 
450 >0.9999 1020 0.0179 
465 >0.9999 1035 0.0317 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 0.0004 
510 0.9996 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 0.9957 
555 >0.9999 1125 >0.9999 
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Table 4.15 (continued) 
1140 >0.9999 1710 <0.0001 
1155 >0.9999 1725 <0.0001 
1170 0.092 1740 <0.0001 
1185 0.2357 1755 <0.0001 
1200 0.1501 1770 <0.0001 
1215 0.2357 1785 <0.0001 
1230 0.1501 1800 <0.0001 
1245 0.0029 1815 <0.0001 
1260 0.9199 1830 <0.0001 
1275 0.0179 1845 <0.0001 
1290 0.0008 1860 <0.0001 
1305 0.2357 1875 <0.0001 
1320 0.0179 1890 <0.0001 
1335 0.0002 1905 <0.0001 
1350 0.0015 1920 <0.0001 
1365 0.0029 1935 <0.0001 
1380 <0.0001 1950 <0.0001 
1395 0.0099 1965 <0.0001 
1410 0.0004 1980 <0.0001 
1425 <0.0001 1995 <0.0001 
1440 <0.0001 2010 <0.0001 
1455 0.0054 2025 <0.0001 
1470 <0.0001 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.16 Sidak’s multiple comparisons test with Tween 40 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 0.0112 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.0636 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 <0.0001 
375 >0.9999 945 >0.9999 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 0.4109 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 >0.9999 
555 >0.9999 1125 >0.9999 
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Table 4.16 (continued) 
1140 >0.9999 1710 <0.0001 
1155 >0.9999 1725 <0.0001 
1170 >0.9999 1740 <0.0001 
1185 >0.9999 1755 <0.0001 
1200 >0.9999 1770 <0.0001 
1215 >0.9999 1785 <0.0001 
1230 >0.9999 1800 <0.0001 
1245 >0.9999 1815 <0.0001 
1260 >0.9999 1830 <0.0001 
1275 >0.9999 1845 <0.0001 
1290 0.5721 1860 <0.0001 
1305 0.9989 1875 <0.0001 
1320 0.9559 1890 <0.0001 
1335 0.0636 1905 <0.0001 
1350 0.1077 1920 <0.0001 
1365 0.4109 1935 <0.0001 
1380 0.9904 1950 <0.0001 
1395 0.0204 1965 <0.0001 
1410 0.0204 1980 <0.0001 
1425 0.0204 1995 <0.0001 
1440 0.0002 2010 <0.0001 
1455 0.0365 2025 <0.0001 
1470 0.1077 2040 <0.0001 
1485 0.0008 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 0.006 2085 <0.0001 
1530 <0.0001 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.17 Sidak’s multiple comparisons test with Tween 80 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 0.999 
330 >0.9999 900 0.8522 
345 >0.9999 915 0.6068 
360 >0.9999 930 >0.9999 
375 >0.9999 945 0.3515 
390 >0.9999 960 >0.9999 
405 >0.9999 975 0.999 
420 >0.9999 990 0.8522 
435 >0.9999 1005 0.0043 
450 >0.9999 1020 0.0313 
465 >0.9999 1035 0.0043 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 0.0043 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 0.9759 
555 >0.9999 1125 >0.9999 
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Table 4.17 (continued) 
1140 >0.9999 1710 <0.0001 
1155 >0.9999 1725 <0.0001 
1170 0.3515 1740 <0.0001 
1185 >0.9999 1755 <0.0001 
1200 >0.9999 1770 <0.0001 
1215 >0.9999 1785 <0.0001 
1230 0.3515 1800 <0.0001 
1245 0.3515 1815 <0.0001 
1260 0.999 1830 <0.0001 
1275 0.0043 1845 <0.0001 
1290 0.0313 1860 <0.0001 
1305 0.999 1875 <0.0001 
1320 0.1738 1890 <0.0001 
1335 <0.0001 1905 <0.0001 
1350 0.0005 1920 <0.0001 
1365 0.0005 1935 <0.0001 
1380 0.0015 1950 <0.0001 
1395 0.3515 1965 <0.0001 
1410 0.012 1980 <0.0001 
1425 0.0769 1995 <0.0001 
1440 0.0005 2010 <0.0001 
1455 0.3515 2025 <0.0001 
1470 0.3515 2040 <0.0001 
1485 <0.0001 2055 <0.0001 
1500 <0.0001 2070 <0.0001 
1515 <0.0001 2085 <0.0001 
1530 0.0769 2100 <0.0001 
1545 <0.0001 2115 <0.0001 
1560 <0.0001 2130 <0.0001 
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Table 4.18 Sidak’s multiple comparisons test with α-ketoglutaric acid 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 0.0005 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.0005 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 <0.0001 
375 >0.9999 945 >0.9999 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 0.9998 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 >0.9999 
555 >0.9999 1125 >0.9999 
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Table 4.18 (continued) 
1140 >0.9999 1710 <0.0001 
1155 >0.9999 1725 <0.0001 
1170 >0.9999 1740 <0.0001 
1185 >0.9999 1755 <0.0001 
1200 >0.9999 1770 <0.0001 
1215 >0.9999 1785 <0.0001 
1230 >0.9999 1800 <0.0001 
1245 >0.9999 1815 <0.0001 
1260 >0.9999 1830 <0.0001 
1275 0.9961 1845 <0.0001 
1290 0.9998 1860 <0.0001 
1305 >0.9999 1875 <0.0001 
1320 >0.9999 1890 <0.0001 
1335 0.9676 1905 <0.0001 
1350 >0.9999 1920 <0.0001 
1365 0.8729 1935 <0.0001 
1380 0.9998 1950 <0.0001 
1395 0.9998 1965 <0.0001 
1410 >0.9999 1980 <0.0001 
1425 0.9961 1995 <0.0001 
1440 0.4958 2010 <0.0001 
1455 0.9676 2025 <0.0001 
1470 0.9998 2040 <0.0001 
1485 0.0005 2055 <0.0001 
1500 0.0997 2070 <0.0001 
1515 0.0997 2085 <0.0001 
1530 0.183 2100 <0.0001 
1545 0.0516 2115 <0.0001 
1560 0.0997 2130 <0.0001 
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Table 4.19 Sidak’s multiple comparisons test with glucuronamide 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 0.5762 
30 >0.9999 600 >0.9999 
45 >0.9999 615 0.9995 
60 >0.9999 630 >0.9999 
75 >0.9999 645 0.9659 
90 >0.9999 660 >0.9999 
105 0.9995 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 0.1643 
150 >0.9999 720 >0.9999 
165 >0.9999 735 0.7496 
180 >0.9999 750 0.9659 
195 0.7496 765 0.994 
210 >0.9999 780 >0.9999 
225 >0.9999 795 0.7496 
240 >0.9999 810 0.9995 
255 >0.9999 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 >0.9999 900 >0.9999 
345 >0.9999 915 >0.9999 
360 >0.9999 930 >0.9999 
375 >0.9999 945 >0.9999 
390 >0.9999 960 >0.9999 
405 >0.9999 975 >0.9999 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 >0.9999 1080 >0.9999 
525 0.8877 1095 0.8877 
540 0.994 1110 0.5762 
555 0.8877 1125 0.1643 
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Table 4.19 (continued) 
1140 0.8877 1710 0.0085 
1155 0.9659 1725 0.0001 
1170 0.4059 1740 <0.0001 
1185 0.1643 1755 0.0085 
1200 0.0551 1770 0.0022 
1215 0.0163 1785 0.0085 
1230 0.2659 1800 <0.0001 
1245 0.4059 1815 <0.0001 
1260 0.7496 1830 0.0005 
1275 0.0163 1845 <0.0001 
1290 0.0551 1860 0.0005 
1305 0.994 1875 0.0005 
1320 0.2659 1890 <0.0001 
1335 0.0304 1905 0.0022 
1350 0.0011 1920 <0.0001 
1365 0.0551 1935 0.0044 
1380 0.0969 1950 0.0022 
1395 0.2659 1965 <0.0001 
1410 0.0969 1980 <0.0001 
1425 0.0969 1995 0.0001 
1440 0.0085 2010 0.0001 
1455 0.0304 2025 <0.0001 
1470 0.9659 2040 0.0001 
1485 0.0011 2055 <0.0001 
1500 0.0002 2070 0.0002 
1515 0.0044 2085 0.0022 
1530 0.0005 2100 <0.0001 
1545 0.0022 2115 0.0001 
1560 0.0085 2130 <0.0001 
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Table 4.20 Sidak’s multiple comparisons test with methyl pyruvate 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 0.8648 
15 >0.9999 585 0.9937 
30 0.9999 600 0.9999 
45 0.9999 615 >0.9999 
60 0.7623 630 >0.9999 
75 0.9766 645 0.9365 
90 >0.9999 660 >0.9999 
105 >0.9999 675 0.9766 
120 0.9937 690 >0.9999 
135 0.9937 705 0.9988 
150 >0.9999 720 0.9988 
165 0.7623 735 >0.9999 
180 0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 0.9937 780 >0.9999 
225 0.9988 795 0.9365 
240 0.9999 810 >0.9999 
255 0.9937 825 >0.9999 
270 >0.9999 840 >0.9999 
285 >0.9999 855 >0.9999 
300 >0.9999 870 >0.9999 
315 >0.9999 885 >0.9999 
330 >0.9999 900 >0.9999 
345 >0.9999 915 >0.9999 
360 >0.9999 930 >0.9999 
375 0.9999 945 >0.9999 
390 >0.9999 960 >0.9999 
405 >0.9999 975 >0.9999 
420 0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 0.6393 1020 >0.9999 
465 0.9988 1035 >0.9999 
480 0.9988 1050 >0.9999 
495 >0.9999 1065 0.8648 
510 0.9766 1080 >0.9999 
525 0.9937 1095 0.9766 
540 0.8648 1110 0.2888 
555 0.9988 1125 0.9365 
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Table 4.20 (continued) 
1140 >0.9999 1710 0.0025 
1155 >0.9999 1725 <0.0001 
1170 0.2063 1740 <0.0001 
1185 0.8648 1755 <0.0001 
1200 0.7623 1770 <0.0001 
1215 0.9766 1785 0.0001 
1230 0.7623 1800 <0.0001 
1245 0.3915 1815 <0.0001 
1260 0.7623 1830 <0.0001 
1275 0.6393 1845 <0.0001 
1290 0.0976 1860 <0.0001 
1305 0.9937 1875 <0.0001 
1320 0.8648 1890 <0.0001 
1335 0.0068 1905 <0.0001 
1350 0.0976 1920 <0.0001 
1365 0.2888 1935 <0.0001 
1380 0.0042 1950 <0.0001 
1395 0.0427 1965 <0.0001 
1410 0.5112 1980 <0.0001 
1425 0.7623 1995 <0.0001 
1440 0.0651 2010 <0.0001 
1455 0.9365 2025 <0.0001 
1470 0.5112 2040 <0.0001 
1485 0.0009 2055 <0.0001 
1500 0.011 2070 <0.0001 
1515 0.0175 2085 <0.0001 
1530 0.0042 2100 <0.0001 
1545 0.0175 2115 <0.0001 
1560 0.0427 2130 <0.0001 











    
391 
 
Table 4.21 Sidak’s multiple comparisons test with L-serine 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 0.5665 585 >0.9999 
30 0.4273 600 >0.9999 
45 0.9249 615 >0.9999 
60 >0.9999 630 >0.9999 
75 0.0014 645 >0.9999 
90 0.0216 660 >0.9999 
105 0.091 675 >0.9999 
120 0.3068 690 >0.9999 
135 0.2113 705 >0.9999 
150 0.9992 720 >0.9999 
165 0.4273 735 >0.9999 
180 0.4273 750 >0.9999 
195 0.0044 765 >0.9999 
210 0.3068 780 >0.9999 
225 0.9992 795 >0.9999 
240 0.9745 810 >0.9999 
255 0.9249 825 >0.9999 
270 0.9249 840 >0.9999 
285 0.7094 855 >0.9999 
300 0.9745 870 >0.9999 
315 0.9992 885 >0.9999 
330 0.7094 900 >0.9999 
345 >0.9999 915 >0.9999 
360 >0.9999 930 >0.9999 
375 >0.9999 945 >0.9999 
390 >0.9999 960 >0.9999 
405 >0.9999 975 >0.9999 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 >0.9999 
450 >0.9999 1020 >0.9999 
465 0.9992 1035 >0.9999 
480 >0.9999 1050 >0.9999 
495 >0.9999 1065 >0.9999 
510 0.9745 1080 >0.9999 
525 0.8349 1095 >0.9999 
540 >0.9999 1110 >0.9999 
555 >0.9999 1125 >0.9999 
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Table 4.21 (continued) 
1140 >0.9999 1710 0.0008 
1155 >0.9999 1725 <0.0001 
1170 0.5665 1740 <0.0001 
1185 >0.9999 1755 0.0008 
1200 0.9992 1770 <0.0001 
1215 >0.9999 1785 <0.0001 
1230 0.9941 1800 <0.0001 
1245 0.9745 1815 <0.0001 
1260 >0.9999 1830 <0.0001 
1275 0.9745 1845 <0.0001 
1290 0.9745 1860 <0.0001 
1305 >0.9999 1875 <0.0001 
1320 >0.9999 1890 <0.0001 
1335 0.7094 1905 <0.0001 
1350 >0.9999 1920 <0.0001 
1365 0.9941 1935 <0.0001 
1380 >0.9999 1950 <0.0001 
1395 0.2113 1965 <0.0001 
1410 0.9745 1980 <0.0001 
1425 0.9745 1995 <0.0001 
1440 0.0575 2010 <0.0001 
1455 0.8349 2025 <0.0001 
1470 0.3068 2040 <0.0001 
1485 0.091 2055 <0.0001 
1500 0.091 2070 <0.0001 
1515 0.5665 2085 <0.0001 
1530 0.1406 2100 <0.0001 
1545 0.0575 2115 <0.0001 
1560 0.091 2130 <0.0001 
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Table 4.22 Sidak’s multiple comparisons test with D-fructose 
 
time (minutes) adjusted P value time (minutes) adjusted P value 
0 >0.9999 570 >0.9999 
15 >0.9999 585 >0.9999 
30 >0.9999 600 >0.9999 
45 >0.9999 615 >0.9999 
60 >0.9999 630 >0.9999 
75 >0.9999 645 >0.9999 
90 >0.9999 660 >0.9999 
105 >0.9999 675 >0.9999 
120 >0.9999 690 >0.9999 
135 >0.9999 705 >0.9999 
150 >0.9999 720 >0.9999 
165 >0.9999 735 >0.9999 
180 >0.9999 750 >0.9999 
195 >0.9999 765 >0.9999 
210 >0.9999 780 >0.9999 
225 >0.9999 795 >0.9999 
240 >0.9999 810 >0.9999 
255 >0.9999 825 0.0095 
270 >0.9999 840 <0.0001 
285 >0.9999 855 <0.0001 
300 >0.9999 870 0.0319 
315 >0.9999 885 <0.0001 
330 >0.9999 900 <0.0001 
345 >0.9999 915 <0.0001 
360 >0.9999 930 0.0003 
375 >0.9999 945 >0.9999 
390 >0.9999 960 <0.0001 
405 >0.9999 975 <0.0001 
420 >0.9999 990 >0.9999 
435 >0.9999 1005 <0.0001 
450 >0.9999 1020 >0.9999 
465 >0.9999 1035 >0.9999 
480 >0.9999 1050 <0.0001 
495 >0.9999 1065 <0.0001 
510 >0.9999 1080 >0.9999 
525 >0.9999 1095 >0.9999 
540 >0.9999 1110 >0.9999 
555 >0.9999 1125 >0.9999 
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Table 4.22 (continued) 
1140 >0.9999 1710 >0.9999 
1155 >0.9999 1725 0.7107 
1170 >0.9999 1740 0.0095 
1185 >0.9999 1755 0.9877 
1200 >0.9999 1770 0.5426 
1215 >0.9999 1785 >0.9999 
1230 >0.9999 1800 0.005 
1245 >0.9999 1815 0.0007 
1260 >0.9999 1830 0.7107 
1275 0.9472 1845 0.5426 
1290 >0.9999 1860 0.0319 
1305 >0.9999 1875 0.0562 
1320 >0.9999 1890 <0.0001 
1335 0.5426 1905 0.254 
1350 >0.9999 1920 <0.0001 
1365 >0.9999 1935 0.5426 
1380 >0.9999 1950 0.0013 
1395 >0.9999 1965 <0.0001 
1410 >0.9999 1980 0.0026 
1425 >0.9999 1995 <0.0001 
1440 >0.9999 2010 0.0007 
1455 >0.9999 2025 <0.0001 
1470 >0.9999 2040 0.0007 
1485 >0.9999 2055 0.0095 
1500 0.9472 2070 0.0002 
1515 >0.9999 2085 <0.0001 
1530 >0.9999 2100 <0.0001 
1545 0.9472 2115 0.0026 
1560 >0.9999 2130 <0.0001 















Table 4.23 Hits from the phenotypic metabolic screen 
substrate metabolic 
information 
information regarding Cryptococcus 









pentose cycle); as 
uridine diphosphate 
(UDP), UDP-α-







involved in fungal 
metabolism: as 






structural element of GXM of C. neoformans 
(Bhattacharjee et al., 1979b; Cherniak et al., 
1980; Marrifield and Stephen, 1980; 
Bhattacharjee et al., 1981) and C. gattii 
(Bhattacharjee et al., 1978, 1979a, 1980; 
Bacon and Cherniak, 1995) or GalXM of C. 
neoformans (Cherniak et al., 1982; Turner et 
al., 1984) and C. gattii (James and Cherniak, 
1992); the GXMs of C. neoformans and C. 
gattii differ in the amount of xylose 
substitutions (Young and Kozel, 1993); 
GalXMs are also variable amongst 
cryptococcal species(de Jesus et al., 2010); a 
sole carbon source through the 
pentophosphate pathway (hexose mono- 
phosphate shunt) in C. neoformans (Cherniak, 
O’Neill, et al., 1998); assimilated by C. gattii 
(Lazéra et al., 1998) and utilised by 
Cryptococcus spp. (Vimercati et al., 2016); 
utilised by both C. neoformans and C. gattii 
(Hagen et al., 2015); UDP-xylose is a 
transporter of capsular xylose in C. 
neoformans (Li et al., 2018) 
D-mannose hexose 
disaccharide sugar; 
C’-2 epimer of 
glucose;  
 








structural element of GXM of C. neoformans 
(Rebers et al., 1958; Bhattacharjee et al., 
1979b, 1981; Cherniak et al., 1980; Marrifield 
and Stephen, 1980) and C. gattii 
(Bhattacharjee et al., 1978, 1979a, 1980; 
Bacon and Cherniak, 1995) or GalXM of C. 
neoformans (Cherniak et al., 1982; Turner et 
al., 1984) and C. gattii (James and Cherniak, 
1992); assimilated directly into GXM of C. 
neoformans (Cherniak, O’Neill, et al., 1998; 
Zaragoza et al., 2006); GDP-mannose is a 
transporter of capsular mannose in C. 
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Table 4.2 (continued) 
tricarballylic 
acid 
an inhibitor of the 
enzyme aconitase 
and therefore 








sugar; C'-2 carbon 





used as a substrate for xylose reductase by 
C. flavus (Mayr et al., 2003);  
D, L-malic 
acid 
*involved in fungal 
metabolism: L-
malate is an 
intermediate in 
Krebs cycle and 
therefore involved 









L-malic is assimilated by Cryptococcus spp. 
(Vimercati et al., 2016) and by serotypes B 
and C of C. neoformans but not by serotypes 
A and D but (Bennett et al., 1978)  
bromosuccinic 
acid  
both D- and L-
bromosuccinate 
cause the loss of 
activity in the 





an enzyme that 
catalyses the first 




et al., 1990)  
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Table 4.2 (continued) 
L-asparagine  α-amino acid;  
 
*not generally 









induces melanin production in C. neoformans 
(Chaskes and Tyndall, 1975); Cryptococcus 





*involved in fungal 
metabolism: 
carbohydrate 




involved in fungal 
metabolism: 
carbon fixation (not 






utilised by Cryptococcus spp. (Vimercati et 
al., 2016); utilised by both C. neoformans 
(Benham, 1956; Hagen et al., 2015) and C. 
gattii (Hagen et al., 2015) 
L-lactic acid L-lactate is involved 
in  




(pyruvate turnover);  
alternative 
respiration;  
not assimilated by C. gattii (Lazéra et al., 
1998); lactose not utilised by either C. 
neoformans or C. gattii (Hagen et al., 2015) 
citric acid as citrate: 
 




Roche Ltd, 2014) 
assimilated by C. gattii serotype B after 
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Table 4.2 (continued) 
fumaric acid as fumarate: 
 













involved in fungal 
metabolism: amino 
acid metabolism 
















assimilated by C. neoformans serotypes B 
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Table 4.2 (continued) 
acetic acid as acetate: 
*involved in fungal metabolism: bacterial 
metabolism (butanol/butyrate, fermentation); 
amino acid metabolism (lysine); amino acid 
metabolism (glutamate, proline, hydroxyproline; 
amino acid metabolism (urea); carbohydrate 
metabolism (pyruvate turnover); carbohydrate 
metabolism (pentoses and pentose cycle); 
carbohydrate metabolism (amino sugar 
derivatives); tetrapyrrole metabolism (porphyrins, 
cobalamin) 
*not generally involved in fungal metabolism: 
amino acid metabolism (serine, proline, 
hydroxyproline; amino acid metabolism (serine, 
threonine, cysteine, methionine); C1 metabolism; 
steroid metabolism (androgens and estrogenes); 
lipid metabolism (fatty acids); lipid metabolism 
(glyco- and phospholipids) 
 
as active acetate, acetyl-coenzym A (acetyl-
CoA): 
 *involved in fungal metabolism: bacterial 
metabolism (butanol/butyrate, fermentation); 
amino acid metabolism (serine, proline, 
hydroxyproline); amino acid metabolism 
(histidine); amino acid metabolism (lysine); amino 
acid metabolism (leucine, isoleucine, valine); C1 
metabolism; carbohydrate metabolism (pyruvate 
turnover); carbohydrate metabolism (pentoses 
and pentose cycle); carbohydrate metabolism 
(amino sugar derivatives); carbohydrate 
metabolism (pyruvate turnover)  
*not generally involved in fungal metabolism: 
citrate and glyoxalate cycle; amino acid 
metabolism (serine, proline, hydroxyproline); 
amino acid metabolism (leucine, isoleucine, 
valine); carbohydrate metabolism (amino sugar 
derivatives); lipid metabolism (fatty acids); lipid 









mating in C. 
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Table 4.2 (continued) 
pyruvic acid as pyruvate: 
*involved in fungal metabolism: amino acid 
metabolism (leucine, isoleucine, valine); amino 
acid metabolism (serine, threonine, cysteine, 
methionine); amino acid metabolism (glutamate, 
proline, hydroxyproline); amino acid metabolism 
(histidine); carbohydrate metabolism (pyruvate 
turnover); carbohydrate metabolism (amino sugar 
derivatives); carbohydrate metabolism (glycolysis 
and glyconeogenesis); carbohydrate metabolism 
(acidic carbohydrate derivatives); lipid 
metabolism (glyco- and phospholipids); 
prokaryotic membranes; alternative respiration 
*not generally involved in fungal metabolism: 
amino acid metabolism (glutamate, proline, 










(Lis et al., 
2013) 
m-tartaric acid D-tartrate involved in the Krebs cycle (van Vugt-
Lussenburg et al., 2013);  
C. neoformans 










Tween 40 emulsifier; not involved in metabolic pathways used to assess 
lipase activity of 
C. neoformans 
or C. gattii 
(Hagen et al., 
2015) 
Tween 80 emulsifier; not involved in metabolic pathways used to assess 
lipase activity of 
C. neoformans 
or C. gattii 
(Hagen et al., 
2015); utilised 
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*involved in fungal metabolism: amino acid 
metabolism (glutamate, proline, hydroxyproline); 
amino acid metabolism (serine, threonine, 
cysteine, methionine); amino acid metabolism 
(leucine, isoleucine, valine); amino acid 
metabolism (lysine); citrate and glyoxalate cycle; 
 
*not generally involved in fungal metabolism: 
amino acid metabolism (lysine) (not included in 
fungal metabolism); amino acid metabolism( 
histidine) (not included in fungal metabolism); 
amino acid metabolism (glutamate, proline, 
hydroxyproline) (not included in fungal 
metabolism); amino acid metabolism (leucine, 
isoleucine, valine) (not included in fungal 
metabolism); nucleotide metabolism (NAD, 
NADP) (not included in fungal metabolism); 
carbohydrate metabolism (glycolysis and 














secreted by C. 
neoformans 
(Jacobson and 















(Xu et al., 
2006) 
glucuronamide hexose monosaccharide derivative related to 
glucuronic acid 
utilised by C. 
flavescens 
(McSpadden 




more favourable substrate for the tricarboxylic 
acid (TCA) cycle than pyruvic acid (Lembert et 
al., 2001; Duffer et al., 2002)  






L-serine ɑ-amino acid 
 
*involved in fungal metabolism: amino acid 
metabolism (serine, threonine, cysteine, 
methionine); lipid metabolism (glyco- and 
phospholipids);  
 
*not generally involved in fungal metabolism: lipid 
metabolism (sphingolipids); carbohydrate 
metabolism (glycolysis and gluconeogenesis) 
serine 
proteases are 
produced by C. 
neoformans 




and C. gattii 
(Min and Kwon-
Chung, 1986) 
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Table 4.2 (continued) 
D-fructose hexose monosaccharide sugar;  
 
*involved in fungal metabolism: β-D-fructose is 
involved in carbohydrate metabolism (di- and 
polysaccharides); D fructose in carbohydrates 
metabolism (glycolysis and gluconeogenesis 
(Hoffman-La Roche Ltd, 2014) 
D-fructose 
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